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ABSTRACT 
This work centers on the development of a novel passive transport system for two 
tissue engineering applications – cell distribution and cell separation. This approach relies 
on a wicking fiber-based system, derived from the textile field that functions by directing 
and maintaining transport of cells as well as fluids and biomolecules. This system has the 
ability to enhance cell movement for both the purpose of cell seeding distribution as well 
as to isolate specific cell types from heterogeneous cell populations. 
The success of spinal fusions and large bone defects is often limited by the 
decreased surrounding vasculature and the ability of cells to penetrate and proliferate both 
the surface and interior regions of large scaffolds. Therefore, the transport system was 
tested for improved mass transport, distribution of bone-forming cells, and infiltration of 
biomolecules in a commonly used spinal fusion scaffold. Heterogeneous cell solutions 
containing cancerous and benign cell types were used as the proof-of-concept isolation 
system, where the transport system rapidly and efficiently identifies and isolates cancer 
cells. Methods to identify cancer cells rely considerably on biomarker detection and 
analysis of gene expression, with biomarker detection often unreliable and limited. The 
transport system distinguishes and isolates cancer cells of varying metastatic potential. An 
integrated, interactive hands-on learning module was developed to introduce middle school 
female students to transport and tissue engineering principles. The hands-on activity 
introduces the engineering design process and promotes engineering problem solving. 
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PREFACE 
Wicking systems are commonly used in the textile industry. Wicking is a passive 
mode of transport using capillary action to move fluids. The purpose of this work involves 
the development and optimization of novel wicking fiber bundles to sustain transport of 
nutrients and biomolecules, as well as direct and identify particular cell types. In one 
application, wicking fiber bundles were applied to large tissue engineered scaffolds to 
increase cellular distribution throughout the scaffold. Another application involved the 
development of a wicking fiber system to separate and identify cell types. Different cells 
move through the fiber bundles at varying rates and distances based on cell characteristics, 
providing a means of isolating and analyzing pathological and multipotent cells.  
The first application of the wicking fiber system involved improving the transport 
limitations of bone grafts that are used for large bone defects, specifically in spinal fusions. 
Spinal fusions are the standard treatment for lower back pain, as well as spinal deformities 
and trauma. In the past 3 decades, there has been a significant increase in number and cost 
of spinal fusions compared to other common surgical procedure[2]. Bone graft material is 
an essential component used in spinal fusions and are also used in other large defect 
fracture repair procedures. Successful bone formation can be controlled by the properties 
of the bone graft. Alternate bone grafts such as allograft or synthetic substitutes lack the 
bone-forming qualities of autologous bone graft. Due to availability limitations of 
autologous grafts, there is a need and competitive market to improve bone substitutes that 
augment bone formation in spinal fusion procedures[1]. The environment of the fusion site 
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also greatly impacts the success of the fusion. The environment surrounding the implant 
provides vasculature and the essential bone-forming factors. The success of bone formation 
is highly dependent on the surrounding vasculature and is often overlooked when designing 
tissue engineered constructs[4]. The current tissue engineering methods used to create 
vascularity and improve transport of the bone construct have had very limited success. 
Researchers have discovered non-homogeneous bone formation within the spinal fusion 
site[5, 6]. Regions closer to the source of vasculature form bone more rapidly than regions 
further away. The regions lacking vascular supply are more susceptible to pseudarthrosis, 
which causes the fusion to fail. The first part of the work involved developing and testing 
the novel non-biological wicking fiber approach to improve vascularity and direct transport 
of essential bone-forming biomolecules and cells to all regions of the bone graft in the 
implant site.  
The second application of the wicking fiber bundles involved the development of a 
wicking fiber system to separate and identify particular cell types, specifically cancer and 
normal cells. The National Cancer Institute estimates 1 in 30 Americans have or have had 
some form of cancer, with an annual cost of $126 billion[7]. This high incidence rate drives 
the need for reliable and accurate testing. The occurrence of diagnostic error, including 
failure to diagnose the existing cancer and delayed diagnosis, can be as frequent as 1 in 5 
cancer cases[8]. A major contributing factor for this error is the extensive oncologic 
pathology testing process. This extensive process provides frequent opportunities to switch 
or contaminate samples, as well as to inadequately prepare, analyze, or interpret 
specimens[9]. The gold standard for cancer detection involves histological analysis using 
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phenotypic and genotypic biomarkers. A major limitation of biomarkers in the 
identification of cancer is the absence of a universal tumorigenic marker. The complexity 
and heterogeneity of a tumor create a challenge for researchers to characterize the tumor 
based on phenotypic and genotypic biomarkers alone. Tumors are reported to have 
different subpopulations of cancer cells with varying phenotypes and degrees of tumor-
initiating capabilities [12]. The transient phenotypes of these cells create complexities for 
current detection methods and treatments[19]. For instance, cancer stem cells have the 
potential to be dormant or aggressive[20]. This ability to phenotypically change may cause 
resistance to treatment and recurrence[21]. 
An emerging field for oncology diagnostics involves the use of non-invasive liquid 
biopsy tests. This involves testing blood, urine, or other bodily fluids for cancer cells or 
oncologic related proteins and biomolecules. Again, these liquid biopsy samples are 
typically analyzed using conventional methods for identifying progenitor or cancer cells, 
which involve detecting phenotypic biomarkers and analyzing gene expression[13]. The 
use of phenotypic and genotypic biomarkers to identify progenitors is unreliable, lacks 
specificity, and provides limited information regarding the cancer cell potential. This work 
involved the development of new physical biomarkers based on cell behavior through the 
wicking fiber system. The goal of this application was to establish a method to better 
capture and characterize cancer cells of different metastatic capabilities.  
The goal of this work was to develop a novel approach using a wicking fiber system 
that can achieve sufficient transport of biomolecules and cells throughout the entirety of 
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the scaffold as well efficiently identify pathological cell types from heterogeneous samples 
or tissues. To accomplish these overall goals the following specific aims were recognized:  
Specific Aim 1 – Evaluate the effects of wicking fibers on the transport of biomolecules 
and progenitor cells in tissue engineered scaffolds  
 Phase A – Characterize wicking fluid properties of wicking bundles 
 Phase B – Evaluate the effects of wicking fibers on recruitment of progenitor cells 
and biomolecule transport in 3-dimensional scaffolds 
Specific Aim 2 – Investigate the use of a wicking fiber system to improve the success 
rates of bone graft used for spinal fusion 
 Phase A– Determine if wicking fibers improve cellular viability, proliferation, and 
distribution of large bone scaffolds  
 Phase B – Evaluate if incorporating wicking fibers in large bone scaffolds 
improve cellular differentiation and bone formation 
Specific Aim 3 – Develop and assess a passive transport system to improve large tissue 
engineered constructs  
 Phase A - Develop and assess the capabilities of the passive transport system to 
sustain movement and direct cell and biomolecule movement  
 Phase B - Investigate the effectiveness of the passive transport system as an 
antibiotic eluting system and assess the release of antibiotic  
Specific Aim 4 – Assess the ability of the wicking fibers to identify and isolate 
subpopulations of cancer cell with different metastatic capabilities  
 Phase A – Optimize the wicking fiber approach to identify cancerous cells from a 
mixture of benign and more aggressive cancer cells 
 Phase B – Investigate the distribution of cancer cells of varying metastatic 
potential and changes in cells mechanical properties 
 Phase C – Assess the efficiency of the wicking fiber and absorbent construct to 
rapidly collect cancer cells of high metastatic potential  
Specific Aim 5 – Develop and assess an interactive learning module that introduces 
middle school female students to tissue engineering and related transport phenomena   
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Chapter 1 provides an overall literature review of the topic; various sections 
published in Critical Reviews in Biomedical Engineering, 2014. Studies supporting the 
first aim, described in chapter 2, investigated fluid transport properties of various 
configurations of wicking fibers, and the ability of wicking fibers to transport biomolecules 
and progenitor cells; work published in the Journal of Tissue Engineering & Regenerative 
Medicine, 2014. Studies supporting the second aim, presented in chapter 3, explored the 
effects of wicking fiber bundles on cell viability, proliferation, and distribution in all 
regions of the scaffold, predominately in regions in the center of the scaffold or furthest 
from the vascular source. The final study in chapter 3 determined the effect of wicking 
fiber on osteoblastic differentiation. Studies building toward the third aim (Chapter 4) 
involved the development of a passive transport system using the wicking fiber bundles 
and evaluation of whether the system can sustain transport longer and more efficiently 
direct the movement of progenitor cells and biomolecules to the center of the scaffold 
where necrosis or delayed bone formation occurs. In Chapter 5, the cross-sectional effects 
of the fiber bundles on antibiotic elution were explored, as well as, various mechanisms to 
load the antibiotic into the system. Experiments supporting the final technical aim, 
presented in chapters 6, investigated the ability of the wicking fiber transport system to 
identify and isolate cancer cells of different stages of aggressiveness. This chapter further 
explores the use of the wicking system to separate progenitor cells of varying 
differentiation potential. The factors affecting cell of cell type separation were investigated 
in Chapter 7. The final chapter reviews the development of an educational module designed 
to effectively introduce young middle school students to tissue engineering and the impacts 
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of tissue engineering on advancing the medical field; the module impact was evaluated 
using pre- and post- quizzes to assess if there is an improvement in the understanding of 
tissue engineering. Survey assessments were implemented to evaluate if the module 
influenced a change in interest in the field of science and engineering. The following flow 
chart illustrates the specific aims of this work.  
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CHAPTER ONE 
LITERATURE REVIEW 
Introduction 
 Bone grafting is required in sites where bone formation will not spontaneously 
occur, to bridge a large bone defect or fusion site. These grafts are used to improve the 
formation of bone in critical defect sites that can result from trauma, complex non-unions, 
fusions, or resections from pathologies1,2. In the United States, 1.5 million bone grafting 
procedures are conducted annually and are increasing at an annual growth rate of 13%3,4. 
Spinal fusions are the most common grafting procedure, constituting half of all bone graft 
orthopaedic procedures5. Even with the use of bone grafts to augment bone regeneration, 
non-unions or impaired bone formation occur in both critical bone defects and fusions. 
Delayed bone formation or non-union occurs in 5-10% of all fracture cases and in 20% of 
high-energy trauma fractures1,6. Non-union rates in spinal fusions are reported at a relative 
frequency of 5-40% based on the location, surgical technique, type of graft used, and 
patient indications7.   
 The cause of pseudoarthrosis, or non-unions, can be related to both patient and 
surgical factors, including metabolic abnormalities, smoking, infection, fracture location 
and pattern, soft tissue damage, and excessive motion at the fusion or defect site8,9. 
Regardless of which surgical approach is used to treat a patient with a large critical bone 
defect, there are necessary contributing factors that result in successful bone formation. 
These contributing factors include the use and choice of instrumentation, the amount and 
type of graft material, the surgical technique, and the surrounding environment7,10–13.   
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 Successful bone formation in spinal fusion and fracture repair procedures can, in 
part, be controlled by the properties of the bone graft. Even with advancements in tissue 
engineering and the development of composite grafts, autologous bone grafts remain the 
gold standard for bone grafting procedures14,15. Due to availability and limited amounts of 
autologous bone graft, there is a need and competitive market to develop bone substitutes 
that enhance bone formation in fusion procedures and critical size bone defects16. 
Currently, no alternative bone grafts, including allograft, synthetic, and composite 
substitutes, have stimulated comparable bone forming qualities to autologous bone graft. 
In fact, only 10% of the bone grafting procedures globally are performed with synthetic 
bone graft17. Vast research has been conducted to identify the critical cellular and 
molecular events during the well-orchestrated bone formation process18,19. By 
understanding the local and systemic molecular and cellular factors, synthetic bone grafts 
can be improved.  
 The local surrounding environment of the implant site influences the bone healing 
process and plays a critical role in the success of the graft. The implant environment varies 
based on location, fracture pattern, patient indication, quality and loss of bone, as well as 
surgical technique. Therefore, it is critical to understand the interactions and effects of the 
surrounding tissue environment with bone grafts to improve success rates. Critically 
important to this implant environment is the presence of vasculature. The success of bone 
formation is highly dependent on the surrounding vasculature and is often overlooked when 
designing tissue engineered constructs20. Many tissue engineering methods fail to account 
for the contribution of the surrounding environment. By understanding the interaction 
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between the surrounding tissue of the fusion or defect site and the bone graft, tissue 
engineered constructs can be better tailored to lower rates of non-unions. 
 Critical defects and fusions require large amounts of bone formation to successfully 
repair or fuse the bone. Hence, a large bone graft is desired to fill the region and stimulate 
bone formation. The intrinsic limitation of large bone scaffolds is their inability to promote 
mass transport and encourage penetration of bone-forming cells and biomolecules into the 
scaffold’s interior21. Bone formation is directly impacted by the vascularity of the scaffold 
and the surrounding implant site. Researchers have shown that lack of vasculature in the 
central region results in high risk for pseudoarthrosis and failure of complete fusion 22–25. 
Likewise, avascular regions in critical fracture defects have led to necrosis of cells in the 
interior of large scaffolds, as well as heterogeneous formation of bone26.  
 This first section of this chapter will provide background information on the 
anatomy and physiology of the spine as well as clinical information regarding the types of 
spinal fusion procedures and their limitations. The second section of this chapter will assess 
the importance of vasculature and related environmental factors during the bone healing 
process both for spinal fusions and for large fracture defects. This next section will focus 
on the vascular, cellular, and biomolecular contribution of local surrounding tissue, 
including the adjacent muscle and periosteum, to bone formation. The final sections will 
evaluate currently available bone substitutes and bone tissue engineering approaches to 
improve transport and vascularity within large bone scaffolds for critical defects.   
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Market for Spinal Fusion Surgeries  
Spinal fusion procedures are standard treatments for lower back pain caused by 
disc degeneration, spinal deformities, or trauma27. The worldwide market for spinal 
devices totals 3-5 billion in revenue and is growing approximately 25% each year28. A 
recent article in Spine analyzed the frequency and trends of spinal fusions in the United 
States from 1998 to 200827.  Figure 1.1 shows the frequency of spinal fusion surgeries in 
this decade compared to other common surgical techniques, which include: total knee 
replacement (TKR), total hip replacement (THR), laminectomy, coronary artery bypass 
graft (CABG), and percutaneous transluminal coronary angioplasty (PTCA)27.  In the 
past three decades, there has been a significant increase in the number and cost of spinal 
fusion surgeries in contrast with other surgical procedures with lumbar fusions 
experiencing the largest increase in number of procedures performed this decade.27 
Fusion procedures require the use of a bone graft. Over 500,000 orthopedic 
procedures are conducted with the use of bone grafts in the United States. Spinal fusions 
make up roughly 50% of these procedures28. The increase in prevalence of lower back 
pain and, subsequently, the increase in spinal fusion procedures show there is a need and 
competitive market to improve bone substitutes that augment bone formation in spinal 
fusion procedures16.  
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Figure 1.1: Graph depicts the rate of common surgical procedures in past decade 
(Adapted from Rajaee et al. (2012) Spine)27. 
 
Problems with Spinal Fusion Procedures 
Spinal fusion treats lower back pain and other spinal deformities by restoring 
stability29. A non-successful spinal fusion indicates pseudoarthrosis, or the formation of a 
“false joint” caused from failure of bone formation, union, or remodeling. Pseudoarthrosis 
can result in pain, instability, and disability. A 2013 review article from Journal of the 
American Academy of Orthopaedic Surgeons have reported non-unions to occur at a 
relative frequency between 5-40% based on the location, surgical technique, type of graft 
used, and patient indications. Posterolateral spine fusion (PLS) is the most common spinal 
fusion procedure and involves placing the bone graft in the posterolateral portion of the 
spine, where fusion occurs. The incidence rate of pseudoarthrosis for this procedure has a 
similar relative frequency between 5-44%7.   The cause of pseudoarthrosis, or non-unions, 
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in spinal fusion surgeries can be related to a number of factors, including metabolic 
abnormalities, smoking, infection, and excessive motion at the fusion site. Regardless of 
which surgical treatment is used to treat a patient with a degenerative spinal disorder, there 
are necessary contributing factors that result in a successful spinal fusion. These 
contributing factors include the use and choice of instrumentation, the amount and type of 
graft material, and the surgical technique7,10–12.  Like most implanted tissue engineered 
constructs, the surrounding environment and its interaction with the construct plays a 
critical role in the success of the graft. The environment of the fusion site is unique in that 
bone forms where it normally does not. Therefore, understanding the contributing factors 
from surrounding tissue and interaction with the bone graft is essential for improving fusion 
rates. The surrounding environment of the implant provides vasculature. The success of 
bone formation is highly dependent on the surrounding vasculature and is often overlooked 
when designing tissue engineered constructs20. Although tissue engineering advancements 
have resulted in synthetic bone substitutes with attributes that contribute to bone formation, 
autologous bone graft is still the gold standard. Many of the tissue engineering methods 
fail to emphasize the contribution of the surrounding environment. By understanding the 
interaction between the surrounding tissue of the fusion site and effect on the bone graft, 
and using this knowledge for tissue engineering constructs, the success of bone grafts will 
increase, ultimately resulting in lower rates of pseudoarthrosis.     
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Anatomical Background 
Bone 
Bone regeneration is a multifaceted intrinsic process involved predominately in 
bone healing and skeletal remodeling30.   This process can be compromised in bone 
conditions such as large bone defect, tumor resection, or skeletal abnormalities. Often in 
orthopaedic surgeries, such as oral and maxillofacial surgery or spinal fusions, bone 
regeneration and formation is required in large quantities that the body cannot generate 
normally. When bone regeneration is compromised, bone substitutes and other bone tissue 
engineering solutions are critical for improving bone repair and bone formation30. 
Understanding the components of bone, the dynamic processes, and the factors that 
maintain bone, will greatly contribute to developing a bone tissue engineering solution 
when bone regeneration and formation is compromised.    
Bone is a dynamic, specialized connective tissue with the inherent ability to 
remodel and renew itself. The dynamic processes of bone are controlled by physiological 
stimuli, such as hormones, external mechanical loads, and pathological conditions31. Bone 
contains both mineralized and nonmineralized content. The mineralized content comprises 
mostly hydroxyapatite. This component of bone provides support and a storage site for 
calcium and phosphate. The organic component, or nonmineralized content, of bone is 
produced by osteoblasts and consists of collagen type 1 and ground substance of 
proteoglycans and noncollagenous glycoproteins31,32.    
Bone tissue can be characterized by the porosity or volume fraction of soft tissue. 
There are two types of bone tissue: cortical or trabecular (cancellous). Cortical bone 
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comprises dense and compact bone, with 5%-10% porosity. Cortical bone is formed from 
densely packed osteons, or Haversian systems, the functional unit of bone33.  Cortical bone 
is found primarily on the diaphysis of long bones, such as the femur31.  This type of bone 
forms a rather thick cortex, which provides essential strength for the mechanical loading 
conditions of the femur. Low vasculature found in cortical bone is a result of the dense 
packing, and is supplied by the Haversian canal system31.  Trabecular, or cancellous, bone 
is less dense than cortical bone and is most abundant in cuboidal bone, such as vertebrae. 
Trabecular bone has a much higher porosity, 75%-95%, than cortical bone. The bone 
matrix of trabecular bone is formed by trabeculae, which are plates or struts. The porous 
interlocking structure of trabeculae provides compressive strength for the tissue33. In 
comparison to cortical bone, trabecular bone is greatly vascularized as a result of its highly 
porous structure and abundant vascular complexes between trabeculae31. Trabecular bone 
responds quicker to metabolic alterations due to the high vascularity. As a result, bone 
tissue composed of trabecular bone, such as vertebral bodies, is more susceptible to 
processes, such as osteoporosis, that can increase bone resorption31.    
The four types of bone cells include osteoclasts, osteoblasts, osteocytes, and bone-
lining cells. The primary functions of these bone cells are to form and maintain bone 
matrix. These cells either form or resorb bone in response to mechanical or physiological 
stimuli. Osteoclasts are multinuclear cells related to macrophages that resorb bone. In 
contrast, osteoblasts are mononuclear cells that differentiate from mesenchymal cells. 
These cells are involved in bone formation by producing osteoid. Osteoblasts that are 
surrounded by bone matrix are considered osteocytes, and housed in cavities called 
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lacunae. However, osteoblasts that remain quiescent on the surface are bone-lining cells. 
These cells function to transfer mineral, sense mechanical strain, and initiate bone 
remodeling33. Bone cells play an essential role in physiological remodeling, which occurs 
throughout life and consists of bone resorption and bone formation. Adaptive remodeling 
will occur in response to alterations in physiological and mechanical conditions, also 
described in Wolff’s Law34.    
Understanding the processes associated with maintaining and forming bone tissue 
provides a foundation for solutions when bone regeneration and formation is compromised. 
Spinal fusion surgeries require the formation of a large quantity of bone between vertebrae. 
Bone substitutes are necessary to augment and accelerate the bone forming process 
required for fusion. Understanding the biology of spinal fusions and the bone forming 
process can help improve the bone substitutes needed for spinal fusions.    
Anatomy and Physiology of the Spine 
Vertebrae are classified as irregular bones due to the complexity of their shape. 
Vertebrae contain both cortical and cancellous bone tissue. The micro-architecture of the 
bone tissue dictates the strength and functionality of the vertebrae. The vertebral column 
consists of thirty-three vertebrae connected by intervertebral discs. The three distinct 
regions of vertebrae include: the cervical spine, the thoracic spine, and the lumbar spine35–
37. There are typically seven cervical vertebrae, twelve thoracic vertebrae, five lumbar 
vertebrae, five fused vertebrae to form the sacrum, and four fused vertebrae to form the 
coccyx36,37. Lower back pain targets the lumbar region of the spine and, consequently, most 
spinal fusion surgeries are performed in this region. The lumbar vertebrae are the largest 
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moveable vertebrae in the spine, supporting more weight than any other region of the 
spine36.    
Structure of Vertebrae 
As shown in Figure 1.2, the lumbar vertebrae contain a large vertebral body, which 
forms the anterior element of the vertebrae. The vertebral body comprises primarily 
trabecular bone. The micro-architecture of the trabecular bone dictates the strength and 
mechanical properties of the vertebral body. The trabecular bone is highly dense and 
organized along the peripheral and the posterior region. The center and anterior regions of 
the vertebral body contain smaller, irregular, and less dense trabeculae, which contribute 
to the reduced compressive strength of these regions38.    
The posterior arch is composed of two pedicles and laminae, which join to form the 
spinous process31,36. Superior and inferior articulating processes form the bilateral facet 
joints. Transverse processes attach on both lateral sides of the arch. The vertebral body and 
posterior arch form the vertebral foramen as a triangular opening. The cauda equine, a 
system of spinal nerves, transverse this opening. Compression of these nerves by spinal 
abnormalities or disc herniation can result in lower back pain35.  Muscle tissue attaches to 
the transverse and spinous processes31,39. The lumbar ligaments function to prevent anterior 
separation of vertebral bodies and provide stability35. The transverse processes, which are 
located on either side of the arch, play a role in supplying vasculature for posterolateral 
spinal fusion surgeries.  
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Intervertebral Disc Anatomy and Function 
The intervertebral disc is a complex fibrocartilaginous tissue located between the 
vertebral bodies of the spine and plays a significant role in spinal support, flexibility, and 
durability40,41. The intervertebral disc is the largest avascular tissue in the human body, 
with essentially no repair capabilities. Furthermore, there is a sensitive and multifaceted 
interaction between the small local cell population within the discs and the surrounding 
matrix40,42. The normal highly heterogeneous tissue micro-architecture of the intervertebral 
disc is intricately and precisely constructed to provide the spine optimal support and 
stability. These factors contribute to the challenges and difficulties for tissue engineering 
solutions.   
The intervertebral discs are defined by three structures: the nucleus pulposus (NP), 
the annulus fibrosus (AF), and the vertebral end-plates42.   The nucleus pulposus, located 
in the central region of the intervertebral disc, contains collagenous and noncollagenous 
proteins, which include: collagen types III, V, IV, IX, elastin, fibronectin, and laminin40. 
This region is highly mechanically loaded in compression. The high density of 
proteoglycans located in this region maintains a large amount of water content in the 
intervertebral disc to resist the compressive loads. Proteoglycans are core proteins, with at 
least one hydrophilic, negatively charged glycosaminoglycan (GAG) attached. This 
hydrophilic component causes osmotic pressure or interstitial swelling pressure, which 
maintains the hydration of the disc37.   
The concentration of proteoglycans and water content decreases toward the 
periphery of the disc. The inhomogeneous radial distribution of proteoglycans contributes 
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to even distribution of forces within the spine, resulting in spine stability. The low cell 
density of chondrocytes in the NP primarily functions to maintain synthesis of the 
surrounding extracellular matrix40,42. The balance of matrix synthesis and degradation is 
controlled by cytokines and growth factors released from surrounding cells and matrix43. 
This balance maintains the normal function and structure of the disc. Alterations of growth 
factor and cytokine concentrations can lead to structural changes that will potentially 
disrupt normal function. In comparison to the NP, the annulus fibrosus is composed 
primarily of collagen with much less proteoglycan content. The outer region of the AF is 
formed by densely packed collagen oriented in concentric arrays. Toward the central region 
of the AF, the collagen is less dense and organized. In contrast to the cellular components 
of the NP, the AF contains fibroblast-like cells that are thin and elongated. The concentric 
arrangement of collagen fibers and radial composition changes contribute to anisotropic 
mechanical properties to resist complex mechanical loads37.   
Vertebral Endplates 
The vertebral end plates are located between the vertebral bodies and intervertebral 
disc. The endplates consist of a uniform layer of hyaline cartilage and cortical bone, which 
provide even distribution of loads. The blood supply for the end plates and vertebral bodies 
is the segmental artery41. The end plates are semipermeable and facilitate diffusion of 
water, solute, and wastes, through marrow channels, to the intervertebral disc44. The red 
arrows in Figure 3 indicate the supply of nutrients from the vertebral endplates to the 
nucleus pulposus and annulus fibrosus. The mechanical properties of the end plates vary 
radially as well37. The thickness is largest in the periphery and smallest in the center. 
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Understanding the biomechanics of normal vertebral components and how they are altered 
with age and other abnormal spinal conditions is essential for developing tissue engineering 
solutions38.    
 
 
Figure 1.2: Indicates three components of intervertebral discs. Red arrows indicate 
vascular channels in endplates supplying the disc (Adapted from Ullrich et al. (2004) 
Spine-Health)45. 
 
Most of the vertebral components are innervated. The dorsal root ganglion and 
branches innervate most of the lumbar region. The nerve endings and mechanoreceptors 
located in these components can contribute to lower back pain. The annulus fibrosus and 
posterior longitudinal ligament contain nociceptive fibers, which are branches from the 
sino-vertebral nerve. In addition, facet joints contain sensory autonomic nerve fibers in the 
capsule. Abnormal spinal conditions, aging, and disc degeneration can influence the 
innervated components of the lumbar region, triggering pain.   
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Spinal Fusion Procedures 
Causes of Spine Instability and Altered Environment  
 The spinal segments of intervertebral disc and vertebral components influence each 
other. The mechanical stability of the intervertebral disc is dependent on the integrity of 
the nucleus pulposus and annulus fibrosus. The normal intervertebral disc main function is 
to create stability in the spine by redistributing compressive stresses. Degeneration to the 
disc will alter the ability of the disc to distribute stresses46–48. Load alterations of the disc 
will also affect bone density distribution in the vertebral body and load alterations in the 
vertebral component, especially the facet joints46. These spinal abnormalities can lead to 
altered spinal motion and cancellous bone architecture, which have adverse consequences, 
including back pain and segmental instability. 
The natural aging process alters the vertebral micro-architecture, cell interplay, and 
overall function of essentially every anatomical structure in the spine. Intervertebral disc 
degeneration and lower back pain is linked with age. The frequency of lower back pain and 
disc alterations increases with age. Miller and coworkers used data from published reports 
regarding cadavers and disc degeneration incidence. They found that 97% of the 
individuals had developed some level of disc degeneration by age 4942,49. The natural aging 
process of the spine includes bone mass reduction and degenerative changes. The effects 
of normal aging and degenerative disc disease are difficult to differentiate50.  It has been 
suggested that disc degeneration disease is a result of accelerating this aging process, 
however, the exact causes are unknown50,51. The aging process will result in a continuous 
loss of bone mass, alterations in architecture of the spine components, and degeneration of 
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the disc33,38. Disc degeneration results when the intervertebral disc goes through 
degenerative changes that cause a loss or destruction of tissue, ultimately altering the load 
transfer which affects the mechanical properties and tissue composition of the vertebral 
components42,50. Disc degeneration can result due to abnormal components of the matrix 
or abnormal concentrations of growth factors that promote matrix degradation; for 
example, IL-1 or TNF-α will lead to structural changes and impaired function of the disc43. 
Understanding the effects of age and disc degeneration on the mechanical properties of the 
vertebral endplates and vertebrae is imperative for developing spinal treatments that 
include instrumentation and tissue engineered bone scaffolds.    
Aging and disc degeneration alter the environment and vasculature of the spine and 
surrounding tissue. Age and other conditions, such as atherosclerosis, reduce the blood 
supply by altering vertebral capillaries that supply the lumbar vertebrae components. As a 
result, there is a significant decrease in blood perfusion of the vertebral bone marrow, 
which supplies nutrients to the intervertebral disc. In one particular study, dynamic 
contrast-enhanced MRI was used to evaluate two vertebral bodies from 25 patients. The 
vertebral bodies evaluated were either between two adjacent normal discs or between two 
adjacent degenerated discs. This study found a 14% decrease in blood perfusion between 
two degenerated intervertebral discs compared to the perfusion between two normal discs, 
suggesting there is a relationship between insufficient vertebral marrow perfusion and 
degenerative disc disease41,52.    
Aging affects the composition of the vertebral endplates and causes both 
calcification of the cartilage and vertebral bone sclerosis. The architecture and alterations 
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in calcification of the vertebral end plates will affect transport of nutrients into the nucleus 
pulposus. Consequently, there is a reduction in blood flow and transport into the disc53,54. 
In another study, the diffusion and temporal pattern of paramagnetic contrast medium in 
regions of vertebral bone and intervertebral disc were evaluated in 96 normal discs and 54 
degenerative discs using magnetic resonance. The temporal pattern of enhancement 
between the vertebral bone and intervertebral disc was evaluated throughout both regions. 
This study determined the diffusion into the nucleus pulposus is related to the amount of 
perfusion in the bone and endplate. Furthermore, endplate changes due to age or 
degenerative disc resulted in altered diffusion patterns. Vertebrae with intact cartilage 
showed no changes in response to the diffusion pattern, while vertebral endplates 
containing damaged tissue or alterations changed the diffusion pattern53.  
 Cell function in the intervertebral disc is altered due to the reduction in blood flow 
from vertebral end plate alterations and from local vasculature changes. This reduction will 
initiate or enhance degeneration55. Other factors shown to influence degeneration include 
nerve and vessel ingrowth into the nucleus pulposus as well as cytokine alterations55. An 
increased level of inflammatory mediators and cytokines has been shown to affect disc 
degeneration and cause lower back pain. Understanding the environmental changes due to 
these factors will affect the design of tissue engineering solutions and therapeutics. The 
environment and surrounding vasculature plays an essential role in bone formation. The 
degenerative environment of the vertebrae and interaction with native cell populations must 
be taken into account when developing tissue engineering solutions, such as scaffolds, to 
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promote bone formation. The complexity of the intervertebral disc and the environment 
provide major challenges for developing tissue engineering solutions for the spine56.  
Spinal Indications for Lumbar Fusion Treatment 
Spinal fusion surgery was originally used to treat infectious conditions. In later 
years, these surgeries were used to treat deformities and traumatic injuries. With better 
surgical techniques, instrumentations, and understanding of the pathology, these treatments 
are frequently used and are currently standard treatment for degenerative spinal 
conditions11.   
Spinal fusion treatment is a procedure performed to generate stability in painful 
spinal segments by immobilizing the region. Panjabi describes the stability of the spine as 
a system consisting of three subsystems: the spinal column, the spinal muscles surrounding 
the column, and the neural control unit coordinating and evaluating responses. Panjabi 
developed a mathematical model evaluating the contribution of each of these components 
to the biomechanical stability of the spine. This model evaluated changes in these 
components due to degenerative disorders or spinal abnormalities. It also provides a basis 
for spinal treatment and the rationale to recreate biomechanical stability by limiting 
mobility. Instability defined by Panjabi is the loss of the ability of the spine to maintain 
normal patterns and distributions of physiological loads11. Degenerative disorders and 
spinal deformities alter intervertebral motion, which can lead to lower back pain. 
Therefore, treatments such as spinal fusions decrease intervertebral motion to treat the pain. 
The intervertebral disc and components of vertebral bone, if causing pain, can be removed.   
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There are various types of spinal fusion procedures; however, in general a fusion 
procedure immobilizes painful segments of vertebral bone by generating new bone 
between the segments57.  Spinal fusion can be performed in combination with other 
procedures such as discectomy, decompression, and laminectomy. The type of spinal 
fusion and treatment is governed by a number of indications presented by the patient. These 
factors include the spinal disorder or disease, the quality of bone, and the patient’s age. The 
most common spinal conditions treated with fusions include scoliosis, spondylolisthesis, 
disc degeneration, spinal stenosis, spinal instability due to trauma, or adverse changes to 
vertebrae due to infection or malignancy. Spondylolysis is a defect such as a fracture in the 
pars interarticularis, which is a vertebral structure between the inferior and superior 
articular processes. Spondylolisthesis is the forward displacement of one vertebra over the 
other. In some spondylolysis cases, a slip may occur and the situation progresses to 
spondylolisthesis; this is also known as isthmic or spondylolytic spondylolisthesis58.  In 
fact, 50-81% of individuals with spondylolysis also have spondylolisthesis59.  Patients can 
be affected by multiple conditions or the development of one condition can initiate and 
progress to another. For example, a patient with degenerative disease can subsequently 
have narrowing of the spinal canal or spinal stenosis. Spinal stenosis can also develop with 
degenerative spondylolisthesis and degenerative scoliosis. The alterations in 
biomechanical loading due to one spinal abnormality can alter the structure of the vertebrae 
leading to progressive degeneration.   
Degenerative disc disease in the lumbar region is the most common indication of 
spinal fusion treatment. From the years 1998 to 2008, it is important to note the significant 
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increase in degenerative disc disease and spinal stenosis of the lumbar region correlates 
with the increase in average age of patients receiving spinal fusions. In 1998, the average 
age of patients was 48.8 years and increased to 54.2 years in 2008. Due to the increasing 
average age of our population, degenerative spinal disorders are more frequently 
diagnosed60–62.  A study evaluated a Medicare population of patients 65 years of age and 
older who had surgical procedures for lumbar stenosis. From 2002 to 2007, the analysis of 
Medicare recipients showed a decrease in treatments that include only decompression or 
simple fusion. However, the surgical rate employing complex fusion procedures increased 
approximately 15-fold. Complex fusion involves both anterior fusion with posterior or 
transverse fusion33.   
Spondylolisthesis is the most recognized indication for spinal fusion in the lumbar 
spine. This condition is defined by the forward translation of the superior vertebrae on the 
inferior vertebrae. There are five different types of spondylolisthesis. However, type III or 
degenerative spondylolisthesis is most often treated with spinal fusion surgeries. This type 
of spondylolisthesis occurs due to chronic disc degeneration with vertebral segment 
instability from facet joint arthritis. Disc degeneration causes the narrowing of the disc 
space and instability in the ligamentum flavum, which leads to instability in the sagittal 
plane, which can progress to spondylolisthesis11. Degenerative scoliosis is another 
indication for fusion, primarily in the lumbar spine. Scoliosis is a structural disorder to the 
spine that results in a lateral curvature. This spinal abnormality is caused by disc 
degeneration that results in instability in the frontal plane. There are various types and 
degrees of scoliosis63; however, degenerative scoliosis is directly related to disc 
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degeneration.  Spinal fusion can also be employed to treat instability caused by other spinal 
treatments. This includes patients who had an extensive laminectomy, which is the removal 
of vertebrae on the posterior arch to alleviate pain by reducing pressure on the nerve roots.   
Types of Spinal Fusions 
One of the first types of fusions in the early 20th century was a posterior fusion 
performed by placing bone graft on lamina. Major complications resulted due to placement 
of bone graft. These included pseudoarthrosis and overgrowth of bone into the spinal canal, 
a condition called stenosis57. This posterior fusion surgery was improved by placing bone 
graft on the side of the vertebrae between the transverse processes, a procedure known as 
posterolateral fusion. This technique remains is still the gold standard of posterior fusion57.   
 Spinal fusion can augment other procedures such as decompression, which can 
involve laminectomy and or discectomy procedures. A laminectomy involves the removal 
of lamina, ligamentum flavum, and portions of the facet joints that are causing pressure on 
nerve roots, resulting in pain. This procedure and foraminectomies, which are frequently 
performed with laminectomies, typically approach the spine posteriorly64.  Similarly, a 
discectomy is a removal of disc material adversely affecting nerve roots, or the removal of 
the annulus if the patient indicates discogenic pain, or stimulated nociceptors in the outer 
annulus. Discectomies are typically performed to treat herniated discs. Decompression is 
somewhat controversial. Studies suggest this treatment to cause instability and contribute 
disc degeneration. However, there is evidence in literature supporting treatments of 
decompression and fusion for certain indications, such as degenerative spondylolisthesis. 
Instrumentation is typically recommended with fusion surgeries; however, depending on 
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the diagnosis of the patient before fusion, this may not always be the case65.  Spinal 
instrumentation augments the spinal fusion by straightening and stabilizing the spine. 
Typically, hooks, rods and wires are used to redistribute stresses and align the bones66.  
One of the first methods of using instrumentation, developed by Dr. Harrington, used hooks 
placed the under lamina and connected by rods. This led to further advances using bone 
screws attached through facet joints and then to screw plate fixation. Screw-plate fixation 
remains an important method for augmenting a fusion. This technique involves the 
placement of screws through the pedicle and the screws are connected with rods57–65,67.   
 Numerous spinal fusion procedures implemented are based on the spinal condition. 
Each surgery incorporates the use of a bone graft to promote bone growth between the 
vertebral bodies and generate fusion45. The most common lumbar spinal fusion surgeries 
include posterolateral fusions and lumbar interbody fusions68. These procedures are 
typically approached from the posterior or anterior. The standard method for approach is 
posterior, which allows direct decompression of neural structures. However, an advantage 
to the anterior approach is better restoration of the disc height and ability to prepare the site 
for graft material.    
Posterolateral spine fusion is the most common procedure and involves placing the 
bone graft, usually autologous bone graft from the iliac crest, in the posterolateral portion 
of the spine. This procedure does not always remove the intervertebral disc, as shown in 
Figure 1.3a. Furthermore, instrumentation such as pedicle screws and rods are used for 
greater stability69,70.  One study found the addition of instrumentation to posterolateral 
spine fusion has improved spinal fusion rates from roughly 60% to 90%45.  However, the 
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use of this instrumentation is still controversial due to the increased complication rates and 
inconsistent clinical outcomes71. Posterolateral spinal fusions are frequently used to treat 
degenerative conditions such as degenerative spondylolisthesis and spinal stenosis. This 
surgery has high clinical success rates with degenerative spondylolisthesis patients50,72. A 
study involving a long-term follow up of patients of various spinal degenerative conditions 
and abnormalities that were treated with posterolateral fusion with instrumentation found 
that patients with degenerative spondylolisthesis had the greatest improvement overall with 
the treatment.  
Interbody fusions each involve the removal of the intervertebral disc, which is replaced 
by bone graft and stabilized with hardware68.   Four types of interbody fusion surgeries 
include posterior lumbar interbody fusion (PLIF), anterior lumbar interbody fusion (ALIF), 
transforminal lumbar interbody fusion (TLIF), and circumferential interbody fusion. 
Posterior lumbar interbody fusion is also used to treat degenerative disc disease and chronic 
back pain. This treatment first involves a laminectomy, which is the removal of bone and 
disc to relieve the pressure from a pinched nerve. A spinal cage containing a bone graft can 
be incorporated into the empty disc space. The addition of the bone graft will promote a 
bone bridge, or fusion, between the vertebral bodies45.  Anterior lumbar interbody fusion 
parallels the PLIF technique but is approached from the anterior region of the spine, as 
shown in Figure 1.3b. This approach is less frequently used to treat degenerative conditions 
because of the difficulty in performing decompression73. Transforminal lumbar interbody 
fusion surgery, shown in Figure 1.3c, is similar to the posterior lumbar interbody fusion, 
but only requires one insertion site from the side to perform the procedure, which enhances 
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recovery time. Laminectomy and implantation of bone graft in the empty disc space still 
occurs. Additional instrumentation, such as pedicle screws and rods are often used for more 
stability45.  Anterior/posterior or circumferential lumbar fusion is a type of spinal fusion 
surgery that fuses the vertebral bodies from both the anterior and posterior. Circumferential 
fusion typically involves anterior lumber interbody fusion and posterolateral fusion with 
instrumentation74.  Several clinical studies showed better clinical results and 
pseudoarthrosis rates with circumferential fusion in comparison to posterolateral fusion 
with instrumentation74,75.  Although the additional fusion technique results in better 
outcomes, there are supplementary complications. These include operation time, cost, and 
neurological issues75.   
  
 
Figure 1.3: Spinal fusion surgeries. A: posterolateral spinal fusion. B: Anterior lumbar 
interbody spinal fusion. C: Transforminal lumbar interbody fusion (Adapted from Ullrich 
et al. (2004) Spine-Health)45 
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Vascularity and Bone Regeneration 
The amount of bone formation is directly related to the amount of vasculature, which 
provides the mass transport of oxygen and nutrients, and a mode of delivery for cells and 
growth factors that contribute to bone formation21,76,77. In general, large-area bone defects 
require large scaffolds that promote the transport of oxygen and nutrients through 
vascularization77.   This transport is essential for bone tissue constructs that include 
mesenchymal stem cells or other osteogenic cell types. Oxygen diffusion is limited to 
200μm from the blood vessel. Mesenchymal cells in a large tissue construct will not 
proliferate, differentiate, and ultimately lead to ontogenesis without a transport of oxygen, 
nutrients, and essential growth factors that promote bone formation24.   Non-unions and 
pseudoarthrosis may occur due to poor blood supply, which is essential for the bone healing 
process12.   Spinal fusions require large bone grafts. For successful fusions, sufficient 
vascular supply must be incorporated and maintained. For example, cervical fusions have 
a higher success rate compared to fusions of the lumbar region due to increased vascularity 
to the cervical region12,67.  The cervical region of the spine, the abundance of vertical source 
arteries, anastomoses, and segmental branches provides considerably more blood flow, 
resulting in bone fusion even when the site is not sufficiently prepared67. In posterolateral 
lumbar spinal fusion, bone formation is needed in a space greater than the critical size 
defect. As shown in Figure 1.4, this treatment requires large amounts of bone regeneration 
and therefore a large quantity of bone graft that promotes transport of nutrients and oxygen.  
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Figure 1.4: Schematic A shows the furthest cell supported by a capillary vessel is 0.1 mm. 
Red arrows in Image B depict the flow of nutrients from a vascular network on the 
transverse processes. This supply must span the entire length of fusion (30 mm)78. 
   
 Vascular supply and types of tissue surrounding a defect will vary based on 
anatomical location and impact bone formation accordingly. Spinal fusions of the 
cervical region have a higher success rate compared to fusions of the lumbar region, due 
to increased vascularity to the cervical region12,79. In the cervical region of the spine, the 
abundance of vertical source arteries, anastomoses, and segmental branches provides 
considerably more blood flow, resulting in bone fusion even when the site is not 
sufficiently prepared79. In posterolateral fusion of the lumbar spine, bone formation is 
needed in a region comparable to a critical size defect. The lumbar spine does not have 
Capillary   
0.1 mm 
0.05 mm 
Tissue 
Lumbar 
vertebrae 
Lumbar 
vertebrae 
30mm   
A B 
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the vascular supply of the cervical region, increasing the susceptibility for non-unions. 
 
Figure 1.5A indicates the transverse processes as the major blood supply of 
posterolateral fusion80. This type of spinal fusion involves high surrounding muscle tissue 
coverage, as compared to interbody fusion which involve the formation of bone in the 
intervertebral disc space between adjacent vertebral bodies80. In contrast, interbody 
fusion has a greater supply of blood and osteoprogenitor cells from the high surface area 
of the perforated inferior and superior vertebral endplates81, seen in Figure 1.5. 
 Generally interbody fusion procedures have successful fusion rates due to the 
enhanced vascularity and access to bone marrow80. The design of a large bone graft for 
fusion procedures should not only consider the amount and orientation of vascular supply 
but the contribution of biomolecules and osteoprogenitor cells from the surrounding 
tissues. 
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Figure 1.5. Diffusion distances of vasculature; (A) depicts the flow of nutrients from a 
vascular network on the transverse processes, this supply must span the entire length of 
fusion, 30mm78; (B) major vascular supply for interbody fusions, must span the 
intervertebral distance of 10mm. (Also published in Tabbaa et al. (2014) Critical Reviews 
in Biomedical Engineering82) 
  
 Similarly, in long bone defects the vascular supply and soft tissue coverage of the 
bone segment will contribute to the success of the fracture repair. Figure 1.6 indicates the 
major blood supplies to long bone, including blood vessels, periosteum, bone marrow, and 
other surrounding soft tissues. Fractures in the tibia, especially in the distal shaft, have the 
highest rate of non-unions compared to other long bone fractures. The limited vascular 
supply to the tibia is a significant factor for the high rates of non-unions83. The tibia is 
supplied by nutrient, periosteal, and epiphyseal-metaphyseal vascular systems. The 
periosteal blood supply can support the entire tibia. A traumatic fracture to the tibia will 
typically result in stripping of the periosteum, resulting in loss of major vasculature supply 
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and high risk for non-union84. Long bone defects like femoral diaphyseal fractures have 
much lower rates of non-unions. In contrast to tibia fracture sites, diaphyseal fracture sites 
have increased vascular supply and significantly greater soft tissue coverage83.  
 
Figure 1.6. Surrounding vascular supply of tibia. Contributing factors are the 
surrounding musculature as well as the highly vascularized periosteum, the anterior 
tibial artery, and the bone marrow. (Also published in Tabbaa et al. (2014) Critical 
Reviews in Biomedical Engineering82) 
 
Vascularity and Tissue Contribution in Posterolateral Spinal Fusions 
 Bone formation in spinal fusion occurs through two different mechanisms based on 
the region in the spine. Intramembranous formation is one mechanism, where bone forms 
by direct ossification of fibrous tissue. Endochondral formation is the other mechanism, 
where bone replaces a cartilaginous intermediate85. The process of bone formation in 
posterolateral spinal fusion begins with the migration of osteoprogenitor cells from 
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decorticated transverse processes and marrow cavity of autologous bone graft. 
Osteoinductive factors and osteoclast resorption promote the differentiation of 
osteoprogenitor cells into osteoblasts. These bone-forming cells deposit bone matrix, 
which is remodeled. The bone forming process begins at the decorticated surfaces86.   
Boden and coworkers developed an intertransverse process arthrodesis model using 
New Zealand white rabbits to simulate the human environment better than previous 
models—demonstrating a nonunion rate similar to that in humans. This model provides 
insight into the biology of the bone-forming process in posterolateral fusion17,24,80,87–89. The 
technique included an intermuscular posterolateral approach, decortication of transverse 
processes, and the use of autologous bone graft to augment bone formation. The bone 
healing process was analyzed through various methods, including manual palpation, x-ray, 
light microscopy, quantitative histology, and molecular biology.   
The manual palpation and macroscopic imaging revealed a nonunion rate 
comparable to that in humans. The results of quantitative histology demonstrated three 
temporal phases of spine fusion healing in posterolateral fusion, which occur at different 
times in the different regions of the fusion. These phases include inflammatory, reparative, 
and remodeling. In regions near the decorticated transverse processes, also called the “outer 
zones”, bone formation was most advanced. Quantitative histology in these regions 
demonstrated bone was formed through intramembranous formation. Conversely, in the 
“central zone”, or region furthest away from the transverse processes, bone formed via an 
endochondral bone-forming mechanism. Figure 1.7 indicates the location of outer and 
central zones in relation to adjacent vertebrae (V) and fusion mass (FM)88.   
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Figure 1.7: Depicts the central and outer regions. The central region forms bone later 
than outer regions and is often a cause for fusion failure. (Adapted from Boden et al. 
(2000) Tissue Engineering89) 
 
This central region experienced a lag effect, where the formation of bone was 
delayed with a cartilage intermediate. The lag effect, shown in Figure 1.8 below, correlates 
to non-unions occurring in the central zone. The lack of inadequate blood supply and 
increased mechanical motion resulted in lack of remodeling and ossification in this region 
and rendered it susceptible to nonunions24,80,88–90.   
 
Figure 1.8: Faster cancellous bone formation in the outer zones compared to the central 
zone. (Adapted from Boden et al. (2000) Tissue Engineering89)  
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Bone formation in this posterolateral fusion model was further characterized by 
gene expression, which was analyzed by real-time polymerase chain reaction from 
ribonucleic acid (RNA) in both the central and outer zones. Osteoblast-related gene 
expression demonstrated a temporal and spatial pattern. Osteocalcin peak expression in the 
central zone occurred 2 weeks later than in the outer zone, which agrees with the delayed 
bone formation depicted via histology. The temporal patterns of mRNA expression of bone 
morphogenetic proteins were analyzed in the outer and central zones. BMP-2, BMP-4, and 
BMP-6 depicted different levels of expression at various time points. BMP-6 was 
expressed in the outer zones the earliest and had the greatest increase over time. The 
expression of BMP-6 in the central zone showed a different temporal pattern, with delayed 
expression, which corresponds to the smaller bone formation and susceptibility of 
nonunion in this region22,24,26,80,88,90,91.  
 The delayed bone formation in the central zone of posterolateral fusion is a result 
of less vascularization. In another study, Giannicola and coworkers showed that 
neovasculature is essential to support osteogenic potential cells and bone formation92.  In 
this study, the rabbit posterolateral fusion model was employed. The neovasculature in the 
interapophyseal zone (central zone) and periapophyseal zone (outer zone) were evaluated 
using immunostained histology sections with α-smooth muscle actin antiserum. The 
number of blood vessels per surface area (VD) was calculated in both regions. Giannicola 
and coworkers found a significant difference in VD between central and outer zones of 
posterolateral fusion. VD was significantly higher in the periapophyseal region than in the 
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interapophyseal region, reflecting a gradient of VD across the regions. The most significant 
source of blood supply is from the transverse processes. As a result, the central or 
interapophyseal region is furthest from the blood supply and contains the least amount of 
new blood vessel formation. Similar to critical bone defects, the area of bone formation in 
the central region is a critical size92.  In a similar study, Toribatake and coworkers evaluated 
the extent of vascularization using microangiograms in solid fusions, cartilaginous cleft 
type fusions, and nonunion type fusions in New Zealand white rabbits26.  This study related 
the success of posterolateral fusion to the amount of area vascularized on the transverse 
processes. Area of vasculature on transverse processes and fusion mass were greatest for 
solid fusion. The cartilaginous cleft area of vascularization was greatest along the edges 
but did not penetrate the fusion mass. Nonunion type fusions had no vessels along the 
transverse processes. This study confirmed that adequate decortication is necessary for 
branches of the transverse process blood vessels to penetrate the fusion mass. These studies 
are consistent with trends shown by Boden and coworkers22–24,80,88,91.  Both bone formation 
and BMP temporal expression lagged in the central region because this region is the 
furthest from the decorticated transverse processes, the major source of vasculature and 
osteogenic potential factors and cells. 
In addition to adequate decortication, the integrity and quality of the surrounding soft 
tissue also plays an important role in bone formation. In posterolateral fusion, the 
paraspinal muscles comprise most of the surrounding soft tissue. Part of the surgical 
procedure involves placement of the muscles to secure the graft material as shown in Figure 
1.9 below. The surrounding soft tissue, including the paraspinal muscles, must support 
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osteogenic potential cells in the graft, as well as the migration of bone-forming cells and 
inflammatory cells into the fusion mass. The effect of the surrounding soft tissue on bone 
formation was evaluated using a dog posterior spinal fusion model. In one group, a plastic 
porous membrane permeable to tissue fluids but not to cells was placed between the site of 
the fusion mass and the surrounding muscle tissue. Another group contained a membrane 
between the fusion site and muscle tissue that was impermeable to tissue fluids and cells. 
The latter of the two groups resulted in nonunions. This study suggests the surrounding 
soft tissue provides nutrition and osteogenic factors and cells necessary for fusion93–95.  
 
Figure 1.9. Location of posterolateral placement of bone graft and paraspinal muscle 
tissue. (Figure was also published in Tabbaa et al. Critical Reviews in Biomedical 
Engineering, 201482) 
 
Bawa and coworkers evaluated whether the paraspinal muscles have any adverse 
effects on the fusion mass. Muscle tissue becomes incorporated into the bone graft, 
resulting in formation of fibrous tissue and inhibits bone formation. To further evaluate the 
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role of paraspinal muscles on posterolateral fusion, Bawa and coworkers used a rabbit 
posterolateral fusion model, where the animal was treated with iliac crest autologous bone 
graft with and without a porous or nonporous barrier sheet. The computed tomography 
(CT) scans and histological results demonstrated the group with a porous polymer barrier 
sheet between the fusion site and paraspinal muscles had the highest rate of fusion (90%). 
The nonporous barrier group and control group had fusion rates of 40% and 55%, 
respectively. This study suggests the porous barrier improves the fusion rate by preventing 
interposition of the muscle tissue and providing local growth factors and cells that result in 
bone formation and vessel ingrowth. Histology samples of the bone-muscle interaction 
revealed vascular ingrowth into the fusion mass in the group with the porous barrier sheets. 
The nonporous group contained no neovessel formation from the muscle tissue to the 
fusion mass. The control group had vascular ingrowth from both muscle and transverse 
processes. However, the increased numbers of cases of pseudarthrosis are thought to be a 
result of muscle interposition or migration of bone graft from the fusion site. Although the 
mechanism and specific factors regarding the contribution of surrounding muscle to spinal 
fusion is unknown, the surrounding soft tissue significantly contributes to the spinal 
fusion96,97. Tissue engineering should evaluate the mechanism soft tissue contributes to 
spinal fusions to develop new tissue engineering solutions to improve the success rates of 
fusions93.   
Tissue Contribution to Fracture Repair 
 Similar to fusions, the composition of tissues surrounding the defect site will 
influence healing and susceptibility for nonunion. The loss of tissue and soft tissue damage 
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of a fracture plays a critical role in the successful bone repair. The tissue surrounding a 
fracture will vary depending on the type of fracture and anatomical location. For example, 
high-energy fractures typically lose bone marrow and periosteum and are supported by the 
vasculature of the local muscle and soft tissues. In closed fracture cases, the main sources 
of tissue that promote healing include bone marrow and periosteum—experimentally 
shown to enhance fracture healing. Both sources are accepted as the major contributors of 
osteoprogenitor cells, vasculature, and bone forming biomolecules. The role of 
surrounding soft tissue, including muscle and fat, is less established. Muscle tissue 
coverage has been shown to increase vasculature and bone formation in both fusion and 
long bone defect animal models98. Non-unions are more prevalent in defects or fusions 
lacking muscle tissue and an intact periosteum. The degree of soft tissue damage will 
influence the activity of the periosteum, blood flow, and rate of bone formation99,100. 
Landry and coworkers showed that moderate soft-tissue damage of the muscle tissue will 
actually enhance the periosteum, suggesting that injury to the muscle will not impair 
fracture healing. However, muscle resection has been shown to adversely affect bone 
healing of a trauma defect100.  
 The fracture healing process is generally described with cellular and vascular 
contribution from the periosteum and bone marrow. Also of importance are the cellular, 
biomolecular, and vascular contributions from surrounding soft tissues including muscle 
and fasciocutaneous tissue. Harry and coworkers investigated the role of muscle or 
fasciocutaneous tissue in a murine mouse open tibia fracture model with stripped 
periosteum and soft tissue disruption. The outcomes indicated the group with muscle tissue 
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coverage had faster bone formation, 50% higher bone mineral content, and three-fold 
stronger union101. Harris and colleagues suggested the rich vascular supply from the muscle 
tissue enhanced the bone formation in the tibia defect101. In a follow-up study, Harry and 
coworkers investigated the amount of vasculature in muscle and fasciocutaneous tissue 
when in contact with the open tibia fracture site102. The vascular density was determined 
using immunohistochemistry post fracture at various time points throughout the fracture 
healing process. The outcomes showed the fasciocutaneous tissue coverage of the tibia 
fracture contained higher vascular density at each time point throughout the fracture 
healing process.102 However, the muscle tissue coverage indicated accelerated bone 
formation. This study suggests other factors from the muscle tissue are enhancing the bone 
healing process.102  
 To investigate potential contributing factors from muscle tissue, other researchers 
have explored the osteogenic potential of myogenic cells103,104. Studies have demonstrated 
the ability of isolated muscle-derived progenitor cells to differentiate towards osteoblast 
lineages, both in vitro and in vivo105. Liu and colleagues investigated the contribution of 
muscle progenitor cells (MyoD- lineage cells) in vivo using a MyoD-Cre+: Z/AP+ 
conditional reporter mouse with MyoD-lineage cells labeled with a human alkaline 
phosphatase (hAP) reporter106. The contribution of the MyoD-lineage cells were assessed 
in both open and closed mouse tibia fracture models. The closed fracture model consisted 
of an intact periosteum, whereas the open fracture model simulated a high-energy fracture 
with tissue trauma and a stripped periosteum. Although the outcomes from the closed 
fracture group showed no significant contribution of the MyoD-lineage cells to the fracture 
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callus, the open fracture group contained approximately 50% of the MyoD-lineage cells. 
The outcomes suggest the muscle acts a “secondary periosteum”, as described by Liu and 
coworkers. In cases such as closed fractures where the periosteum is intact, the muscle 
demonstrated limited contribution. The periosteum can directly supply the fracture with 
vasculature and mesenchymal progenitor cells as well as other bone forming growth 
factors. In fracture cases where the periosteum is stripped or damaged the muscle will 
directly impact the fracture healing contribute significant amounts of progenitor cells107. 
This work suggests that muscle supplies vasculature as well as muscle-derived progenitors, 
which play a critical role in the bone repair process in addition to the conventional 
contributors, periosteum and bone marrow. 
Table 1.1: Soft tissue contribution to fracture repair and spinal fusion (Table was also 
published in Tabbaa et al. Critical Reviews in Biomedical Engineering82) 
Soft tissue 
evaluation 
Animal 
model  
Experimental 
groups 
Outcomes  Comments 
Auth
ors 
Posterolateral fusion     
Paraspina
l muscle 
Rabbit 
posterolatera
l fusion 
model  
Control - autograft 
in one side of rabbit; 
Group 1 - autograft 
contained in porous 
barrier sheet; Group 
2 - autograft 
contained in 
nonporous barrier 
Control - graft in 
contact with muscle, 
55% fusion; Group 
1 -  porous sheet 
allows blood vessel 
and cell penetration,  
90%  fusion; Group 
2 - nonporous sheet 
prevented muscle 
contact, 40% fusion  
The porous sheet 
allowed 
vasculature and cell 
penetration, 
creating fusion 
rates. The porous 
barrier prevents 
muscle 
interposition that 
can lead to 
pseudoarthrosis 
Baw
a et 
al. 
2006
93 
Paraspina
l muscle 
Canine 
posterior 
fusion model 
Group 1 - 
posterolateral fusion 
with autograft; 
Group 2 - posterior 
fusion with 
paraspinal muscle 
flap 
Group 1 – 50% 
fusion rate after 16 
weeks; Group 2 – 
87.5% fusion rate 
after 16 weeks 
Outcomes suggest 
the blood supply 
and muscle derived 
factors contribute 
to the enhanced 
fusion rates 
Xi et 
al. 
2010
94 
Tibial 
fracture 
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Fasciocuta
neous and 
muscle 
tissue 
coverage 
Murine open 
tibial 
fracture 
model with 
stripped 
periosteum 
and soft 
tissue 
disruption 
Group 1 - tibial 
fracture covered 
with muscle tissue; 
Group 2 - tibial 
fracture covered 
with 
fasciocutaneous 
tissue 
Muscle coverage 
group: faster bone 
formation, higher 
bone mineral 
content, stronger 
union                           
Fasciocutaneous 
coverage: Greater 
vascular density  
The 
fasciocutaneous 
revealed slower 
bone formation 
than muscle tissue 
coverage group, 
however, the tissue 
did not impair 
callus formation 
Harr
y et 
al. 
2008 
Fasciocuta
neous and 
muscle 
tissue 
contact 
Murine open 
tibial 
fracture 
model  
Control - no fracture 
with soft tissue and 
periosteum 
dissected; Group 1 - 
fracture covered 
with muscle; Group 
2 - fracture covered 
with 
fasciocutaneous 
tissue 
Fasciocutaneous 
tissue resulted in 
higher vascular 
density than muscle 
throughout the 
fracture healing, 
muscle showed 
accelerated bone 
formation 
Outcomes imply 
factors other than 
vascularity are 
contributing to the 
accelerated bone 
formation with 
muscle tissue 
coverage 
Harr
y et 
al. 
2009 
Myogenic 
progenitor 
cells 
Murine tibial 
fracture 
model 
Group 1 - closed 
fracture; Group 2 - 
open fracture 
Group 1 - muscle-
derived progenitor 
cells had no 
significant 
contribution                         
Group 2 - 50% of 
muscle-derived 
progenitor cells 
contributed to 
fracture callus  
Suggests muscle 
directly affects 
repair in fractures 
with damaged 
periosteum; intact 
periosteum is the 
major contributor 
in cases such as 
closed fractures  
Liu 
et al. 
2011
106 
Injured 
muscle on 
periosteu
m 
Rat tibial 
bone defect 
Group 1 - Bone 
defect with muscle 
injury                              
Group 2 - Bone 
defect without 
injury 
The bone defect 
with muscle injury 
resulted in increased 
proliferation of the 
periosteum and 
increased osteoblast 
activity 
Moderate soft 
tissue damage to 
the muscle initiates 
the inflammatory 
response and 
increases 
periosteum activity 
Land
ry et 
al. 
2000
99 
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Cellular Contribution in Fracture Site from Surrounding Tissues 
In addition to vascular contribution, the surrounding connective tissues may also 
supply osteogenic progenitor cells and bone initiating biomolecules critical for bone 
formation. Researchers have investigated the osteogenic cellular contribution from 
surrounding tissues, including the periosteum, local bone, bone marrow, muscle, fat, soft 
tissues, as well as homing through the systemic circulation108.  
Vascular pericytes are considered multipotent osteoprogenitor cells that penetrate 
the fusion or defect site through invading capillaries and other microvessels109,110. Several 
research groups have investigated the osteogenic potential of vascular pericytes isolated 
from aortic intima. The studies found, both in vitro and in vivo, that vascular pericytes are 
osteogenic and capable of differentiation into functional osteoblasts111.  
Muschler and coworkers investigated the osteoprogenitor cells in the systemic 
circulation and their ability to migrate through the systemic circulation to contribute to 
bone formation of the defect112. This study used a mouse parabiotic murine model with 
transgenic green fluorescent mice (GFP+) and wild type mice (GFP-). The outcomes 
indicated the GFP+ cells from the donor mouse home through the peripheral blood and 
contribute to the fracture. Furthermore, the results showed an increase in GFP+ cells 
between 7-14 days post fracture, suggesting the osteoprogenitor circulating cells coincide 
with revascularization and hard callus formation112.  The outcomes of this study support 
the outcomes of earlier investigations, finding the fracture site may provide a homing single 
for circulating progenitor cells112,113.  
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 Shirley and coworkers used New Zealand rabbits to study the systemic transport of 
bone marrow-derived stem cells in an osteotomy model113. Bone marrow mesenchymal 
stem cells were isolated and fluorescently tagged to allow image analysis. After osteotomy, 
cells were transplanted into the fracture site intravenously, or into a remote tibial bone 
marrow cavity. Interestingly, general systemic MSCs implanted intravenously did not 
relocate to the site of the osteotomy, while both the directly implanted MSCs and remotely 
located MSCs within the tibial remained and migrated to the site, respectively. Not only 
are stem cells recruited from the adjacent tissue during fracture repair, but also they are 
recruited systemically from locations of higher mesenchymal stem cell reservoirs. 
Table 1.2: Osteogenic Cell Contributions. (Also published in Tabbaa et al. (2014) 
Critical Reviews in Biomedical Engineering82) 
Stem cell  Source 
Plastic 
potential 
Procedural notes Outcomes 
Autho
r 
Mesench
ymal 
Human 
adipose 
tissue 
Proangio
genic 
Hind limb ischemic 
model of nude mice 
using human adipose-
derived stem cells 
(ADSC); isolated by 
collagenase-I 
Increased blood perfusion in 
the injury model; potential for 
improved neovascular support 
Kim et 
al. 
200711
4 
Muscle 
Rat 
hind-
limb 
muscle 
Osteogen
ic 
Rat muscle; cell isolation 
by collagenase-XI 
digestion and plating 
onto collagen-coated 
flasks 
Potential for highly osteogenic 
source of stem cells for tissue 
engineering applications  
Kim et 
al. 
200810
5 
Muscle 
Human 
skeletal 
muscle 
Myogeni
c, 
adipogeni
c, 
osteogeni
c, 
chondrog
enic 
Cells isolated by 
modified pre-plate 
technique and subjected 
to immunomagnetic 
separation 
Demonstrates muscle stem 
cells as a potential multipotent 
stem cell, needs further testing 
to demonstrate osteogenic 
potential 
Lu et 
al. 
201011
5  
Pericyte 
Bovine 
retina 
Chondro
genic, 
adipogeni
c 
Pericytes identified by 
morphology, expression 
of α-smooth muscle 
actin, and cell-surface 
ganglioside  
Preliminary evaluation 
demonstrating the potential for 
these two lineage cell 
maturation; further studies 
needed to confirm 
Farrin
gton-
Rock 
et al. 
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200410
9 
Pericyte 
Human 
gracilis 
and 
semite
ndinos
us 
muscle 
 
Isolation by collagenase-I 
and plating onto 
collagen-coated flasks 
Adult skeletal muscle could be 
an important source of 
multipotent stem cells; 
isolated cells do not express 
endothelial cell surface 
markers 
Levy 
et al. 
200111
6 
Periostea
l 
Mouse 
hind-
limb 
periost
eum 
Adipogen
ic, 
osteogeni
c 
Tissue explants cultured 
on fibronectin-coated 
flasks 
MC3T3-E1 preosteoblast cells 
exhibited  higher levels of 
ALP activity; fibroblasts 
demonstrated higher levels of 
Oil Red O over periosteal 
cells; periosteal stem cells 
have potential but potentially 
limited 
Arnsd
orf et 
al. 
200911
7 
Mesench
ymal 
Rat 
bone 
marro
w 
Osteogen
ic 
Bone marrow of femora, 
centrifuged through cell 
strainer and adherent 
cells used 
Had lower colony forming 
units but demonstrated highest 
levels of osteogenic potential  
Hayas
hi et 
al. 
200811
8 
Rat 
periost
eum 
Diaphyseal areas of 
femora and tibiae; 
collagenase and 
centrifuged through cell 
strainer, adherent cells 
used 
Periosteal cells demonstrated 
osteogenic potential, only 
slightly lower than MSC; 
differs from other literature 
potentially due to passage 
levels of cells evaluated 
Rat 
adipose 
tissue 
Inguinal adipose tissue; 
collagenase  
Demonstrated lower 
osteogenic potential than bone 
marrow and periosteal stem 
cells; should be considered 
when investigating sources for 
bone tissue engineering 
 
Review of Bone Tissue Engineering and Bone Substitutes  
Bone Tissue Engineered Scaffolds 
The field of tissue engineering is based on understanding normal tissue formation 
and regeneration and applying this knowledge to produce new functional tissue when 
normal repair process is impaired and there is a need for new tissue formation. The design 
of tissue engineered constructs incorporates skills from the fields of cell biology, medicine, 
and engineering. The goal of tissue engineering is to generate functional tissue; one 
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approach encompasses incorporating progenitor cells and growth factors on a scaffold (also 
termed “matrix” or “construct”) designed for a specific anatomical region or purpose. One 
typical approach for developing a tissue engineering construct involves isolating cells from 
the patient, differentiating cells on a 3-dimensional matrix with growth factors, and 
culturing the composite to form an in vitro tissue construct that can be implanted into the 
patient15. When designing constructs for tissue engineering it is essential to understand the 
pathological environment and anatomical location of the defect or area where bone 
regeneration is required. The location for bone regeneration will vary in terms of 
mechanical load, type of bone, and degree of vascularity. Furthermore, the altered 
environment due to the patient’s condition will affect the fixation, vascularization, and 
integration of the construct30,34,76,119–122.   In comparison to organ transplants, tissue 
engineered bone grafts lack pre-existing vascular networks. This avascularity is a 
considerable problem for spinal fusion, where a large amount of bone formation is needed. 
The tissue engineered construct depends on diffusion from surrounding tissue for nutrient 
supply and waste removal as well as essential growth factors and osteoprogenitor 
cells21,123,124.  Designing tissue-engineered scaffolds that promote transport or stimulate 
vasculature is essential for the success of bone grafts in areas requiring large amounts of 
bone formation.     
Bone tissue engineered scaffolds or bone grafts are defined by three main attributes: 
osteogenic, osteoinductive, and osteoconductive. Osteogenic is defined as the ability of the 
construct to form bone tissue by containing and supporting cells that can differentiate into 
functional osteoblasts. Osteoinduction is defined as the recruitment and stimulation of local 
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bone-forming cells, typically through growth factor signaling, such as bone morphogenic 
proteins (BMPs). Osteoconduction describes the ability of the bone graft to act as a scaffold 
and generate new bone by allowing infiltration of osteogenic cells and neovasculature. The 
diamond concept of bone tissue engineering describes four essential factors for bone 
formation. These factors necessary for optimal bone formation include the biological 
attributes of osteoinduction, osteoconduction, and osteogenesis as well as the mechanical 
environment 77,125,126.   In spinal fusion treatments, mechanical stability is a significant 
factor in contributing to successful fusion. Mechanical stability can be achieved using 
instrumentation, which has increased the fusion rates. The significant impact of mechanical 
stability in the success of spinal fusion is reflected by fusions in the lumbosacral junction. 
This region is disposed to instability due to excessive motion. As a result, this region of the 
spine in particular has elevated rates of spinal failure124,127,128.   
 The diamond concept of bone tissue engineering describes four essential factors for 
bone formation, including the biological attributes of osteoinduction, osteoconduction, and 
osteogenesis as well as a proper mechanical environment77,126,129. Although these four 
factors are critical for bone formation, a fifth element of sufficient vascularization is critical 
for optimizing bone formation.  
 depicts an additional apex to the diamond shaped model, thus establishing the star concept 
for bone healing. That is, successful tissue engineering bone grafts should not only 
incorporate the diamond concept attributes, but should also factor in principles of 
vascularization76,120. For successful bone formation, the principles of vascularization 
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include preparation of the recipient site, the vascular supply from surrounding tissue, and 
vascularization of the bone graft.   
 
Figure 1.10. Bone fracture healing concepts. Schematic shows an additional apex for 
vascularity, revealing the star concept model (Also published in Tabbaa et al. (2014) 
Critical Reviews in Biomedical Engineering82) 
 
Types of Bone Grafts for Spinal Fusion 
Autologous Grafts 
 Autologous bone, or autograft, is the clinical gold standard for bone repair and 
spinal fusions. Autografts contain the necessary attributes for promoting bone formation, 
including osteoinduction, osteoconduction, osteogenesis, and vascular elements.  
Autografts are obtained by a secondary surgical procedure, commonly derived from the 
iliac crest or intramedullary canal. The most common and successful autograft in spinal 
fusion surgery is corticocancellous bone harvested from the iliac crest. Cancellous bone 
contains marrow that the cortical bone lacks, and provides osteogenic cells and inductive 
proteins. Furthermore, the porosity of the cancellous bone promotes neovasculature at the 
fusion site and an influx of osteogenic cells91. Disadvantages of autografts include tissue 
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morbidity at the bone graft harvest site, lack of structural integrity, increased operative 
time, and increased blood loss. Most importantly, autografts are limited by the total amount 
available. This drawback is especially an issue in spinal fusion surgeries, where large 
amounts of bone grafts are needed for fusion, or patients require multiple levels of 
fusion6,17,85,129,130.  
Allografts 
 Allografts incorporate the necessary attributes to some degree but do not 
revascularize or remodel as well as autografts15,30,34,120,123. Allografts are mostly 
osteoconductive, somewhat osteoinductive, and are not osteogenic. In comparison to 
autografts, allografts are more available but have a higher failure rate in spinal fusion 
surgeries. Slower fusion rate and higher graft resorption were also observed with 
allografts130.  Other associated problems include the risk of disease transmission. 
Demineralized bone matrix (DBM) can be allografts or xenografts. DBM contains growth 
factors, proteins, and a portion of the mineral phase; the major disadvantage of DBM is 
variability between grafts. The macrostructure and mechanical properties significantly vary 
and are challenging to control.  
Synthetic Grafts 
 The shortcomings of allografts and autografts led to the use of synthetic materials 
and composites of materials from natural and synthetic origin. Synthetic bone substitutes 
include the use of ceramics, polymers, metals, and cements8,131,132. Polymer materials used 
as osteoconductive scaffolds include polyglycolide, poly-L-lactide, and polylactide-co-
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glycolide. Ceramics are the most commonly used synthetic material in surgery. Ceramics 
include calcium phosphates that incorporate hydroxyapatite (HA) and tricalcium phosphate 
(TCP). Various ratios of HA and TCP are used to obtain optimal bone fusions. HA 
biodegrades slowly, which increases the mechanical strength but hinders remodeling. On 
the other hand, TCP biodegrades too fast to support bone fusion130.    
 Ceramics are strongly osteoconductive but lack the osteoinductive and osteogenic 
capabilities of autologous bone. This has led to the use of composite bone substitutes, 
which include osteoinductive factors coupled with osteogenic potential cells to augment an 
osteoconductive material17. Bone morphogenetic proteins, in native (BMP) and 
recombinant forms (rhBMP), are the most effective inductive agents for bone-forming 
applications. BMP, in combination with a biodegradable osteoconductive polymer or 
ceramic, has been reported to increase union rate and has been shown to be effective in 
spinal fusion treatment. However, more recent literature shows BMP use in the clinic to 
have adverse effects on patients and complications133. The addition of osteogenic 
progenitor cells, ranging from sources such as bone marrow aspirate to a synthetic 
osteoconductive material that contains osteoinductive agents, creates a composite that 
encompasses all of the bone-forming properties similar to autologous bone grafts. 
Composite synthetic bone grafts, as an alternative to autologous bone grafts, have huge 
potential since these grafts incorporate the bone-forming attributes but do not have the 
limitations of autologous grafts22,91,134. Other inductive growth factors, including 
transforming growth factor-beta (TGF-β), fibroblast growth factor (FGF), and growth 
differentiation factor 5 (GDF-5), augment the bone forming process91. Autologous bone 
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marrow aspirate is used to augment synthetic bone grafts. The marrow is typically obtained 
from the posterior iliac crest and contains progenitor cells that can be isolated and 
expanded17,89,127.  Tissue engineering techniques are employed to produce composites that 
are effective and assist the natural bone-forming process.   
 The ideal bone graft should incorporate all the bone-forming attributes of the star 
concept to some degree. Most bone grafts used in the clinic lack one or multiple properties 
essential for promoting spinal fusions. Figure 1.11 depicts the attributes various bone grafts 
possess and quantifies the strength of each attribute. Most bone grafts contain some degree 
of osteoconductive and osteoinductive properties while very few bone grafts incorporate 
vascularity via factors that promote angiogenesis or neovessel formation. Vascularized 
autografts and cancellous autografts are the only bone grafts that incorporate all five 
attributes to some degree. The inclusion and strength of each bone-forming property is 
directly related to the functionality of the bone graft. Autografts are the only type 
containing each of the five attributes to some degree and, as a result, have the most success 
in spinal fusions and remain the gold standard. This further illustrates the need for a bone 
graft to promote vascularity for bone regeneration.   
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Figure 1.11. Functionality of various bone grafts based on the strength of the start 
concept attributes. (Also published in Tabbaa et al. (2014) Critical Reviews in 
Biomedical Engineering82) 
 
Bone Substitutes in the Clinic 
 Autologous iliac crest bone graft is the most commonly used bone substitute and is 
still today the gold standard for lumbar fusion. The complications involved with using this 
bone substitute are still present135.  Graft alternatives, in addition to bone substitutes, 
include graft enhancers and graft extenders. Graft extenders are used in combination with 
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autologous bone graft and provide a comparable fusion rate to autologous bone alone. Graft 
extenders are employed when there is a limited supply of autologous bone graft, 
predominantly for patients who require multiple levels of fusion136.  Graft enhancers 
function to improve the fusion rates of autologous bone used in adequate amounts. Graft 
extenders and enhancers are both used in the clinics.   
Animal Studies to Test the Efficacy of Bone Substitutes  
Relevant animal studies must allow simulation of the surgical procedure of 
posterolateral fusion and replication of similar bone formation as in humans. During the 
surgical technique of posterolateral fusion, the surgeon must extensively prepare the site 
for fusion by decortication; instrumentation is frequently employed. The animal models 
used to study posterolateral fusion do not accurately replicate all the aspects of this surgical 
technique nor the pathology and spinal abnormalities the patient indicates. An animal 
model must not only simulate fusion from the surgical technique but must also create a 
pathological environment that demonstrates the instability of spinal conditions134.   
In the rabbit model, no instrumentation is used and decortication is limited to the 
transverse processes. Dog and sheep models are anatomically better in size. A sheep model 
allows decortication and use of instrumentation; however, the model does not replicate the 
human environment better than rabbits127. The canine models use posterior thoracic 
fusions, which do not correlate well to lumbar posterolateral intertransverse fusions. 
Another issue with the canine model is the 100% autologous bone graft fusion rate, which 
is not analogous to humans91.  The evolutionary complexity of the species will affect the 
biological factors affecting spinal fusions. Animals with lower complexity, such as rats, 
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used in studies exhibits a much higher spinal fusion rate compared to other, more complex, 
species. Furthermore, the chronology of fusion will differ between species. For example, 
rabbit lumbar intertransverse spinal fusion develops after 4-6 weeks, whereas this process 
in humans and primates take months. Several animal studies are used to demonstrate the 
efficacy of a bone substitute for posterolateral fusion. The athymic nude rat muscle pouch 
assay can demonstrate the concept. The rabbit posterolateral fusion model can demonstrate 
the feasibility. The nonhuman primate spinal fusion model is used as an efficacy study. 
However, due to the cost and ethical issues associated with experimenting with primates, 
this type of study is only performed when the feasibility models are highly successful134.   
Clinical Studies and the Efficacy of Bone Substitutes in Posterolateral Spinal Fusion 
The effectiveness of ceramics in posterolateral spinal fusions has been studied in 
animals and in clinical trials. In some studies, the ceramic bone substitutes showed 
comparable fusion rates to autologous bone. Other researchers have demonstrated that 
ceramics are a successful graft extender for autologous bone130,135,137.  
 The clinical use of ceramics in spinal fusion procedures involves the use of bone 
marrow aspirate (BMA), which contains osteoprogenitor cells and osteoinductive 
factors138.  The success rate of ceramics and BMA in the clinic for spinal fusions has had 
varied results. Several researchers have claimed ceramic and BMA composites have 
comparable results to autologous bone graft, whereas other studies have shown less 
successful fusions. The contribution of BMA in improving fusion is not well understood. 
BMA is highly cellular, containing hematopoietic and mesenchymal cells that both 
contribute to bone formation. However, only the mesenchymal-derived cells can lead to 
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bone forming cells. The osteoprogenitor cells within the BMA are a very small sub-fraction 
of the cellular component. In fact, one mesenchymal cell is present in 100,000 cells of the 
BMA. The lack of mesenchymal or osteoprogenitor cells in the BMA is a major 
limitation139,140.  Other limitations include variability between patients and loss of 
osteoinductive cells and factors from the site through migration or diffusion135,137.  The 
cellular composition of the bone marrow aspirate will affect its success in spinal fusion and 
contribution to bone formation. This is reflected in the variability of BMA in efficacy trials 
for spinal fusion procedures. 
Researchers have proven platelets to provide an ample amount of growth factors. 
Activated growth factor (AGF) platelet gel consists of ultraconcentrated growth factors. 
AGF platelet gel is suggested to improve fusions by stimulating pathways that promote 
osteogenesis, reducing postoperative blood loss by initiating clot formation, and stabilizing 
the site141,142. Multiple clinical studies have demonstrated the addition of platelet gel to 
autologous bone graft to decrease the fusion rate has no benefit as a graft extender in 
posterolateral spinal fusions. Rihn and coworkers suggests the platelet gel may dissolve 
via fibrinolysis, reducing the amount of growth factors in the site and reducing the fusion 
rate. This article suggests platelet gel is inadequate as a bone graft enhancer due to the 
potential reduction in concentration of growth factors and because the specific types of 
growth factors in the platelet gel may inhibit osteogenesis143.   
Demineralized bone matrix (DBM) contains osteoinductive glycoproteins that 
contribute to bone formation. Similar to BMPs, several animal studies have evaluated if 
DBM increases the success rate for spinal fusions when combined with autologous bone 
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graft. Boden and coworkers suggested the use of DBM as an extender for autologous bone 
graft. The researchers performed bilateral posterolateral lumbar spinal fusion on 47 New 
Zealand white rabbits. Groups were evaluated based on the ratio of autograft to DB with 
which they were treated. The results of this study suggest that DB combined with 
autologous bone graft is comparable to using only autologous bone graft. The fusion rates 
were similar for each group and were determined by manual palpation22. The results of this 
study are comparable to a study evaluating DBM in dogs, which had similar findings.   
A review of DBM to augment spinal fusion treatments found significant 
inconsistencies between animal studies and efficacy in spinal treatments. A major 
contributing factor to these inconsistencies is the variability in DBM. The osteogenic 
potential of this bone substitute is dependent on the type, the donor, and how the DBM is 
prepared. These factors in DBM contribute to the inconsistencies of the results in animal 
studies and clinical trials22,144.   Wang and coworkers evaluated the osteoinductive potential 
of three commercially available DBM bone grafts. This study found each product contained 
various amounts of DBM, with different osteoinductive potential between products, 
altering the efficacy of the products. The author suggests the processing procedures, the 
donor quality, and the sterilizing techniques alter the quality of DBM products. Bae and 
coworkers evaluated the amount of BMP in commercially available DBM products using 
enzyme-linked immunosorbent assay. Interestingly, this study determined there were 
varying amounts of BMPs in DBM from different lots of the same manufacturer. DBM 
quality and osteopotential is inconsistent between DBM products and between lots within 
the commercial products145,146.    
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Molecular biology analysis of posterolateral spinal fusion shows bone morphogenic 
proteins (BMP-2, BMP-4, BMP-6) play a critical role in formation of bone. In a review by 
Boden and coworkers, the effect of recombinant human morphogenetic protein-2 (rhBMP-
2) combined with autologous bone used in posterolateral fusions in rabbits was analyzed. 
Histology and CT scans showed the fusion mass formed from the composite had greater 
volume and more contact with host bone than that formed with just autograft. Histology, 
and analysis of gene expression of rhBMP-2 and other bone related genes, showed rhBMP-
2 recruited bone-forming cells and expressed bone forming genes more homogeneously in 
both zones, indicating no delay in bone formation of the central zone. The use of rhBMP-
2 with autologous bone graft in rabbits resulted in 100% success rate of fusion. In general, 
bone formation in lower vertebrae is much faster and requires less of a dose compared to 
nonhuman primates. This success rate was further replicated in a primate model, however, 
at a significantly higher dose and after a much longer fusion time. The incorporation of this 
osteoinductive factor with autologous bone resulted in local production of BMPs, 
migration of osteoprogenitor cells from surrounding muscle, and similar rates of bone 
formation in the central and outer zones. Human clinical trials of rhBMP-2 combined with 
HA and tricalcium phosphate granules showed the ability of rhBMP-2 to induce bone on 
an appropriate carrier. Generating large doses of recombinant and extracted BMP is not 
feasible or cost-effective. Furthermore, a delivery system is required to maintain levels of 
BMP expression corresponding to the unimpaired natural bone healing process24,88,91.    
The US Food and Drug Administration (FDA) approved two recombinant human 
bone morphogenetic proteins (rhBMP-2 and rhBMP-7) for specific spinal fusion 
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procedures. Infuse, a bone substitute containing rhBMP-2 (Medtronic; Memphis, 
Tennessee), is a commercially available product approved for 1-level anterior lumbar 
interbody fusion. Osteogenic protein-1 (OP-1), BMP-7 (Stryker Biotech; Hopkinton, 
Massachusetts), is also a commercially available product approved for revision 
posterolateral fusion. All other uses are off-label and not approved135. Numerous clinical 
studies were conducted to evaluate the efficacy of BMPs. Based on these studies, the 
efficacy of BMPs is difficult to define. The indications of the patients, the surgical 
techniques, the outcome measures, and varying types of bone grafts used with BMPs were 
all varying factors between studies. Major disadvantages of BMPs are the possible 
complications, which include: heterotopic bone formation, resorption or osteolysis, 
seromas or hematomas, antibody formation, inflammatory reaction, and adverse effect on 
neural elements135,140.   Table 2 provides a list of various commercially available bone 
grafts and evaluates the use of various commercially available products.   
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Table 1.3: A summary of bone grafts used in posterolateral fusions provides examples of 
commercially available bone grafts and their potential use as a bone substitute or bone 
graft extender. (Also published in Tabbaa et al. (2014) Critical Reviews in Biomedical 
Engineering82) 
Graft 
Material 
Commercial 
name 
Discrepancies 
Efficacy of graft 
material 
References 
Ceramic + 
BMA 
Bonograft 
(India) 
Radiographically 
cannot determine 
quality of fusion, 
cannot be assessed 
with histology 
Studies have 
suggested both 
comparable and 
poorer fusion rates 
with the use BMA 
Bansal et 
al. 
Ceramic +  
BMA 
osteoset, 
Wright 
Medical 
Technologies, 
Arlington, TN 
Range of patients 
degenerative or 
spondylolytic 
spondylolisthesis, 
smokers and 
nonsmokers 
TCP and HA 
ceramic can be used 
as an effective graft 
extender 
Niu et al. 
DBM 
Grafton, DBM 
(Osteotech 
Eatontown, 
NJ) 
Variability between 
DBM products 
DBM can be used as 
graft extender. 
Several studies have 
shown comparable 
fusion rates to 
autologous bone 
graft 
Vaccaro et 
al. 
DBM 
Acela 
Connexus 
(IsoTis 
OrthoBiologics 
Inc., Irvine, 
CA) 
Low patient 
number 
Results suggest can 
be used as extender 
with comparable 
fusion rates 
Schizas et 
al. 
Activating 
growth 
factor 
(AGF) 
platelet gel 
Interpore Cross 
International 
(Irvine, CA) 
Controversial use in 
spinal fusions 
Activated growth 
factor platelet gel is 
not an effective graft 
extender 
Rihn et al. 
rhBMP-2 
Infuse 
(Medtronic, 
Memphis, 
Tennessee) 
Off-label use, 
uncertain dosages, 
and possible 
complications 
BMP use is effective 
in spinal fusions 
however adequate 
dosages and 
complications are 
unclear 
Taghavi et 
al. 
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In summary, autografts are the most effective bone substitute for posterolateral 
surgery. However, the amount available is limited and donor site morbidity may result as 
a complication. Allografts are more available and cost effective than autografts but are not 
effective bone substitutes in posterolateral fusion due to their variability and loss of 
osteoinductive factors and cells. DBM, however, demonstrate comparable fusion rates to 
autografts when used as a graft extender. BMPs are also effective graft extenders. 
However, the cost is high and there are complications such as adverse effects to neural 
elements. Ceramics, similar to DBM, have proven to be effective graft extenders when 
combined with BMA or BMPs. Currently, there is no effective replacement for autologous 
bone grafts.   
Table 1.4: Characteristics of bone grafts used for posterolateral fusion. 
 Efficacy 
as 
substitute 
Efficacy 
as 
extender 
Donor 
site 
morbidity 
Cost Disease 
transmission 
Availabilit
y  
Limita
tions 
Autograft High High High Low None Low Yes 
Allograft Low Moderate None Moderate Low High None 
rhBMPs Moderate Moderate None High None Moderate Yes 
BMA Low Moderate None Low Low Low None 
Ceramic Low Moderate None Moderate None Moderate None 
 
Bone Tissue Engineering Strategies to Improve Vascularity  
The design of tissue-engineered constructs incorporates skills from the fields of cell 
biology, medicine, and engineering. The goal of tissue engineering is to generate functional 
tissue, specifically in an environment that is indicated for poor healing. Conceptually, 
tissue engineering has focused on the potential of using a patient’s progenitor cells and a 
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biologically indicative scaffold to develop an active and healthy tissue construct through 
in vitro culture techniques that could then be implanted into a patient15. When designing 
constructs for tissue engineering it is essential to understand the pathological environment 
and anatomical location of the defect or area where bone regeneration is required. The 
location for bone regeneration will vary in terms of mechanical load, type of bone, and 
degree of vascularity. Furthermore, the altered environment due to the patient’s condition 
will affect the fixation, vascularization, and integration of the construct30,34,76,119,120,122. In 
comparison to organ transplants, tissue engineered bone grafts currently lack pre-existing 
vascular networks. This avascularity is a considerable problem for spinal fusions and 
critical bone defects, where a large amount of bone formation is needed. Tissue-engineered 
constructs depend on diffusion from surrounding tissue for nutrient supply and waste 
removal as well as essential growth factors and osteoprogenitor cells21,123,124.  Designing 
tissue-engineered scaffolds that promote transport or stimulate vasculature is essential for 
the success of bone grafts in areas requiring large amounts of bone formation.  
 Tissue engineering provides tools to develop vascularity in bone grafts to improve 
the overall functionality and success of critical defects. Table 1.5 summarizes various 
tissue engineering methods to improve vasculature and the complexities that parallel the 
benefits. A major limitation is often the slow rate of vasculature formation. This rate 
hinders cellular proliferation, recruitment, and osteoblastic differentiation. Other 
limitations of current tissue engineering techniques to improve vasculature are 
predominately seen in large or thick tissue constructs. Tissue engineering methods, where 
progenitor cells such as endothelial progenitor cells are seeded to promote and develop 
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vasculature or new vessels prior to implantation, often fail because the cells and 
neovasculature are not supported from surrounding vasculature and compete for limited 
supplies of nutrients and oxygen.   
 Current tissue engineering methods to develop or accelerate vasculature formation 
in bone grafts overlook the support of the surrounding vasculature. The anatomical location 
of the defect, composition of surrounding soft tissues, and degree of tissue damage will 
influence the bone formation process. Tissue engineered bone grafts should be designed 
specifically to the intended application area. The design of a tissue engineered scaffold 
should consider optimization of the transport of osteogenic factors, nutrients, and cells 
from surrounding tissue. Current bone substitutes on the market are comparable or less 
efficient than autologous bone graft. However, without a mode of transport, such as 
vascularization, the transplanted or recruited osteogenic cells will not be supported and 
osteoinductive factors will not be spatially or temporally present to contribute to cell 
recruitment and differentiation. Due to the environment of many spinal fusions and trauma 
fractures, the damage to or lack of surrounding vascular supply requires development of 
tissue engineered constructs to specifically address transport characteristics to improve 
bone regeneration.   
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Table 1.5: Comparison of current tissue engineering methods to improve vasculature. 
(Also published in Tabbaa et al. (2014) Critical Reviews in Biomedical Engineering82) 
Tissue engineering 
method to improve 
vasculature 
Potential Benefits Shortcomings References 
Modify scaffold 
architecture 
Improve mass transport by 
adjusting porosity, pore size, 
and scaffold filaments  
Provides limited mass 
transport in large scaffolds 
and may decrease 
mechanical strength  
Liu et al. 
2012 
Use angiogenic factors 
Enhance and accelerate 
vascularization 
Causes slow rate of 
vascularization, can cause 
necrosis  
Muschler et 
al. 2004 
Transplant 
vasculogenic cells such 
as endothelial 
progenitor cells 
Form new vessels within the 
scaffold 
Creates competition of 
oxygen and nutrients inside 
the scaffold, limiting cell 
proliferation and viability  
Tsigokou et 
al. 2009 
Genetically modify 
cells to secrete factors 
that promote 
vasculature 
Produce proteins that 
promote vasculature  
Creates biological risk with 
genetic manipulation  
Shen et al. 
2005 
Generate in vitro 
vasculature prior to 
implantation 
Develop new vessels within 
the scaffold that can be 
anastomosed with host 
vasculature 
Forms vessels requiring 
vasculature from 
surrounding tissue  
Johnson et 
al. 2011 
Implant construct into 
subcutaneous region 
prior to implanting in 
implantation site 
Minimize cost using existing 
vasculature to form new 
vasculature networks in the 
scaffold 
Forms random blood vessels 
in the bone, limiting 
vasculature; injury may 
result in surrounding 
vascular network and new 
network  
Safak et al. 
2000 Kneser 
et al. 2006 
Stimulate electrically  
Upregulate osteoinductive 
factors necessary for vascular 
formation, improves 
vascularity 
Generates expense and lack 
of evidence for efficacy in 
spinal fusion surgeries  
Gan et al. 
2006 
 
Summary 
 Bone grafts should be designed specifically to the area they are implemented. The 
design of the tissue engineered scaffold should ideally consider how to optimize the 
transport of osteogenic potential factors and cells from surrounding tissue. Current bone 
substitutes on the market are comparable or less efficient than autologous bone graft. The 
substitutes are designed to incorporate attributes of osteoconduction, osteoinduction, and 
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osteogenesis. However, without a mode of transport, such as vascularization, the 
transplanted or recruited osteogenic cells will not be supported and osteoinductive factors 
will not be spatially or temporally present to contribute to cell recruitment and 
differentiation. Due to the environment of posterolateral fusion and lack of vascular supply, 
the improvement of transport characteristics of the bone graft is essential for improving 
fusion rates.   
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CHAPTER TWO 
EFFECT OF WICKING FIBERS IN TISSUE ENGINEERED SCAFFOLDS 
Introduction 
Large fracture defect sites and spinal fusions require large amounts of additional 
bone tissue; therefore, bone substitutes (commonly referred to as scaffolds) are used to 
augment bone tissue reformation1–4. These large tissue-engineered scaffolds are limited 
by a diminished capacity to transport nutrients, oxygen, large biomolecules, and 
osteoprogenitor cells 5,6. Conventional approaches to improve the transport properties in 
large bone tissue-engineered scaffolds involve the inclusion of biomolecules that promote 
angiogenesis and of co-cultured endothelial progenitor cells and other vasculogenic cells 
that stimulate neovasculature7–9. These approaches have shown limited success due to the 
slow rate of angiogenesis and the formation of nonfunctional vessels; requiring 
substantial improvement before consideration for clinical trials10.   
A novel approach to improve transport involves incorporating polymeric wicking 
fibers into a tissue-engineered construct. A wicking fiber has a grooved cross-section and 
parallel continuous channels that run the length of the fiber. The fiber configuration, 
shown in Figure 2.1, has been geometrically optimized by Eastman Chemical Company 
to enhance capillary action along the channels, resulting in enhanced transport properties. 
It is well established that the proprietary wicking fiber shape provides highly efficient 
transport in textile and chromatographic separations11–16. The fibers were later introduced 
by our research team, to the field of tissue engineering17. 
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Figure 2.1: Scanning electron microscope (SEM) image of a wicking fiber. Adapted with 
permission from Elsevier (Marcus RK et al. 2005). Image shows non-circular grooved 
cross-section and parallel channels of the wicking fiber, which facilitate strong wicking 
action and greatly increase surface area. 
 
The increased transport properties of the wicking fiber is achieved through 
geometrically optimized intra-fiber spaces or grooves that combine capillary pressure to 
enhance fluid transport along a single wicking fiber as opposed to a single capillary 
channel14. The cross-sectional geometry increases the shape factor of the wicking fiber so 
the surface area is 2.5-3.2 times a conventional circular cross-sectional fiber or macro 
channel of nominal diameter, resulting in significantly greater wicking capabilities18,19.  
The objective of these studies was to investigate the capabilities of wicking fibers 
to enhance the transport of not only fluid, but transport of biomolecules and progenitor 
cells. The first phase of this study assessed the transport efficacy of round and wicking 
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polylactide fibers of various bundled configuration. The second phase of this aim 
investigated the movement of fluorescently labeled biomolecules in a 3-dimensional (3D) 
collagen-agarose hydrogel 3-dimensional (3D) constructs containing round or wicking 
fibers. The final phase investigated the ability of wicking fibers to transport and distribute 
osteoprogenitor cells both along the fiber and through a 3D construct.   
 
Fluid Transport of Fibers 
Methods and Materials 
Polymer Extrusion 
  Poly-L-lactide (Natureworks LLC, USA) wicking fibers were extruded with 
irregular cross-sectional dimensions of 0.72 mm by 0.55 mm and poly-L-lactide round 
fibers were extruded with cross-sectional diameter of 0.5 mm. Wicking and round fibers 
were sliced with razor blade into individual fibers of 2, 3, and 6 cm lengths. Both fiber 
types were cleaned in three changes of ethanol, for 1 hour each, and placed under 
ultraviolet light for 6 hours. Samples were then soaked in a phosphate-buffered saline 
(PBS, Invitrogen) solution for 2 hours and air-dried overnight in a sterile hood.  
Fluid Transport Tests of Round and Wicking Fibers 
The transport phenomena through fibers includes diffusion and wicking--the 
spontaneous flow of liquid driven by capillary action. The wicking behavior of the fibers 
can be assessed using a vertical wicking test, commonly performed in the textile industry 
to characterize transport phenomena in fabrics20–22. The wicking tests were performed 
using two methods. The first method assessed wicking capabilities of the fibers by 
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recording the height of the fluid front moving vertically along the fiber at various time 
points, shown in image A of Figure 2.2. The second method assessed the wicking rate of 
the fibers by evaluating the change in mass of the fluid reservoir over regular time 
intervals presented in image B.  
 
Figure 2.2: (A) Vertical test apparatus to evaluate the rate of the fluid front in various 
fiber configurations. (B) Vertical test set-up to assess the amount of fluid wicked through 
the fiber over a time interval 
 
Both test methods were used to evaluate the wicking capabilities of round and the 
wicking properties were characterized in conformations of single fibers and of bundled 
fibers in a braided or twisted configuration (Table 2.1: Experimental groups of fiber 
configuration for vertical test investigating wicking height).  
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Table 2.1: Experimental groups of fiber configuration for vertical test investigating 
wicking height 
Experimental 
Group 
Fiber Type Configuration 
Number of fibers in 
bundle 
1 Round Single  1 
2 Wicking Single  1 
3 Round Twisted bundle 3 
4 Wicking Twisted bundle 3 
5 Round Braided bundle 3 
6 Wicking Braided bundle 3 
 
One end of the 6 cm fiber configuration was attached to the clamp shown in the 
Figure 2.2A. The bottom end was weighed down by a clip and lowered into a reservoir of 
dye solution to create contact of only 10 mm of fiber. The dye solution was comprised of 
phosphate buffered saline (PBS, Invitrogen) and 10% blue assorted food coloring 
(McCormick). The vertical displacement of the fluid front was measured after 30, 60, 90, 
120, 150, 300 seconds for each sample configuration, with each having a sample size of 
n=4. The fluid front rate was determined for each sample.  
Vertical Test - Wicking Rate Assessment  
To determine the mass of liquid removed by the fibers from the reservoir over 
time, the balance was set up to collect mass data measurements. The balance was 
connected to the computer using a USB to RS232 cable. PuTTY software was used to 
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transfer information from the balance to the computer. The balance was programmed to 
continuously measure the weight of the reservoir at a rate of two measurements per 
second. Fiber samples were then vertically dipped into the liquid reservoir using a clip 
and string to lower the samples through the top window of the balance. The fibers were 
suspended so only the tip was interfacing the fluid. Measurements were taken from the 
time of contact with the fiber to the fluid reservoir over 10 minutes. After ten minutes the 
continuous function was stopped and the recorded data was saved as a text file for further 
analysis in Excel. The wicking rate for each sample was calculated using a mass (mg) 
versus time (minutes) plot. The plots for each experimental group were normalized by an 
experimentally determined equation for the rate of evaporation of liquid from the 
reservoir, found in a similar method to sample evaluation. 
Statistical Analysis  
JMP software was used to conduct an unpaired two-sample t-test to compare the 
change in wicking rate of single wicking and round fibers using a significance level of 
p<0.05. The average wicking rate of twisted wicking bundles was compared to the 
average wicking rate of twisted round bundles using an unpaired two-sample t-test. The 
final statistical assessment used an unpaired two-sample t-test to compare the mean 
wicking rate of braided wicking fibers and braided round fibers.  
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Results 
Fluid Transport Tests  
To characterize the round and wicking polylactide fibers the vertical test was used 
to evaluate the height of the fluid front over a 10 minute time interval. The qualitative 
results are shown in Figure 2.3. The blue dye-solution in the images corresponds to the 
height the fluid front traveled through the fiber.  
 
Figure 2.3: Results from vertical wicking test. Left image shows the vertical test 
apparatus. (A) Bundled and (C) single wicking fiber samples depict greater vertical 
movement of the dye-solution than (B) bundled and (D) single round fiber samples 
 
The wicking rate was calculated for each experimental group by plotting the 
height of the fluid front by the time in seconds, as shown in image A of Figure 2.4. The 
wicking rate was determined by calculating the change in height of the liquid front over 
the time interval. The results (image B) show the single and bundled wicking fibers 
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wicking rate is significantly higher than samples of round fiber configurations. The 
height of the fluid front (image C) in both single and bundled wicking fiber samples is 
significantly greater than the round fiber samples. The twisted bundle round fibers depict 
greater vertical wicking height than the single round fibers. Additionally, the height and 
rate of the fluid front was assessed for wicking fibers of braided and twisted 
configurations. The twisted configurations showed higher wicking heights and increased 
wicking rate than braided wicking fiber configurations. The wicking rate was also 
assessed by measuring the change in mass continuously over a 10 minute time interval. 
The loss of water from the fluid reservoir on the balance correlates to the water gain from 
the fiber bundles. The results were normalized to the rate of evaporation from the fluid 
reservoir. The results show the wicking fiber samples have a significantly greater wicking 
rate than the twisted round fiber samples (Imaged D). Consequently, the wicking fibers 
also absorb greater amounts of water than round fiber samples.  
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Figure 2.4: Wicking behavior of round and wicking fibers (A) Plot of wicking height vs 
time for round and wicking fibers (B) The wicking rate (cm/min) of single, bundle, and 
braided round and wicking fibers (C) The maximum height reached for each fiber type 
(D) Wicking rate (mg/min) of round and wicking twisted bundles (*) signifies significant 
difference between round and wicking fiber types, p<0.05. 
 
Effect of Wicking Fibers on Biomolecule Transport 
Materials and Methods 
Unimolecular Diffusion of FITC-Conjugated Bovine Serum Albumin in a Hydrogel  
The effect of fibers on protein movement in a 3D system was evaluated by 
analyzing the unimolecular diffusion of FITC-conjugated bovine albumin (Sigma; St. 
Louis, MO, USA) in a 50:50 collagen-agarose composite hydrogel containing individual 
round or wicking fibers.  
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A 50:50 collagen-agarose hydrogel was formed creating a solution consisting 
45% (by volume) of 2% (w/v) agarose (Sigma, St. Louis, MO, USA) in 1x phosphate-
buffered saline (PBS, Invitrogen), 45% (by volume) of 3.2 mg/mL PurCol, Bovine 
Collagen Solution Type 1 (Advance Biomatrix; San Diego, CA, USA), and 10% (by 
volume) of collagen reconstitution buffer. The collagen reconstitution buffer was 
comprised of 4.8% HEPES buffer (Fisher Scientific; Waltham, MA USA), and 2.2% 
NaHCO3 (Fisher Scientific) in deionized water. To make 2% agarose solution agarose 
powder was autoclaved at 124°C for 45 min and added to PBS solution. To dissolve the 
agarose the solution was stirred at low heat using a magnetic stirrer and hot plate. After 
agarose is completely dissolved the solution is cooled and stored at 4°C until further use. 
The agarose solidifies at room temperature and is melted in the microwave prior to use. 
The collagen gel is formed by change in pH using collagen reconstitution buffer and 
incubating at 37°C. The 50:50 collagen-agarose hydrogel was formed by first adding the 
collagen solution to the reconstitution buffer. After thorough mixing using the pipette, the 
melted 2% agarose solution was quickly added at the appropriate dilution. The agarose 
component was solidified by cooling the hydrogel at room temperature for 10 minutes 
followed by incubation at 4°C for 5 minutes. The samples were placed in a 37°C 
incubator overnight to allow the collagen to solidify. 
The 50:50 collagen-agarose hydrogel was formed in half of an individual well on 
a 2-well chamber slide by turning the chamber slide on its side and loading it with 1 mL 
of collagen-agarose solution, as seen in image A of Figure 2.5. Three fibers with lengths 
of 2 cm were placed vertically, with forceps, in the center of the hydrogel while the 
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chamber slide was on its side and before the hydrogel was gelled as shown in figure 
below. Two samples with each fiber type were formed. After the hydrogel gelled, 1 mL 
of 100 μg/mL solution of FITC-conjugated bovine albumin and serum free medium was 
pipetted into the section of the chamber well without the hydrogel, as shown in image B 
of Figure 2.5.  
 
Figure 2.5: Schematics of experimental set-up of collage-agarose gel containing fibers. 
(A) Digital image of the rotated chamber well to create a hydrogel in half the well and 
with inserted fibers. (B) The sample was then laid back on its side and tested and then 
imaged using fluorescent confocal imaging of the FITC albumin along the horizontal axis 
with laser confocal microscopy 
 
The rate of FITC-albumin diffusing horizontally through the different fiber-
hydrogel systems was evaluated using fluorescent laser confocal microscopy (Nikon 
Eclipse TI); NIS-Elements imaging software was used to obtain 3D time-lapse images. 
The intensity was measured in 7-second intervals for 15 minutes along the center image 
frame containing the fiber. The rate of FITC-albumin movement was determined in 
regions of interest (ROI) along the fibers at various distances from the interface of the 
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collagen-agarose gel and FITC-albumin solution. As shown in Figure 2.6, ROI at various 
distances from the interface were used to calculate the average rate of albumin 
movement.  
 
Figure 2.6: (A) Schematic of an individual well in a 2-well chamber slide filled partially 
containing with collagen-agarose gel containing either round or wicking fibers. The 
other portion of the well is filled with medium containing the BSA-FITC solution. (B) 
Image frame from confocal real-time video of the BSA-FITC diffusion diffusing into the 
collagen-agarose gel. 
 
Statistical Analysis  
JMP 10 statistical software was used to perform a repeated measures analysis with 
(p<0.05) was performed to compare the rate of FITC-albumin movement in hydrogels 
containing wicking or round fibers for each distance from the interface. 
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Figure 2.7: (A) Schematic indicates interface between hydrogel and FITC-albumin 
solution and the region of interest locations. (B) The rate of BSA-FITC in the collagen-
agarose gel at various distances into the hydrogel. The hydrogel samples containing 
wicking fibers have a significantly greater rate than the samples with round fibers; 
*p<0.001. The rate of BSA-FITC is consistent for various distances from the interface for 
both fiber types into the sample. (also published in Tabbaa et al. 2014 JTERM23) 
 
Results 
The diffusion of FITC-albumin was analyzed in collagen-agarose hydrogels 
containing wicking or round fibers. The results showed the rate of the FITC-albumin 
movement in hydrogels with wicking fibers was significantly (p<0.001) greater than in 
the gels containing round fibers for each ROI as presented in Error! Reference source 
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not found.. Statistical analysis also showed the distance from the interface did not 
significantly affect the rate of protein movement (p=0.9342), suggesting the wicking 
fibers increase the rate of movement homogeneously through the gel.  
 
Enhanced Cell Transport Using Wicking Fibers 
Materials and Methods 
Progenitor Cell Transport through Wicking Fibers  
The effect of fiber type on the transport of progenitor cells was evaluated using 
D1 mouse mesenchymal stromal cells (ATCC; Manassas, VA, USA). The cells were 
cultured in Dulbecco’s Modified Eagle’s medium (DMEM; Invitrogen; Grand Island, 
NY, USA) supplemented with 10% fetal bovine serum (FBS; Gibco; Grand Island, NY, 
USA), 10,000 U penicillin, and 10 mg streptomycin/mL (Sigma; St. Louis, MO, USA). 
D1 cells were labeled with CellTrackerTM Green CMFDA probe (Invitrogen; Grand 
Island, NY, USA), following the manufacturer’s protocol using a long term labeling 
concentration of 25μM, to evaluate the movement of cells along wicking and round 
fibers. Twelve poly-L-lactide wicking and twelve round fibers were cut into 3-cm length 
samples. The fibers were cleaned by extensive washes with 70% ethanol. After ethanol 
washes, the samples were soaked in 1x-phosphate buffered saline (PBS, Invitrogen; 
Grand Island, NY, USA) for 3 hours, washed three times with PBS, and air dried before 
use. Lids, with fitted holes and plastic tubes, were custom-made for the 12-well plate to 
securely hold the 3 cm wicking or round fibers vertical. After lids were prepared, 1 mL of 
D1 cell solution, containing 1 million cells in growth media, was pipetted into each well 
94 
 
of a low attachment 12-well, the fibers were individually and vertically placed into each 
well and secured by the custom-made lid.  
 
 
Figure 2.8: Schematic depicts experimental set-up to assess progenitor cells wicking in 
round or wicking fibers. The purple cylinders depict the holding mechanism of the fibers 
 
The fluorescently tracked cells are carried in the media solution and wick with the 
media along the conduits of the fiber. The cells penetrating the fibers present the same 
spherical morphology as when the cells are suspended in solution. The vertical 
displacement of the cells along the fibers was determined at time points of 0.5, 6, and 24 
hours with the initial time point being fiber placement into the cell solution. To assess the 
cell vertical displacement, the fibers were transferred to microscope slides and evaluated 
using fluorescent microscopy and imaging software. 
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Statistical Analysis  
JMP 10 statistical software was used to perform statistical analysis for vertical 
cell movement. A block design of time was conducted to compare the vertical 
displacement of D1 cells on wicking fibers or round fibers with (p<0.05). 
Transport of Progenitor Cells through Fibers in Hydrogel  
This study has adapted a 3-D in vitro system established by Takata et al. to 
evaluate the effects of progenitor cell movement in a collagen gel24. This assay involves a 
simple system to assess cellular movement by preparing a double-layered collagen gel 
hemisphere with the first layer containing the cells and the second layer containing a 
growth factor molecule that has shown to be a chemotactic molecule that stimulates and 
encourages cell migration as shown in Figure 2.9. The distribution of progenitor cells 
within hemispheres containing round fibers, wicking fibers, or no fibers was assessed 
after 24 hours.  
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Figure 2.9: Schematic illustrates the arrangement for double-layered collagen 
hemispheres (A) without fibers and (B) with round or wicking fibers. The pink sphere 
corresponds to the first hemisphere layer containing fluorescently tracked D1 mouse 
progenitor cells. The blue sphere depicts the second larger collagen hemisphere 
containing a chemotactic growth factor encapsulating the first hemisphere with or 
without fibers.   
  
Forming First and Second Layer of Collagen Gel Hemispheres 
D1, mouse mesenchymal stromal (ATCC), cells were cultured in Dulbecco’s 
Modified Eagle’s medium (Invitrogen; Grand Island, NY, USA) supplemented with 10% 
fetal bovine serum (Gibco; Grand Island, NY, USA), 10,000 U penicillin, and 10 mg 
streptomycin/mL (Sigma; St. Louis, MO, USA). D1 cells were labeled with 
CellTrackerTM Red CMTPX probe (Invitrogen; Grand Island, NY, USA), following the 
manufacturer’s protocol using a long term labeling concentration of 25μM. The first layer 
of the 1.0mg/mL collagen gel hemisphere was formed by mixing 3.2mg/mL PurCol, 
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Bovine Collagen Solution Type 1 (Advance Biomatrix; San Diego, CA, USA), D1 mouse 
mesenchymal DMEM growth media, and 1 N NaOH. Immediately following mixing, D1 
cells labeled with red tracker at a cell density of (2x106 cells/mL) were added to the 
collagen gel prior to gelation. The second layer was formed without cells using the same 
collagen gel composition and methods with the addition of 1% recombinant human 
vascular endothelial growth factor (rhVEGF, R&D Systems, Minneapolis, MN).  
Fiber Preparation 
To prepare the fibers, poly-L-lactide wicking and round fibers were cut into 5-mm 
length samples. The fibers were cleaned by extensive washes with 70% ethanol. After 
ethanol washes, the samples were soaked in phosphate buffered saline (Invitrogen; Grand 
Island, NY, USA) for 3 hours, washed three times with phosphate buffered saline, and air 
dried before use. 
Forming Collagen Hemisphere Composite 
Three different groups of collagen hemisphere composite samples were formed. 
The groups included hemispheres with round, wicking, or no fibers; each with a sample 
size of four and set up as shown in Figure 2.10.  
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Figure 2.10: Two 8-well chamber slides were used to make two-layered collagen 
hemispheres samples (n=4) with and without fibers. 
 
To form the first layer, 5 μL of 1 mg/mL collagen gel solution containing 2x104 
D1 cells was dropped directly onto the glass bottom in each well of an 8-well glass 
chamber slide system (Fisher Scientific, Pittsburgh, PA). Single 5 mm round or wicking 
fibers were centered and placed directly on top of the first layer. Samples were incubated 
at 37°C and 5% CO2 for 1 hour. After the first layer gelled, the second layer of 1mg/mL 
collagen gel containing 1% VEGF was directly dropped on the fiber encapsulating both 
fiber and first layer forming a double-layered collagen gel hemisphere. In samples 
without fibers the second layer was directly added to the first layer. After incubating the 
samples at 37°C and 5% CO2 for 1 hour 250 μL of growth media was added to each 
sample incubated again for 24 hours. Following incubation the collagen hemispheres 
were imaged with an inverted fluorescence microscope and camera using 50x total 
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magnification. A tetramethyl rhodamine iso-thiocyanate (TRITC) filter was used to 
image the distribution of the red-labeled D1 cells. Image J software was used to 
quantitatively determine the extent of D1 cell expansion in the collagen hydrogel 
composite for each experimental group. To do this each image was converted to 
greyscale and split into each specific color channel: red, blue, or green. The cellular 
information from red-labeled D1 cells was solely on the red channel. Blue and green 
channel images were removed. Using the red channel the image was converted to a 
binary image. Figure 2.11 illustrates the conversion of a captured image through this 
imaging J processing method.  
 
 
Figure 2.11: Depicts images after image J processing methods. (A) The initial fluorescent 
image captured, (B) the split red channel image, and (C) the converted binary image. 
 
An elliptical region of interest was used to measure the distance of cell expansion 
from the center. The perimeter (in number of pixels) of cell expansion was calculated for 
each sample based on the elliptical region. The number of pixels was converted to 
micrometers using the length of the scale bar. The perimeter of expansion was 
determined for each experimental group using the same image processing method.  
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Statistical Analysis for Transport of Cells through a Fiber in a Hydrogel 
Statistical analysis was assessed using JMP 10 software. The perimeter of 
expansion of cells was compared in double layer hemisphere samples with round and 
wicking fibers as well as samples without fibers.  
Results 
Progenitor Cell Transport through Wicking Fibers  
The vertical displacement of fluorescently green-labeled D1 cells was assessed along 
wicking and round fibers. The results show a significantly (p<0.001) greater vertical cell 
displacement along the wicking fiber than on the round fiber. Figure 2.12 illustrates a 
much higher density of cells along the wicking fiber compared to the round fibers 
suggesting the wicking fibers can significantly augment cell recruitment.  
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Figure 2.12: (A) Schematic illustrating the location of the captured fluorescent images 
shown in (B) along wicking or round fibers. Measurements of progenitor cell movement 
quantified through imaging software and shown in the chart (C). The vertical 
displacement and cell density along the wicking fibers is significantly greater than the 
round fibers; *p<0.001. 
 
Effect of Fibers on Transport of Progenitor Cell through a Hydrogel with and without 
Fibers 
The expansion and distribution of progenitor cells was assessed in a double-
layered collagen hydrogel in samples with and without round or wicking fibers after 24 
hours of incubation. The fluorescent and binary images shown in Figure 2.13 depict 
greater progenitor cell expansion in collagen hemisphere hydrogels containing wicking 
fibers than hydrogel samples with round fibers or without fibers. The images further 
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illustrate greater progenitor cell expansion in collagen hemisphere samples with round 
fibers than hemispheres containing no fibers.  
 
 
Figure 2.13: Qualitative fluorescent and binary images of collagen hydrogel hemisphere 
samples containing no fibers and samples with round or wicking fibers. Images show 
greatest cell expansion with wicking fibers compared to samples with round fibers or no 
fibers 
 
The data was semi-quantitatively analyzed using image J processing. The 
perimeter of expansion of each hydrogel sample was determined in number of pixels and 
converted into units of micrometers using the scale bar. The chart below shows the 
results perimeter of cell expansion for each sample types. Expansion for hydrogel 
samples containing wicking fibers is significantly greater (p<0.05) than all other 
treatment groups. Hydrogels with round fibers are also significantly greater than just the 
control group without fibers.   
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Figure 2.14: Results of progenitor cell expansion in double-layered collagen hydrogels. 
Samples with wicking fibers showed greatest cell distribution compared to all other 
experimental groups. (* represents significantly different groups with p<0.05) 
 
Discussion 
It is well established that the proprietary wicking fiber shape provides highly 
efficient fluid transport in textile and chromatographic separation applications11–13,15,25. 
The increased transport properties of the wicking fiber is achieved through geometrically 
optimized intra-fiber spaces or grooves that combine capillary pressure to enhance the 
fluid transport or wicking along a single wicking fiber11,14. The unique architecture of a 
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single fiber greatly enhances the capillary action as opposed to a single channel. This is 
confirmed by the fluid transport studies conducted in this chapter.  
Wicking occurs when fluid initially contacts the inter- or intra- fiber space and 
travels due to capillary pressure. The enhanced transport shown by the wicking fibers is a 
result of the shape factor19,20,26.  
Brojeswari Das and coworkers showed a linear relationship between shape factor 
and water uptake. As the shape factor of the fiber increases the water uptake and fluid 
transport increases linearly. The wicking fibers contain 2.5-3.2 times the surface area of 
conventional circular cross-sectional fibers with nominal diameter18. The increase in 
shape factor significantly increases the capillary pressure of the fiber, which improves the 
wicking properties of the fiber. This phenomena is described by Young-Dupre’s equation 
shown below. Chung and coworkers showed that Polylactide wicking fibers have a much 
lower contact angle and superior wetting behavior than round PLA fibers27. The capillary 
pressure is also directly related to the contact angle as described in Young-Dupre’s 
equation. The low contact angle and high shape factor contribute to the superior capillary 
pressure and wicking behavior of the wicking fibers.19,20,27 
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Equation 2.1: Young-Dupre’s Equation 
𝑃𝐶𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦 =  𝛾𝐿𝑉𝑐𝑜𝑠𝜃𝑋   
 
𝑤ℎ𝑒𝑟𝑒, 
𝜃 = 𝑐𝑜𝑛𝑡𝑎𝑐𝑡 𝑎𝑛𝑔𝑙𝑒 
𝑋 = 𝑆ℎ𝑎𝑝𝑒 𝑓𝑎𝑐𝑡𝑜𝑟 
𝑋𝑤𝑖𝑐𝑘𝑖𝑛𝑔 𝑓𝑖𝑏𝑒𝑟 = 3 
𝑋𝑟𝑜𝑢𝑛𝑑 𝑓𝑖𝑏𝑒𝑟 = 1 
 𝜃𝑤𝑖𝑐𝑘𝑖𝑛𝑔 𝑓𝑖𝑏𝑒𝑟 =  67° 
𝜃𝑟𝑜𝑢𝑛𝑑 𝑓𝑖𝑏𝑒𝑟 =  121° 
𝑃𝑤𝑖𝑐𝑘𝑖𝑛𝑔 𝑓𝑖𝑏𝑒𝑟 ≫  𝑃𝑟𝑜𝑢𝑛𝑑 𝑓𝑖𝑏𝑒𝑟 
 
The equation below shows the relationship between spontaneous wicking and 
contact angle and shape factor. Spontaneous wicking will occur with a wicking fiber due 
to the high shape factor and low contact angle. This relationship is not satisfied for round 
fibers.  
𝑺𝒑𝒐𝒏𝒕𝒂𝒏𝒆𝒐𝒖𝒔 𝒘𝒊𝒄𝒌𝒊𝒏𝒈 𝒐𝒄𝒄𝒖𝒓𝒔 𝒊𝒇 𝒕𝒉𝒆 𝒇𝒐𝒍𝒍𝒐𝒘𝒊𝒏𝒈 𝒆𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝒊𝒔 𝒔𝒂𝒕𝒊𝒔𝒇𝒊𝒆𝒅: 
(1 − 𝑋𝑐𝑜𝑠𝜃) < 0  
 
𝑤ℎ𝑒𝑟𝑒, 
𝜃 = 𝑐𝑜𝑛𝑡𝑎𝑐𝑡 𝑎𝑛𝑔𝑙𝑒  
𝑋 = 𝑆ℎ𝑎𝑝𝑒 𝑓𝑎𝑐𝑡𝑜𝑟  
(1 − 𝑋𝑐𝑜𝑠𝜃) < 0 (𝑊𝑖𝑐𝑘𝑖𝑛𝑔 𝑓𝑖𝑏𝑒𝑟) 
(1 − 𝑋𝑐𝑜𝑠𝜃) > 0 (𝑅𝑜𝑢𝑛𝑑 𝑓𝑖𝑏𝑒𝑟) 
 
Fewer studies have assessed the effects of various bundling configurations on the 
diffusive and wicking properties of the fibers. Multiple groups have investigated the 
parallel packing of the wicking fibers for chromatography applications. Wicking occurs 
when fluid initially contacts the inter- or intra- fiber space and travels due to capillary 
pressure 19,20,26. By bundling the wicking fibers more intra- and inter- fiber spaces are 
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created. The increased spaces within the fiber bundles generates more capillary pressure 
and consequently leads to enhanced wicking rates. The studies assessing wicking 
properties of various bundled fibers showed a significant difference in wicking potential 
between braided and twisted fibers. The braided configuration creates discontinuities 
within the conduits of the bundle impeding the fluid flow. The braided configuration also 
shows larger pore sizes between fibers reducing the capillary pressure resulting in a lower 
maximum height of the fluid. Twisted fibers showed both higher fluid front heights and 
greater wicking rates. The twisted configuration shows less inter-fiber space with greater 
contact between individual fibers. The smaller inter-fiber spaces generate smaller pore 
sizes that will increase the capillary pressure of the bundle and result in higher maximum 
heights. The twisted bundles increase the continuity of the channels, which will improve 
the wicking rate of the sample.  
The individual cross-sectional size of the wicking fibers comprising a fiber bundle 
and the number of individual fibers in a bundle will greatly influence the wicking 
properties. The tension of the twisted fiber bundles also plays a major role in the fluid 
properties. Fiber bundles of high tension may distort the grooves of the individual fibers 
blocking fluid flow. On the other hand, bundles with less tension lack the formation of 
inter-fiber spaces that create an increased number of capillary channels along the bundle. 
Future work will investigate the effect of various tensions and of cross-sectional sizes of 
the wicking fibers.  
The wicking fibers were also able to significantly enhance the movement of 
biomolecules into a 3D collagen-agarose hydrogel. It has been well demonstrated that 
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wicking fibers can transport and separate compounds such as proteins, triglycerides, and 
inorganic and organic lead compounds for chromatographic separation by providing 
increased surface area and fluid transport 12,28,29. Similarly, the wicking fibers facilitate 
the transport of the FITC-albumin protein into the hydrogel. The parallel channels along 
the wicking fiber provide high surface area and increased capillary pressure that greatly 
increases the fluid transport and subsequently the rate of protein movement 
These wicking fibers have previously been considered for tissue engineering 
constructs but investigation into the cellular movement was never evaluated12,29,30. The 
final studies in this chapter investigated the potential of wicking fibers to transport 
progenitor cells to assess if these fibers can be used in tissue engineered constructs to 
improve progenitor cell recruitment. The results demonstrated the wicking fibers have 
capabilities to promote both cellular infiltration and distribution. The large surface area 
and superior capillary action and wettability properties promote cellular infiltration along 
the grooves of the wicking fibers. Cell transport was demonstrated by the vertical 
movement of green-labeled D1 cells along the wicking round fiber samples. Significantly 
more cells penetrated the wicking fibers and traveled higher than the round fibers. This 
influx of cells into the wicking fibers is enhanced by the increased surface area and 
wicking properties of the fibers. The intrinsic fluid properties of the fiber were shown to 
enhance the transport of cells, which can provide a unique approach to improving cellular 
seeding in scaffolds. Future work involves tailoring the fibers to recruit and transport 
specific cell types along the conduits.   
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In the last analysis collagen hemisphere hydrogels were used to investigate cell 
distribution and expansion in hydrogel samples containing round or wicking fibers. Prior 
to adapting and developing the collagen hemisphere hydrogel earlier systems using 
collagen-agarose hydrogels were used to optimize a system to assess cell movement in 
the gels with and without fibers. Optimization involved developing a system to observe 
cell mobility. Mobility of cells is dictated by matrix microarchitecture. Factors of the 
matrix that influence cell movement includes fiber density, pore size, stiffness, and bulk 
modulus. 
Prior systems involved embedding round or wicking fibers in a collagen-agarose 
gel comprised of various ratios and assessing movement of fluorescently labeled cells 
into the hydrogel. The addition of agarose to the hydrogel greatly increases stiffness of 
the gel and reduces pore size. Cells show increased mobility in substrates with greater 
stiffness but lose mobility in substrates with reduced pore size. The addition of agarose 
increases stiffness, however, the reduction in pore size greatly inhibits cell movement. 
One mechanism to simulate cell movement is through gradients of stiffness. Cells interact 
with the matrix through mechanosensory molecules and will migrate to regions of higher 
stiffness. Mesenchymal progenitor cells move by binding to collagen fibers through their 
actin cytoskeleton. These cells move through contractility and relaxation of the matrix by 
their actin skeleton1.   
To stimulate progenitor cell movement, the hydrogels were formed to generate a 
gradient of stiffness. One mechanism for changing stiffness of the substrate is by 
adjusting the concentration of the hydrogel. In this case, varying amounts of agarose were 
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added to create a gradient of stiffness. This was reflected by the preliminary studies 
assessing cell movement in collagen-agarose hydrogels. To drive cell migration the 
hydrogels were formed with a gradient of stiffness. The hydrogels were comprised of 
various ratios of collagen-agarose (50:50, 65:35, and 80:20) to stimulate cell migration. 
The preliminary studies showed minimal cell migration in all ratios of collagen-agarose 
hydrogel illustrating the inhibitory effects of agarose on cell movement. 
Building from the preliminary work, other systems were developed to assess the 
use of VEGF to drive cell migration in a collagen hydrogel. VEGF is a growth factor that 
can function and a mitogen and chemoattractant for mesenchymal stem cells. Preliminary 
systems showed both VEGF and changes in collagen concentration can be utilized in this 
to assess cell movement.  
The collagen hemisphere hydrogel study described in this chapter used VEGF as 
the stimulant for the D1 cells to migrate into the second layer of the hemisphere. The 
results from this study showed the wicking fiber greatly increased the distribution and 
expansion of progenitor cells in the double-layered hemisphere compared to hemispheres 
without fibers and with round fibers. The increased surface area of the wicking fiber 
provided conduits within the collagen gel to augment the movement and dispersal of cells 
within the collagen hemisphere. The enhanced surface area and unique cross-section of 
the wicking fibers can be used to improve large tissue engineered scaffolds with limited 
transport capabilities. The fibers can be applied to these large scaffolds to provide 
conduits and capillary forces necessary to recruit and distribute cells.   
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Conclusion 
The results indicate wicking fibers not only play a major role enhancing the 
movement of biomolecules into a 3-dimensional system, but also recruiting and 
transporting cells. This work suggests the intrinsic fluid properties of the wicking fibers 
have potential to greatly improve large bone tissue engineered constructs by providing 
conduits and enhanced capillary forces necessary for enhancing the transport of nutrients 
and movement of biomolecules and cells essential for bone formation.     
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CHAPTER THREE 
IMPROVING TRANSPORT LIMITATIONS OF LARGE SCAFFOLDS  
Introduction 
Spinal fusions are considered large volume bone defects and require large area 
bone grafts to augment repair similar to traumatic fractures. Like most implanted large 
tissue-engineered scaffolds, the surrounding environment and its interaction with the 
scaffold plays a critical role in the success of the graft. When the bone graft is first 
implanted in the fusion site the cellular component of the graft is supported by diffusion 
from the vascular sources of the surrounding site until new vessels are formed during the 
healing process. Therefore, understanding the vascular contribution of the bone graft and 
the surrounding tissue is essential for improving fusion rates1.  
Even with advancements in tissue engineering, the transport properties and 
vascularity of large bone scaffolds are very limited. In most cases, the furthest distance 
oxygen can reach from a capillary vessel via diffusion is roughly 100 μm through tissue. 
Most clinically available synthetic bone grafts exhibit structures that, while are not as 
densely packed as native tissue and may allow for better diffusion ability, are still ten 
times the maximum diffusive distance to the center of the bone graft2 creating oxygen 
limitations. Typically, bone marrow aspirate (BMA) containing osteoprogenitor cells is 
seeded on the bone graft prior to implanting in the fusion site. Due to the increased 
diffusion distance in these scaffolds progenitor cells seeded on the grafts compete for 
oxygen and nutrients. The diffusion distance in large scaffolds limits the amount of viable 
cells that can be supported and proliferate. Muschler and coworkers describes a simple 
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engineering model that relates the size of the bone graft, the seeded cell density, oxygen 
levels, and cell viability2. Necrosis within a bone graft can be theoretically modeled 
based on the oxygen levels at the surface, the cell density within the scaffold, the 
metabolic activity of the cells, and the diffusivity properties of the scaffold. The graph in 
the figure below illustrates the decreased ability of oxygen to reach the central region of 
the scaffold.  
 
 
Figure 3.1: (A) The model developed by Muschler and coworkers shows the highest 
concentration of oxygen is at the surface of the graft and decreases towards the center of 
the graft2. (B) The minimum oxygen concentration occurs at the center of the graft. 
Depending on the number of cells seeded and their metabolic activity necrosis can occur.  
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Equation 3.1: Muschler’s Model Describing of Oxygen Consumption and Diffusion2 
𝑑 (𝐶 𝐶𝑜
⁄ )
𝑑(𝑥 𝐿)⁄
=  𝜙2 =
[𝐶𝑒𝑙𝑙]𝒬𝑐𝑒𝑙𝑙𝐿
2
𝐶𝑜𝐷𝑜𝑥𝑦𝑔𝑒𝑛
→
𝑅𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑒
𝐷𝑖𝑓𝑓𝑢𝑠𝑖𝑜𝑛 𝑟𝑎𝑡𝑒
< 2 
𝐶 = 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑜𝑥𝑦𝑔𝑒𝑛 𝑖𝑛 𝑖𝑚𝑝𝑙𝑎𝑛𝑡 𝑠𝑖𝑡𝑒   
[𝐶𝑒𝑙𝑙] =  𝐶𝑒𝑙𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑐𝑎𝑓𝑓𝑜𝑙𝑑  
𝑥 = 𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑓𝑟𝑜𝑚 𝑠𝑢𝑟𝑓𝑎𝑐𝑒 𝑖𝑛𝑡𝑜 𝑠𝑐𝑎𝑓𝑓𝑜𝑙𝑑 
𝑄𝑐𝑒𝑙𝑙 = 𝑂𝑥𝑦𝑔𝑒𝑛 𝑐𝑜𝑛𝑠𝑢𝑚𝑝𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑒 𝑝𝑒𝑟 𝑐𝑒𝑙𝑙  
𝐿 = 𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑓𝑟𝑜𝑚 𝑡ℎ𝑒 𝑠𝑢𝑓𝑎𝑐𝑒 𝑡𝑜 𝑡ℎ𝑒 𝑐𝑒𝑛𝑡𝑒𝑟 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑐𝑎𝑓𝑓𝑜𝑙𝑑 
𝐷𝑜𝑥𝑦𝑔𝑒𝑛 = 𝐷𝑖𝑓𝑓𝑢𝑠𝑖𝑜𝑛 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 
 
The solution to the theoretical equations described by this model provides the 
oxygen concentration profile with the lowest oxygen concentration occurring at the 
center of the device. This is determined by the cellular consumption of oxygen and 
diffusion of oxygen. The parameter, Φ2, represents the relative ratio of consumption to 
diffusion. When the ratio of consumption to diffusion of this parameter is equal to two 
the oxygen concentration at the center is zero. This model can be useful to predict 
necrosis in large bone scaffolds and determine the optimal number of cells to seed the 
grafts to prevent necrosis. This model can also be used to predict the mass transport of 
small biomolecules such as glucose, fatty acids, amino acids, and other small 
biomolecules transport into and out of scaffolds2. Larger molecules, such as growth 
factors are transported by convection caused from the surrounding vasculature. The 
convection generates pressure gradients to transport the larger biomolecules2. The lack of 
transport of biomolecules will also contribute to necrosis or inadequate tissue formation 
in the central region.  
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In this chapter, the transport limitations of a commercially available bone graft, 
chronOS strip, and potential modifications to improve this were investigated. The 
chronOS strip is a commercially available synthetic bone graft manufactured by Synthes 
and FDA approved for use in posterolateral fusion shown in image A of Figure 3.2 
below. This graft is a composite osteoconductive bone graft comprised from beta 
tricalcium phosphate granules and poly(lactide-co-ε-caprolactone) resorbable polymer.  
Similar to most bone grafts used in large defects, the chronOS strip has a 
thickness of 6 mm as shown in Image B below. The oxygen diffusion distance to the 
center of the graft is 3mm, which is 30 times the normal diffusion distance resulting in 
inadequate sustainable oxygen levels or essential bone forming biomolecules2. It is 
important to note, the main vascular supplies of the posterolateral fusion site are the 
transverse processes, positioned at the outer region of the fusion site, and surrounding 
tissue muscle shown in images C and D. Decortication of the transverse processes allows 
them to contribute as a source of vasculature to the fusion site. Image D depicts the 30 
mm fusion site to which the transverse processes must provide vasculature. This gap 
places the central region of the bone graft 15 mm from the vasculature source; more than 
100 times the normal diffusion distance. Other research groups have shown the 
surrounding muscle, depicted in image C, also plays a major role in contributing 
nutrients, biomolecules, and progenitor cells to the fusion site3. However, the extent of 
contribution from the muscle tissue as well as the mechanism and factors contributed 
from muscle are less established.  
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Figure 3.2: (A) Illustrates placement of chronOS strip during posterolateral fusion (B) 
Dimensions of chronOS strip (C) and (D) depict the two major sources of vasculature to 
the fusion site, transverse processes and paraspinal muscles, respectively. (Also published 
in Tabbaa et al. 20144) 
 
The limited transport to the central region of the fusion site is mirrored in the 
research conducted by multiple groups, most notably Boden and coworkers, who 
discovered a discrepancy between bone formation in the outer regions of the fusion site 
near the transverse processes and in the central region of posterolateral fusion using a 
New Zealand rabbit model. The outer regions experienced significantly faster cancellous 
bone formation compared to the central region, which experience a lag effect or delayed 
bone formation5–9. The delayed bone formation or fibrous formation in the central region 
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greatly increases the susceptibility of pseudarthrosis9–13. Cinotti et al. confirmed the 
vascular density in the outer regions is significantly higher than the central region 
indicating the transverse processes are the main source of vascular supply12–14. The 
delayed bone formation in the central zone is a result of both a lack of neovascularization 
within the region as well as a limited surrounding vascular supply.  
 Tissue engineering approaches for improving mass transport in large bone grafts 
involve modifying scaffold architecture. Scaffold porosity, shape, interconnectivity, 
permeability along with other parameters can affect mass transport properties. Optimal 
pore size has been extensively studied and defined typically between 150μm to 500μm to 
improve mass transport and promote bone in growth15,16. Researchers have also 
extensively studied the ideal porosity for effective diffusion and cell penetration for bone 
regeneration. Typically, researchers have shown a higher porosity of around 90% and a 
greater surface area improves mass transport and overall bone regeneration17–19. 
However, other studies have shown porosity and permeability to have limited effects on 
cell penetration and proliferation, and found the macrostructure including pore shape, 
distribution, and alignment to have a greater influence on the success of the scaffold20,21.  
In this chapter wicking fiber bundles were incorporated into the chronOS scrip 
scaffolds to improve the transport properties by increasing porosity and providing 
conduits that enhance transport and diffusion. The goals of this study were to first test if 
the intrinsic transport properties and architecture of the wicking fibers will improve fluid 
transport. The porosity, as well as the fluid retention and distribution of the chronOS strip 
scaffolds were investigated with and without wicking fibers. The second goal of this 
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chapter was to analyze the effects of the fiber bundles on cell viability, distribution, and 
proliferation in the chronOS strip. The last goal was to investigate if the wicking fibers 
would improve bone formation by evaluating the differentiation of bone progenitor cells 
into an osteoblast phenotype within the chronOS strips.  
 
Scaffold Characterization with Fibers 
Materials and Methods 
ChronOS Strip Preparation 
Commercially-available chronOS strips (Synthes Inc.; West Chester, PA, USA) 
with length of 2.0 cm, width of 2.0 cm, and thickness of 0.60 cm; or length of 4.0 cm, 
width of 2.0 cm and thickness of 0.60 cm were modified with wicking fibers. Poly-L-
lactide (Natureworks; LLC, USA) wicking fibers were extruded with non-circular cross-
sectional dimensions of 0.12 mm x 0.05 mm. Three bundles containing ten wicking 
fibers, 2.0 cm in length, were securely fit through three separately drilled tunnels with 
diameter and length, 1.04 mm and 2.0 cm, respectively that parallel the long axis of 
chronOS strip. Two bundles of ten wicking fibers, 2.0 cm in length, were securely fit 
through two separately drilled holes in the chronOS strips with smaller dimensions.  
Porosity Measurements  
A liquid displacement method established by Ramay and coworkers was used to 
determine the porosity of the chronOS strip samples, 2.0 cm x 2.0 cm x 0.60 cm, with and 
without wicking fiber bundles22. To determine the porosity, the chronOS strip scaffold 
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with or without fibers was submerged in a graduated cylinder containing a known volume 
of 100% ethanol (Vo). The graduated cylinder containing the scaffold was placed under 
vacuum in a transparent desiccator as shown in image below (NalgeneTM Transparent 
Polycarbonate Classic Design Desiccator, Thermo Scientific, Waltham, MA, USA).   
 
 
Figure 3.3: Experimental set-up to assess porosity in chronOS strip scaffolds with and 
without fibers 
 
The vacuum allows the ethanol to penetrate the scaffold and displace the air from 
the scaffold. After no air bubbles were observed the volume of the ethanol was recorded 
(V1). The graduated cylinder was removed from the desiccator and final volume (V2) was 
determined by removing the scaffold from the ethanol and the measuring the remaining 
ethanol volume in the graduated cylinder. To determine the porosity, ε, the following 
equation was used.  
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Equation 3.2: Porosity22 
𝜀 =
(𝑉0 − 𝑉1)
(𝑉1 − 𝑉2)
 
 
Statistical Analysis 
JMP software was used to conduct an unpaired two-sample t-test to compare the 
average porosity for chronOS strip samples with and without fibers using a significance 
level of p<0.05. 
Fluid Transport in Scaffolds 
The vertical test method described in chapter 2 was used to assess absorption, 
wicking, and distribution of fluid in chronOS strip samples of dimensions, 2.0 cm x 4.0 
cm x 0.60 cm. One end of the chronOS strip samples with or without fibers was vertically 
submerged in a reservoir of dye-solution that was comprised of phosphate buffered saline 
(PBS, Invitrogen) and 10% green assorted food coloring (McCormick). The vertical 
displacement of the fluid font was measured through video recording over a 30 minute 
interval with the initial time point starting at the time the scaffolds contact the dye 
solution, shown in image A of Figure 3.4 below. The rate of the capillary rise of the fluid 
front was determined for each sample.  
 A “horizontal test” was also conducted to investigate absorption and distribution 
of fluid in the chronOS strip samples with and without fibers of dimensions, 1.0 cm x 1.0 
cm x 0.60 cm. To simulate direct cellular seeding, 50μL of a dye-solution containing PBS 
and 10% blue green food coloring was pipette directly to the top face of the chronOS 
strip scaffolds. The initial time point is shown in image B in Figure. After 24 hours, the 
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scaffolds were sectioned in half lengthwise and the digital images of the cross-section 
were imaged to analyze the distribution of the dye-solution. 
 
 
Figure 3.4: (A) Initial time point of chronOS strips scaffolds with (Right) and without 
fibers (Left) (B) Horizontal test initial time point 
 
Results 
Porosity Measurements  
 The average porosity for chronOS strip samples containing wicking fibers and 
without fibers was 74.5% and 65.6%, respectively. The porosity of chronOS strip 
samples with wicking fibers was significantly higher than the unmodified chronOS strip 
samples (Figure 3.5). 
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Figure 3.5: The wicking fibers increase the porosity of the chronOS strip samples by 
~10%. The asterisk (*) represents statistically significant differences with p<0.05 
 
Fluid Transport in Scaffolds 
 The vertical test of the dye-solution in scaffolds with and without fibers assessed 
the wicking rate and absorption of fluid. The digital images in Figure 3.6 illustrate the 
modified scaffolds enhanced the wicking rate and absorption of fluid over the 30 minute 
time interval. 
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Figure 3.6: (A) Digital image of vertical test after 5 minutes (B) Digital image of vertical 
test after 30 minute. Images depict wicking fibers enhance fluid transport in scaffolds  
 
The horizontal test evaluated fluid distribution in scaffolds with and without 
fibers after applying the fluid through direct seeding method by directly pipetting the 
solution to the front face of the scaffold. Image B of Figure 3.7 shows the spread of the 
dye-solution in the cross-sectional images of the samples after 24 hours. Samples 
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containing fibers showed more homogenous distribution of dye-solution along the 
interior cross-section.  
 
Figure 3.7: Results from horizontal test. (A) Scaffolds prior to directly seeding dye-
solution to top face of scaffolds (B) Interior cross-sectional images of chronOS strips 
with and without fibers. Scaffolds with fibers show more homogenous distribution of dye-
solution 
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Assessment of Progenitor Cell Recruitment into ChronOS strip  
Materials and Methods 
ChronOS strip Preparation 
Commercially-available chronOS strips (Synthes Inc.; West Chester, PA, USA) 
were sectioned into samples with length of 2.0 cm, width of 1.3 cm, and thickness of 0.61 
cm. Samples were prepared with and without wicking fiber bundles (N=3). Poly-L-
lactide (Natureworks; LLC, USA) wicking fibers were extruded with non-circular cross-
sectional dimensions of 0.12 mm x 0.05 mm. Three bundles containing ten wicking 
fibers, 2.0 cm in length, were securely fit through three separately drilled tunnels with 
diameter and length, 1.04 mm and 2.0 cm, respectively that parallel the long axis of 
chronOS strip. ChronOS strip samples, with and without wicking fibers, were cleaned by 
soaking in three changes of ethanol for 1 hour, and placed under ultraviolet light for 6 
hours. After cleaning, the samples were soaked in three changes of phosphate-buffered 
saline solution for 2 hours (Invitrogen; Grand Island, NY, USA) and soaked in growth 
media consisting of Dulbecco’s Modified Eagle’s medium (Invitrogen; Grand Island, 
NY, USA) supplemented with 10% fetal bovine serum (Gibco; Grand Island, NY, USA), 
10,000 U penicillin, and 10mg streptomycin/mL (Sigma; St. Louis, MO, USA) for 12 
hours.  
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Figure 3.8: Experimental set-up assessing if wicking fibers improve cellular penetration 
and distribution in chronOS strip scaffolds 
  
Progenitor Cell Distribution in chronOS Strip 
Cellular recruitment and distribution was evaluated in modified and unmodified 
chronOS samples of dimensions 1.3 x 2.0 x 0.61 cm using a vertical wicking procedure 
illustrated in the figure below. The vertical wicking procedure involves submerging 10% 
of a vertically aligned scaffold into a well of a low-attachment 24-well plate containing 
500μL of cellular solution with 1 million cells, and analyzing the vertical wicking of 
medium and cells into the scaffolds.  
The wicking and distribution of D1 mouse mesenchymal stromal cells (ATCC; 
Manassas, VA, USA) in chronOS scaffolds, with and without fibers, was evaluated using 
the vertical test method. D1 cells were cultured in Dulbecco’s Modified Eagle’s medium 
(Invitrogen; Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco; 
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Grand Island, NY, USA), 10,000 U penicillin, and 10mg streptomycin/mL (Sigma; St. 
Louis, MO, USA). These progenitor cells were labeled with CellTrackerTM Green 
CMFDA probe (Invitrogen; Grand Island, NY, USA), following manufacturer’s protocol, 
using a long-term labeling concentration of 25μM. After samples were placed vertically 
in cell-tracker solution for 12 and 48 hours, the samples were halved along the 
longitudinal axis and the interior center region of the cross-section was imaged for each 
scaffold, as shown in the figure above.  
The distribution of green-labeled D1 cells was also assessed after directly seeding 
the cell solution onto the top face of the scaffold, experimental set-up shown in Figure 
3.9.  
 
Figure 3.9: Schematic illustrating experimental set-up to assess the horizontal test of 
green labeled cells in scaffolds with and without fibers 
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One million D1 cells labeled with CellTrackerTMGreen were seeded on scaffolds 
with and without fibers by pipetting 50 μL of cell solution directly on the top face of the 
samples. After 24 hours, the scaffolds were bi-sectioned lengthwise to assess the cell 
distribution of the samples in the central interior region. Fluorescent microscopy was 
used to image the cell distribution in the cross-sectional regions of the scaffolds. Cell 
penetration and attachment to wicking fiber bundles was also investigate.  
Evaluation and Statistical Analysis of Cell Distribution  
The images were semi-quantitatively analyzed using ImageJ cell counter software 
and plugin from the National Institutes of Health. The graph in Figure 3.10 depicts the 
percentage of cells in the center region of the cross-section images at the various time 
points for scaffolds with and without wicking fibers. Statistical analysis was conducted 
using an unpaired t-test through JMP statistical software to compare modified and 
unmodified chronOS scaffolds.  
Results 
Cross-section images of chronOS strips containing fibers revealed an increase in 
cell count and homogeneous distribution in the center region following the vertical test. 
The cross-section images of samples without wicking fibers depicted fewer cells, 
distributed mostly along the periphery of the scaffolds. The results showed a statistically 
significant difference (p< 0.05) of percentage of cells in the center when comparing 
scaffolds with fibers and scaffolds without fibers.  
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Figure 3.10: The schematic illustrates the vertical wicking of cells into scaffolds with and 
without fibers. (A) Fluorescent cross-section of densely populated green-tracked cells 
distributed homogeneously in the center region of the scaffold with fibers (B) Fluorescent 
cross-section of fewer green-tracked cells unevenly distributed in the center region of the 
scaffold without fibers (C) Data associated with the fluorescent images comparing the 
percentage of cells in the center region of the scaffolds with and without fibers using 
image J software 
  
The results from the horizontal test, conducted by directly seeding cell solution on 
the top face of scaffolds with and without fibers, showed greater cell penetration and 
distribution in scaffolds containing fibers. The fluorescent images below (Figure 3.11) are 
of the central region of the cross-sectional regions of scaffolds with fibers (A) and without 
fibers (B).  
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The images depict enhanced penetration and distribution of the green-labeled bone 
progenitor cells in scaffolds with fibers. The wicking fiber bundles were directly imaged 
to assess if cells penetrate and attach to polylactide fibers. Images (C) and (D) below show 
significant cell penetration and attachment to wicking fiber bundles after 24 hours.  
 
 
Figure 3.11: Fluorescent images of central region of cross-sectional regions of chronOS 
strips with and without fibers. (A) Scaffolds with fibers depict greater green-labeled cell 
penetration and distribution (B) Unmodified chronOS strip scaffolds shows fewer cells 
and less spread. (C) and (D) show significant cell penetration of the polylactide wicking 
fiber bundles  
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Cell Viability and Proliferation in ChronOS  
Materials and Methods 
ChronOS Strip Preparation 
Commercially-available chronOS strips (Synthes Inc.; West Chester, PA, USA) with 
length of 1.0 cm, width of 1.0 cm and thickness of 0.61 cm were modified with wicking 
fiber bundles. Poly-L-lactide (Natureworks; LLC, USA) wicking fibers were extruded 
with non-circular cross-sectional dimensions of 0.12 mm x 0.05 mm. Three bundles 
containing ten wicking fibers, 1.0 cm in length, were securely fit through two separately 
drilled tunnels with diameter and length, 1.04 mm and 1.0 cm, respectively that parallel 
the long axis of chronOS strip. ChronOS strip samples with and without wicking fibers, 
were cleaned by soaking in three changes of ethanol for 1 hour, and placed under 
ultraviolet light for 6 hours. After cleaning the samples were soaked in three changes of 
phosphate-buffered saline solution for 2 hours (Invitrogen; Grand Island, NY, USA) and 
soaked in growth media consisting of Dulbecco’s Modified Eagle’s medium (Invitrogen; 
Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco; Grand 
Island, NY, USA), 10,000 U penicillin, and 10mg streptomycin/mL (Sigma; St. Louis, 
MO, USA) for 12 hours.  
Cell Seeding and Experimental Set-up 
D1 cells were seeded on scaffolds with and without fibers by pipetting 50 μL of 
cell solution containing 1 million cells in growth media along the tunnels or on the 1.0 x 
0.61 cm face of samples not containing fibers. The samples were placed in a low-
attachment 24-well plate and placed in the incubator for 3 hours to allow the progenitor 
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cells to adhere. After 1 hour, 500 μL of growth medium was added to the scaffolds and, 
after 3 hours, the samples were submerged in growth medium. Cell viability and 
proliferation were assessed by Live/Dead viability/cytotoxicity assay (Life Technologies; 
Grand Island, NY USA), ViaCount assay (Guava Technologies, Hayward, CA, USA) 
using flow cytometry, and PicoGreen assay (Invitrogen; Grand Island, NY USA) 
Live/Dead assay was used to qualitatively analyze the number of viable and dead cells 
after 12 and 48 hours. ViaCount assay quantified the number of viable cells in both 
experimental groups after days 1, 3, 7 and 10 were evaluated using flow cytometry 
(Guava Technologies; Hayward, CA, USA). Cell proliferation was determined by 
quantifying the total amount of double stranded DNA (dsDNA) on both sample types 
using PicoGreen assay after days 4 and 7. The table below summarizes the experimental 
set-up of the study including the time points and number of samples uses for each 
analysis. Medium was replaced every two days for each experimental group.  
Table 3.1: Experimental setup 
 
Live/Dead             
(12 and 48 hours) 
PicoGreen         
(Days 4 and 7) 
ViaCount             
(Days 1,3,7,10) 
chronOS strip 
(unmodified) 
N=3 N=3 N=3 
chronOS strip  
(with wicking 
fibers) 
N=3 N=3 N=3 
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Initial Cell Viability on Interior of Scaffolds 
Live/Dead viability/cytotoxicity assay (Invitrogen; Grand Island, NY, USA) was 
used to qualitatively access the initial cell viability in the interior central region of the 
scaffolds after 12 and 48 hours of culturing cells. Two fluorescent probes, calcein AM 
and ethidium homodimer-1, were used according to manufacturer’s protocol to determine 
live and dead cells in the samples. Samples were bisectioned lengthwise to assess the 
viability of the samples in the central interior region. The sections were washed with 
phosphate-buffered saline (PBS, Invitrogen, Grand Island, NY) and 500μL of 2μM 
calcein AM and 4μM of ethidium homodimer was added to each sample. After 45 
minutes of incubation live and dead cells on the scaffolds were imaged using the 
fluorescein isothiocyanate (FITC) and tetramethyl rhodamine isothiocyanate (TRITC) 
filters, respectively, of the inverted fluorescent microscope (Zeiss Axiovert 135; Zeiss). 
The CCD camera (ProgRes C10plus; Jenoptik) was used to capture images. Image J 
processing was used to semi-quantitatively assess the number of live and dead cells in 
each sample and overlay the respective red and green channels of the images. The 
percentage of dead cells in the center interior region was determined for each scaffold 
type.   
Long-term Cell Viability  
Cells were removed from scaffolds by pipetting 1mL of trypsin-EDTA solution 
(Sigma; St. Louis, MO, USA) into each well and placing the plate on a flattop shaker 
(VWR maybe) set at 200 rpm in a 37oC incubator for 20 min. Following cell removal, the 
removed cells were resuspended in 1mL of growth medium and diluted with ViaCount 
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reagent in a 96-well plate (Guava Technologies, Hayward, CA, USA). The flow 
cytometer was calibrated using Guava Easy Check Kit (EMD Millipore, Billerica, MA, 
USA). The ViaCount assay was conducted following the manufacturer’s instructions. The 
ViaCount assay determines the total number of viable and non-viable cells based on a 
fluorescent dye that stains nucleated cells. The number of viable cells and total cell count 
was determined after Days 1, 3, 7 and 10 of culturing cells on scaffolds.  
Cell Proliferation on Scaffolds 
After culturing samples for 4 and 7 days cell proliferation of chronOS strip 
samples with and without fibers was assessed using PicoGreen Assay (Quanti-iT 
PicoGreen dsDNA Kit; Invitrogen). Samples were washed with PBS and 1 mL of 1X 
Tris-EDTA buffer was added to each sample. The samples were lysed by ultasonicating 
(Sonic Dismembrator, Fisher Scientific) the samples for two 30-second cycles. The lysate 
was collected and stored in microcentrifuge tubes. The DNA concentration in each lysate 
from both experimental groups was determined using the PicoGreen assay by following 
the manufacturer’s protocol. Acellular chronOS strip samples were used as controls. The 
number of cells for each scaffold was determined by using a calibration curve that was 
found by correlating the amount of DNA isolated to a known number of D1 cells counted 
using an automated hemocytometer (EMD Millipore, Billerica, MA,).  
Statistical Analysis 
Statistical analysis was conducted with JMP statistical software using a block model of 
time to compare the amount of viable cells in modified chronOS strips with wicking 
fibers and unmodified chronOS strips, with p<0.05. 
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Results 
Live/Dead assay investigated the number of viable and dead cells in the center 
region of chronOS strip scaffolds with and without fibers. The fluorescent images of the 
modified scaffolds illustrated significantly more viable cells (green) and less dead cells 
(red) in the center region of the scaffolds than scaffolds without fibers at both 12 hour 
and 24 hour time points as depicted in the figure. Image J software was used to quantify 
the percentage of dead cells in both scaffolds types. The semi-quantitative data shown in 
the chart shows significantly less dead cells in scaffolds with fibers than scaffolds 
without at 12 and 48 hours.  
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Figure 3.12: Top image shows an overlay of composite live/dead fluorescent images for 
chronOS strip samples with and without wicking fibers. Bottom chart illustrates 
percentage of dead cells in both scaffold types 
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Cell proliferation was determined by quantifying the amount of DNA in each 
scaffold type using PicoGreen assay. The amount of DNA was correlated to the number 
of D1 cells using the established calibration curve shown in graph below.  
 
 
Figure 3.13: Calibration line that relates a known number of D1 cells to the DNA 
concentration found by using PicoGreen. Determined lysing a known number of cells 
placed in microvials.  
 
The PicoGreen results show greater amounts of D1 cells in scaffolds with fibers 
than unmodified chronOS strip scaffolds after days 4 and 7. Both scaffold types show an 
increase in D1 cell count from Day 4 to Day 7, which indicates cells are proliferating on 
chronOS with and without fibers.   
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Figure 3.14: Results of the PicoGreen assay. ChronOS strips with fibers show more D1 
cell proliferation on Days 4 and 7 
 
Cell proliferation and viability was also quantified using flow cytometry. 
ViaCount assay successfully stained the viable and non-viable cells for each scaffold 
type. The results of viable cells from Days 1, 3, 7, and 10 are shown in the graph below. 
The results show the chronOS scaffolds containing fibers have significantly more viable 
cells and a higher level of proliferation compared to scaffolds without fibers.  
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Figure 3.15: Flow cytometry analysis indicate significantly more viable cells after days 
3, 7, and 10 in scaffolds containing wicking fibers; *p<0.05. 
 
Statistical analysis was conducted with JMP statistical software using a block 
model of time to compare the amount of viable cells in modified and unmodified 
scaffolds. The results showed the cell viability in scaffolds with fibers is significantly 
greater (p< 0.01) than scaffolds without fibers. Both scaffold type results indicate a 
significant difference of cell number between days (p<0.001).  
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Effect of Wicking Fibers on Bone Formation 
Methods and Materials 
Scaffold Preparation 
Commercially-available chronOS strips (Synthes Inc.; West Chester, PA, USA) with 
length of 1.0 cm, width of 1.0 cm and thickness of 0.61 cm were modified with wicking 
fibers. Poly-L-lactide (Natureworks; LLC, USA) wicking fibers were extruded with non-
circular cross-sectional dimensions of 0.12 mm x 0.05 mm. Three bundles containing ten 
wicking fibers, 1.0 cm in length, were securely fit through two separately drilled tunnels 
with diameter and length, 1.04 mm and 1.0 cm, respectively that parallel the long axis of 
chronOS strip. ChronOS strip samples with and without wicking fibers, were sterilized 
with ethylene oxide for 12 hours in an AN74i cabinet sterilizer (Anprolene, Haw River, 
NC) with sterilizing gas ampule of 5cc (Anprolene, Anderson Products Inc., Haw River, 
NC). Samples were degassed in a chemical hood for 72 hours prior to use. Following the 
degassing period, scaffolds were transferred to three 24-well plates using autoclaved 
tweezers and were washed and soaked in PBS for two hours. The PBS was removed and 
1.5 mL of growth media containing was added to each well containing scaffolds and 
placed in the incubator (37°C and 5% CO2) overnight to allow protein attachment. The 
growth media was comprised of Minimal Essential Medium α without ascorbic acid 
(Gibco; Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco; 
Grand Island, NY, USA), 10,000 U penicillin, and 10mg streptomycin/mL (Sigma; St. 
Louis, MO, USA). 
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Cell Seeding and Experimental Set-up 
MC3T3E1 Subclone 4 (ATCC) mouse preosteoblast cells, were cultured by growing 
cells until they reached confluence in a 75 cm2 size area culture flask (Corning, Fisher 
Scientific) and splitting the smaller flask into four larger 150 cm2 area cell culture flasks. 
The larger culture flasks were used to grow a large number of preosteoblast cells needed 
for the study. The study required 54 chronOS strip samples with and without fibers total 
with 1 million cells per sample. Cells were cultured with growth medium consisting of 
Minimal Essential Medium α without ascorbic acid (Gibco; Grand Island, NY, USA) 
supplemented with 10% fetal bovine serum (Gibco; Grand Island, NY, USA), 10,000 U 
penicillin, and 10mg streptomycin/mL (Sigma; St. Louis, MO, USA). Once the large 
culture flasks reach confluence the cells were split and one million MC3T3E1 cells were 
seeded on scaffolds with and without fibers by pipetting 50μL of cell solution along the 
tunnels or on the 1.0 x 0.61 cm face of samples not containing fibers. The samples were 
placed in low-attachment 24-well plates and placed in the incubator for 3 hours to allow 
the progenitor cells to adhere. After 1 hour, 500μL of growth medium was added to the 
scaffolds and, after 3 hours, the samples were submerged in growth medium. Three low-
attachment 24-well plates, containing nine samples for each group (chronOS with or 
without fibers), were used for each endpoint of the study, which included Days 0, 7, and 
14. Each endpoint assay contained three samples (n=3) of chronOS strip scaffolds with 
fibers or without fibers as well control samples (n=3). The control group was MC3T3E1 
cells cultured directly on the 2-dimensional surface of the well plate. The endpoint 
analyses include: alkaline phosphatase (ALP) activity, PicoGreen assay, 
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Immunohistochemistry (IHC), Histological staining, and reverse transcription real-time 
polymerase chain reaction (qRT-PCR). The experimental set-up is depicted in the 
schematic below. 
 
Figure 3.16: Experimental set-up for each endpoint (Days 0, 7, and 14). Each 24-well 
plate includes both experimental groups (chronOS with and without fibers) and a control 
group with no scaffold 
 
Osteogenic Medium 
Samples were cultured in growth medium to promote cellular attachment 
proliferation for 4 days on the scaffolds prior to adding osteogenic differentiation 
medium. After cell growth for 4 days the samples and controls were stimulated with 
osteogenic medium. Day 0 is considered the first day samples are cultured in the 
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osteogenic medium. The osteogenic medium consists of Minimal Essential Medium α 
without ascorbic acid (Gibco; Grand Island, NY) supplemented with 10% fetal bovine 
serum (Gibco; Grand Island, NY), 10,000 U penicillin, and 10mg streptomycin/mL 
(Sigma; St. Louis, MO), 10nM dexamethasone (Sigma; St. Louis, MO), 10mM β-
glycerophosphate (Sigma; St. Louis, MO), and 50μg/mL ascorbic acid (Sigma; St. Louis, 
MO). The first 24-well plate initial time point samples (Day 0) were also collected 
accordingly, as described in subsequent sections, for each endpoint analyses.   
RNA Isolation and RT-PCR 
Related bone forming gene expression markers were assessed for chronOS strip 
samples. The related bone forming markers investigated in this assay, shown in table 
below includes: BMP-2, osteopontin, RUNX2, ALP, and osteocalcin. At days 0, 7, and 
14 chronOS strip samples with and without fibers and controls were collected for RNA 
isolation using Trizol Reagent (Invitrogen; Grand Island, NY, USA). Prior to adding 
Trizol, scaffolds were snap frozen using liquid nitrogen and pulverizer (Tissue pulverizer, 
Cole-Parmer; IL, USA). One mL of Trizol reagent was added to samples containing 
samples and controls to lyse the cells. To isolate the RNA 0.2 mL of chloroform 
(Honeywell; Muskegon, MI, USA) was added to 1 mL Trizol reagent. The addition of the 
chloroform results in a phase separation with the RNA in the aqueous top phase. The 
aqueous phase was collected and isopropyl alcohol (VWR; Radnor, PA, USA) was added 
to precipitate the RNA. The samples were centrifuged, and the RNA was isolated from 
the samples by removing the supernatant. The samples were washed once with 1 mL of 
75% ethanol (Sigma; St. Louis, MO), centrifuged, and the supernatant was carefully 
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removed. Prior to resuspending the participated RNA in 30μL of nuclease-free water 
(Life Technologies; Grand Island, NY, USA) the samples were air dried for 15 minutes. 
DNA was removed from the isolated RNA samples using a TURBO DNASE-Free kit 
(Life Technologies; Grand Island, NY, USA) and following manufacturer’s instructions. 
The quality and quantity of the isolated RNA samples was determined using the 
Nanodrop 2000 spectrophotometer (Thermo Fisher Scientifc Inc.; Waltham, MA, USA). 
Reverse transcriptase was performed using 1μg of RNA for each sample and the 
RETROscript kit (Ambion; Life Technologies; Grand Island, NY, USA) to synthesize the 
RNA to cDNA with a final concentration of 25ng/1μl according to manufacturer’s 
instructions.  
Table 3.2: Primer Sequences for RT-PCR 
Primer Sequence Tm (°C) 
ALP 
F   5’ - GCCTTCTCATCCAGTTCGTAT – 3’ 
R   5’ – CAAGGACATCGCATATCAGCTA – 3’ 
54.2 
54.5 
RUNX2 
F   5’ – CGTCCACTGTCACTTTAATAGCTC – 3’ 
R   5’ – GTAGCCAGGTTCAACGATCTG – 3’ 
55.3 
55.5 
Osteocalcin 
F   5’ – GCTTGGACATGAAGGCTTTG – 3’ 
R   5’ – ACCATCTTTCTGCTCACTCTG – 3’ 
54.5 
54.5 
BMP-2 
F   5’ – ACACTCTCCATCACAGTAGTTG – 3’ 
R   5’ – AGAAGCATGAGCTCTATGTGAG – 3’ 
54.1 
54.2 
GAPDH 
(Internal Standard) 
F   5’ - AATGGTGAAGGTCGGTGTG – 3’ 
R   5’ – GTGGAGTCATACTGGAACATGTAG – 3’ 
54.3 
54.9 
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 Real-time PCR was performed using the primers shown in the table below and the 
QuantiTech SYBR Green PCR kit (QIAGEN; Gaithersburg, MD, USA). The primers 
used were predesigned assays with optimized sequences (PrimeTime qPCR Primers; 
Integrated DNA Technologies; Coralville, Iowa, USA). However, prior to use the 
efficiency of the primers were tested using the QuantiTech SYBER Green PCR kit. The 
standard curve for each primer showed an efficiency greater than 99% for each primer 
tested. PCR was performed using StepOnePlusTM Real-Time PCR System (Life 
Technologies; Grand Island, NY, USA). The cycling parameters used were cycling for 40 
cycles, denaturing at 94°C for 15 seconds, annealing at 54°C for 20 seconds, and 
extending at 72°C for 20 seconds. The Comparative CT method or ΔΔCT method was 
used to calculate the relative gene expression ratios using GAPDH as the internal 
standard and comparing the target gene expression to the undifferentiated samples.  
Equation 3.3: Comparative Ct Method 
𝛥𝐶𝑡(𝑆𝑎𝑚𝑝𝑙𝑒) = 𝐶𝑡(𝑇𝑎𝑟𝑔𝑒𝑡) − 𝐶𝑡(𝐺𝐴𝑃𝐷𝐻) 
𝛥𝐶𝑡( 𝐶𝑜𝑛𝑡𝑟𝑜𝑙) = 𝐶𝑡(𝑇𝑎𝑟𝑔𝑒𝑡) − 𝐶𝑡(𝐺𝐴𝑃𝐷𝐻) 
𝛥𝐶𝑡 = 𝐶𝑡(𝑆𝑎𝑚𝑝𝑙𝑒) − 𝐶𝑇(𝐶𝑜𝑛𝑡𝑟𝑜𝑙) 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝐸𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 = 2−𝛥𝛥𝐶𝑡 
Cell Proliferation Assay 
Cell proliferation of the scaffold groups and the controls were assessed using 
PicoGreen Assay (Quanti-iT PicoGreen dsDNA Kit; Invitrogen) at days 0, 7, and 14. 
Samples were washed with PBS and 1 mL of 1X Tris-EDTA buffer is was added to each 
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sample. The samples were lysed by ultasonicating (Sonic Dismembrator, Fisher 
Scientific) the samples for two 30-second cycles. The lysate was collected and stored in 
microcentrifuge tubes. The DNA concentration in each lysate from both experimental 
groups was determined using the PicoGreen assay by following the manufacturer’s 
protocol. The amount of DNA determined in this assay was used to normalize the 
determined ALP activity.  
Alkaline Phosphatase (ALP) Activity 
ALP activity of the scaffold groups and the controls were assessed using a 
standard colorimetric enzyme ALP Assay (Quanti-iT PicoGreen dsDNA Kit; Invitrogen) 
at days 0, 7, and 14. This assay measures the amount of produced yellow p-nitrophenol 
product by the cells due to the ALP-catalyzed hydrolysis reaction with p-nitrophenyl 
phosphate (pNPP). The same lysate samples that were collected and stored for PicoGreen 
assay were analyzed for ALP activity. A standard curve was prepared by diluting 
phosphate substrate (pNPP, Sigma; St. Louis, MO) to concentrations shown in Table 3.3. 
Table 3.3: Phosphate substrate dilutions for standard curve 
Standard 
Samples 
Initial 
concentration 
pNPP solution 
(μM) 
Initial volume 
of pNPP 
solution (μL) 
Final 
Concentration 
of pNPP 
standard (μM) 
Final Volume 
of standard 
solution (μL) 
Sample 1 0 0 0 120 
Sample 2 1000 1 8.33 120 
Sample 3 1000 2 16.67 120 
Sample 4 1000 4 33.33 120 
Sample 5 1000 8 66.67 120 
Sample 6 1000 16 133.33 120 
Sample 7 1000 20 166.67 120 
Sample 8 1000 40 333.33 120 
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The phosphatase substrate was made by dissolving pNPP in ALP buffer, 
comprised of 16.7 mL of 1.5M Alkaline buffer (Sigma; St. Louis, MO), deionized (DI) 
water, and 50mg MgCl2 (Sigma; St. Louis, MO). Each 96-well plate contained two sets 
of the ALP standard. In the remaining wells, 80 μL of lysate sample and 50 μL of pNPP 
solution were added accordingly. Each sample was added in triplicate. One mg/mL ALP 
enzyme solution (Sigma; St. Louis, MO) was added to the standard wells. The plate was 
covered with foil and incubated for 1 hour at room temperature. Following incubation, 
3M NaOH solution (Thermo Fisher Scientific Inc.; Waltham, MA, USA) was added to 
each well to stop the reaction. The absorbance of the samples was read at 410 nm using a 
Synergy MX Multi-Mode Reader (BioTek; Winooski, VT USA). A standard curve with a 
linear curve fit and equation was generated using the known ALP dilutions. The ALP 
activity was determined by the fit equation and the following ratio. 
𝐴𝐿𝑃 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =  
𝐴
𝑉⁄
𝑇
 
𝐴 =  𝐴𝑚𝑜𝑢𝑛𝑡 (𝜇𝑚𝑜𝑙)𝑜𝑓 𝑝ℎ𝑜𝑠𝑝ℎ𝑎𝑡𝑒 𝑠𝑢𝑏𝑠𝑡𝑟𝑎𝑡𝑒 𝑏𝑎𝑠𝑒𝑑 𝑜𝑛 𝑙𝑖𝑛𝑒𝑎𝑟 𝑐𝑢𝑟𝑣𝑒 
𝑉 =  𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 (𝑚𝐿) 
𝑇 = 𝑅𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒 (𝑚𝑖𝑛𝑢𝑡𝑒𝑠) 
Histology and Immunohistochemistry 
At days 0, 7, and 14 samples for histological an immunohistochemistry (IHC) 
analysis were fixed in 10% formalin solution (Sigma; St. Louis, MO) and stored in PBS 
at 4°C. Prior to cryosectioning samples the scaffolds were decalcified for approximately 
four days using decalcifying solution (Sigma; St. Louis, MO). Routine chemical test for 
determining the end of decalcification was performed by preparing a working solution of 
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equal parts 5% ammonium hydroxide solution and 5% ammonium oxalate solution. 
Decalcification solution below samples was removed and mixed with the working 
solution. No precipitate was observed confirming the end of the decalcification process.  
Following decalcification, optimal cutting temperature (OCT) tissue freeze 
medium (Tissue-Tek O.C.T. Compound; VWR, Radnor, PA) was used to infiltrate the 
scaffolds. OCT medium was used to completely submerge the samples in a disposable 
mold prior to sectioning with the cryostat. To enhance infiltration of freeze medium 
samples were covered with parafilm and placed in the vacuum overnight. After 12 hours 
under vacuum samples were removed and placed on cryostat chuck in the cryostat to 
freeze at -26°C. Samples were sectioned with 6μm thickness and mounted on a positively 
charged microscope slides (Superfrost Plus Microscope Slides; Fisher Scientific; 
Waltham, MA, USA). Sections were taken from the top, middle, and bottom regions of 
the sample. Frozen sectioned samples were immersed in acetone for 24 hours prior to 
histological stains and IHC to improve the adherence of the section to the slide. Sections 
were stained hematoxylin and eosin (H&E) following the protocol outline below in the 
table.  
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Table 3.4: H & E procedures for frozen sections 
 
 
Prior to performing IHC, frozen sections were immersed in acetone for 24 hours 
to improve the sample adherence to the slide. Samples were rinsed extensively in PBS 
and blocked at room temperature for 1 hour in a blocking solution containing 2% BSA, 
5% goat serum, and 0.1% triton X. Following the blocking step, the samples were 
incubated overnight at 4°C with primary antibodies BMP-2 (mouse anti-human), Abcam; 
Cambridge, MA, USA) and osteopontin (rabbit-anti-mouse, Abcam; Cambridge, MA, 
USA) using a 1:500 dilution for both antibodies. After the overnight incubation the 
primary was removed and stored for later use and the samples were gently washed with 
PBS and incubated in the diluted secondary antibody solution at room temperature for 2 
hours. The secondary antibodies used include Alexa Fluor 488 goat anti-mouse antibody 
(Life Technologies Molecular Probes; Grand Island, NY, USA) and Alexa Fluor 568 goat 
anti-rabbit antibody (Molecular Probes; Grand Island, NY, USA). The antibodies used for 
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immunofluorescence staining and the dilutions are summarized in the table below. 
Following the 2 hour incubation with the secondary antibody the sections were washed 
three times with PBS and coverslips were mounted using 40μL of ProLong Gold 
Antifade Mountant with DAPI (Molecular Probes; Grand Island, NY, USA). Samples 
were stored at 4°C away from light until the samples were imaged with the fluorescent 
microscope.  
Table 3.5: Antibodies used for IHC staining 
Primary Antibody  Dilution 
Anti-BMP2 (mouse) 1:500 dilution (1μg/mL) 
Anti-Osteopontin (rabbit) 1:500 dilution  
Secondary Antibody  Dilution 
Alexa Fluor 488 goat anti 
mouse 
1:1000 dilution 
Alexa Fluor 568 goat anti 
rabbit  
1:1000 dilution  
 
Statistical Analysis  
For each target gene the average relative gene expression and standard deviation 
were determined. JMP 11 was used to perform a student’s t-test to determine significant 
differences in average gene expression between fibers and no fibers for each time point. 
A student’s t-test was also used to compare the average ALP activity at each time point 
for chronOS strips with or without fibers.  
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Results 
Alkaline Phosphatase Activity 
The outcomes from the ALP activity assay depicted in Figure 3.17 showed the modified 
chronOS strip samples had significantly higher ALP activity after Days 0 and 7. The 
unmodified chronOS strip samples demonstrated significantly higher ALP activity after 
Day 14. The modified samples showed a decrease in ALP activity at Day 14.   
 
 
Figure 3.17: ALP activity of chronOS strips with and without fibers normalized by 
amount of DNA. Day 0 and Day 7 show chronOS samples with fibers had significantly 
higher ALP activity than chronOS without fibers. Day 14 showed significantly higher 
ALP activity for chronOS samples without fibers; *p<0.05.  
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Real Time-PCR 
The osteogenic differentiation of MC3T3E1 cells was analyzed by monitoring 
gene expression of ALP, Runx2, osteocalcin, and BMP-2. Relative expression of 
osteocalcin showed no significant difference between modified and unmodified chronOS 
strip samples. The modified chronOS strip samples showed higher Runx2 expression 
after Days 0 and 14. Similarly, the modified samples showed higher levels of ALP after 
Days 7 and 14. BMP-2 is a late osteogenic marker and was only observed for both 
samples at the Day 14 time point and showed no significant difference.  
 
 
Figure 3.18: qRT-PCR results for osteoblastic differentiation markers: osteocalcin (A), 
Runx2 (B), ALP (C), and BMP2 (D). Modified chronOS showed significantly higher 
Runx2 expression than unmodified chronOS, *p<0.05.  
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Histology 
The H&E staining for chronOS strips samples are illustrated in Figure 3.19. 
Sections were obtained from the interior regions of the scaffolds. For both groups the 
staining showed greater cell densities after Days 7 and 14. Modified chronOS scaffolds 
show more cellular content and collagen than scaffolds without fibers. Image E shows the 
fibers have oriented the cellular and collagen content.  
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Figure 3.19: H&E staining for chronOS strip samples with fibers after Day 0 (A), Day 7 
(C), and Day 14 (E), as well as chronOS strip samples without fibers after Day 0 (B), 
Day 7 (D) and Day 14 (F). Images show more cells in samples containing fibers. Day 14 
samples with fibers show the aligned cells and formation of collagen. 
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Immunohistochemistry (IHC) 
IHC was used to analyze the amount of osteoblast related proteins. The protein 
expression of BMP-2 and osteopontin was analyzed in sections from the interior of 
modified and unmodified chronOS scaffolds. Fluorescent images after Day 0, Figure 
3.20, showed higher expression of BMP-2 in modified scaffolds. Both scaffolds types 
show low expression of osteopontin.  
 
Figure 3.20: IHC staining for BMP-2 (green), osteopontin (red), and nuclei (blue) for 
Day 0 time point. Top row and bottom row depict chronOS with fibers and without, 
respectively. (A) Overlaid images of BMP-2, osteopontin, and nuclei. (B) Osteopontin 
expression and nuclei staining (C) BMP-2 and nuclei staining. ChronOS containing 
fibers shows greater expression of BMP-2. Both scaffold types show low expression of 
osteopontin.  
 
 After Day 7 both scaffold types showed an increase in BMP-2 and osteopontin 
expression. However, the modified chronOS strip samples showed significantly more 
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BMP-2 and osteopontin expression after Day 7 as indicated by the fluorescent images in 
Figure 3.21.  
 
Figure 3.21 IHC staining for BMP-2 (green), osteopontin (red), and nuclei (blue) for Day 
7 time point. Top row and bottom row depict modified and unmodified chronOS, 
respectively. The modified chronOS scaffolds show significantly more (B) osteopontin 
expression and (C) BMP-2 expression compared to the unmodified scaffolds.  
  
Day 14 shows the greatest expression of BMP-2 and osteopontin for chronOS 
with and without fibers. The chronOS strip samples with fibers show greater expression 
of BMP-2 and osteopontin, depicted in Figure 3.22. The modified scaffold showed a 
significant increase in osteopontin expression, fluorescently labeled red in image B.  
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Figure 3.22: IHC staining for BMP-2 (green), osteopontin (red), and nuclei (blue) for 
Day 14 time point. Top row and bottom row depict modified and unmodified chronOS, 
respectively. The modified chronOS scaffolds show significantly more (B) osteopontin 
expression and (C) BMP-2 expression compared to the unmodified scaffolds.  
 
Discussion 
The goal was to investigate the effects of wicking fibers on a commercially 
available bone graft with limited diffusion to the central region due to the thickness of the 
scaffold. The fluid transport, cell viability, distribution, proliferation, and osteogenic 
differentiation were assessed in both the available scaffold and the wicking fiber altered 
scaffold. Changes in porosity by the incorporation of the wicking fibers into the chronOS 
strip samples were also investigated.  
Fluid and cellular infiltration and distribution were investigated using horizontal 
and wicking tests of the chronOS strip scaffolds. The scaffolds were bi-sectioned 
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longitudinally for both tests to investigate the ability of the fibers to improve both 
transport of cells and fluid to the central region of the scaffold, where transport via 
diffusion is most limited. The outcomes depict the wicking fibers enhance both fluid and 
cell infiltration especially to the central region of the scaffold. Fluid and cell transport 
assessment showed the wicking fibers also significantly improved the distribution of cells 
and fluid in both the central and peripheral regions of the scaffold. Adequate cell 
infiltration to the central region is essential to promote cell growth on the surface and the 
interior regions simultaneously reducing the potential for heterogeneous bone formation 
in the central and peripheral regions. The outcomes from these studies suggest the 
architecture and transport capabilities of the wicking fibers promote cell penetration and 
distribution. The bundled wicking fibers provide increased micro-conduits as well as 
nano-sized and macro-sized channels that greatly enhance the fluid and cellular transport. 
The twisted configuration of the wicking fibers creates inter- and intra- fiber spaces of 
micro-sized channels of limited tortuosity. Micro-size pores have been shown to promote 
cell migration and movement. The bundling effects of the fibers increases the number of 
micro-channels, which will increase the initial fluid and cell transport through enhanced 
capillary action. Furthermore, the fiber bundles greatly increase the surface area to 
volume ratio as well as the porosity and interconnected pores. The results from the 
porosity tests showed the wicking fibers increases the porosity of the chronOS strip 
scaffolds by approximately 10%. It is well documented that higher porosity will improve 
cell infiltration and diffusion. The increased scaffold porosity by the wicking fiber 
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bundles, limited tortuosity, and interconnectivity by the channels provides more efficient 
mass transport and channels to facilitate cell movement and attachment. 
Fluorescent images of the D1 green-labeled cells on the wicking fibers after 24 
hours of direct cell seeding show increased amount of cell penetration and attachment 
along the wicking fiber bundles. As mentioned in chapter 2, the contact angle of 
polylactide fibers with the wicking fiber 8-grooved cross-sectional shape is significantly 
lower than round cross-sectional fibers resulting in a more hydrophilic fiber compared to 
a similar round cross-sectioned polylactide fiber. The enhanced wettability and grooved 
surface promote cell infiltration and cell adhesion, which is mirrored by the fluorescent 
images of the wicking fiber bundles. Interestingly, the wicking fiber architecture of the 
polylactide improves cell adhesion of progenitor cells. Typically polylactide surfaces are 
modified structurally through microtexture, adsorption of adhesive proteins, or chemical 
modifications, to enhance cell adhesion23–25.  The results suggest the 8-grooved 
architecture of the wicking fibers promote the adhesion of cells. This outcome may be a 
result of the hydrophilic and transport properties of the polylactide wicking fibers and 
their ability to enhance the accumulation of extracellular matrix proteins providing a 
favorable environment for the progenitor cells to adhere26.  
 The outcomes assessing cell viability and proliferation suggest the wicking fibers 
improve both cell viability and proliferation of chronOS strip scaffolds. The Live/Dead 
results showed the wicking fibers significantly improved the amount of viable cells in the 
scaffold as well as a significant reduction in the percentage of dead cells in the interior 
central region of the scaffolds. These results suggest the wicking fiber bundles increase 
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mass transport and cells to the central region of the scaffold due to the increased porosity, 
micro-sized conduits, and increased surface area architecture. The ViaCount assay 
quantified the number of viable and dead cells after days 1, 3, 7 and 10 and PicoGreen 
assay assessed proliferation after days 4 and 7. The outcomes showed a significant 
increase in viable cells initially after a week of culture and increase in cell proliferation 
after Day 4. This suggests the wicking fiber may provide enhanced mass transfer both 
initially and long-term.   
The effect of wicking fibers on osteogenic differentiation of pre-osteoblast cells 
was investigated in this chapter. The RT-PCR results showed significantly higher 
expression of the early bone differentiation marker, RUNX2. No significant difference 
was observed for ALP, BMP-2, or osteocalcin. The ALP assay showed significantly 
higher activity for chronOS with fibers at the earlier time points. These outcomes suggest 
the scaffolds with fibers showed earlier differentiation than scaffolds without fibers. 
Furthermore, the immunohistochemistry results revealed high levels of expression of 
BMP-2 and osteopontin for chronOS scaffolds containing fibers after days 7 and 14. 
These results also indicate that differentiation may occur faster in scaffolds containing 
fibers and may improve the amount of bone formation. The limitation of this study was 
the scaffold size used. The chronOS strip samples used for this study were 1cm x 1cm x 
0.6 cm (length x width x thickness) and completely submerged in media. Due to the small 
geometry used there may not be a significant mass transport deficiency to the central 
regions of the scaffold. Future work will investigate bone formation in larger scaffolds in 
a more physiologically relevant environment.  
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CHAPTER FOUR 
IMPROVING CELL SEEDING OF LARGE SCAFFOLDS  
Introduction 
Another limitation of bone scaffolds is effective cell seeding. This includes cell 
distribution as well as cell viability in all regions of the scaffold. Large scaffolds are 
limited by the ability of cells to fully penetrate scaffolds and retain cell viability. 
Researchers have well established these limitations with large scaffold and have shown 
viable cells to proliferate only on the periphery of the scaffold approximately 250 to 500 
μm from the interface of fluid and the scaffold in vitro or the vascular source and implant 
in vivo1. The architecture of bone scaffolds is designed to provide a network for cells to 
proliferate, migrate, and develop matrix. As cells proliferate and form matrix within the 
scaffold, nutrients are diminished in the interior of the scaffold and the developed matrix 
provides a barrier for diffusion. Cells remain along the peripheral regions where 
sufficient nutrients and biomolecules are diffusing. This leads to viable tissue along the 
peripheral regions of the scaffold and limited tissue formation in the interior. Karande 
and coworkers describe this process as an “M&M effect”2. This analogy correlates the 
hard shell of the M&M candy with the peripheral tissue formation and the soft interior of 
the candy with the lack of formation of tissue in the center. Furthermore, researchers have 
correlated cells in different spatial regions of the scaffold alter the diffusion profile of 
nutrients, oxygen, and waste products leading to non-homogeneous tissue formation3. 
Adequate cellular distribution and viability in large scaffold is dictated by the scaffold 
architecture, vascularization, porosity, and other factors discussed in Chapter 2. However, 
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just as importantly, the sufficient uniform cellular seeding with high cellular infiltration 
plays a critical role in homogeneous bone formation.  
Various cellular seeding methods have been explored by previous work conducted 
in our lab as well as by numerous researchers in the field1,4,5. Typically, cell seeding 
approaches are described as static, perfusion, or dynamic techniques. Static techniques 
are the most commonly used and typically involve direct surface seeding and spinner 
flask seeding methods. Table 4.1 shows the outcomes of using various seeding methods.  
Table 4.1: Limitations of various cell seeding strategies 
Approaches to improve 
cell seeding 
Outcomes Reference 
Oscillating Perfusion 
Bioreactors 
Perfusion improves the cell 
distribution compared to 
static approaches 
Wendt. et al. 20033 
Orbital shaker seeding 
Homogeneous distribution 
on surface but distribution 
interior depends on 
scaffold 
Thevenot et al. 20085 
Static seeding 
Homogeneous distribution 
on surface with limited cell 
penetration 
Thevenot et al. 20085 
Low pressure vacuum Vacuum seeding showed 
less homogeneous 
Buizer et al. 20146 
 
The effectiveness of seeding methods can vary based on scaffold type, which is 
defined by the architecture, porosity, overall size, and pore size 7. The aim of this chapter 
is to modify the chronOS strip using a passive transport system to more effectively 
distribute high densities of cells homogeneously on the surface and interior of the 
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scaffold. The chronOS strip is frequently augmented with bone marrow aspirate prior to 
implantation in the defect site. Typically the scaffolds are seeded with cells by injecting 
the scaffold with bone marrow aspirate (BMA). Synthes has developed a perfusion pack 
system to more effectively distribute cells from the BMA within the scaffold. The 
perfusion pack, shown in image below, is a vacuum-sealed system that allows the 
surgeon to inject and cycle BMA using a syringe.   
 
Figure 4.1: Synthes developed perfusion pack for chronOS strip (www.synthes.com) 
  
 Synthes Spine has conducted an in vitro study comparing the cell seeding of 
progenitor cells isolated from BMA by applying the cells with the perfusion pack seeding 
method or by the direct seeding method. The outcomes of this study showed no 
significant difference in cell viability between the two seeding methods, but around a 
40% increase in cell count using the perfusion pack method. The distribution of cells was 
also analyzed in this study. Synthes showed the perfusion pack allowed more cells to 
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infiltrate the central region and bottom face of the scaffold compared to the direct seeding 
method. Although the perfusion method is better than direct application, the amount of 
cells on the top surface is still significantly greater than the amount of cells in the center 
and bottom surface of the scaffold as shown from the fluorescent images below captured 
in this study.   
 
Figure 4.2: Results from Synthes in vitro assessment of the perfusion pack seeding. (A) 
Top surface of scaffold shows significantly more cells than the central region (B) and 
bottom surface of the scaffold (C) 
  
 The limitations of the current cell seeding systems have motivated the development 
of this system that has the potential to be incorporated into other large dense scaffolds with 
limited mass transport and cell infiltration. The objective of this study was to develop and 
evaluate if our proprietary passive transport system, comprised of bundled wicking fibers 
and an absorbent alginate cap (referred to as a “modified wicking bundle”) will improve 
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cell seeding efficiency of the chronOS strip samples. The wicking fiber and absorbent cap 
construction mimics a passive pump that creates an intrinsic cell seeding system within the 
scaffold. The absorbent cap component provides high absorption that enhances transport 
through the wicking fiber bundles and provides a sink to direct and collect progenitor cells. 
Each hydrogel cap encloses one end of the wicking fiber bundle. The cap increases the 
volume, rate, and duration of the transported liquids and cells. The first phase of this 
chapter characterized and assessed the fluid transport properties of the modified wicking 
bundle, as well as, the ability of this system to transport biomolecules and progenitor cells. 
The second phase of this chapter involved the development of a vacuum-sealed perfusion 
pack to assess the perfusion cell seeding efficiency in (1) chronOS strip samples containing 
the modified wicking bundle (referred to as a “modified chronOS strip”) and (2) 
unmodified chronOS strip scaffolds. To assess cell seeding, assays were performed 
investigating cell viability, proliferation, and count in varying locations of the scaffolds.  
 
Characterizing the Modified Wicking Fiber Bundle  
Fluid Transport Tests 
Production of the Modified Wicking Bundle 
  Poly-L-lactide (Natureworks LLC, USA) wicking fibers were extruded with 
irregular cross-sectional dimensions of 0.72 mm by 0.55 mm and poly-L-lactide round 
fibers were extruded with cross-sectional diameter of 0.5 mm. Wicking fibers were sliced 
with razor blade into individual single wicking fibers of 10 cm lengths. The 10 cm wicking 
fibers were used to form wicking fiber bundles. Ten individual fibers were twisted, using 
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an apparatus, at 11 rotations per centimeter twist. The bundle was sliced into 10 cm, 2 cm, 
and 3 cm long sections. Single and bundled wicking fibers were cleaned by soaking in three 
changes of ethanol for 1 hour each, and placed under ultraviolet light for 6 hours. Samples 
were then soaked in a phosphate-buffered saline (PBS, Invitrogen) solution for 2 hours and 
air-dried overnight in a sterile hood. The alginate cap was formed by dipping one end of 
the wicking fiber bundle in 100 μL of 5M CaCl2 solution (Fisher Scientific; Waltham, MA, 
USA) in a well of a 96-well plate and pipetting 100 μL of 1.4% (w/v) alginate solution, 
comprised of alginic acid sodium salt from brown algae (Sigma; St. Louis, MO) in 155 
mM NaCl (Sigma; St. Louis, MO), directly on the submerged fiber tip in the well. The 
alginate immediately adheres to the fiber end and solidifies forming the modified fiber 
construct shown below.  
 
 
Figure 4.3: Modified wicking bundle comprised of 1.4% alginate hydrogel cap and a 
wicking fiber bundle 
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Wicking Tests of Modified Wicking Bundle  
The wicking behavior of the modified wicking bundles were assessed using the 
vertical test methods introduced in Chapter 2. The first test assessed the wicking rate of 
modified and unmodified wicking fiber bundles by evaluating the change in mass of the 
fluid reservoir over regular time intervals depicted in image A of Figure 4.4. The second 
test (image B) investigated the amount of fluid absorbed in modified and unmodified 
wicking bundles after 12 and 24 hours by measuring the volume of fluid remaining in the 
well. The final test assessed the wicking capabilities of the modified wicking bundles, 
unmodified wicking bundles, and unmodified round bundles by recording the wicking 
height of the fluid front moving vertically upward along the fiber at various time points 
shown in image C.  
 
Figure 4.4: Wicking behavior tests. (A) Assessing the change in mass over various time 
intervals. (B) Measuring fluid absorbed after 12 and 24 hours in modified and 
unmodified fiber bundles (C) Measuring fluid height front every minute for a 10 minute 
interval.  
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Both tests methods were used to evaluate the wicking capabilities of round and 
wicking fibers. The experimental groups are described in table below.  
Table 4.2: Experimental groups of twisted bundle configurations for round and wicking 
fibers 
Experimental 
Groups 
Fiber Type Bundle 
Configuration 
Number of Fibers 
in Bundle 
1 Round Twisted bundle 10 
2 Modified Wicking  Twisted bundle 10 
3 Unmodified Wicking Twisted bundle 10 
  
Vertical Test 1 – Fluid Height Assessment 
One end of the various 10 cm long fiber bundles was placed in a dye-solution 
reservoir and held vertical using a custom-made apparatus shown in Figure 4.4 image C. 
The bundles were dipped in the reservoir to assess the wicking height of the dye-solution 
comprised of phosphate buffered saline (PBS, Invitrogen) and 10% blue assorted food 
coloring (McCormick). The fluid front vertical displacement of each sample was 
measured every minute for a 10 minute interval. The capillary rise rate of the fluid front 
was determined for each sample.  
Vertical Test 2 – Volume of Fluid Absorbed  
 The amount of fluid absorbed in modified and unmodified wicking bundles was 
determined after 12 and 24 hours. Samples were vertically placed in individual wells of a 
12-well plate with 1 mL of dye-solution, 10% blue assorted food coloring in PBS, using a 
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custom lid to hold the samples vertical. After 12 and 24 hour time points the bundles 
were removed and the amount of fluid remaining was measured.  
Vertical Test 3 – Wicking Rate Assessment  
To determine the change of mass in the liquid reservoir over time, the balance 
was connected to the computer using a USB to RS232 cable. PuTTY software was used 
to connect to the serial port and transfer information from the balance to the computer. 
The balance was programmed to continuously measure the weight of the reservoir at a 
rate of two measurements per second. After 10 minutes, the continuous function was 
stopped and the recorded data was saved as a text file and imported into Excel for further 
analysis. To measure the amount of fluid the bundles transported, the fibers were 
suspended so only the tip was interfacing the fluid. The wicking rate for each sample was 
calculated from the mass (mg) by time (minutes) plot. The average wicking rate was 
determined in one minute intervals (0-1 minutes, 1-2 minutes, and 2-3 minutes) to 
determine the average instantaneous wicking rate. The change in wicking rate was 
determined by plotting the instantaneous wicking rate at each time point.  
Statistical Analysis  
JMP 10 software was used to conduct an unpaired two-sample t-test to compare 
the average volume of liquid drawn out of the reservoir by modified and unmodified 
wicking bundles at 12 and 24 hours using a significance level of p<0.05. The same 
analysis was used to compare the change in wicking rate of unmodified and modified 
wicking bundles using a significance level of p<0.05. 
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Results 
Vertical Test 1 – Fluid Height Assessment 
Test 1 evaluated the fluid height change between experimental bundles over a 10 
minute interval. The results presented in Figure 4.5 image A show the modified wicking 
bundles have a significantly greater wicking rate (change in height/time interval) 
compared to the unmodified wicking bundles and unmodified round bundles. The digital 
image (Image B) shows the enhanced fluid transport of the modified wicking bundle 
(left) compared to the unmodified (right).  
 
Figure 4.5: (A) The modified wicking bundle depicts the greatest change in fluid front 
height over a 10 minute interval (B) Modified wicking bundles on left depicts 
significantly greater fluid absorption and fluid height than unmodified wicking fiber 
bundles on the right 
 
Vertical Test 2 – Volume of Fluid Absorbed  
The second test evaluated the amount of fluid absorbed by the modified and 
unmodified wicking bundles. The modified wicking bundles absorbed significantly more 
fluid after 12 and 24 hours compared to the unmodified (Image A below). Digital images 
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after 5 minutes and 12 hours qualitatively show significantly more fluid transport in 
modified wicking bundles.  
 
 
Figure 4.6: (A) Modified wicking bundles absorb significantly more fluid after 12 and 24 
hours than unmodified (*) indicates significant difference of p<0.05 (B) Qualitatively 
illustrates enhanced fluid absorption by modified wicking bundles after 5 minutes and 12 
hours 
 
Vertical Test 3 – Wicking Rate Assessment  
The final test investigated the change in wicking rate of modified and unmodified 
wicking bundles. The linear plot of the wicking rate versus time (Figure 4.7) shows the 
modified bundles have an acceleration of 0.2934 mg/min2 with increasing wicking rate 
over time and the unmodified wicking fiber bundles show a deceleration of 0.4022 
mg/min2.  
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Figure 4.7: Plot of the change in wicking rate over a 3 minute time interval. Modified 
wicking bundles show an increasing wicking rate over time 
 
Unimolecular Diffusion of FITC-Conjugated Bovine Serum Albumin in a Hydrogel  
Protein movement in a 3D system was evaluated by analyzing the unimolecular 
diffusion of FITC-conjugated bovine serum albumin (Sigma; St. Louis, MO, USA) in a 
composite hydrogel containing modified wicking bundles, unmodified wicking bundles, 
or no fibers.  
Using the methods described in chapter 2, a 50:50 collagen-agarose hydrogel was 
formed in half of an individual well on a 2-well chamber slide by turning the chamber 
slide on its side and loading it with 1 mL of collagen-agarose solution. Three modified 
wicking bundles (2 cm in length), unmodified wicking bundles (2 cm in length), or no 
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fibers were placed vertically in the center of the hydrogel while the chamber slide was on 
its side and before the hydrogel solidified, as shown in image A of (Figure 4.8). 
Following hydrogel solidification, 1 mL of 100μg/mL solution of FITC-conjugated 
bovine albumin and serum free medium was pipetted into the section of the chamber well 
without the hydrogel, as shown in Figure 4.8.  
 
Figure 4.8: Schematic of experimental set-up of collagen-agarose hydrogel containing 
modified or unmodified wicking bundles. (A) Digital image of rotated chamber well to 
apply hydrogel to half the well (B) Fluorescent microscopy to image diffusion of FITC-
albumin into hydrogel using time-lapse  
 
The rate of FITC-albumin diffusing horizontally through the different 
experimental groups was evaluated using time-lapse fluorescent microscopy (EVOS; 
Floid Cell Imaging Station, Life Technologies); Image J imaging software was used to 
combine the 3D time-lapse images into a z-stack stack and measure the average intensity 
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of a 350x350 pixel square region of interest (ROI) for each time frame. The intensity was 
measured in 1 minute intervals for 30 minutes along the center image frame containing 
the fiber. The rate of FITC-albumin movement was determined in a ROI adjacent the 
interface of the collagen-agarose gel and FITC-albumin solution shown in the schematic 
below.  
 
Figure 4.9: (A) Schematic of an individual well in a 2-well chamber slide filled partially 
containing with collagen-agarose gel containing either modified or unmodified wicking 
fiber bundles. The other portion of the well is filled with medium containing the BSA-
FITC solution. (B) Image frame from time-lapse video of the BSA-FITC diffusion into the 
collagen-agarose gel. Average intensity was measured from labeled ROI adjacent to 
interface 
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Statistical Analysis 
Statistical analysis was performed in JMP 10 using a Student’s t-test to compare 
the average rate of protein movement between each treatment group using significance 
level of p<0.05.  
Progenitor Cell Transport through Modified Wicking Fiber Bundle   
This study tested the ability of the modified wicking fiber bundles to transport 
progenitor cells by wicking phenomena. D1 mouse mesenchymal stromal cells (ATCC; 
Manassas, VA, USA) were cultured in Dulbecco’s Modified Eagle’s medium (DMEM, 
Invitrogen; Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco; 
Grand Island, NY, USA), 10,000 U penicillin, and 10 mg streptomycin/mL (Sigma; St. 
Louis, MO, USA). D1 cells were labeled with CellTrackerTM Green CMFDA probe 
(Invitrogen; Grand Island, NY, USA), following the manufacturer’s protocol using two 
different concentrations of 25μM and 0.5μM, to evaluate the movement of cells through 
modified and unmodified wicking bundles using fluorescent microscopy and flow 
cytometry (Guava EasyCyteTM, Guava Technologies), respectively. The CellTracker 
Green label was optimized for flow cytometry use with D1 cells prior to performing this 
study (See appendix A for cell tracker optimization for flow cytometry study). Six poly-
L-lactide modified (with alginate cap) and unmodified wicking fiber bundles were made 
using the wicking fiber of 3 cm lengths. Lids, with fitted holes and plastic tubes, were 
custom-made for the 12-well plate to securely hold the fiber bundles vertical. One million 
D1 cells tracked with 25μM were pipetted into 6 wells of a low attachment 12-well plate. 
The remaining 6 wells contained 1 million D1 cells of 0.5μM tracker concentration as 
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shown in the experimental set-up below Figure 4.10. Immediately following cell seeding 
the modified and unmodified wicking bundles were vertically placed into each well and 
secured by the custom-made lid.  
 
 
Figure 4.10: Schematic represents experimental set-up evaluating cell wicking in 
modified and unmodified wicking bundles 
 
 The vertical displacement of the cells along the unmodified and modified wicking 
bundles were determined after 1 hour with the initial time point being fiber placement into 
the cell solution. To assess the cell vertical displacement, the fibers were transferred to 
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microscope slides and were evaluated using fluorescent microscopy and imaging software. 
To quantify the cell recruitment into the fiber bundles, the cells were removed from the top 
and bottom regions of the samples. The bundles were sectioned with a blade and the top 
and bottom regions were placed into separate wells of a 24 well plate, Figure 4.11. 
 
 
Figure 4.11: Schematic illustrating cell isolation from top and bottom regions of 
unmodified and modified wicking bundles 
  
 Samples were rinsed with PBS and untwisted. Cells were removed by adding 500 
μL of trypsin-EDTA solution into the well with the fiber region and placing the plate on a 
flat-top (VWR) shaker at 200 rpm in a 37oC incubator. After 15 min the cells were 
diluted in 500 μL of growth media and the number of D1 cells in both regions of the 
constructs were evaluated using a Guava easyCyteTM flow cytometer (Guava 
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Technologies). The number of green-labeled D1 cells in each region was evaluated by 
following the manufacturer’s instructions for InCyte software (Guava Technologies). D1 
cells of known cell densities with and without green tracker, were used as positive and 
negative controls to calibrate the machine before measurements of the treatment groups 
were made.  
Statistical Analysis 
Statistical analysis was assessed using JMP 10 software. An unpaired two-sample 
t-test was conducted to compare the average cell count of D1 cells in the top and bottom 
regions of the unmodified and modified wicking fiber bundles using a significance level 
of p<0.05. 
Cell Recruitment in a Submerged System 
This study investigated the ability of the modified wicking bundles to recruit 
fluorescently green-labeled D1 cells in a submerged system. D1 mouse mesenchymal 
stromal cells (ATCC; Manassas, VA, USA) were cultured in Dulbecco’s Modified 
Eagle’s medium (Invitrogen; Grand Island, NY, USA) supplemented with 10% fetal 
bovine serum (Gibco; Grand Island, NY, USA), 10,000 U penicillin, and 10 mg 
streptomycin/mL (Sigma; St. Louis, MO, USA). D1 cells were labeled with 
CellTrackerTM Green CMFDA probe (Invitrogen; Grand Island, NY, USA), following the 
manufacturer’s protocol using 25μM, to fluorescently image the movement of cells 
through the bundles.  
Poly-L-lactide modified (with alginate cap) and unmodified wicking bundles 
(n=6) were made using 10 wicking fibers of 3 cm lengths. Samples were added to a well 
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of a low-attachment 6 well plate and submerged in 4 mL of growth media and incubated 
for 30 minutes at 5% CO2 and 37°C on an orbital shaker. Following incubation 500μL of 
500,000 fluorescently green-labeled D1 cells were pipette into each of the wells. After 12 
hours of culture the samples were washed with PBS and fixed with 10% formalin. 
Fluorescent microscopy was used to assess the cell infiltration and distribution in the top 
and bottom regions of the unmodified and modified constructs.  
 
 
Figure 4.12: Experimental set-up to assess cellular infiltration in a submerged system. 
Modified and unmodified bundles were submerged in growth media in a 6-well culture 
plate. Cell solution was added to the wells after the samples were submerged. After 12 
hours, the cellular recruitment was assessed by imaging various regions of the modified 
and unmodified bundles, depicted in schematic.  
 
Results 
Unimolecular FITC-albumin diffusion 
The diffusion of FITC-albumin was analyzed in collagen-agarose hydrogels 
containing unmodified or modified wicking bundles, as well as control samples without 
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fibers. The plot depicted in Image A of Figure 4.13 shows the average intensity of 
modified wicking bundles was greatest compared to the other experimental groups over 
the 30 minute time-lapse interval. The results showed the rate of the FITC-albumin 
movement in hydrogels with modified wicking bundles was significantly (p<0.05) greater 
than in the gels containing unmodified wicking bundles and hydrogels without fibers 
(Image B) Error! Reference source not found..  
 
 
Figure 4.13: (A) Plot depicts the modified wicking fiber constructs show greatest 
increase in intensity over 30 minute time interval (B) Hydrogel containing modified 
wicking fiber constructs have significantly greater rate than samples with unmodified 
wicking fibers and samples without fibers; *p<0.05.  
 
Progenitor Cell Transport through Modified Wicking Bundle   
Cell penetration by wicking phenomena was investigated in modified and 
unmodified wicking bundles. Both fluorescent microscopy and flow cytometry analysis 
(Image B and D) of bottom regions of samples showed similar cell densities in both 
construct types. The outcomes from cell isolation from the top regions showed 
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significantly more cell infiltration in the modified wicking bundles than in unmodified 
samples. The fluorescent images confirm the quantitative data and illustrate considerably 
more cell penetration in the top region of the modified wicking bundles.    
 
Figure 4.14: (A) Shows significantly more cells isolated from top regions of the modified 
wicking bundle than unmodified, *p<0.05. (B) No significant cell count in bottom regions 
of bundles (C) Illustrates greater cell penetration in the top region of the modified 
wicking bundle (D) Qualitatively shows no significant difference in cell count in bottom 
regions  
 
 Cell Recruitment in a Submerged System 
Modified and unmodified wicking bundles were submerged in growth media to 
investigate if the modified wicking bundles would enhance cell infiltration in a fluid 
environment. The fluorescent images showed higher cell influx into the modified 
187 
 
wicking bundles than unmodified wicking bundles, shown in Figure 4.14. The modified 
wicking bundle depicted greater cell penetration in the fiber bundle region (image C) as 
well as in the absorbent component (image D).  
 
Figure 4.15: (A and B) Ends of unmodified wicking bundle show less cellular infiltration 
than (C) Modified wicking bundle end and (D) Alginate component   
 
Cell Seeding Efficiency of Modified chronOS Strip  
Development of Perfusion Pack  
Six vacuum-sealed perfusion packs were custom-made using a Food Saver 
Vacuum Sealing System (V2244; Sunbeam Products; Boca Raton, FL). Heat seal pre-cut 
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bags (Food Saver; Sunbeam Products; Boca Raton, FL) were sliced into smaller 8 cm X 8 
cm square plastic sheets. The ends of two square pieces were sealed along the edges of 
the perimeter leaving two sides open to add an injection valve on one side and add the 
sample through the other open edge. The injection valve was attached to the edge using a 
hot glue gun to completely seal the interface between the valve and the plastic sheets. The 
remaining edge containing the valve was heat sealed using the system. One edge was 
remained unsealed to add the chronOS strip samples and vacuum seal the pack using the 
system. Prior to use the perfusion packs were tested to confirm the sheets were sealed 
sufficiently and there were no air leaks.  
chronOS strip samples (Synthes Inc.; West Chester, PA, USA) of length of 2.0 
cm, width of 1.0 cm, and thickness of 0.60 cm were prepared by incorporating modified 
wicking bundles, (referred to as “modified chronOS strips”), N=30. To incorporate the 
modified wicking bundles, containing a wicking fiber bundle and alginate cap, two 
separate tunnels were drilled along the center region parallel to the long axis of the 
chronOS strip with diameter and length, 1.04 mm and 2.0 cm, respectively. Poly-L-
lactide (Natureworks; LLC, USA) wicking fibers were extruded with non-circular cross-
sectional dimensions of 0.12 mm x 0.05 mm. Two bundles containing ten wicking fibers, 
3.0 cm in length, were securely fit through two separately drilled tunnels of the chronOS 
strip. The 1.4% alginate cap was formed on one end of both wicking fiber bundles. The 
wicking fiber bundle was dipped in 100 μL of 5M CaCl2 solution (Fisher Scientific; 
Waltham, MA, USA) in a well of a 96-well plate. Immediately following 100 μL of 1.4% 
(w/v) (Sigma; St. Louis, MO) in 155 mM NaCl (Sigma; St. Louis, MO) was pipette 
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directly on the submerged fiber tip in the well. The alginate immediately adheres to the 
fiber end and solidifies forming the cap. ChronOS strip samples directly used out of 
packaging acted as the control (referred to as “unmodified chronOS strip”). 
 ChronOS strip samples, as well as the perfusion packs were cleaned by soaking in 
three changes of ethanol for 1 hour, and placed under ultraviolet light for 6 hours. After 
cleaning the samples were soaked in three changes of phosphate-buffered saline solution 
for 2 hours (Invitrogen; Grand Island, NY, USA) and allowed to air dry for 24 hours prior 
to vacuum sealing the samples in the perfusion packs. ChronOS strip samples were added 
through the unsealed edge of the perfusion pack and oriented in the central region of the 
pack below the inlet valve. Modified chronOS samples were positioned with the wicking 
fiber bundles facing the inlet and the alginate cap distal the valve. The perfusion packs 
were capped to prevent air from penetrating the packs and the unsealed edge was vacuum 
and heat-sealed using the food saver system. The vacuum-sealed samples in the perfusion 
packs are depicted below, Figure 4.16.  
 
Figure 4.16: (A) Modified chronOS strip sample vacuum sealed with absorbent cap 
positioned distal the inlet valve (B) Unmodified chronOS strip vacuum sealed 
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ChronOS Cell Seeding and Experimental Set-up 
MC3T3E1 Subclone 4, mouse preosteoblast cells, were cultured in a 150 cm2 size 
area culture flask (Corning, Fisher Scientific) with growth media consisting of Minimal 
Essential Medium α without ascorbic acid (MEMα; Gibco; Grand Island, NY, USA) 
supplemented with 10% fetal bovine serum (Gibco; Grand Island, NY, USA), 10,000 U 
penicillin, and 10mg streptomycin/mL (Sigma; St. Louis, MO, USA). Once the large 
culture flasks reached confluence the cells were split and resuspended in 30 mL of 
MEMα at a cell density of 500,000 cells per mL. A 10 mL Becton Dickinson (BD) 
disposable luer-lock syringe (Cole-Parmer; Vernon Hills, IL) was used to seed the 
scaffold in the perfusion packs. The syringe was filled with 5 mL of cell solution and 
inserted securely on the insertion valve immediately after removing the cap, Figure 4.17 
(Image A). The cell solution was injected into the perfusion pack and the syringe was 
used to inject the cell suspension into the pack using 5 cycles of perfusion, following 
manufactures recommended instructions for infiltrating the chronOS strip scaffolds. 
Samples were incubated at room temperature for a clinically relevant waiting period of 
60 minutes in the culture hood (Image B).  
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Figure 4.17: (A) Injected progenitor cell solution into vacuum-sealed perfusion pack 
through inlet valve (B) Incubated perfused samples with cell solution for 60 minutes at 
room temperature 
 
 After 60 minutes of incubation, cell infiltration, distribution, viability, and 
proliferation were assessed using the following assays shown in the Table 4.3 
Table 4.3: Experimental set-up  
 
Live/Dead 
assay 
ViaCount 
assay 
PicoGreen 
assay 
Cell 
Tracker 
Distribution 
Cell 
Metabolic 
Activity 
Dapi/Actin 
Distribution 
Time 
Points 
1 hour 1 hour 1 hour 1 hour 
1, 24, 48, 
72 hours 
72 hours 
Sample 
size 
N=3 N=3 N=3 N=3 N=3 N=3 
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Cell Viability and Total Cell Count  
Initial cell viability was qualitatively assessed using Live/Dead 
viability/cytotoxicity assay (Invitrogen; Grand Island, NY, USA) in the interior central 
and peripheral regions after 1 hour. Samples were bisectioned lengthwise to assess the 
viability of the samples in the central interior region. Two fluorescent probes, calcein AM 
and ethidium homodimer-1, were used according to manufacturer’s protocol to determine 
live and dead cells in the samples, respectively. The sections were with washed with 
phosphate-buffered saline (PBS, Invitrogen, Grand Island, NY) and 500μL of 2 μM 
calcein AM and 4 μM of ethidium homodimer was added to each sample. After 45 
minutes of incubation live and dead cells on the scaffolds were imaged using the 
fluorescein isothiocyanate (FITC) and tetramethyl rhodamine isothiocyanate (TRITC) 
filters, respectively, of the inverted fluorescent microscope (Zeiss Axiovert 135; Zeiss). 
The CCD camera (ProgRes C10plus; Jenoptik) was used to capture images. Image J 
processing was used to semi-quantitatively assess the number of live and dead cells in 
each sample and overlay the respective red and green channels of the images.  
ViaCount assay using flow cytometry was used to quantify the number of dead 
and viable cells. Cells were removed from scaffolds by pipetting 1 mL of trypsin-EDTA 
solution (Sigma; St. Louis, MO, USA) into each well and placing the plate on a flat-top 
shaker set at 200 rpm in a 37oC incubator for 20 min. Following cell removal, the 
removed cells were resuspended in 1 mL of growth medium and diluted with ViaCount 
reagent in a 96-well plate (Guava Technologies, Hayward, CA, USA). The flow 
cytometer was calibrated using Guava Easy Check Kit (EMD Millipore, Billerica, MA, 
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USA). The ViaCount assay was conducted following the manufacturer’s instructions. The 
ViaCount assay determines the total number of viable and non-viable cells based on a 
fluorescent dye that stains nucleated cells. The number of viable cells and total cell count 
was determined after the 1 hour time point.   
PicoGreen Assay (Quanti-iT PicoGreen dsDNA Kit; Invitrogen) was used to 
determine the relative number of progenitor cells on each scaffold type by determining 
DNA concentration. After 1 hour chronOS strip samples were washed with PBS and 1 
mL of 1X Tris-EDTA buffer was added to each sample. The samples were lysed by 
ultasonicating (Sonic Dismembrator, Fisher Scientific) for two 30-second cycles at 20 
Hz. The lysate was collected and stored in microcentrifuge tubes. The double stranded 
DNA concentration in each lysate from both experimental groups was determined using 
the PicoGreen assay by following the manufacturer’s protocol.  
Cell Infiltration and Distribution 
Cell distribution after 1 hour was evaluated by fluorescently labeling the 
MC3T3E1 preosteoblast cells with CellTracker Green CMFDA probe (Invitrogen; Grand 
Island, NY, USA), following manufacturer’s protocol, using a long-term labeling 
concentration of 25μM, before seeding the chronOS strips with perfusion packs.  After 1 
hour of incubation the scaffolds were removed from the perfusion packs, washed with 
PBS, and fixed with 10% formalin for 20 minutes. Samples were sectioned in half along 
the longitudinal axis and the cell infiltration and distribution was evaluated in the central 
and peripheral regions of chronOS strips using fluorescent microscopy.  
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Cell distribution and proliferation was assessed after 72 hours by tagging the cells 
with nuclei and phalloidin molecular probes (Invitrogen). Following the 1 hour 
incubation period the samples were removed from the perfusion packs and placed in a 6-
well plate. The samples were cultured for 72 hours at 37°C and 5% CO2. After the 72 
hour culture period the samples were washed with PBS and fixed with 10% formalin for 
20 minutes. Formalin was removed and samples were further rinsed in PBS. To stain for 
actin and nuclei samples were blocked for 1 hour using blocking solution containing 2% 
BSA (Sigma; St. Louis, MO, USA), 5% goat serum (Sigma), and 0.1% triton X 
(ThermoScintific; Rockford, IL). Samples were washed with PBS and incubated in 500 
μL of Alexa Fluor 488 phalloidin (Invitrogen; Grand Island, NY) solution using a 1:20 
dilution for two hours at room temperature. Following the two hour incubation the 
phalloidin solution was removed and 1 mL of a 2mg/mL Hoechst 33342 solution 
(Thermo Scientific; Rockford, IL) of was added the samples at a 1:2000 dilution and 
incubated for 5 minutes at room temperature. Samples were rinsed with PBS and stored 
at 4°C. To analyze cell distribution and proliferation samples were transferred to a 
microscope slide and imaged using fluorescent microscopy (EVOS; Floid Cell Imaging 
Station, Life Technologies); Image J imaging software was used to overlay images.  
Cell Metabolic Activity 
After 1 hour incubation, 1 mL of media from perfusion pack was removed from 
each sample to measure the amount of glucose consumption and lactic acid production 
using a YSI 2900 biochemistry analyzer (Yellow Springs Instruments; Yellow Springs, 
OH). Samples were removed from perfusion packs, transferred to a 6-well plate, and 
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cultured in growth medium for 72 hours. A volume of 1 mL was removed from the 
samples every 24 hours prior to a medium change for biochemical analysis. Samples 
without cells were also cultured in growth media and collected as negative controls for 
glucose and lactic acid concentrations. The YSI 2900 instrument was run according to 
manufacturer protocol and the glucose and lactic acid measurements from each time point 
were normalized to acellular controls.  
Results 
Cell Viability and Total Cell Count 
  The cell viability after 1 hour in modified and unmodified chronOS strip scaffolds 
was analyzed in the central plane of the scaffolds. Fluorescent images of viable (green) 
and dead cells (red) were obtained from the central and peripheral regions of the interior 
of the samples, shown in Figure 4.18. The Live/Dead fluorescent images of the peripheral 
regions of the modified chronOS scaffolds depicted more viable cells than unmodified 
chronOS strips, Figure 4.19. Similarly, the central regions also illustrated significantly 
more viable cells in the modified chronOS strip samples. The unmodified samples 
showed greater number of dead cells, especially in the central regions as shown in Figure 
4.20.  
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Figure 4.18: The interior cross-section of the modified and unmodified chronOS strip 
samples. Schematic illustrates central and peripheral regions along the cross-section 
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Figure 4.19: Composite images of viable (green) and dead (red) cells in modified and 
unmodified chronOS strip scaffolds. Illustrates more viable cells in modified chronOS 
strip samples 
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Figure 4.20: Unmodified chronOS scaffolds depict greater numbers of dead cells and 
fewer viable cells than modified chronOS strip samples 
  
 The incorporated modified wicking bundles (both the bundle and the alginate cap) 
were imaged to assess cell viability and recruitment of cells into the scaffolds. The 
fluorescent images, Figure 4.21, depict Live/Dead images. The schematic shows the 
regions where the fluorescent images were obtained along the bundle. The images 
illustrate high densities of viable cells along the wicking fiber bundle and in the alginate 
cap. The images suggest the modified wicking bundles significantly increase the amount 
of viable cells penetration the interior regions of the scaffold.  
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Figure 4.21: Schematic illustrations location of Live/Dead images along the modified 
wicking bundles in the chronOS strip scaffolds. The Live/Dead composite images 
illustrate significant cell penetration into the construct and high numbers of viable cells 
along the wicking fiber and alginate component. 
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Cell viability and total cell count was quantified using flow cytometry by removing cells 
from modified and unmodified chronOS samples. The outcomes showed the modified 
chronOS strip samples contained significantly more viable cells and total cells than the 
unmodified samples, Figure 4.22 (Image A).   
 
 
Figure 4.22: (A) Modified chronOS strip samples contained significantly more viable 
cells and total cell than unmodified samples, *p<0.05. (B) Modified samples contained 
four times the amount of DNA isolated from unmodified samples, *p<0.05 
 
Cell Infiltration and Distribution 
The modified and unmodified chronOS samples were perfused with fluorescently 
green-labeled progenitor cells. The cellular infiltration and distribution in both scaffold 
types was assessed with fluorescent microscopy. Cell densities and distribution were 
assessed in the central and peripheral regions of the cross-section. The central regions 
depicted in the fluorescent images below (Figure 4.23) show greater cell infiltration and 
more homogeneous distribution of progenitor cells in the modified chronOS samples than 
201 
 
the unmodified samples. The cell penetration and distribution in the peripheral regions of 
the modified scaffolds were similar to the unmodified scaffolds, Figure 4.24. Progenitor 
cell infiltration was also assessed in the modified wicking bundle that was incorporated 
into the modified chronOS strip scaffolds. Figure 4.25 depicts high progenitor cell 
recruitment into the modified wicking bundle.   
 
 
Figure 4.23: Central regions of the modified chronOS strip scaffolds depict greater cell 
penetration  
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Figure 4.24: Peripheral regions of modified and unmodified chronOS strips show similar 
cell densities and distribution 
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Figure 4.25: Depicts cell recruitment in modified wicking bundles of modified chronOS 
strips. Images depict cells along the twisted fiber bundle embedded in the chronOS 
scaffold. 
  
The actin and nuclei fluorescent stains depicted cell distribution and proliferation after 72 
hours. The images showed similar trends of cell distribution and penetration to the 2 hour 
time point. The peripheral images of both scaffold types showed high cell densities with 
increased proliferation and homogenous distribution (Figure 4.26).  
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Figure 4.26: Actin and nuclei staining of progenitor cells shows high cell penetration and 
proliferation in the peripheral regions of both modified and unmodified chronOS strip 
scaffolds 
 
The central region of the unmodified chronOS strip scaffolds illustrate 
significantly less cell infiltration and proliferation than the modified samples, as shown in 
unmodified labeled fluorescent images, Figure 4.27. The modified samples depict greater 
cell infiltration and proliferation in the central region of the scaffold than unmodified 
samples. The fluorescent images in Figure 4.28 show increased cell penetration and 
proliferation along the modified wicking bundle component.  
 
205 
 
 
Figure 4.27: Cell distribution and proliferation in central regions of modified and 
unmodified chronOS strip scaffolds. Modified samples show significantly more cell 
penetration and proliferation, as well as cell infiltration along the modified wicking 
bundle component 
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Figure 4.28: Images show significant cell infiltration along the wicking fiber - alginate 
construct. Images depict high cell densities along the wicking fiber bundle component 
 
Cell Metabolism  
Lactic acid production was higher in modified scaffolds than unmodified 
scaffolds for each time point, but only significantly higher at Day 2 with a significant 
value of p<0.05. Both scaffold types also showed an increasing lactic acid production 
over the 72 hour time interval. The glucose consumption of modified and unmodified 
scaffolds were not significantly different. Both scaffolds showed increased glucose 
consumption after the 72 hour time point.  
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Figure 4.29: (A) Normalized glucose consumption after 2 hours, 48 hours, and 72 hours. 
No statistical significance was observed on any time point. (B) Normalized lactic acid 
production in modified and unmodified chronOS strip samples. Both scaffolds show 
increase in lactic acid production after 72 hours. The modified scaffolds show greater 
production than unmodified but are statistically significant after 1 hour.  
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Discussion 
In this chapter we developed a passive fluid-driving pump based on wicking, or 
transport driven by capillary action. The outcomes of the fluid transport tests showed the 
absorbent alginate cap enhances the wicking behavior and fluid transport of wicking fiber 
bundles. The vertical test results demonstrated the absorbent cap significantly increases 
the change in the fluid front height over a ten-minute time interval as well as the amount 
of fluid absorbed after 12 and 24 hours. The final wicking test measuring the change in 
mass of the fluid transported over time revealed the wicking rate for the modified 
wicking bundle increases over time while the unmodified wicking bundle showed a 
decreasing wicking rate over time. The wicking rate plot for the unmodified wicking 
bundle will eventually plateau when the sample saturates. The saturation point of the 
fiber correlated to when the wicking rate reaches zero and the fluid reaches the maximum 
height. Interestingly, the wicking plot of the modified wicking bundle is parabolic with 
an increasing wicking rate. This suggests the absorbent cap provides an accelerating 
wicking rate. The acceleration is caused by the evaporation from the alginate cap. As the 
water evaporates from the cap the change in pressure of the system increases driving an 
increase in capillary pressure and consequently increasing the wicking rate. Root system 
in trees analogous phenomena, the fluid in the xylem conduits of trees is driven up by 
negative pressure or tension caused from the evaporation of water from the surface of 
leaves8–10. The modified wicking bundle follows the same mechanism of action. As water 
is evaporating from the alginate cap the water molecules from the conduits in the wicking 
fiber bundle are pulled into the more hydrophilic alginate component by adhesive forces. 
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The transport in the modified wicking bundle system can be described using tree 
hydraulics. The pressure that causes the upward fluid movement in the modified wicking 
bundle is due to the transpiration pressure from the absorbent material and the capillary 
pressure developed from the surface tension of the fiber surface (Equation 4.1)8,11. The 
capillary pressure generated from the surface tension of the wicking fiber bundle is 
described using Laplace equation. The wicking rate is directly proportional to the change 
in pressure of the system. Hagen-Poiseuille law is used to describe liquid capillary rise 
(Equation 4.2). The modified wicking bundles contain the alginate cap that primes the 
system. The change in pressure of the modified and unmodified wicking bundles is 
illustrated in Equation 4.3 and Equation 4.4. The transpiration pressure generated from 
the cap increases the change in pressure of the modified system, as reflected by the 
equation. The modified wicking bundles shows a greater pressure change compared to 
the unmodified bundles driving the enhanced wicking rate presented in the experimental 
data.   
Equation 4.1: Laplace Equation 
 𝑃𝐶𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦 =  
𝛾𝐿𝑉𝑐𝑜𝑠𝜃
𝑅𝑐
 
𝜃 = 𝑐𝑜𝑛𝑡𝑎𝑐𝑡 𝑎𝑛𝑔𝑙𝑒 
𝑅𝑐 = 𝑅𝑎𝑑𝑖𝑢𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦 
𝛾𝐿𝑉 = 𝑆𝑢𝑟𝑓𝑎𝑐𝑒 𝑡𝑒𝑛𝑠𝑖𝑜𝑛 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑙𝑖𝑞𝑢𝑑 𝑎𝑛𝑑 𝑎𝑖𝑟 
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Equation 4.2: Hagen-Poiseuille Law 
 
dh
dt
=
r2
8ηh
ΔP =
r2
8ηh
(
2γcosθ
r
− ρgh) 
𝜃 = 𝐶𝑜𝑛𝑡𝑎𝑐𝑡 𝑎𝑛𝑔𝑙𝑒 
𝑅𝑐 = 𝑅𝑎𝑑𝑖𝑢𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦 
𝛾 = 𝑆𝑢𝑟𝑓𝑎𝑐𝑒 𝑡𝑒𝑛𝑠𝑖𝑜𝑛  
𝜌 = 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑙𝑞𝑖𝑢𝑖𝑑 
𝜂 = 𝐷𝑦𝑛𝑎𝑚𝑖𝑐 𝑣𝑖𝑠𝑐𝑜𝑠𝑖𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑙𝑞𝑖𝑢𝑖𝑑 
ℎ = 𝐻𝑒𝑖𝑔ℎ𝑡 𝑟𝑒𝑎𝑐ℎ𝑒𝑑 𝑏𝑦 𝑙𝑖𝑞𝑢𝑖𝑑 𝑏𝑦 𝑡𝑖𝑚𝑒 𝑡 
Δ𝑃 = 𝑃𝑟𝑒𝑠𝑠𝑢𝑟𝑒 𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 
 
Equation 4.3: Pressure Change of Modified Bundles 
Δ𝑃 = 𝑃𝑇 + 𝑃𝐶 − 𝑃𝐻 
𝑃𝑇 = 𝑇𝑟𝑎𝑛𝑠𝑝𝑖𝑟𝑎𝑡𝑖𝑜𝑛 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 
𝑃𝐶 = 𝑐𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 =
𝛾𝐿𝑉𝑐𝑜𝑠𝜃
𝑅𝑐
 
𝑃𝐻 = 𝐻𝑦𝑑𝑟𝑜𝑠𝑡𝑎𝑡𝑖𝑐 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 = 𝜌𝑔ℎ 
 
Equation 4.4: Pressure Change in Unmodified Bundles 
Δ𝑃 = 𝑃𝐶 − 𝑃𝐻 
𝑃𝐶 = 𝑐𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 =
𝛾𝐿𝑉𝑐𝑜𝑠𝜃
𝑅𝑐
 
𝑃𝐻 = 𝐻𝑦𝑑𝑟𝑜𝑠𝑡𝑎𝑡𝑖𝑐 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 = 𝜌𝑔ℎ 
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 The bundling effect of the fibers creates inter-fiber spaces that will also generate 
capillary pressure. This will increase the upward force moving the fluid. The additive 
effects of bundling the fibers and the absorbent cap transpiration pressure contribute the 
heightened wicking capabilities and fluid transport of this modified construct. 
 The improved fluid transport potential of the modified wicking bundle also 
increased the rate of biomolecule transport and progenitor cell recruitment. The outcomes 
revealed the modified wicking bundle increases the rate of FITC-albumin diffusion into a 
hydrogel compared to unmodified wicking bundles and the control group, a hydrogel 
without fibers. The intensity profiles over the first 5 minute time interval of the modified 
wicking bundle showed a significantly steeper slope than the unmodified bundle. 
Interestingly, we observed similar slopes after the first 5 minute interval. This profile 
indicates the modified wicking bundle was initially primed by the alginate causing an 
enhanced wicking rate. Once the alginate is saturated the wicking rates of the unmodified 
and modified bundles were comparable. This suggests the modified wicking bundle can 
initially improve the recruitment and distribution of biomolecules into a tissue engineered 
construct. Increased transport of bone-forming biomolecules to all regions of the scaffold 
will augment more homogeneous bone tissue formation. The results also depicted the 
modified wicking bundles can increase the initial cell penetration to the top regions of the 
fiber compared to the unmodified wicking bundles, implying the modified bundle may 
improve cell penetration into 3-dimensional scaffolds. Similar to the analysis of protein 
transport, the enhanced wicking is dependent on the saturation of the alginate. After the 
alginate is saturated the system will reach equilibrium. Pilot studies were conducted 
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investigating the equilibrium point of the alginate when submerged. Preliminary results 
demonstrated the alginate saturates after being submerged for 3 hours. Future will 
investigate the saturation point of the alginate and approaches to modify the absorbent 
material to sustain transport beyond the initial seeding phase.  
 The final study of this chapter tested the capabilities of the modified wicking 
bundle to recruit progenitor cells, provide homogeneous cell distribution, and improve 
cell viability and proliferation in a commercially available large bone graft. The 
outcomes showed we can effectively improve cell infiltration and distribution by 
incorporating modified wicking bundles in a diffusion-limited scaffold. Cross-sectional 
images of the central region of modified chronOS strip scaffolds demonstrated 
significantly more cell penetration and distribution than those of unmodified scaffolds. 
We also observed notable amounts of cell penetration along the wicking bundle and 
alginate cap. This verifies the modified wicking system will enhance transport of cells in 
a vacuum-sealed seeding technique. The high surface area of the wicking fiber bundles 
and increased capillary pressure from the alginate cap drives a sizeable force to transport 
not only fluid, but cell populations and biomolecules into a scaffold.  In addition, the 
inter- and intra- fiber spaces generated by the fiber bundle are of varying micro- macro- 
and nano- conduit sizes. The micro sized conduits promote the capillary action of fluid 
and the nano- and macro- sized conduits have been shown to encourage cell adhesion and 
tissue ingrowth, respectively12.  
 Modified chronOS strip scaffolds also revealed improved cell viability and cell 
seeding. Qualitative fluorescent images depicted significantly more viable cells in the 
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cross-sectional images of the modified scaffolds. The flow cytometry results validated the 
high number of viable cells on the modified chronOS strips. The total cell count 
determined by both DNA concentration and flow cytometry was significantly higher for 
modified scaffolds indicating the modified wicking bundles provide a mechanism to 
perfuse and distribute more cells in the scaffolds. The final assessment measuring lactic 
acid production and glucose consumption showed significantly more lactic acid 
production by the modified scaffolds than unmodified after the initial 1 hour waiting 
period. The modified scaffolds showed increased lactic acid production for all time 
points; however, no significant difference was observed after 48 and 72 hours. The 
outcomes further confirm the modified scaffolds initially have improved cell seeding. 
Future work will investigate proliferation after longer time points and bone 
differentiation and formation both in vitro and in vivo in an animal model.  
 
Conclusion 
 Typically seeding progenitor cells on large-sized bone grafts for bone 
regeneration in critical defects have not been successful due to the diffusion limitations of 
the scaffold as well as the ability of the scaffold to effectively infiltrate cells and promote 
homogeneous bone formation. This work with the modified wicking bundle provides an 
intrinsic passive transport system, without the need for an external seeding system, to 
effectively infuse the scaffold with sufficient amounts of progenitor cells and 
successfully distribute the cells in the interior and surface regions.  
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CHAPTER FIVE 
DEVELOPMENT OF AN ANTIBIOTIC RELEASE SYSTEM 
Introduction 
 The incidence of infection is another major limitation of critical bone defects. 
Although the infection rate will vary based on type of fracture and patient indications, the 
addition of bone supplementation to the procedure increases the propensity to infection 
and can reach rates of 13%1. These cases of infection become problematic as the 
treatment for infection is costly and risk for reinfection is very high1–3. Conventional 
systemic antibiotic delivery limitations involve systemic toxicity and poor penetration 
into the postoperative tissue. As an alternative and more effective solution, local drug-
eluting antibiotic is used preoperatively to help prevent the primary infection. The host 
matrix, the type of drug used, and the clearance rate dictate the efficiency of the current 
local release systems4.  The major disadvantage of these delivery systems is the short-
term burst release profile. Many systems release high effective concentrations of 
antibiotic up to 120 hours but subsequently drop out of the therapeutic window 
potentially resulting in resistant subpopulations of infective agents2,53.  Prolonged high 
antibiotic concentrations are needed to eradicate bacteria and prevent the formation of 
any resistant bacteria2,6. Conversely, many of the current antibiotic eluting systems 
release drugs at concentrations significantly higher than the minimal inhibitory 
concentration (MIC) for preventing bacteria. High concentrations over the MIC can cause 
local toxicity and adversely affect bone formation7. The pharmacokinetics of the current 
systems is often not known and difficult to control and reproduce2.  
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 The goal of this chapter was to develop an antibiotic release system using the 
wicking fiber-alginate construct to effectively elute antibiotic long-term at optimal 
concentrations. The following studies tested the release profile of gentamicin for proof-
of-concept. Gentamicin is frequently used as a locally administered antibiotic for 
orthopedic procedures. This antibiotic has the ability to eradicate staphylococcus aureus, 
the most common pathogen in orthopedic procedure related infections. The goal for 
antibiotic release of the system is to provide concentrations above the minimal inhibitory 
concentration and below the nephrotoxicity concentration8. Additionally, we aimed to 
maintain this range in effective concentration over a time span of 2 weeks to improve 
upon current clinical systems. Specifically, we investigated three different antibiotic 
loading mechanisms into the fiber bundles and tested the elution profile and effect on the 
properties of the polylactide. This work also investigated the antibiotic loading of the 
alginate cap and release profile over two weeks. The loading mechanisms were optimized 
to provide a long-term antibiotic release profile at sufficient inhibitory concentrations to 
reduce the rate of infection.  
Gentamicin Release Profile from Fiber Bundles and Alginate Caps 
Materials and Methods 
Extrusion and Experimental Set-up of Fiber Bundles 
 Three different antibiotic loading mechanisms were tested with polylactide round 
and wicking cross-sectional fibers. The first mechanism involved loading the fibers after 
extrusion by wicking the antibiotic solution into the fiber bundles using the previously 
discussed vertical test procedure. The second and third loading mechanisms incorporated 
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the antibiotic during the polymer extrusion process. Briefly, the extrusion process, also 
depicted in the schematic below, involves feeding polymer beads into a funnel through a 
hopper that is connected to a barrel with a feed screw controlled by an electrical motor 
that transports the polymer through a heated conduit. The pellets are incrementally heated 
to a melting temperature, determined through differential scanning calorimetry (DSC), 
producing an amorphous polymer melt. The extruder contains a pump that provides 
pressure to push the polymer melt through the dye containing the cross-sectional mold. 
Changes in fiber diameter can partially be attributed to changes in the rotational speed of 
the pump motor. The extruded fiber is wrapped around sequential rollers and a spool, 
which can be manipulated to control the drawing rate also affecting fiber diameter. A 
water bath can be applied directly below the die to quench the polymer fibers 
immediately after extruding to reduce the effects of drawing on the fibers 
  
  
219 
 
 
Figure 5.1: Schematic shows the extruding process of polymer fibers. Polylactide beads 
are inserted through a funnel into a hopper with a screw that transport the polymer 
through a heating cylinder. The pump pushes the melted polymer through a die to form 
the cross-section shape of the fiber 
 
The second loading mechanism involves quenching the fibers immediately after 
the polymer is drawn from the die (outlet) into a water bath containing antibiotic solution. 
The final approach to incorporate antibiotic during the extrusion process involves mixing 
antibiotic powder with the polylactide beads prior to adding the beads to the funnel. The 
table below summarizes the antibiotic loading mechanisms and experimental groups 
tested in this study.  
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Table 5.1: Loading Mechanisms 
 Loading Mechanism 1 Loading Mechanism 2 Loading Mechanism 3 
Description 
Wicking antibiotic 
solution into bundles 
Incorporate antibiotic 
power with polymer 
pellets prior to 
extruding 
Quench the extruded 
fiber in a water bath 
containing antibiotic 
solution 
Round PLA 
fibers 
N=5 N=5  
Wicking PLA 
fibers 
N=5 N=5 
N=5 (Small wicking 
Bundle) 
N=5 (Large wicking 
fiber) 
 
Loading Mechanism 1  
 Round and wicking fiber bundles were extruded using a continuous melt-extruder 
and spinneret system (Alex James and Associates, Inc.; Greenville, SC) Polylactide 
(PLA) pellets (PL biopolymer ~228,000 Da; Natureworks LLC) were melt-spun into 
monofilament fibers. The extrusion melt temperature of the PLA pellets was based on the 
glass transition (Tg) and melt temperatures (Tm) previously determined using differential 
scanning calorimetry (DSC). The pellets were melt-spun at 167°C. The melted polymer 
was extruded through spinnerets containing either the wicking (eight-grooved) or round 
cross-sectional die. The wicking die used has an irregular cross-section with a long axis 
of 0.2045 inches and the short axis of 0.1494 inches as depicted in image A of the 
drawing below. The die used to extrude the round fibers had a diameter of 0.1500 inches. 
A slower pump speed of 5 RPMs was used to extrude both round and wicking fibers to 
produce monofilaments of smaller cross-sections. A water bath was used to quench the 
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fibers directly 12 inches below the die at the outlet of the system. The water bath system 
was modified with a rolling track to feed the polymer fiber through the quenching liquid 
and onto the successive rollers as demonstrated in the digital image below. 
 
 Figure 5.2: Depicts the feeding of the polymer monofilament from the outlet through the 
water bath and along the rollers 
 
The extruding monofilament was wrapped around five successive rollers 
controlled by motors to effectively draw and collect the fiber onto a spool. The motor 
speed of the pump used in the extrusion process produced round extruded monofilaments 
with a cross-sectional diameter of 0.50 mm. The extruded wicking fibers had dimensions 
of 0.51 mm and short axis 0.33 mm, depicted in image B of figure 5.1.  
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Figure 5.3: (A) Long and short axis dimension of the die used for extruding the wicking 
fibers. (B) Cross-sectional image of the PLA extruded wicking monofilament 
 
Round and wicking bundles were sliced into individual fibers of 3 cm length from 
the spool. Ten of the individual fibers were twisted to form fiber bundles of round or 
wicking fibers. The fiber bundles were vertically placed in a 12-well plate with a custom-
made lid to hold the fiber bundles vertically. Each well contained 1 mL of gentamicin 
sulfate salt powder (Sigma; St. Louis, MO) and phosphate-buffered saline (PBS, 
Invitrogen, Grand Island, NY) at a concentration of 150 μg/mL. . The gentamicin solution 
was loaded into the fiber bundles by allowing the solution to wick into the bundles. After 
1 hour of vertical wicking, the samples were removed and transferred to a 6-well plate 
containing 2 mL of PBS containing eluted gentamicin. This procedure was performed to 
determine the amount of gentamicin elution over 14 days. The initial time point was 
collected immediately following the placement of the wicking fiber bundles in the well 
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plates. The PBS was collected in 1.5 mL microcentrifuge tubes and stored at -20°C until 
the gentamicin analysis was performed. The wells were refilled with 2 mL of PBS and 
incubated at 37°C and 5% CO2 until the next time point. Samples were collected initially 
for short time intervals after 15, 30, 45 minutes, and 12 hours. Samples were also 
collected for longer time intervals with daily collection after days 1-7. After the day 7 
time point, samples were collected after day 10, 14, 21, and 28.   
Loading Mechanism 2 
The extrusion system and settings were used to extrude the round and wicking 
fiber bundles as in the first loading mechanism. However, instead of wicking the 
gentamicin solution, 250 mL of gentamicin solution (Sigma) was added directly to the 
water bath used to quench the fibers. The gentamicin solution again was at a 
concentration of 150 μg/mL in PBS. After the round and wicking fibers were extruded 
bundles were formed, and the elution profile was determined using the same procedure 
described in mechanism 1. 
Loading Mechanism 3  
The gentamicin solution was incorporated into the PLA by mixing a 1% w/w 
gentamicin sulfate salt powder (Sigma) with polylactide pellets (Natureworks) prior to 
loading the pellets into the extruder. Specifically, 500 mg of gentamicin sulfate was 
added to 50 g of PLA pellets. The inlet of the extruder is illustrated in figure 5.2. After 
mixing, the gentamicin coated polylactide beads were loaded into the inlet of the 
extruder. Wicking fibers were extruded with the melt-extruder and spinneret system with 
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the same extruding settings described in mechanism 1 with removal of the water bath. 
This approach drew the fibers directly onto the rollers without quenching the fibers with 
the water bath prior, shown in schematic below.  
 
 
Figure 5.4: Depicts third approach for incorporating antibiotic into extruded polymer 
fibers by mixing the gentamicin powder and polylactide pellets prior to loading the 
extruder 
 
The third mechanism investigated gentamicin elution from wicking fiber 
monofilaments extruded with two different cross-sectional sizes. The experimental 
groups of this loading approach involved two different sized wicking fiber filaments. The 
first experimental group (N=5) included a twisted fiber bundle of 10 individual small 
extruded filaments with cross-sectional dimensions of 0.51 mm x 0.33 mm and of 3 cm in 
length. The second experimental group (N=3) for this loading mechanism analyzed a 
single large wicking fiber that was extruded by removing all drawing functionality of the 
spooling process. The extruded large wicking fiber had dimensions of 1.4 mm and short 
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axis 0.83 mm. The large monofilaments were sliced into individual samples each 3 cm in 
length. Both experimental groups were placed in 2 mL of PBS and incubated at 37°C and 
5% CO2. Samples for this mechanism were collected after days 1, 2, 4, 10 and 14.  
Experimental Set-up for Alginate Caps 
 The elution profile from the alginate caps was also investigated. The gentamicin 
loaded caps were formed by first creating an alginate-gentamicin solution of 1.4% (w/v) 
alginic acid sodium salt from brown algae (Sigma; St. Louis, MO) and 150 μg/mL of 
gentamicin sulfate salt (Sigma; St. Louis, MO) in 155 mM NaCl. The solidification 
agent, 5M CaCl2 solution (Fisher Scientific; Waltham, MA, USA), was pipetted at 100 μL 
into a well of a 96-well plate. To form the cap, 100 μL of the alginate-gentamicin 
solution was directly added to the CaCl2 solution in the well and immediately solidified. 
The alginate caps (N=5) were transferred to a 6-well plate containing 2 mL of PBS. To 
determine the elution profile of gentamicin from alginate the PBS was collected and 
replaced at the initial time point, immediately after submerging the caps in PBS, as well 
as after short term time points of 15 min, 30 min, 45 min, 1 hour, and 12 hours.  Samples 
were also collected to investigate long term release after Days 1-3, 7, 14, 21, and 28.  
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Determining the Total Amount of Incorporated Gentamicin 
 This assay determined the total amount of gentamicin bound and incorporated 
into the round and wicking fibers from the various loading mechanisms. All sample types 
from each fiber loading mechanism (N=3) were dissolved in 1 mL chloroform 
(Honeywell; Muskegon, MI, USA) in glass microvials at room temperature for 10 
minutes and mixed with a vortex mixer (VWR; Radnor, PA, USA) every 5 minutes. To 
isolate the gentamicin from chloroform 500 μL of distilled water was added to the 
chloroform and mixed with the vortex. The samples were centrifuge resulting in a phase 
separation with water-soluble gentamicin in the aqueous phase. The aqueous phase was 
collected and analyzed using the following described gentamicin detection assay.  
 To assess the amount of gentamicin that was bound to the alginate, the hydrogel 
was dissolved in a dissolution buffer comprised of 100mM sodium citrate (Fisher 
Scientific; Waltham, MA USA), 10 mM HEPES buffer (Sigma; St. Louis, MO USA), 
and 27 mM NaCl (Sigma; St. Louis, MO USA) in 50 mL of distilled water. The alginate 
caps were transferred to a 1.5 mL Eppendorf microcentrifuge tubes (Sigma; St. Louis, 
MO USA) containing 1 mL of the stock dissolution buffer. The alginate caps were 
dissolved for 30 minutes at 37°C and mixed vigorously using the vortex every 5 minutes. 
Following complete dissolution of the alginate cap the amount of gentamicin left in the 
solution was analyzed following the detection assay.  
Gentamicin Detection Assay  
The amount of gentamicin over the 28 day time interval was determined using a 
spectrophotometric technique developed by Frutos and coworkers. To create a detectable 
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compound the gentamicin was derivatized by adding equal proportions of fluorescent 
agent o-phthaldialdehyde (OPA)9. Specifically, the OPA reagent reacts with the primary 
amine functional groups on the gentamicin forming a fluorescent detectable complex. 
Prior to analyzing the samples, a standard curve was generated and tested by creating the 
gentamicin in PBS concentrations seen in the table below. 100 μL of each standard 
concentration was added to a well of a black-bottom 96 well plated (Corning; Fisher 
Scientific, Waltham, MA USA). To detect the gentamicin, 100 μL of phthaldialdehyde 
regent (Sigma; St. Louis, MO) was added and mixed with each well containing standard 
sample. The plate containing the standard was incubated at room temperature for 10 
minutes and read with a Synergy MX Multi-Mode Reader (BioTek; Winooski, VT USA) 
at an excitation wavelength of 340 nm and an emission wavelength of 455 nm. The 
standard curve was generated using the fluorescent readings and a linear curve fit was 
performed to determine the equation.  
Table 5.2: Standard curve concentrations for gentamicin detection assay 
Standard 
curve 
concentrations 
0
𝜇𝑔
𝑚𝐿
 1
𝜇𝑔
𝑚𝐿
 2
𝜇𝑔
𝑚𝐿
 5
𝜇𝑔
𝑚𝐿
 10
𝜇𝑔
𝑚𝐿
 20
𝜇𝑔
𝑚𝐿
 100
𝜇𝑔
𝑚𝐿
 150
𝜇𝑔
𝑚𝐿
 
 
To analyze the elution profile the samples stored at -20°C were thawed to room 
temperature and 100 μL of the sample were added to a black clear-bottom 96-well plate 
(Corning; Fisher Scientific, Waltham, MA USA). Subsequently, 100 μL of o-
phthaldialdehyde regent was added and mixed with each well containing sample. Due to 
the variability of readings between plates each 96-well plate containing samples 
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contained standard gentamicin samples in duplicate to generate a standard curve for each 
plate. The sample was incubated at room temperature for 10 minutes and the fluorescent 
spectrometry was performed using a Synergy MX Multi-Mode Reader (BioTek; 
Winooski, VT USA) at an excitation wavelength of 340 nm and an emission wavelength 
of 455 nm.  
Differential Scanning Calorimetry 
Differential scanning calorimetry (DSC) was used to investigate any effects of the 
loaded gentamicin on the melting point and glass transition temperature as well as the 
endothermic and exothermic processes during the physical transitions of the polylactide 
monofilaments. The experimental groups analyzed were (1) polylactide monofilaments 
without gentamicin (2) polylactide monofilaments with gentamicin from the loading 
approach using the water bath (Mechanism 2) and (3) polylactide monofilaments with 
gentamicin from incorporating antibiotic with pellets prior to extrusion (Mechanism 3). 
Fiber samples were sliced with a razor and added to the bottom of a standard aluminum 
pan. Approximately 2-3 g of sample were added to each pan bottom. A lid was used to 
cover the pan and tweezers were used to manually crimp the pan to seal the edges. The 
DSC was performed using a TA instruments Q1000 DSC (TA Instruments; New Castle, 
DE) using helium purge gas. The scans were performed from 10°C to 200°C with a 
heating rate of 10°C/minute. Universal Analysis 2000 software was used to integrate the 
peaks. The melting point and glass transition temperatures were compared for each 
experimental group. The DSC curves were also qualitatively analyzed to determine any 
alterations in percent crystallinity.  
229 
 
Statistics 
JMP 10 software was used to conduct an unpaired two-sample t-test to compare 
the average gentamicin concentration release from round and wicking fibers for both 
loading mechanisms 1 and 2 for each time point. The average amount of antibiotic 
initially loaded in round fiber bundles by mechanism 2 was compared to the initial 
antibiotic loaded in wicking fiber bundles using an unpaired two-sample t-test.  
 
Results 
Elution Profile from Fiber Bundles (Mechanism 1 and 2) 
 Gentamicin was incorporated into extruded round or wicking fibers by wicking 
the antibiotic solution into the bundles (Mechanism 1) and by quenching the fibers in a 
water bath (Mechanism 2). The loading mechanisms were tested by analyzing the elution 
profile of gentamicin from both round and wicking fiber bundles at various time points. 
The short-term release of gentamicin by the fiber bundles was evaluated for the first 45 
minutes. The outcomes depicted the highest release of gentamicin at the initial time point 
from the fiber bundles for all experimental groups, presented in image A of Figure 5.5. 
The wicking fiber bundles loaded through mechanism 1 showed significantly more 
release of antibiotic initially than any other group (p<0.05). The gentamicin released from 
the wicking fibers modified with mechanism 2, showed significantly higher 
concentrations at the initial time point than round fiber bundles loaded with gentamicin 
from either mechanism. After 15 minutes the wicking fibers incorporated with antibiotic 
through mechanism 1, showed significantly more release of gentamicin than round fibers 
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loaded with antibiotic through the same mechanism. The later time points show no 
significant difference in gentamicin release from any of the experimental groups. The 
results demonstrate that the loading mechanism and fiber type will affect the initial 
release of antibiotic but neither factor plays a significant role after 15 minutes. The 
minimal inhibitor concentration (MIC) for various bacterial strands is considered around 
1μg/mL, indicated by the red dotted line. Ideally, the antibiotic delivery system should 
elute above the MIC value. The outcomes show only the wicking fiber groups reach this 
concentration after the initial time point, and none of the experimental groups reach the 
MIC concentration after time zero. The results illustrated in image B of Figure 5.5 shows 
the cumulative release of gentamicin from the fiber bundles after 45 minutes. This can be 
used to determine how much antibiotic is left in the fiber bundles.  
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Figure 5.5: (A) Gentamicin release from round or wicking fiber bundles loaded with 
gentamicin from mechanism 1 or 2. At the initial time point all the experimental groups 
show a significantly different concentration of gentamicin (#,$,*,+) signify each group is 
significantly different within the initial time point (p<0.05). After 15 minutes the wicking 
fiber group loaded by mechanism 1 is significantly greater than the round fiber group 
loaded by the same mechanism, (*) signifies statistical differences between these groups 
with p<0.05.  The red dotted line indicates the target elution concentration. (B) Depicts 
the cumulative release of gentamicin from each experimental group  
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 The release profile of gentamicin was also analyzed over longer time intervals. 
The results shown in Figure 5.6 below show similar eluted concentrations of gentamicin 
from each experimental group for each time point. From 12 hours to 2 days all 
experimental groups depicted negligible concentrations of gentamicin except the wicking 
fiber group loaded by mechanism 2. However, after days 7 and 14 gentamicin was 
released and detectable. After days 7 and 14 there is no significant difference in eluted 
concentrations between fiber bundle groups. Image B depicts the cumulative release 
profile of gentamicin from each experimental group. The wicking fiber bundle group 
loaded with gentamicin through mechanism 2 shows the greatest cumulative 
concentrations over time compared to the other experimental groups.  
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Figure 5.6: (A) Release of gentamicin from wicking fiber bundles after longer time 
intervals. Gentamicin was undetectable in early time points for all experimental groups. 
No significant difference in gentamicin elution was found at any of the time points (B) 
Cumulative release profile of the gentamicin elution from each experimental group shows 
the wicking fiber loaded by mechanism 2 has the greatest cumulative elution over this 
time interval. 
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Gentamicin Elution from Mechanism 3 
 This study investigated the elution profile of gentamicin in a bundle of small 
wicking fibers and a single large fiber to explore the effect of cross-sectional size on 
elution of gentamicin. This mechanism incorporated the antibiotic by mixing the PLA 
pellets and gentamicin prior to extruding. The release profile, shown in image A of 
Figure 5.7, shows both wicking fiber types eluted above the MIC concentration for the 
duration of the study. Both fiber types showed an initial burst release of gentamicin. The 
burst release from the large wicking fiber was much greater than the release from the 
small fiber bundle. The cumulative release for each time point from the large single 
fibers, Image B, of gentamicin was greater than the release from the small fiber bundles. 
Amount of Antibiotic Loaded for Mechanism 2 and 3 
 The amount of antibiotic loaded into each of the fiber types by mechanism 2 or 
mechanism 3 was determined by dissolving the PLA fibers and isolating the gentamicin 
in the aqueous phase. The amount of antibiotic loaded by mechanism 3 was significantly 
greater than the second loading mechanism, Figure 5.8. The wicking fiber loaded by 
mechanism 2 contained ten times the amount of gentamicin loaded by the same 
mechanism. This confirms the high surface area of the wicking fiber can incorporate 
more gentamicin. The large single fiber loaded by mechanism 3 has less total gentamicin 
loaded than the single fiber bundles.  
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Figure 5.7: Release profile of gentamicin loaded by mechanism 3. (A) Elution profile of 
small bundled wicking fiber and a single large wicking fiber (B) Cumulative release of 
both wicking fiber types over a 14 day time period. 
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Figure 5.8: The amount of gentamicin incorporated into the PLA fibers from loading 
mechanisms 2 and 3 
 
Elution Profile from Alginate Caps 
The gentamicin release profile from the alginate caps is depicted in Figure 5.9. 
The results demonstrate a burst of antibiotic from the initial time point and slower steady 
release of antibiotic after 15 minutes. The total amount of gentamicin loaded in the caps 
was determined by dissolving the alginate, indicated by the “dissolved” group in Figure 
5.9. Image B depicts the cumulative release of gentamicin from the alginate caps. The 
profile illustrates by 15 minutes almost half of the total concentration of antibiotic has 
been eluted and by day 14, the entire loaded antibiotic was released. Image A also depicts 
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the red dotted line that correlates to the target elution concentration. The outcomes reveal 
the alginate reaches this target concentration until Day 7.  
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Figure 5.9: (A) Elution from alginate caps shows an initial burst and steady release of 
gentamicin. The total amount of gentamicin loaded in the alginate is depicted in both 
graphs. The red dotted line indicates MIC. The release from the alginate cap reaches the 
target concentration until Day 7. (B) The cumulative release profile shows that all of the 
gentamicin loaded was completely eluted by day 14.  
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Differential Scanning Calorimetry  
The DSC plots of the control polylactide wicking fiber group and the 
experimental groups containing gentamicin through loading mechanisms 2 and 3 are 
shown in Figure 5.10. Plot A shows the DSC curve after the first heat cycle. Mechanism 
2 (red) and the control group (green) show similar glass transition temperatures (Tg) and 
melting temperatures (Tm). Mechanism 3 (blue) depicts similar Tg value with different 
heat flow values compared to Mechanism 2 and the control group. Mechanism 3 also 
shows two different melting temperatures, as indicated by the double blue peaks (Image 
A). Mechanism 3 also demonstrates a different crystallinity profile than both the control 
group and mechanism 2. Image B shows the DSC plots after the second heating cycle. 
The Tg values and heat flows are similar for all groups. The melting curves show similar 
melting temperatures for each group but different heat flow values. The table reported 
below summarizes the Tg and Tm values for the control and experimental groups. The plot 
also shows varying crystallinity curves for each group. The DSC preliminary results 
suggest the gentamicin may alter the crystallinity and raw properties of the 
monofilaments, which may affect the mechanical performance and degradation rate.  
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Table 5.3: Results from DSC showing Tg and Tm for each polylactide wicking fiber 
experimental group 
 Tm (Cycle 1) Tg (Cycle 1) Tm (Cycle 2) Tg (Cycle 2) 
No Gentamicin 149.6 59.42 151.68 57.87 
 Mechanism 2 150.98 60.55 150.98 59.41 
Mechanism 3 
147.61 
154.47 
62.00 150.87 59.07 
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Figure 5.10: (A) DSC plot after first heating cycle of the experimental and control group. 
The control group and Mechanism 2 show different heat flow curves at the Tg value. 
Control group and Mechanism 2 show the same Tm values. Mechanism 3 depicts a 
different Tm value with two melting temperatures. All the groups show a varying 
crystallinity curve (B) DSC curve after second heat cycle shows similar Tg and Tm values 
but different crystallinity curves than the control polylactide group 
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Discussion 
The outcomes demonstrate the fiber type, round or wicking, will affect the elution 
of gentamicin. Mechanism 1 successfully incorporated the gentamicin by wicking the 
antibiotic solution through round or wicking fiber bundles. Mechanism 2 loaded the fiber 
bundles by quenching the monofilaments in a water bath containing the gentamicin 
solution. The wicking fiber bundles loaded by mechanism 1 showed greater gentamicin 
release initially. By wicking solution into the bundles the gentamicin remains on the 
surface of the bundles trapped between the inter fiber spaces and grooves. Since 
gentamicin is water-soluble we expect to see high releases of the antibiotic from the 
surface initially for samples loaded by mechanism 1. The wicking fiber bundles showed 
significantly greater release of gentamicin at the initial time point than round fibers. This 
suggests the wicking fibers incorporate more gentamicin through wicking than the round 
fibers. The later time points show the wicking fiber bundles loaded by mechanism 2 has 
the greatest cumulative release from day 1 to day 14. By incorporating the antibiotic 
during the quenching process the gentamicin will bind more strongly to the surface, since 
the polymer has not quite solidified. The results show the antibiotic is released more 
slowly from mechanism 2 compare to mechanism 1. The wicking fibers loaded by 
mechanism 1 and 2 reached the minimal inhibitory concentration (MIC) of 1μg/mL at the 
initial time point and remained below the MIC for the remaining time points. This 
implies the loading concentration of the water bath should be increased or the amount of 
fibers used should be increased to produce higher elution concentrations. The results 
demonstrate the wicking fibers initially elute significantly higher concentrations of 
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antibiotic compared to the round fibers suggesting the increased surface area and 
geometry of the fibers plays a role in the gentamicin elution profile. This was also 
confirmed by the dissolution of the PLA fibers to determine the total concentration of 
antibiotic loaded. The wicking fiber loaded by mechanism 2 showed a ten-fold increase 
in gentamicin loaded than the round fibers loaded by the same mechanism.  
Mechanism 3, however, showed a rapid burst release of the antibiotic after 24 
hours and a steady release of the antibiotic above the minimal inhibitory concentration 
for 14 days. This high release can be attributed to incorporating the gentamicin into the 
raw material. Mechanism 1 and mechanism 2 incorporate gentamicin primarily on the 
surface leading to quick release of the antibiotic. The large single fiber showed a much 
higher burst release and cumulative release of the gentamicin. Interestingly, the amount 
of gentamicin loaded in the large single fibers was less than the gentamicin incorporated 
into the small wicking bundles. This implies the bundle has a slower release profile than 
the single large wicking fiber. The large fiber bundle has significantly greater surface 
area in contact with the buffer solution compared to the small fiber bundle. The reduced 
surface area in contact with the buffer and the tortuosity of the small fibers may 
contribute to the slower release from the bundle. After Day 14 most of the gentamicin has 
eluted from the large fiber bundle. The small fiber bundle, however, has eluted 
approximately 30% of the total antibiotic incorporated. We would expect consistent 
release from the bundles for 4 more weeks. Future work will investigate the long-term 
release from mechanism 3.  
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The antibiotic loading mechanisms 2 and 3 incorporate the antibiotic into the 
polylactide fiber. This was confirmed by the change in crystallinity of the DSC plots. 
Further work will investigate if the gentamicin will alter the degradation of the polymer.  
Other research has been conducted investigating the release of gentamicin from 
polylactide beads or films for bone regeneration applications. Methods to incorporate 
gentamicin into polylactide involve creating a polymer solvent with gentamicin and 
casting the solution to form a film7,10. Other methods have created polylactide beads 
loaded with gentamicin by sintering the polymer and antibiotic into a mold to form the 
bead10.  Wang et al. has correlated the degradation of polylactide and antibiotic release. 
This research showed significant degradation and weight loss of the polymer at the 
surface with fractures and holes forming in the interior of the material over time. After 1 
week, the surface degradation showed large holes on the surface and small holes 
initiating in the center. The increased concentration of gentamicin at days 7 and 14 in our 
study can correlate to the degradation rate of the polylactide. This suggest the fiber 
bundles may provide a long-term sustained release critical to preventing infections over 
months. Future work needs to investigate the release over longer periods of time. The 
water bath mechanism may not have bound gentamicin to the interior bulk of the polymer 
fibers.  
The combined elution profiles of the alginate and wicking fiber construct has the 
potential to elute high concentrations of antibiotic initially when there is high infection 
risk for the patient by the alginate and also sustain release long-term with polylactide 
fibers.  
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CHAPTER SIX 
DEVELOPMENT AND TESTING OF THE MODIFIED WICKING BUNDLE FOR 
CELL SEPARATION AND ISOLATION  
Introduction 
The National Cancer Institute estimates ten million Americans have or have had 
some form of cancer. The annual economic cost of cancer is $126 billion1. The high 
incidence rate of cancer drives the need for reliable and accurate testing. While testing 
ability has increased, the incidence of diagnostic error, including failure to diagnosis the 
existing cancer and delayed diagnosis can occur as frequently as 1 in 5 cancer cases2. A 
major contributing factor for this error is the extensive oncologic pathology testing 
process. From the time the test for a patient is ordered to the time the test result is 
obtained the oncology pathology testing consists of 200-300 individual steps. This 
extensive process provides frequent opportunities to switch or contaminate samples, as 
well as chances to inadequately prepare, analyze, or interpret specimen properly3. The 
process can take up to ten days and often requires multiple pathologists and oncology 
specialists to confirm and analyze results. This system is time-consuming, expensive, and 
the testing frequently delivers subjective results.  
The in vitro diagnostic (IVD) tests including histological analysis use biomarkers 
as an essential component for detection. The world market for IVD testing is expected to 
reach $7 billion this year4. This technology is a relatively established market for biopsy 
analysis. However, the biomarker market is emerging for technologies that analyze liquid 
biological samples such as blood, serum, and urine5. Although the use of biomarkers has 
247 
 
improved prognosis of patients and developing therapeutics it considerably contributes to 
the incidence of oncology diagnostic error. A major limitation in using biomarkers to 
identify cancer is that there is no universal tumorigenic marker. The complexity and 
heterogeneity of the cancer cells within a tumor create a challenge for researchers to 
characterize the tumor based on phenotypic and genotypic biomarkers. Tumors are 
reported to have different subpopulations of cancer cells with varying phenotypes and 
degrees of tumor initiating capabilities 6. Cancer stem cells are primarily considered to be 
a tumor propagating subpopulation that have the ability to self-renew and differentiate to 
form a hierarchy of cancer cells with varying metastatic potential and tumorigenic 
capabilities7–12. The transient phenotypes of these cells create complexities for current 
detection methods and treatments 13. For instance, cancer stem cells have the potential to 
be dormant or aggressive 14. This ability to phenotypically change may cause resistance 
to treatment and recurrence 15. The origin of these cancer stem cells remains elusive; 
however, researchers are finding cancer stem cells to have similar functions and protein 
expressions as progenitor cells16. The conventional methods for identifying progenitor or 
cancer cells involve detecting biomarkers and analyzing gene expression7. The use of 
phenotypic and genotypic biomarkers to identify progenitor lacks specificity, and 
provides limited information regarding the stem cell potential. Similarly, the use of 
biomarkers to detect cancer is very limited due to the heterogeneity of the cancer cells 
and plasticity of the expressed biomarkers.  
Diagnostic techniques are shifting from invasive tissue samples towards liquid 
biopsy analysis, such as blood biopsy. A non-invasive blood biopsy sample can be used 
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for detecting circulating tumor cells (CTCs) to diagnose the cancer stage, monitor 
treatments, and provide insight into the metastatic process4,17. However, major limitations 
for detecting CTCs are the exceedingly low concentrations of CTCs in blood samples and 
the heterogeneous phenotypes within the CTC population18,19. As a result, the current 
CTC detection and isolation systems have low capture efficiencies and low specificity. 
Technologies for CTC detection and separation include macro-scale systems and 
microfluidics that use physical characteristics of the cells as well as surface labels. Most 
macro-scale systems use antibody-dependent techniques that detect epithelial markers to 
target CTCs. These approaches assume all CTCs are expressing epithelial markers, which 
therefore limit these approaches to a specific subpopulation of CTCs. Aggressive CTC 
populations may have mesenchymal phenotype that lack epithelial markers in the 
bloodstream are missed by these conventional technologies13,20–23. Other CTC detection 
methods include microfluidic devices and chips that use both antigen-dependent and –
independent techniques to detect and separate cancer cells. These approaches have better 
specificity and isolation efficiency but are restricted to small volumes of sample and low 
yield of isolated CTCs19,24.  
We have investigated the use of wicking fibers to separate cancerous from normal 
cell types, as well as, progenitor cell types from more differentiated cells. One aspect of 
this chapter was to evaluate the capability of wicking fibers to identify and isolate cancer 
cells from benign cells and metastatic cells from non-metastatic cells in heterogeneous 
cellular solutions. The other aspect was to assess the cell separation and isolation of 
progenitor cells and differentiated cell lines.  
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We first tested the ability of the single and bundled wicking fibers to (1) separate 
a mixture of normal mouse mammary epithelial cells (MMTV-neu) from mouse 
epithelial breast cancer cells (NMuMG), (2) separate and isolate malignant human breast 
epithelial cells (MCF-7) and benign human breast epithelial cells (MCF-10A), and (3) 
separate a mixture of mouse mesenchymal progenitor cells (D1) from mouse pre-
osteoblast cells (MC3T3E1). 
In the subsequent analysis, the ability of the modified wicking bundle (previously 
described in Chapter 4) to increase the rate and number of cells recruited and separated 
was investigated and tested. The cell separation and isolation of various cell types in the 
modified wicking bundle was investigated using (1) Human cancerous breast epithelial 
cells (MCF-7) and benign breast epithelial cells (MCF-10A), (2) Metastatic human breast 
cancer epithelial cells (MDA-MB-231) and benign breast epithelial cells MCF-10A, (3) 
Non-metastatic cancer cells (MCF-7) and metastatic cancer cells (MDA-MB-231), (4) a 
tri-culture mixture of benign (MCF-10A), non-metastatic (MCF-7), and metastatic 
(MDA-MB-231), and (5) Mouse mesenchymal progenitor cells (D1) and mouse pre-
osteoblast cells (MC3T3E1). In this work we analyzed the wicking behavior, 
displacement, and isolation of various cell lines. We believe cellular characteristics 
including cell size, deformability, shape, cell surface charge, and cell surface adhesion 
molecules play a role in the cellular wicking of various cell lines. This chapter 
investigated if various cancer cell types can be distinguished based on their wicking 
behavior. Furthermore, the wicking behavior of progenitor cells and more differentiated 
cell lines was analyzed to compare similarities of progenitor and cancer cells. A summary 
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of the cell lines used and the wicking fiber tests performed in this chapter are presented in 
Table 6.1.  
Table 6.1: Summarizes the cell lines used in this chapter 
CELL LINE DESCRIPTION 
MMTV-NEU Normal mouse mammary epithelial cells 
NMUMG Mouse epithelial breast cancer cells 
MCF-7 Human cancerous breast epithelial cells 
MCF-10A Human benign breast epithelial cells 
MDA-MB-231 Human metastatic breast epithelial cells  
D1 Mouse mesenchymal stem cells 
MC3T3E1 Mouse pre-osteoblast cells 
RAW Mouse macrophage cells 
 
To investigate the cell wicking behavior the cell lines were labeled with a 
fluorescent tracker or transfected with fluorescent protein. Fluorescent microscopy and 
imaging software were used to semi-quantitatively analyze cell displacement. Cells were 
isolated from various regions of the construct and quantified using flow cytometry.   
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Table 6.2 summarizes the wicking fiber configuration used, the cell types 
investigated, and the analysis used to determine the wicking behavior.  
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Table 6.2: Summarizes the type of wicking fiber construct used to cell wicking, the cell 
types analyzed, and the type of analysis 
Wicking fiber 
configurations used 
Cell types used  Analysis  
Single wicking fiber  
Mouse cancer (NMuMG) and 
normal (MMTV-neu) cells 
Fluorescent microscopy and 
imaging software 
Single wicking fiber  
Human cancer (MCF-7) and 
benign (MCF10-A) cells 
Fluorescent microscopy and 
imaging software  
Bundled wicking fiber  
Human cancer (MCF-7) and 
benign MCF-10A cells 
Fluorescent microscopy and 
flow cytometry  
Modified wicking bundle  
Human cancer (MCF-7) and 
benign (MCF-10A) cells 
Fluorescent microscopy and 
flow cytometry  
Modified wicking bundle 
Human metastatic (MDA-MB-
231) and benign (MCF-10A) 
cells 
Fluorescent microscopy and 
flow cytometry  
Modified wicking bundle 
Human metastatic (MDA-MB-
231) and non-metastatic cancer 
(MCF-7) cells 
Fluorescent microscopy and 
flow cytometry  
Modified wicking bundle 
Human metastatic (MDA-MB-
231), cancer (MCF-7), and 
benign cells (MCF-10A) 
Fluorescent microscopy  
Modified wicking bundle 
Progenitor (D1) and 
differentiated pre-osteoblast 
(MC3T3E1) cells 
Fluorescent microscopy and 
flow cytometry  
 
Cell Separation along Single and Wicking Fiber Bundles 
Materials and Methods 
Mouse Cancer Cell Separation Using Single Wicking Fibers 
Cell Culture 
Cells from a normal mouse mammary epithelial cell line, NMuMG (ATCC), were 
stably transfected with Green Fluorescent Protein (NMuMG-GFP). Cells from a cancer 
mouse epithelial cell line (cells isolated from a mammary tumor that spontaneously arose 
in a MMTV-neu transgenic female mouse) were stably transfected with Red Fluorescent 
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Protein (MMTV-neu-RFP). NMuMG-GFP cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS, 
Gibco), and Mammary Epithelial Cell Growth Medium (MEGM) single quots (Lonza) 
while MMTV-neu-RFP cells were cultured in DMEM (Invitrogen) supplemented with 
10% FBS (Gibco), 10,000 U penicillin, and 10 mg streptomycin/mL (Sigma-Aldrich). 
Cells were cultured in a T150 flask (Corning) and maintained in a humidified incubator at 
37°C and 5% CO2. Once cells were confluent, NMuMG-GFP and MMTV-neu-RFP were 
detached using trypsin-EDTA solution (Sigma) and resuspended in growth media to 
prepare for the vertical test.  
Fiber Preparation 
Poly-L-lactide (Natureworks) wicking fiber was extruded to non-circular cross-
sectional dimensions of 0.72 mm x 0.55 mm. Wicking fibers were sliced into individual 
single wicking fibers of 3.5 cm. The fibers were cleaned by soaking in three changes of 
ethanol for 1 hour each, and placed under ultraviolet light for 6 hours. Samples were then 
soaked in a phosphate-buffered saline (PBS, Invitrogen) solution for 2 hours and air-dried 
overnight in a sterile hood.  
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Figure 6.1: Schematic shows cell vertical wicking test set-up. The wells contain 1 mL of 
media consisting of equal densities of normal and cancer cells. The fiber is vertically 
placed into the cell solution so only 3 mm of the fiber is submerged. The cell movement is 
analyzed at various time points 
 
Cellular Vertical Wicking Test  
 The vertical wicking test of cells, shown in Figure 6.1, involved a custom-made 
culture lid for a low-attachment 12-well plate (Corning). The lid provided holes with 
columns to securely hold the 3.5 cm wicking fibers and wicking fiber bundles in a 
vertical position. Both NMuMG-GFP and MMTV-neu cell lines were seeded in each well 
of a low attachment 12-well plate at a density of one million cells per well, along with 1 
mL of growth media. Single wicking fibers were vertically inserted through the columns 
so only the bottom 3 mm of the fiber was contacting the cell solution. The custom 12-
well plate set up was placed on a flattop shaker (VWR) at 100 rpm in a humidified 
incubator at 37oC and 5% CO2. The vertical displacement of the mouse cancer and 
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normal mammary cells along the wicking were determined at time points of 0.5 and 24 
hours, with an initial time point at the time of fiber placement into the cell solution.  
To assess the cell displacement of both cell types the fibers were transferred to 
each well of 6-well plate, rinsed twice with phosphate buffered saline (PBS; Invitrogen), 
and fixed for 15 min with 4% paraformaldehyde. After the cells on the wicking fiber 
constructs were fixed, the fibers were transferred to microscope slides and the entire 
length of the fiber was imaged, using fluorescent microscopy, beginning with the seeded 
end of the wicking fiber construct using 25x total magnification. A FITC filter was used 
to view the vertical movement of normal cells transfected with Green Fluorescent 
Protein, and a TRITC filter was used to view the vertical movement of cancer cells 
transfected with Red Fluorescent Protein. Imaging software was used to determine the 
vertical displacement (μm) of the cells in each image taken along the fiber. Images were 
aligned to qualitatively show the total displacement of both normal and cancer cells, with 
total vertical displacement quantified by the summation of the individual images. 
Statistical Analysis 
Matched pairs analysis was conducting using JMP statistical software to compare 
(p<0.05) the vertical displacement of MMTV-neu-RFP (cancer cells) and MMuMG-GFP 
(normal cells) at each of 0.5 and 24 hours.  
Human Cancer Cell and Isolation Using Wicking Fiber Bundles  
Cell Culture 
 Cells from a mammary epithelial cell line from benign breast tissue, MCF-10A 
(ATCC), were stably transfected with Green Fluorescent Protein (MCF-10A-GFP). 
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Cells from a human breast cancer cell line, MCF-7, (ATCC) were stably transfected 
with Red Fluorescent Protein (MCF-7-RFP). MCF-10A-GFP cells were cultured in 
DMEM (Invitrogen) supplemented with 10% FBS (Gibco), 1% Fungizone, and MEGM 
single quots (Lonza). MCF-7-RFP cells were cultured in DMEM (Invitrogen) 
supplemented with 0.01 mg/mL human recombinant insulin (Gibco), 10% FBS, 1% 
Fungizone (Gibco), 10,000 U penicillin, and 10 mg streptomycin/mL (Sigma-Aldrich). 
Cells were cultured in a T-150 flask (Corning) and maintained in a humidified incubator 
at 37°C and 5% CO2. Once confluent both cell types were removed with trypsin-EDTA 
solution (Sigma-Aldrich) and resuspended in culture medium to prepare for vertical 
testing. 
Fiber Preparation 
 For this assessment, bundled fibers were used to increase the amount of cells along 
the fiber to quantify using the flow cytometer. Poly-L-lactide (Natureworks) wicking fiber 
was extruded to non-circular cross-sectional dimensions of 0.72 mm x 0.55 mm. Wicking 
fibers were sliced into individual single wicking fibers of 10 cm in length. Three of these 
fibers were twisted, using an apparatus, at 11 rotations per centimeter twist to create the 
wicking fiber bundle. The bundle was sliced into 3.5 cm long sections. Similar to the single 
fibers the bundles were cleaned by soaking in three changes of ethanol for 1 hour each, and 
placed under ultraviolet light for 6 hours. Samples were then soaked in PBS solution for 2 
hours and air-dried overnight in a sterile hood.  
257 
 
Cellular Vertical Wicking Test 
 The vertical wicking test of cells as described above was performed using the 
wicking fiber bundles to analyze the wicking behavior of the cancerous cells, MCF-7-RFP, 
and the benign cells, MCF-10A-GFP. The vertical displacement of these cell lines along 
the fibers were determined at time points of 0.25 hours, 2 hours, 12 hours and 24 hours, 
with the initial time point being fiber placement into the cell solution. The fluorescently 
red-labeled cancer and green-labeled normal cells were imaged along the fiber bundles 
with fluorescent microscopy using 25x total magnification and following the same 
procedure described above.  
Isolation of Cancer and Normal Cells from the Fibers 
 After 24 hours the vertical wicking fiber bundles were removed from the custom 
12-well plate and the fibers were sectioned with a blade into top and bottom fiber regions 
(Fig 2). The top and bottom regions were placed in separate wells of a 24-well plate. The 
samples were rinsed with PBS twice and untwisted using forceps. The cells were 
removed by adding 500 μL of trypsin-EDTA solution into the well with the fiber region 
and placing the plate on a flat-top (VWR) shaker at 200 rpm in a 37oC incubator. After 2 
hours the cells were resuspended in 500 μL of growth media and the number of MCF-
10A and MCF-7 in both regions of the fiber were evaluated using a Guava easyCyte flow 
cytometer (Guava Technologies). We evaluated the number of MCF-10A-GFP and MCF-
7-RFP in each region by following the manufacturer’s instructions for InCyte software 
(Guava Technologies). Positive and negative controls with known cell densities were 
used to calibrate the machine before measurements of the treatment groups were made.  
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Figure 6.2: Left schematic shows the vertical test set-up of human cancer and benign 
cells. The right schematic shows the isolation of cells from the top and bottom regions of 
the wicking fiber bundle for analysis. 
 
Statistical Analysis 
A matched pairs analysis was conducted in JMP 10 to compare (p<0.05) the 
fraction of MCF-7-RFP cells in top and bottom regions of the fiber bundle.  
Separation of Mouse Progenitor and Monocyte Cells  
Cell Culture 
Mouse mesenchymal stromal cells, D1 (ATCC), and mouse monocytes, RAW 
264.7 (ATCC), were both cultured in growth media consisting of Dulbecco’s Modified 
Eagle’s Medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS, 
Gibco), 10,000 U penicillin, and 10 mg streptomycin/mL (Sigma-Aldrich). Cells were 
cultured in a T150 flask (Corning) and maintained in a humidified incubator at 37°C and 
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5% CO2. Once cells were confluent, D1 and RAW cells were detached using trypsin-
EDTA solution (Sigma) and resuspended in growth media to prepare for the vertical test. 
RAW and D1 cells were fluorescently labeled with CellTracker Green CMFDA probe 
and CellTrackerTM Red CMTPX probe (Invitrogen; Grand Island, NY, USA), 
respectively, following the manufacturer’s protocol and using a long-term labeling 
concentration of 25μM.  
Fiber Preparation 
Poly-L-lactide (Natureworks) wicking fiber was extruded to non-circular cross-
sectional dimensions of 0.72 mm x 0.55 mm. Wicking fibers were sliced into individual 
single wicking fibers of 3.5 cm. The fibers were cleaned by soaking in three changes of 
ethanol for 1 hour each, and placed under ultraviolet light for 6 hours. Samples were then 
soaked in a phosphate-buffered saline (PBS, Invitrogen) solution for 2 hours and air-dried 
overnight in a sterile hood.  
Vertical Test Set-Up and Analysis  
The vertical wicking test of D1 and RAW cells was performed using single 
wicking fibers. Both cell types were seeded in each of the wells of a low attachment 12-
well plate with a cell density of 1 million cells per mL. The fibers were vertically inserted 
into the custom-made lids designed to keep the fiber vertical and only 3 mm of the tip 
submersed. The displacement of the D1 and RAW cells was determined at time points of 
1 and 24 hours using fluorescent microscopy and imaging software. Imaging software 
was used to determine the vertical displacement (μm) of the cells in each image taken 
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along the fiber. Images were aligned to qualitatively show the total displacement of both 
normal and cancer cells, with total vertical displacement quantified by the summation of 
the individual images. 
Results 
Mouse Cancer Cell Separation Using Single Wicking Fibers 
 We developed a vertical test method to assess the vertical movement of different 
cell mixtures along the fiber. The vertical displacements of mouse mammary normal cells 
expressing green fluorescent protein (NMuMG-GFP) and mouse mammary cancer cells 
expressing red fluorescent protein (MMTV-neu-RFP) were determined at time points of 
0.5 and 24 hours using fluorescence microscopy. Figure 6.3 is a composite of fluorescent 
images, showing the cancer and normal cells along the length of the fiber, aligned to 
qualitatively show the total displacement of both cell types after 24 hours of contacting 
cell solution. Image A demonstrates that MMTV-neu-RFP cells have vertically displaced 
16.2 mm along the wicking fiber after 24 hours. Image B shows NMuMG-GFP cells 
vertically moved 3.0 mm, significantly less than the MMTV-neu-RFP cells, on the same 
wicking fiber. Images also depict higher cell densities of MMTV-neu-RFP cells along the 
fiber. Images qualitatively show a vertical separation of MMTV-neu-RFP and NMuMG-
GFP cells, indicating the wicking fibers move different cell types various distances. 
Imaging software was used to quantify the vertical displacement (μm) of the cells. The 
total vertical displacement was found from assessing each individual image. The vertical 
displacement of the cancer cells, MMTV-neu-RFP, along the wicking fiber was 
significantly (p<0.05) greater than that of the normal cells (NMuMG-GFP) at the 24-hour 
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time point (Image C). No significant difference was shown after 0.5-hour time point. 
Results suggest wicking fibers can separate and allow the rapid identification of cancer 
cells from a liquid with heterogeneous mix of cells. 
 
Figure 6.3: (A) Depicts compiled fluorescent images of the vertical displacement of 
MMTV-neu-RFP, cancer cells, along the length of the fiber. (B) Shows NMuMG-GPF, 
normal cells, progressed significantly less than the cancer cells. (C) Graph shows 
quantitative analysis of the vertical displacement of cancer cells (2759 ± 928.9 (SD), 
n=4) and mouse normal cells (2219 ± 940.6 (SD), n=4) after various time points. After 
24 hours there was significantly greater vertical displacement of MMTV-neu-RFP (14380 
± 1192 (SD), n=4) than displacement of NMuMG-RFP (6220 ± 994.2 (SD), n=4) 
(p<0.05), indicated by (*) in graph.   
 
Human Cancer Cell Separation and Isolation Using Wicking Fiber Bundles  
 To observe and quantify the effects of wicking fibers on human cancer cell 
separation and isolation, we developed a wicking fiber bundle that enhances the rate of 
separation and increases cell capacity. The bundles demonstrated enhanced wicking 
C 
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properties, i.e. the overall wicking rate and volume of liquid transported were enhanced. 
The wicking fiber bundle was used to separate and isolate malignant human breast 
epithelial cells expressing red fluorescent protein (MCF-7-RFP) from benign human 
breast epithelial cells expressing green fluorescent protein (MCF-10A-GFP). Fluorescent 
images of the bundles were used to evaluate the vertical displacement and separation of 
MCF-7-RFP and MCF-10A-GFP after 0.25, 2, 12, and 24 hours. Images show that, after 
15 minutes and 2 hours, MCF-7-RFP cells have progressed along the entire fiber but in 
low numbers. After 12 hour and 24-hour time points, much higher numbers of MCF-7-
RFP have traveled to the top region of the fiber. Fluorescent images indicate after 2 hours 
and the later time points, few benign epithelial cells progressed to the top region of the 
fiber bundles, Figure 6.4. 
 
Figure 6.4: (Left) Approximately equal densities of red and green fluorescently labeled 
cancer and normal cells depicted in bottom region of the fiber. (Right) Mostly 
fluorescently labeled red cells in top region indicating cancer cells displace the entire 
wicking fiber bundle 
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To quantify the number of cancerous and benign cells along the fiber bundles, 
cells were removed from top and bottom regions of the bundles Figure 6.5. The number 
of MCF-7-RFP and MCF-10A-GFP was determined using flow cytometry (Guava 
Technologies) with InCyte software (Guava Technologies). The chart illustrates the 
percentage of each cell type in top and bottom regions; there is a significant difference 
(p<0.05) between the percentage of MCF-7-RFP and the percentage of MCF-10A-GFP in 
the top region of the fiber bundles. These results strongly suggest that the wicking fiber 
bundles can separate and isolate cancerous cells, with high accuracy, from a mixture; as 
the graph indicates, 82% of cells isolated from the top fiber bundle regions are cancerous.  
 
 
Figure 6.5: Schematic of the fiber regions and data depicting percentage of each cell 
type in fiber regions. Left image illustrates axial slicing of fiber bundle to extract cells 
from top and bottom regions. Graph exhibits quantitative analysis of top and bottom 
region of the fiber bundle, demonstrating significantly higher concentration of MCF-7-
RFP cells in the top region of the fiber bundle (82.4 ± 4.3 (SD), n=3) than the bottom 
region of the fiber bundle (61.6 ± 3.04 (SD), n=3) The graph indicates a significantly 
lower concentration of MCF-10A-GFP cells in top region (17.6 ± 4.3 (SD), n=3) than 
bottom region (38.4 ± 3.04 (SD), n=3), (*) indicates significant difference, p<0.05 
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Mesenchymal Stem Cell and Monocyte Separation Using Single Wicking Fibers 
The outcomes of the vertical wicking of D1 and RAW cells along a single 
wicking fiber showed greater displacement of D1 cells after 1 hour and 24 hours than 
RAW cells, Figure 6.6. The composite fluorescent image of RAW and D1 cells after 1 
hour shows higher cell density of D1 cells, labeled red, penetrating the bottom region of 
the fiber. Image J software was used to measure the total displacement of each cell line 
along the fiber. The total vertical displacement of D1 cells along the fiber was greater 
than RAW cells after 1 hour and 24 hours (Image B). The outcomes suggest the 
displacement of different cell types along the wicking fiber may provide a method to 
identify progenitor cells and more a differentiated cell line, monocytes.  
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Figure 6.6: (A) Fluorescent image shows vertical displacement of RAW and D1 cells 
along the bottom region of the wicking fiber bundle. Image shows higher densities of red 
fluorescently labeled D1 cells. (B) D1 cells show increased vertical displacement after 1 
hour and 24 hours 
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Cell Separation and Isolation along Modified Wicking Bundle 
Materials and Methods 
The modified wicking bundle, comprised of wicking fibers and an absorbent cap, 
was developed and tested to separate and isolate different cancer cell types. As shown 
from chapter 4 the absorbent cap enhances the fluid flow and infiltration of cells. The 
modified bundle was used in the following tests to more rapidly separate and isolate 
different cell types and isolate large numbers of cells to quantitatively analyze with flow 
cytometry.  
Human Breast Cancer and Normal Cell Separation and Isolation along Modified 
Wicking Bundle 
Cell Culture 
Cells from a mammary epithelial cell line from benign breast tissue, MCF-10A 
(ATCC), and human breast cancer cell line, MCF-7, (ATCC) were cultured in DMEM 
(Invitrogen) supplemented with 10% FBS (Gibco), 1% Fungizone, and MEGM single 
quots (Lonza) and DMEM (Invitrogen) supplemented with 0.01 mg/mL human 
recombinant insulin (Gibco), 10% FBS, 1% Fungizone (Gibco), 10,000 U penicillin, and 
10 mg streptomycin/mL (Sigma-Aldrich), respectively. Cells were cultured in a T-150 
flask (Corning) and maintained in a humidified incubator at 37°C and 5% CO2. Once 
confluent both cell types were removed with trypsin-EDTA solution (Sigma-Aldrich) and 
resuspended in culture medium to prepare for vertical testing. MCF-10A and MCF-7 
cells were fluorescently labeled with CellTrackerTM Green CMFDA probe and 
CellTrackerTM Red CMTPX probe (Invitrogen; Grand Island, NY, USA), respectively 
following manufacturer’s protocol. Samples were prepared for both imaging and flow 
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cytometry analysis. To fluorescently image cells along the fibers, a long-term labeling 
concentration of 25 μM for both red and green cell tracker was used to label the cells. 
The red and green cell tracker was optimized for each cell line to detect using the flow 
cytometry (Appendix). To detect isolated cells from the wicking fiber-alginate constructs 
with flow cytometer, MCF-7 cells were labeled with 5.0 μM cell tracker red and MCF-
10A cells were labeled with the optimized cell tracker green concentration of 0.05 μM.  
Modified Wicking Bundle Preparation 
Poly-L-lactide (Natureworks LLC, USA) wicking fibers were extruded with 
irregular cross-sectional dimensions of 0.72 mm by 0.55 mm. Wicking fibers were sliced 
with a razor blade into individual single wicking fibers of 10 cm lengths. The 10 cm 
wicking fibers were used to form the wicking fiber bundles comprised of ten individual 
and three individual fibers. The fiber bundles were twisted, using an apparatus, at 
approximately 11 and 5 rotations per centimeter twist for the large and small fiber 
bundles, respectively. The bundle was sliced into 3 cm long sections. Bundled wicking 
fibers were cleaned by soaking in three changes of ethanol for 1 hour each, and placed 
under ultraviolet light for 6 hours. Samples were then soaked in a phosphate-buffered 
saline (PBS, Invitrogen) solution for 2 hours and air-dried overnight in a sterile hood. The 
alginate cap was formed by dipping one end of the wicking fiber bundle in 100 μL of 5M 
CaCl2 solution (Fisher Scientific; Waltham, MA, USA) in a well of a 96-well plate and 
pipetting 100 μL of 1.4% (w/v) alginate solution comprised of alginic acid sodium salt 
from brown algae (Sigma; St. Louis, MO) in 155 mM NaCl (Sigma; St. Louis, MO) 
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directly on the submerged fiber tip in the well. The alginate immediately adheres to the 
fiber end and solidifies forming the modified wicking bundle.  
Experimental Set-up 
The vertical wicking test of MCF-7 and MCF-10A cells was performed using the 
modified wicking bundle. Both cell types were seeded in each of the wells of a low 
attachment 12-well plate with a cell density of 500,000 cells per mL. MCF-7 and MCF-
10A cells labeled with 25 μM cell tracker were seeded into six wells for fluorescent 
microscopy analysis. The remaining six wells were seeded with MCF-7 labeled with 5.0 
μM red tracker and MCF-10A cells labeled with 0.05 μM of green tracker for flow 
cytometry analysis. Modified wicking bundles containing only 3 individual fibers were 
vertically inserted into the wells containing cells for fluorescent imaging, and bundles 
containing 10 fibers were vertically placed in wells containing cells for flow cytometry 
analysis. The bundles containing three fibers were used for imaging to improve the 
contrast and image deeper into the bundle. The bundles for flow cytometry contained 10 
fibers to isolate enough detectable cells for the instrument to analyze. The experimental 
set-up is shown below in a 12-well plate. Immediately following the vertical placement of 
the modified fiber bundles in the appropriate wells the 12-well plate was placed on a 
flattop shaker (VWR) at 100 rpm in a humidified incubator at 37oC and 5% CO2. The 
vertical displacement of the human cancer and benign breast epithelial cells along the 
wicking were determined after 2 hours of incubation, with the initial time point being 
fiber placement into the cell solution.  
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Figure 6.7: Set-up to analyze cell separation and isolation 
 
Analysis of Cell Separation and Isolation 
To qualitatively assess the cell separation along the modified wicking bundle the 
samples were transferred to a well of 6-well plate, rinsed twice with phosphate-buffered 
saline solution, and fixed for 15 min with 4% paraformaldehyde. After the cells on the 
modified wicking bundle were fixed, the fibers were transferred to microscope slides and 
the vertical displacement was evaluated using fluorescent microscopy and imaging 
software was used to overlay the images. Various regions of the construct were imaged 
using fluorescent microscopy, shown in the schematic below.  
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The bottom, middle, top, alginate-bundle interface, and alginate cap regions of the 
modified wicking bundle were imaged with a 20x or 40x total magnification. A FITC 
filter was used to view the vertical movement of normal cells labeled green, and a TRITC 
filter was used to view the vertical movement of cancer cells labeled red. 
 
 
Figure 6.8: Schematic depicts fluorescent microscopy analysis and regions of interest 
images 
  
 To quantify the cancer normal cell separation the construct was sectioned into top, 
bottom and alginate regions and the cells were removed from each region, illustrated in 
schematic. The alginate caps were first removed from the fiber bundles and transferred to 
a 1.5 mL Eppendorf microcentrifuge tubes (Sigma; St. Louis, MO USA) containing 1 mL 
of the stock dissolution buffer. The buffer was comprised of 100mM sodium citrate 
(Fisher Scientific; Waltham, MA USA), 10 mM HEPES buffer (Sigma; St. Louis, MO 
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USA), and 27 mM NaCl (Sigma; St. Louis, MO USA) in 50 mL of distilled water. The 
alginate caps were dissolved for 30 minutes at 37°C and mixed vigorously using the 
vortex every 5 minutes. The wicking fiber bundle region was sectioned with a blade into 
top and bottom regions were placed into separate wells of a 24 well plate, Samples were 
rinsed with PBS and untwisted. Cells were removed by adding 500 μL of trypsin-EDTA 
solution into the well with the fiber region and placing the plate on a flat-top (VWR) 
shaker at 200 rpm in a 37oC incubator. After 15 min the cells were resuspended in 500 μL 
of growth media and the number of red labeled MCF-7 and green labeled MCF-10A cells 
were determined from the alginate caps and top and bottom regions of the fiber bundles 
using a Guava easyCyte flow cytometer (Guava Technologies). The number of cancer 
and normal cells in each region was evaluated by following the manufacturer’s 
instructions for InCyte software (Guava Technologies). MCF-7 and MCF-10A cells of 
known cell densities with and without red and green tracker, were used as positive and 
negative controls to calibrate the machine before measurements of the treatment groups 
were made.  
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Figure 6.9: Schematic shows regions cancer and normal cells were isolated from along 
the modified wicking bundle 
 
Statistical Analysis 
A matched pairs analysis was conducted in JMP 10 to compare (p<0.05) the 
fraction of red-labeled MCF-7 cells in top and bottom regions of the fiber bundle and the 
alginate cap.  
Investigating Cell Separation and Isolation of Metastatic Cancer Cells and Benign 
Breast Epithelial Cells along Modified Wicking Bundle  
Cell Culture 
Cells from a mammary epithelial cell line from benign breast tissue, MCF-10A 
(ATCC), and metastatic breast epithelial cells, MDA-MB-231, (ATCC) were cultured in 
DMEM (Invitrogen) supplemented with 10% FBS (Gibco), 1% Fungizone, and MEGM 
single quots (Lonza) and DMEM (Invitrogen) supplemented with 10% FBS, 1% 
Fungizone (Gibco), 10,000 U penicillin, and 10 mg streptomycin/mL (Sigma-Aldrich), 
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respectively. Cells were cultured in a T-150 flask (Corning) and maintained in a 
humidified incubator at 37°C and 5% CO2. Once confluent both cell types were removed 
with trypsin-EDTA solution (Sigma-Aldrich) and resuspended in culture medium to 
prepare for vertical testing. MCF-10A and MDA-MB-231 cells were fluorescently 
labeled with CellTracker Green CMFDA probe and CellTracker Red CMTPX probe 
(Invitrogen; Grand Island, NY, USA), respectively following manufacturer’s protocol. 
Samples were prepared for both imaging and flow cytometry analysis. To fluorescently 
image cells along the fibers, a long-term labeling concentration of 25 μM for both red and 
green cell tracker was used to label the cells. The red and green cell tracker was 
optimized for each cell line to detect using the flow cytometry (Appendix). To detect 
isolated cells from the wicking fiber-alginate constructs with flow cytometer, MDA-MB-
231 cells were labeled with 5.0 μM cell tracker red and MCF-10A cells were labeled with 
the optimized cell tracker green concentration of 0.50 μM.  
Experimental Set-up and Analysis 
The cell separation and isolation of metastatic cancer cells, MDA-MB-231, and 
benign epithelial cells, MCF-10A, were investigated using the modified wicking bundle. 
The modified wicking bundles were formed using the same procedure above. Those 
containing three wicking fibers were used for imaging analysis and those containing ten 
wicking fibers were used for flow cytometry analysis. Following the vertical wicking 
procedure previously described, 500 μL of cell solution containing a cell density of 
500,000 cells per mL was pipette in each of the wells of a low attachment 12-well plate 
with a custom-made lid to secure the modified fibers vertically in the well. Six samples 
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were prepared for fluorescent microscopy and six samples were prepared for flow 
cytometry analysis. The experimental set-up is shown below in Image A of Figure 6.10. 
Following the procedures above, the plate was placed on a flattop shaker at 100 rpm in a 
humidified incubator at 37oC and 5% CO2. The separation of the human metastatic cancer 
and benign breast epithelial cells along the constructs were determined after 2 hours of 
incubation, with the initial time point being fiber placement into the cell solution. The 
samples were fluorescently imaged (Image B) and analyzed using flow cytometry (Image 
C) following the procedures from the preceding section.  
 
Figure 6.10: (A) Experimental set-up investigating vertical displacement of metastatic 
cancer cells and benign epithelial cells (B) Qualitative analysis using fluorescent 
microscopy (C) Flow cytometry analysis  
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Statistical Analysis 
A matched pairs analysis was conducted in JMP 10 to compare (p<0.05) the 
fraction of metastatic cancer cells (MDA-MB-231) in top and bottom regions of the fiber 
bundle and the alginate cap.  
Investigating Cell Separation and Isolation of Metastatic Cancer Cells and Non-
Metastatic Cancerous Breast Epithelial Cells along Modified Wicking Bundle 
Cell Culture 
Non-metastatic cancerous breast epithelial cells, MCF-7 (ATCC), and metastatic 
breast epithelial cells, MDA-MB-231, (ATCC) were cultured in DMEM (Invitrogen) 
supplemented with 10% FBS (Gibco), 1% Fungizone, and 0.01 mg/mL human 
recombinant insulin (Gibco) and DMEM (Invitrogen) supplemented with 10% FBS, 1% 
Fungizone (Gibco), 10,000 U penicillin, and 10 mg streptomycin/mL (Sigma-Aldrich), 
respectively. Cells were cultured in a T-150 flask (Corning) and maintained in a 
humidified incubator at 37°C and 5% CO2. Once confluent both cell types were removed 
with trypsin-EDTA solution (Sigma-Aldrich) and resuspended in culture medium to 
prepare for vertical testing. MDA-MB-231 and MCF-7 cells were fluorescently labeled 
with CellTrackerTM Green CMFDA probe and CellTrackerTM Red CMTPX probe 
(Invitrogen; Grand Island, NY, USA), respectively following manufacturer’s protocol. 
Samples were prepared for both imaging and flow cytometry analysis. To fluorescently 
image cells along the fibers, a long-term labeling concentration of 25 μM for both red and 
green cell tracker was used to label the cells. The red and green cell tracker was 
optimized for each cell line to detect using the flow cytometry (Appendix). To detect 
isolated cells from the wicking fiber-alginate constructs with flow cytometer, MCF-7 
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cells were labeled with 5.0 μM cell tracker red and MDA-MB-231 cells were labeled 
with the optimized cell tracker green concentration of 0.50 μM.  
Experimental Set-up and Analysis 
The cell separation and isolation of non-metastatic cancer cells (MCF-7) and 
further metastatic cancer cells (MDA-MB-231) were investigated using the modified 
wicking fiber bundle construct. The wicking fiber-alginate cap constructs containing 
three wicking fibers for imaging analysis or ten wicking fibers for flow cytometry 
analysis were formed using the same procedure above. Following the vertical wicking 
procedure previously described, 500 μL of cell solution containing a cell density of 
500,000 cells per mL from each cell type was pipette directly in each of the wells of a 
low attachment 12-well plate with a custom-made lid to secure the modified fibers 
vertically in the well. Six samples were prepared for fluorescent microscopy and six 
samples were prepared for flow cytometry analysis. After performing the vertical test the 
samples were fluorescently imaged and analyzed using flow cytometry following the 
procedures from the preceding section.  
Statistical Analysis 
A matched pairs analysis was conducted in JMP 10 to compare (p<0.05) the 
fraction of metastatic cancer cells (MDA-MB-231) in top and bottom regions of the fiber 
bundle and the alginate cap.  
277 
 
Investigating Cell Separation of Metastatic Cancer Cells, Non-Metastatic Cancerous 
Breast Epithelial Cells, and Benign Breast Epithelial Cells along Modified Wicking 
Bundle 
Cell Culture 
Benign breast epithelial cells (MCF-10A), Non-metastatic cancerous breast 
epithelial cells, MCF-7, and metastatic breast epithelial cells, MDA-MB-231, were 
cultured in were cultured in DMEM (Invitrogen) supplemented with 10% FBS (Gibco), 
1% Fungizone, and MEGM single quots (Lonza), DMEM (Invitrogen) supplemented 
with 10% FBS (Gibco), 1% Fungizone, and 0.01 mg/mL human recombinant insulin 
(Gibco), and DMEM (Invitrogen) supplemented with 10% FBS, 1% Fungizone (Gibco), 
10,000 U penicillin, and 10 mg streptomycin/mL (Sigma-Aldrich), respectively. Cells 
were cultured in a T-150 flask (Corning) and maintained in a humidified incubator at 
37°C and 5% CO2. Once confluent both cell types were removed with trypsin-EDTA 
solution (Sigma-Aldrich) and resuspended in culture medium to prepare for vertical 
testing. MCF-10A and MCF-7 cells were fluorescently labeled with CellTrackerTM Green 
CMFDA probe and CellTrackerTM Red CMTPX probe (Invitrogen; Grand Island, NY, 
USA), respectively following manufacturer’s protocol using the recommended long-term 
labeling concentration of 25 μM. MDA-MB-231 cells were fluorescently labeled blue 
using a 1:500 dilution of a 2mg/mL Hoechst solution (Sigma; St. Louis, MO USA).   
Experimental Set-up and Analysis 
This study assessed the cell separation from a tri-culture of human cancer cells of 
varying metastatic potential. The vertical displacement and separation of metastatic 
cancer cells, MDA-MB-231, non-metastatic cancerous breast epithelial cells, MCF-7, and 
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benign breast epithelial cells was investigated using the modified wicking bundle. 
Modified wicking bundles were formed using the same procedure above. Those 
containing three wicking fibers were used for imaging analysis. Following the vertical 
wicking procedure previously described, 500 μL of cell solution from each fluorescently 
labeled cancer cell line containing a cell density of 500,000 cells per mL was pipette in 
each of the wells of a low attachment 12-well plate with a custom-made lid to secure the 
modified fibers vertically in the well. Following two hours of incubation, the samples 
were removed, fixed with paraformaldehyde, and imaged using fluorescent microscopy.  
 
 
Figure 6.11: Schematic depicting experimental set-up to analyze a tri-culture of benign 
and of cancer cells of varying metastatic potential 
 
Cell Separation and Isolation of Mesenchymal Stem Cells and Pre-Osteoblast Cells 
Cell Culture 
Mouse mesenchymal stem cells, D1 (ATCC), and mouse pre-osteoblast cells, 
MC3T3E1 (ATCC), were cultured in growth media consisting of Dulbecco’s Modified 
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Eagle’s Medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS, 
Gibco), 10,000 U penicillin, and 10 mg streptomycin/mL (Sigma-Aldrich), and Minimal 
Essential Medium Alpha without ascorbic acid (MEMα, Gibco) supplemented with 10% 
fetal bovine serum (Gibco), 10,000 U penicillin, and 10mg streptomycin/mL (Sigma), 
respectively. Cells were cultured in a T150 flask (Corning) and maintained in a 
humidified incubator at 37°C and 5% CO2. Once cells were confluent, D1 and MC3T3E1 
cells were detached using trypsin-EDTA solution (Sigma) and resuspended in growth 
media to prepare for the vertical test. D1 and MC3T3E1 cells were fluorescently labeled 
with CellTrackerTM Green CMFDA probe and CellTrackerTM Red CMTPX probe 
(Invitrogen; Grand Island, NY, USA), following manufacturer’s protocol, respectively. 
Samples were prepared for both imaging and flow cytometry analysis. To fluorescently 
image cells along the fibers, a long-term labeling concentration of 25 μM for both red and 
green cell tracker was used to label the cells. The red and green cell tracker was 
optimized for each cell line to detect using the flow cytometry (Appendix). To detect 
isolated cells with flow cytometer, MC3T3E1 cells were labeled with 5.0 μM cell tracker 
red and D1 cells were labeled with the optimized cell tracker green concentration of 0.50 
μM.  
Statistical Analysis 
A matched pairs analysis was conducted in JMP 10 to compare (p<0.05) the 
fraction of mouse mesenchymal stem cells (D1) in top and bottom regions of the fiber 
bundle and alginate cap.  
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Experimental Set-up and Analysis 
The cell separation and isolation of bone progenitor cells, D1, and further 
differentiated pre-osteoblast cells, MC3T3E1, were investigated using the modified 
wicking bundle. The modified wicking bundles containing three wicking fibers for 
imaging analysis or ten wicking fibers for flow cytometry analysis were formed using the 
same procedure above. Following the vertical wicking procedure previously described, 
500 μL of cell solution containing a cell density of 500,000 cells per mL from each cell 
type was pipette directly in each of the wells of a low attachment 12-well plate with a 
custom-made lid to secure the modified fibers vertically in the well. Six samples were 
prepared for fluorescent microscopy and six samples were prepared for flow cytometry 
analysis. After performing the vertical test the samples were fluorescently imaged and 
analyzed using flow cytometry following the procedures from the preceding section.  
Results 
Human Breast Cancer and Normal Cell Separation and Isolation along Modified 
Wicking Bundle 
The fluorescent images, Figure 6.12, of regions along the modified wicking 
bundle depict a clear separation of benign epithelial cells (MCF-10A) labeled green and 
cancerous epithelial cells (MCF-7) labeled red.  
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Figure 6.12: Fluorescent images of the cancerous MCF-7 (red) and benign MCF-10A 
(green) epithelial cell displacement along the modified wicking bundles. (A) Depicts 
more MCF-10A cells in the bottom region of the fiber bundle where the cell solution 
contacts the fiber bundle. (B) Similar cell densities of MCF-7 and MCF-10A cells in the 
middle region of the fiber bundle. (C) Depicts primarily MCF-7 cells along the top 
region of the fiber in the alginate cap. (D) Reveals significantly more cancer cells in the 
alginate cap 
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 The flow cytometer was used to quantify the amount of green and red 
fluorescently labeled cells in each region of the construct. The flow cytometer scatter 
plots and fluorescent intensity plots indicate the cancer cell lines contain cells of different 
sizes and shapes. The MCF-7 cells depict a wider range of cell sizes and the MCF-10A 
cells illustrate a range of complexities (Figure 6.13). The results in Figure 6.14 report the 
percentages of benign and cancerous cells from each region. Image A shows more than 
80% of the cells isolated from the alginate cap are cancerous cells. Similarly, the 
outcomes presented in image B demonstrate approximately 80% of the cells isolated from 
top region of the fiber bundle are the cancerous MCF-7 cells. The bottom region shows 
comparable amounts of benign and cancer cells. Although there were larger percentages 
of cancer cells in the top region of the bundle and the alginate cap, there were 
significantly less total cells in these regions as indicated by the scatter and fluorescent 
intensity in the decreased amount of cells in the top bundle regions and the alginate cap is 
likely due to the processing methods. The dissolution of the alginate cap may cause 
debris, as well as cell debris and clumping that will limit the number of cells detected. 
Furthermore, cells are tightly bound within the grooves of the fiber bundles, and the 
removal procedures used to isolate cells from the fibers may not reach the cells tightly 
bound in the inter-fiber and groove conduits. However, the amount of cancerous cells 
isolated from the regions is significantly higher than the benign cells and verifies the 
fluorescent images. The outcomes of both analyses show the modified wicking bundles 
can separate cancer cells from benign cells by isolating the cancer cells in the top fiber 
region and alginate cap. The modified wicking bundles enhanced the amount of cells that 
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penetrated the fiber compared to the unmodified wicking bundle and single wicking fiber 
samples. The alginate provided a collection sink for cancer cells as demonstrated by the 
images and by the flow cytometry analysis. 
 
 
Figure 6.13: Scatter plots of control groups from flow cytometry analysis. Depicts the 
forward and side-scattering plots of MCF-7 (Top Row) and MCF-10A (Bottom Row. The 
red and green fluorescent intensity plots show the MCF-7 cells are labeled with red 
fluorescence and the MCF-10A cells are labeled with green fluorescence. 
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Figure 6.14: Flow cytometry results investigating the number of cancer and benign cells 
in each region. Chart illustrates significantly higher percentage of MCF-7 in alginate 
cap (A) and in top region of wicking fiber bundle (*) indicates significant difference of 
p<0.05 (B). No comparable difference in percentage of MCF-7 and MCF-10A cells in 
bottom region of the wicking fiber bundle 
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Figure 6.15: Forward scatter plots and fluorescence intensity of MCF-10A and MCF-7 
cells in each region. The forward scatter plot shows greater numbers of both cell types in 
the bottom region compared to the top fiber region and the alginate cap. The bottom 
region depicts similar red and green fluorescent intensities. The top fiber region and 
alginate cap show high red fluorescent intensity counts correlating to mainly cancer cells 
in these regions 
 
Investigating Cell Separation and Isolation of Metastatic Cancer Cells and Benign 
Breast Epithelial Cells along Modified Wicking Bundle  
 This test investigated the separation of cancer cell line with greater metastatic 
potential than the MCF-7 cells. The fluorescent images (Figure 6.16) show greater 
vertical displacement of the metastatic cancer cells (MDA-MB-231) labeled red into the 
middle and top regions of the fiber bundle. The bottom region (Image A) of the wicking 
fiber bundle depicts comparable cell densities of the MDA-MB-231 cells and benign 
breast epithelial cells (MCF-10A) labeled green. Higher cell densities of the metastatic 
cancer cells are collected in the top region (image C) of the fiber and alginate cap (image 
D).  
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Figure 6.16: Fluorescent images analyzing the vertical displacement of metastatic breast 
cancer cells (red) and benign breast epithelial cells (green). Comparable cell densities 
are depicted in the bottom or seeded region of the fiber (A). Greater numbers of 
metastatic cancer cells (red) wick to the middle (B) and top (C) regions of the fiber. (D) 
The alginate cap consists of greater numbers of the metastatic cancer cells.  
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 The flow cytometry outcomes illustrated analogous results to the previous study 
assessing separation of MCF-7 and MCF-10A cells. Both regions of the wicking fiber 
bundle and the alginate cap contained significantly more red-labeled metastatic cancer 
cells, MDA-MB-231 than the benign epithelial cells, as presented in Image C of Figure 
6.19. The outcomes show modified wicking bundle provides a method to separate the 
metastatic cancer cells and benign cells along the fiber bundles.  
 
Figure 6.17: (A) Scatter and fluorescent intensity plots confirming the red-label of the 
MDA-MB-231 metastatic cancer cells. (B) Scatter and fluorescent intensity plots of 
green-labeled benign cells. (C) Depicts separation of the metastatic cells, MDA-MB-231 
from MCF10A cells in each region of the fiber bundle and alginate cap. 
 
Investigating Cell Separation and Isolation of Metastatic Cancer Cells and Non-
metastatic Cancerous Breast Epithelial Cells along Modified Wicking Bundle 
 The fluorescent images in Figure 6.18 show more metastatic cancer cells (labeled 
green) in the top region (Image C) of the wicking fiber bundle and the alginate cap 
(Image D). Non-metastatic cancer cells (red) were still observed in the alginate cap but 
show in fewer numbers. The bottom and middle regions of the wicking fiber bundle 
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(Image A and B) show greater metastatic cancer cell infiltration. To enhance separation 
of the metastatic and non-metastatic cancer cells further work will increase the specificity 
of the construct by altering the cross-sectional sizes of the wicking fiber bundle and 
modifying the absorbent material.  
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Figure 6.18: (A) and (B) depict similar cell densities of metastatic cancer cells (MDA-
MB-231) labeled green and non-metastatic cancer cells (MCF-7) labeled red. (C) Top 
region of the wicking fiber bundle shows more metastatic cancer cells and (D) alginate 
cap depicts both metastatic and non-metastatic cancer cells.  
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  The outcomes from flow cytometry depicted similar trends. The controls 
confirmed the metastatic cancer cells and non-metastatic cancer cells were successfully 
labeled with green and red cell tracker (Image A and B). The percentage of non-
metastatic and metastatic cancer cells was measured from the cells removed from each 
region. The alginate and bottom region of the wicking fiber bundle contained similar 
amounts of non-metastatic and metastatic cells. The top region contained significantly 
more metastatic cancer cells (MDA-MB-231) than non-metastatic (MCF-7), using a 
significance value of p<0.05.  
 
Figure 6.19: (A) Scatter plot of MDA-MB-231 metastatic cells. Red and green 
fluorescence intensity plots shows high green intensity and low red intensity confirming 
labeling procedure. (B) Scatter plot of MCF-7 non-metastatic cancer cells shows 
variation in size and shape of cells within cell line. The fluorescence intensity plots show 
high red intensity confirming the cells are fluorescently tagged red. (C) Comparable 
amounts of metastatic and non-metastatic cells in bottom region of the fiber bundle and 
the alginate cap. The top region depicts significantly more MDA-MB-231 cells than 
MCF-7 cells, (*) indicates significant difference, p<0.05 
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 The flow cytometry scatter plots showed significantly less total cells from the top 
region of the fiber bundle and the alginate cap. The low cell count detected by the flow 
cytometry in the alginate and wicking fiber bundle is due to the cell removal processing 
technique. More work is needed to improve the cell removal methods to increase the 
amount of cells removed without altering the cells and to obtain a more representative 
number of cells.  
 
 
Figure 6.20: Scatter and fluorescent intensity plots depict low amounts of cell removal 
from the top fiber region and the alginate cap 
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Investigating Cell Separation of Metastatic Cancer Cells, Non-metastatic Cancerous 
Breast Epithelial Cells, and Benign Breast Epithelial Cells along Modified Wicking 
Bundle 
 The vertical displacement of a tri-culture was investigated along the modified wicking 
bundle using fluorescent microscopy, Figure 6.21. The bottom (Image A) and middle 
region (Image B) of the wicking fiber bundle depict all cell types consisting of MCF-10A 
cells labeled green, MCF-7 cells labeled red, and MDA-MB-231 cells labeled blue. The 
top region of the wicking fiber bundle (Image C) and the alginate cap (Image D) depict 
significantly more metastatic cancer cells, MDA-MB-231 cells than benign or cancerous 
cells. Interestingly, the MDA-MB-231 cells spread out in the alginate more than the other 
cell types.   
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Figure 6.21: Cell displacement of metastatic cancer cells, MDA-MB-231 (blue), non-
metastatic cancer cells, MCF-7 (red), and benign breast epithelial cells (green). The 
bottom (A) and middle (B) region of the fiber bundle depict all cancer cell types along the 
fiber. High densities of MDA-MB-231 are depicted in the top region of the fiber bundle 
(C) and the alginate cap (D).  
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Cell Separation and Isolation of Mesenchymal Stem Cells and Pre-Osteoblast Cells 
The final assessment evaluated the potential of the modified wicking bundle to 
separate D1 mouse mesenchymal stem cells from MC3T3E1 pre-osteoblast cells, a 
further differentiated mouse cell type. The fluorescent images depicted cell separation of 
D1 progenitor cells labeled green and from MC3T3E1 pre-osteoblast cells labeled red. 
The bottom region (Image A) and the middle region (Image B) of the wicking fiber 
bundle illustrate a mixture of both cell types. The top and alginate cap (Images C and D) 
depict high cell counts of green-labeled progenitor cells. The outcomes of this assessment 
suggest similarities between the wicking behavior of progenitor and cancer cells.  
The amount of progenitor and pre-osteoblast cells was quantified in each region 
of the wicking fiber bundle and the alginate cap presented in Figure 6.23. The forward 
scatter and fluorescent intensity plots (Images A and B) show the D1 cells and MC3T3E1 
cells were successfully labeled with green and red fluorescent cell tracker. The top and 
bottom regions of the wicking fiber bundle, as wells the alginate cap (Image C) consisted 
of significantly more D1 progenitor cells, labeled with green tracker than MC3T3E1 
cells, p<0.05. The outcomes suggest the modified wicking bundle has potential to sort the 
progenitor cells and pre-osteoblasts. This also implies the progenitor cells may have 
similar behaviors to cancer cell types along the construct. It is also important to note, 
similar to the previous assessments, the alginate and top regions of the construct show 
less cell numbers than the bottom region of the wicking fiber bundle. Again, this is due to 
the inconsistencies and limitations of the cell removal process.  
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Figure 6.22: (A) and (B) Bottom and middle regions of the wicking fiber bundle show 
similar cell densities of D1 cells (green) and MC3T3E1 cells (red). (C) and (D) depict 
more D1 progenitor cells in top region and alginate cap.  
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Figure 6.23: (A) Scatter and fluorescent intensity plots for MC3T3-E1 cells show cells 
were labeled with red tracker. (B) Scatter and fluorescent intensity plot for green 
fluorescently labeled D1 cells. (C) Quantifies the wicking displacement of D1 cells and 
MC3T3E1 cells. Depicts significantly more D1 cells (p<0.05) in the alginate cap and 
fiber bundle regions than MC3T3E1 cells.  
 
Discussion 
The first part of this chapter explored the use of unmodified single and wicking 
fiber bundles to sort cancer and normal cells by their wicking behavior along the fibers. 
The outcomes from the single and bundled fibers assessments showed mouse and human 
cancer cell separation from normal or benign cells in the top region of the fiber. In both 
studies the cancer cells have greater vertical displacement and are presented in the top 
region of the fiber. The single wicking fiber was used to evaluate the vertical 
displacement of mouse mesenchymal stem cells and differentiated mouse monocytes. 
The semi-quantitative data showed progenitor cells displace to the top region of the fiber. 
The outcomes suggest the progenitor cells may share similar physical properties to the 
cancer cells.  
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We previously showed in Chapter 4 the wicking fiber bundles with an alginate 
cap (modified wicking bundles) greatly enhance the fluid transport and amount of cells 
collected within the construct after performing a vertical test assessment. The remainder 
of the chapter explored the use of the modified wicking bundle to separate various cancer 
cell types as well as progenitor cells from further differentiated cells. The wicking tests 
also investigated the use of the alginate cap as a collection source to isolate a cell type 
from a mixture of different cell types.  The outcomes revealed the modified wicking 
bundle can be used to separate cancerous cells from benign cells. The isolation from 
various regions showed a significant increase in either metastatic or non-metastatic 
cancer cells along the fibers and in the alginate cap when tested with benign epithelial 
cells. Flow cytometry results investigating the movement of metastatic and non-
metastatic cancer cells demonstrated a decreased ability to separate as compared to 
separation from benign cells. To increase specificity to isolate metastatic cancer cells in 
the alginate cap various approaches can be used to alter the system. The inter-fiber and 
intra-fiber spaces of the wicking fiber bundle can be altered, as well as, the polymer of 
choice used and the stiffness of the hydrogel.  
Limitations of using the modified wicking bundle approach include 
inconsistencies between the fabricated samples, as well as, the processing technique to 
remove cells from the construct. The fabrication process of the modified wicking bundle 
involves the extrusion and twisting of fibers, as well as, the formation of the alginate cap. 
Inconsistencies between samples develop from the variation in cross-section sizing of the 
extruded fibers as well as the bundling process. To improve specificity the processing 
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technique of the constructs should be improved. The cell removal technique also presents 
a limitation. The cells are wicked through the conduits of the fibers as well as the 
compact intra-fiber spaces. The high tortuosity of the fiber component presents 
difficulties of using trypsin as a cell removal agent. The dissolution of the alginate cap 
takes approximately 30 minutes to dissolve the hydrogel. Small pieces of dissolute 
hydrogel may interfere with removal of cells as well as with detection during flow 
cytometry. Other cell removal techniques may need to be employed to ensure all cell 
information is obtained to provide precise results.  
The mechanism for separation between different cell types is due to the physical 
and functional properties of the cells, wicking characteristics of the fiber bundle, and the 
cell-fiber interaction. Physical properties that may play a role include cell size, 
deformability, surface friction or charge, and expression of cell adhesion molecules. The 
size and shape of the cells may play a role in the ability for cells to penetrate the smaller 
channels created from the bundling of the fibers. Fiber bundle architecture will affect the 
wicking rate and vertical displacement of different cell types. The size of the individual 
fibers, the tension of the bundle, the hydrophobicity, and the inter-fiber space will play a 
role in the wicking of liquid and cell-interaction. These factors can be altered to increase 
the specificity of the system and increase the amount of cells reaching the top region of 
the fiber bundle and the alginate cap.  
Other cellular properties influencing vertical movement include membrane 
impedance, expression of adhesion molecules, and cells stiffness. Membrane impedance, 
cell dielectric properties, or cell electric properties vary between cell types25,26. Electrical 
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properties of the cell will influence the cell-interaction with the fiber based on the 
inherent charge of the fibers and the resultant vertical movement. Cells with greater 
impedance or surface charge may have more interactions with the fiber, thus hindering 
the vertical cell movement. Abdolahab and coworkers evaluated the cellular impedance 
for cancer cells of varying aggressiveness and demonstrated that a more aggressive 
cancer cell type (MDA-MD-231) has a significant reduction in impedance than a less 
aggressive cancer cell (MCF-7). Additionally they found a correlation between metastatic 
progression and membrane impedance reduction27. Cell-fiber interaction and overall cell 
displacement will be affected by different membrane impedances and overall surface 
charge. The specificity and amount of cells wicked into the construct may be improved 
altering the hydrophobicity of the polymer wicking fibers.   
Expression of cell adhesion molecules, such as EpCAM, can play a role in the 
cell-fiber interaction and ability of a cell to move through a confined space. Metastatic 
cells, as shown by the MDA-MB-231, are known to lose endothelial adhesion molecules 
and transition into a more motile mesenchymal phenotype22. Cancerous cells with fewer 
adhesion molecules may have less surface friction and altered shape that have less 
interaction with the fiber, allowing the cells to wick greater distances. The MDA-MB-231 
cells are characterized with a mesenchymal phenotype and are classified as EpCAM-
negative, CD24-negative, and CD44 positive with spindle-like shape 28,29. The high 
penetration of the MDA-MB-231 cells into the alginate cap as shown from the tri-culture 
separation assessment is due the ability of these cells to individually migrate and 
penetrate tissues, whereas MCF-7’s require cell-cell interactions to maintain and 
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function. Future work can modify or layer the alginate to distinguish non-metastatic and 
metastatic cancer cells based on their dispersal through the hydrogel.  
Cell deformability is another factor that will influence the ability for cells to 
deform, penetrate, and wick vertically through the twisted channels. In general, research 
shows cancer cells have a significantly lower Young’s modulus compared to normal 
cells30–32. Researchers have found that cancer cells of increased metastatic potential have 
higher deformability33,34. This point suggests that MCF-7 cells are much softer and 
deform more easily than normal cells, allowing the cancer cells to migrate more readily. 
Microfluidic devices have been employed to distinguish cancer and normal cells, based 
on cellular deformability, by analyzing the ability of cells to squeeze and pass though 
confined constrictions31,35,36. Indeed, Li and coworkers found the apparent Young’s 
modulus of MCF-10A, non-malignant breast epithelial cells, to be significantly higher 
than MCF-737. The softer cytoskeleton and deformability of the MCF-7 cells may play a 
role in their ability to squeeze through channels and wick upward through the confined 
space.  
Undifferentiated and differentiate stem cell separation shown in these tests are 
also affected by the same physical factors. Subpopulations of progenitor cells of varying 
differentiation potential are shown to have different electrical and mechanical properties, 
which can be used to identify the cell differentiation potential. Flanagan and coworkers 
used dielectrophoresis (DEP), a technique that detects the inherent charge characteristic 
of the cells, and established electrical signatures for progenitor cells of varying 
differentiation potential38. Darling and coworkers characterized progenitor cells based on 
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their elastic and viscoelastic properties. The outcomes showed subpopulations of 
progenitor cells can be distinguished based on their mechanical markers39,40. Progenitor 
cells of high differentiation potential are shown to have weaker cell membrane-
cytoskeleton interaction as compared to mature cells. Similar to the cell separation of 
cancer cell types the alginate-modified wicking fiber construct was shown to identify 
progenitor cells from a more differentiated pre-osteoblast cell type. The physical 
properties of the cells such as size, shape, electrical charge, cell stiffness, and expression 
of adhesion molecules will also impact the movement of mesenchymal stem cells and 
differentiated cell types.   
 
Conclusion 
The outcomes of this chapter showed the prototype design of the modified 
wicking bundle separated various cell types based the cancer type and differentiated state 
of the cell. This work also showed similarities in wicking behavior of cancer cells and 
progenitor cell types. Further work needs to investigate the mechanisms affecting cell 
movement along the wicking fiber construct separation to optimize the design to improve 
specificity. The work in Chapter 7 will analyze some of the factors affecting the cell 
wicking behavior of different cell lines to improve the specificity and efficacy of the 
system.  
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CHAPTER SEVEN 
INVESTIGATING THE CELLULAR SEPARATION MECHANISM OF WICKING 
FIBERS 
Introduction 
Technologies for CTC isolation and detection include macro-scale systems and 
microfluidics that use physical characteristics of the cells as well as antigen surface 
labels. Microfluidic devices have better specificity and isolation efficiency than macro-
scale systems but are restricted to small volumes of sample and low yield of isolated 
CTCs1,2. Many microfluidic devices and macro-scale systems use antibody-antigen 
interactions for binding epithelial markers to isolated CTCs. Many isolation methods use 
antibodies interacting with epithelial cell adhesion molecules (EpCAMs) and 
cytokeratins1,3. These approaches assume CTCs are expressing epithelial markers, 
therefore limiting these approaches to a specific subpopulation of CTCs and missing 
aggressive CTC populations with mesenchymal phenotype4–8. Other microfluidic devices 
and chips use antigen-independent techniques to detect and separate cancer cells. These 
approaches use physical characteristics of the cancer cells, including size, deformability, 
and charge9. Methods that singularly use cell size to isolate CTCs, such as porous 
membrane cell filtration techniques, are limited due to the large variation in size of 
cancer cells10. Methods involving cell stiffness and impedance have established 
correlations between the biomechanical and electrical properties of cells and their 
metastatic state. Biomechanical measurements of cell stiffness confirm that cancer cells 
are significantly softer than normal cells, relating to the cancer cell’s increased 
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deformability and metastatic potential11,12. Cell-capture microfluidic devices or chips, 
based on the cell deformability or impedance, have higher capture efficiency and purity, 
but can only process small amounts of volume, therefore limiting the number of isolated 
cancer cells. Furthermore, most microfluidic approaches are complex and require a 
perfusion system with an optimum flow rate and shear stress that may alter or damage the 
isolated cells10. The current limitations of the both antigen-independent and -dependent 
microfluidic devices have motivated the simple, bundled fiber design that can rapidly 
analyze large volumes of sample and that may better capture different CTC 
subpopulations.  
Similar limitations are found with progenitor stem cell isolation techniques. Adult 
tissue contains subpopulations of progenitor cells that are used widely in tissue 
engineering applications. Isolating progenitor cells from these tissues is challenging and 
inefficient due to the heterogeneity and lack of universal biomarkers that identify 
progenitor cells. Methods to isolate progenitor cells are costly, slow, and inefficient. Cell 
adherence assays, colony forming units-fibroblastic (CFU-F) assays, and methods of 
biomarker identification are most commonly used to isolate progenitor cells. The current 
isolation techniques isolate progenitor cells with different phenotypic and molecular 
differences that result in functional variability and different in vitro differentiation 
capabilities. Multiple epitopes or phenotypic biomarkers are used to identify progenitor 
cells. Mesenchymal stem cells (MSCs), also described as bone marrow derived cells, 
have the ability to differentiate into lineage-specific cell types including osteoblasts, 
chondrocytes, and adipocytes13. MSCs are routinely used in surgical procedures that 
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require tissue regeneration. Bone marrow aspirate containing MSCs is commonly used in 
orthopedic applications where the normal bone formation process is compromised to 
facilitate the regeneration of bone as well as other tissues. The outcomes of using isolated 
MSCs from patient or donor tissue have limited success in regenerative applications. 
MSC populations vary from donor-to-donor and contain intra-population heterogeneity 
affecting the functionality of the progenitor cells to differentiate and produce the 
appropriate tissue 13,14. The intrinsic heterogeneity of MSCs and other progenitor cells 
creates a challenge for researchers to develop efficient isolations techniques. The 
standard approach to identify MSCs uses expression of multiple biomarkers including 
CD29, CD44, and CD10514. This method can identify MSCs but does not predict the 
function of the MSCs or identify the differentiating potential of the MSC. Approximately 
1 in 4 MSCs isolated have the ability to differentiate into three pathways. Most isolated 
MSC clones have potential to differentiate into one or two pathways14. There is a need for 
alternative methods to identify and isolate subpopulations of MSCs based on their 
potency and ability to differentiate toward specific lineages14.  
In addition to providing a novel technique to identify and separate progenitor cells 
of varying differentiation potential and different cancer cell types, this work may provide 
more insight into the stem-cell hypothesis15. This theory proposes the metastatic cancer 
cells that disseminate from the tumor have stem-cell properties. Researchers have found 
that subpopulations within tumor cells contain stem-cell like functions have 
differentiating potential. This work further investigated similarities between progenitor 
and derived cell separation with cancer and normal cell separation.  
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The previous chapter investigated the potential use of the modified wicking 
bundle approach to separate varying cancer cell types and progenitor cells. In this 
chapter, the mechanisms for separation of varying cell types was explored. The physical 
properties of the cells such as size, shape, electrical charge, cell stiffness, and expression 
of epithelial adhesion molecules and mesenchymal proteins impact the vertical movement 
and distribution in the wicking fibers. Various cross-sectional geometries of the wicking 
fiber impact on cell separation were also explored. The first part of this chapter 
investigated cell size and the effect of different cross-sectional geometries on cell 
separation. The chapter further investigated cell mechanics of various cancer types and 
progenitor cells along the fibers. The final assessment evaluated the percentage of 
EpCAM expressed by the various cancer cell lines and changes in EpCAM expression 
along the wicking fiber bundle construct. Preliminary work was also conducted to 
investigate the mesenchymal phenotype of the cell lines by evaluating the expression of 
CD44. 
 
Impact of Cell Size and Fiber Geometry on Cell Type Separation 
Materials and Methods 
Cell Size 
Determining Cell Size of MCF-7 and MCF-10A Cells in Suspension 
 This procedure evaluated the diameter of cancer and benign epithelial cells while 
in cell suspension, prior to cell attachment, to mimic the cell behavior during the vertical 
test using the modified wicking bundle. Cells from a mammary epithelial cell line from 
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benign breast tissue, MCF-10A (ATCC), and human breast cancer cell line, MCF-7, 
(ATCC) were cultured in DMEM (Invitrogen) supplemented with 10% FBS (Gibco), 1% 
Fungizone, and MEGM single quots (Lonza) and DMEM (Invitrogen) supplemented with 
0.01 mg/mL human recombinant insulin (Gibco), 10% FBS, 1% Fungizone (Gibco), 
10,000 U penicillin, and 10 mg streptomycin/mL (Sigma-Aldrich), respectively. Cells 
were cultured in a T-150 flask (Corning) and maintained in a humidified incubator at 
37°C and 5% CO2. Once confluent both cell types were removed with trypsin-EDTA 
solution (Sigma-Aldrich) and resuspended in culture medium. To determine the average 
cell diameter, MCF-10A and MCF-7 cells were fluorescently labeled with CellTrackerTM 
Green CMFDA probe and CellTrackerTM Red CMTPX probe (Invitrogen; Grand Island, 
NY, USA), respectively following manufacturer’s protocol using a long-term labeling 
concentration of 25 μM for fluorescent imaging. Approximately 100,000 cells from each 
cell line were suspended in 1 mL of growth media in separate 1.5 mL Eppendorf 
microcentrifuge tubes (Sigma; St. Louis, MO USA). 
The cells were mixed using the vortex to keep the cells homogeneously mixed in 
solution. To determine cell diameter 100 μL of the cell solution we pipette directly onto a 
microscope slide and imaged using a fluorescent microscope. Image J software was used 
to determine the average diameter of each sample (n=3) from both cell lines in 
suspension.  
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Determining Cell Size of D1 and MC3T3-E1 Cells in Suspension 
We also investigated the average cell diameter of D1 and MC3T3E1 cells in 
solution prior to attaching to a surface.  Mouse mesenchymal stromal cells, D1 (ATCC), 
and mouse pre-osteoblast cells, MC3T3E1 (ATCC) were cultured in growth media 
consisting of Dulbecco’s Modified Eagle’s Medium (DMEM, Invitrogen) supplemented 
with 10% fetal bovine serum (FBS, Gibco), 10,000 U penicillin, and 10 mg 
streptomycin/mL (Sigma-Aldrich), and Minimal Essential Medium α without ascorbic 
acid (Gibco) supplemented with 10% fetal bovine serum (Gibco), 10,000 U penicillin, 
and 10mg streptomycin/mL (Sigma), respectively. Cells were cultured in a T150 flask 
(Corning) and maintained in a humidified incubator at 37°C and 5% CO2. Once cells 
were confluent, D1 and MC3T3E1 cells were detached using trypsin-EDTA solution 
(Sigma) and resuspended in growth media. D1 and MC3T3E1 cells were fluorescently 
labeled with CellTrackerTM Green CMFDA probe and CellTrackerTM Red CMTPX probe 
(Invitrogen; Grand Island, NY, USA), following manufacturer’s protocol, respectively 
using the long-term labeling concentration of 25 μM for both red and green cell tracker 
was used to label the cells. Following the same procedure above, fluorescent microscopy 
and Image J software were using to determine the average cell diameter for each cell line.   
Cross-sectional Image of Single and Bundled Wicking Fibers  
Wicking fiber bundles containing 3 individual extruded polylactide (Natureworks) 
fibers of non-circular cross-sectional dimensions of 0.72 mm x 0.55 mm were sectioned 
into 3 cm. The wicking fibers were dyed using a blue stain prior to embedding. Samples 
were placed vertically in boxed molds and infiltrated and embedded with Embed-itTM 
312 
 
Low Viscosity Epoxy Resin (Polysciences, Inc.). The wicking fiber samples were 
embedded and sectioned following manufacture’s protocol. Sections, 5 μm in thickness, 
were cut with a microtone and transferred to a microscope slide. The samples were 
imaged with a light microscope and imaging software was used to measure and 
characterize the inter- and intra- fiber spaces. To assess the cross-section of the single 
fibers containing cross-sectional dimensions of 0.72 mm x 0.55 mm or 0.51 mm x 0.33 
mm, the samples were sectioned and placed vertically on a microscope slide. A light 
microscope was used to image the cross-section and imaging software was used to 
measure the groove sizes.  
Investigating the Displacement of Microbeads 
To evaluate the role cell size plays in the vertical displacement along the wicking 
fiber bundles, polystyrene beads of 6and 20 μm were used to mimic cells of different 
sizes. The vertical wicking test was conducted with a bead solution containing beads of 
both sizes and using the modified wicking bundles. The vertical movement of beads was 
assessed in twisted polylactide wicking fiber bundles containing 10 individual fibers with 
cross-sectional dimensions of 0.72 mm x 0.55 mm (“large fiber bundle”) or 10 individual 
fibers with cross-sectional dimensions of 0.51 mm x 0.33 mm (“small fiber bundle”). The 
bundles were formed by twisting the individual small or large fibers using a twisting 
apparatus at 11 rotations per centimeter twist. The bundles were sliced into 3 cm long 
sections to mimic the bundles used to separate cells. The alginate caps were formed on 
each twisted fiber bundled by dipping one end of the wicking fiber bundle in 100 μL of 5 
M CaCl2 solution (Fisher Scientific; Waltham, MA, USA) in a well of a 96-well plate and 
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pipetting 100 μL of 1.4% (w/v) alginate solution comprised of alginic acid sodium salt 
from brown algae (Sigma; St. Louis, MO) in 155 mM NaCl (Sigma; St. Louis, MO) 
directly on the submerged fiber tip in the well. The alginate immediately adhered to the 
fiber end and solidified forming the modified wicking bundle. 
 Following the fabrication process, the modified wicking bundles were added 
vertically to a 12-well plate containing a custom-made lid to hold the samples vertical 
and 1 mL of bead solution was added to a 12-well plate containing 500,000 beads of each 
size. The samples were placed in the incubator at 37°C and 5% CO2 for 2 hours. After the 
incubation period the samples were removed and beads were isolated from the top and 
bottom regions of the wicking fiber bundle as well as the alginate cap to analyze the 
amount of each bead type in each region using the flow cytometer. Similar to the cell 
removal process, the alginate caps were removed and transferred to 1.5 mL Eppendorf 
microcentrifuge tubes (Sigma; St. Louis, MO USA) containing 1 mL of the stock alginate 
dissolution buffer. The buffer was comprised of 100mM sodium citrate (Fisher Scientific; 
Waltham, MA USA), 10 mM HEPES buffer (Sigma; St. Louis, MO USA), and 27 mM 
NaCl (Sigma; St. Louis, MO USA) in 50 mL of distilled water. The alginate caps were 
dissolved for 30 minutes at 37°C and mixed vigorously using the vortex every 5 minutes. 
The wicking fiber bundle region was sectioned with a blade into top and bottom regions 
that were placed into microcentrifuge tubes containing 1 mL of PBS. The samples were 
mixed using the vortex and the fibers were removed. The amount of 6 μm and 20 μm 
beads in each fiber bundle region and the alginate cap were determined using Guava 
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easyCyteTM flow cytometer (Guava Technologies) and InCyte software (Guava 
Technologies). 
Investigating Separation of MCF-10A and MCF-7 Cells in Large and Small Modified 
Wicking Bundles  
To further explore the effects of size on the system. The vertical test method was 
conducted with benign and cancer cells using modified wicking bundles consisting of 
small or large wicking fibers. The wicking fiber bundles were constructed using 10 
individual fibers with cross-sectional dimensions of 0.72 mm x 0.55 mm (“large fiber 
bundle”) or 10 individual fibers with cross-sectional dimensions of 0.51 mm x 0.33 mm 
(“small fiber bundle”). After the bundles were twisted the samples were cleaned by 
soaking in three changes of ethanol for 1 hour each, and placed under ultraviolet light for 
6 hours. Samples were then soaked in a phosphate-buffered saline (PBS, Invitrogen) 
solution for 2 hours and air-dried overnight in a sterile hood. The 1.4% alginate cap was 
formed using the same methods previously described.  
The benign breast epithelial cells, MCF-10A (ATCC), and breast cancer cells, 
MCF-7, (ATCC) were cultured in DMEM (Invitrogen) supplemented with 10% FBS 
(Gibco), 1% Fungizone, and MEGM single quots (Lonza) and DMEM (Invitrogen) 
supplemented with 0.01 mg/mL human recombinant insulin (Gibco), 10% FBS, 1% 
Fungizone (Gibco), 10,000 U penicillin, and 10 mg streptomycin/mL (Sigma-Aldrich), 
respectively. Cells were cultured in a T-150 flask (Corning) and maintained in a 
humidified incubator at 37°C and 5% CO2. Once confluent both cell types were removed 
with trypsin-EDTA solution (Sigma-Aldrich) and resuspended in culture medium to 
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prepare for vertical testing. MCF-10A and MCF-7 cells were fluorescently labeled with 
CellTrackerTM Green CMFDA probe and CellTrackerTM Red CMTPX probe (Invitrogen; 
Grand Island, NY, USA), respectively following manufacturer’s protocol. To detect 
isolated cells from the modified wicking bundles with flow cytometer, MCF-7 cells were 
labeled with 5.0 μM cell tracker red and MCF-10A cells were labeled with the optimized 
cell tracker green concentration of 0.05 μM.  
Both labeled cell types were seeded in each of the wells of a low attachment 12-
well plate with a cell density of 500,000 cells per mL. The modified wicking bundles 
containing small or large fibers (n=6) were placed into each of the wells, as shown in the 
experimental set-up. The well plate containing the samples was placed on flattop shaker 
(VWR) at 100 rpm in a humidified incubator at 37oC and 5% CO2. The vertical 
displacement of the human cancer and benign breast epithelial cells along the wicking 
were determined after 2 hours of incubation, with the initial time point being fiber 
placement into the cell solution.  
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Figure 7.1: Experimental set-up investigating cell separation of benign and cancerous 
cells in modified wicking bundles containing small or large fibers 
 
To quantify the cancer and normal cell separation, the construct was sectioned 
into top, bottom, and alginate regions and the cells were removed from each region, as 
illustrated in Figure 7.1. The alginate caps were first removed from the fiber bundles and 
transferred to a 1.5 mL Eppendorf microcentrifuge tubes (Sigma; St. Louis, MO USA) 
containing 1 mL of the stock dissolution buffer. The buffer was comprised of 100 mM 
sodium citrate (Fisher Scientific; Waltham, MA USA), 10 mM HEPES buffer (Sigma; St. 
Louis, MO USA), and 27 mM NaCl (Sigma; St. Louis, MO USA) in 50 mL of distilled 
water. The alginate caps were dissolved for 30 minutes at 37°C and mixed vigorously 
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using the vortex every 5 minutes. The wicking fiber bundle region was sectioned with a 
blade into top and bottom regions were placed into separate wells of a 24 well plate, 
Samples were rinsed with PBS and untwisted. Cells were removed by adding 500 μL of 
trypsin-EDTA solution into the well with the fiber region and placing the plate on a flat-
top (VWR) shaker at 200 rpm in a 37oC incubator. After 15 min the cells were diluted 
with 500 μL of growth media and the number of red labeled MCF-7 and green labeled 
MCF-10A cells were determined from the alginate caps and top and bottom regions of 
the fiber bundles using a Guava easyCyteTM flow cytometer (Guava Technologies). The 
number of cancer and normal cells in each region was evaluated by following the 
manufacturer’s instructions for InCyte software (Guava Technologies). MCF-7 and 
MCF-10A cells of known cell densities with and without red and green tracker, were 
used as positive and negative controls to calibrate the machine before measurements of 
the treatment groups were made.  
Statistical Analysis  
 JMP 10 software was used to conduct an unpaired two-sample t-test to compare 
the average cell diameter of MCF-10A and MCF-7 cells, as well as, D1 and MC3T3E1 
cells using a significance level of p<0.05. The same analysis was used to compare the 
mean cell count of 6 μm beads in each region of modified bundles of large fibers and 
modified bundles of small fibers using a significance level of p<0.05. The mean cell 
count of 20 μm beads in each region of the modified bundles containing large and small 
fibers was also analyzed using a two-sample t-test. The average percentage of MCF-10A 
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cells in each region of the modified bundles with small fibers was compared to modified 
bundles with large fibers using an unpaired two-sample t-test.  
Results 
Average Cell Diameter of MCF-7 and MCF-10A Cells 
To determine the cell diameter, benign and cancerous cells were labeled with 
green and red cell tracker. The fluorescent label uniformly stains the cytoplasm as shown 
in Images A and B of Figure 7.2. The fluorescent images were processed using Image J 
software to determine the average cell diameter for each cell in the image. The average 
diameter of the MCF-10A cells (~16 μm) was significantly larger than the average 
diameter of the MCF-7 cells (~ 11 μm), shown in Image C. It is important to note within 
cancer cell lines there are variances in cell size and shape.  
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Figure 7.2:  Fluorescently green labeled MCF-10A cells (A) and red labeled MCF-7 cells 
(B) suspended in growth media. (C) The average diameter of the benign MCF-10A cells 
is significantly larger than the cancerous MCF-7 cells, (*) indicate significant difference, 
p<0.05 
 
Average Cell Diameter of D1 and MC3T3E1 Cells 
The average cell diameter of mesenchymal stromal cells and pre-osteoblasts were 
also analyzed and compared. The fluorescent images depict the MC3T3E1 cells labeled 
red (image A) have larger cell diameters than D1 cells labeled green (Image C). The 
semi-quantitative results showed the D1 cells with average diameter of 11 am were 
significantly smaller than the MC3T3E1 cells with an average diameter of 14 μm.  
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Figure 7.3: Fluorescently red labeled MC3T3E1 cell and green labeled D1 cells 
suspended in cell solution (C) The average cell diameter of D1 cells is significantly 
smaller than the MC3T3E1 cells 
 
Cross-sectional Analysis of Wicking Fibers and Bundles  
 The cross-sectional images of the individual small and large fibers are depicted 
Images A and B of Figure 7.4. Using Image J software, the long and short axes of the 
small fiber were 0.51 mm and 0.33 mm and the large fiber were 0.72 mm and 0.55 mm, 
respectively. The groove sizes were also determined by measuring the length using Image 
J software. The groove sizes for the small fiber ranged from 20 μm to 82 μm and the 
large fiber groove sizes ranged from 34 μm to 150 μm. Histological processing was used 
321 
 
to evaluate the cross-section of the wicking fiber bundle. Prior to sectioning a blue dye 
was used to coat the fiber bundle. The cross-sectional image in Figure 7.4 shows blue dye 
in between the grooves of the fibers as well as the inter-fiber spaces between the wicking 
fibers. The image depicts a range in sizes of the micro channels along the bundle. The 
twisting configuration of the bundles distorts the grooves and spaces into channels 
smaller than along the single fiber. This suggests the small channels may prevent the 
large cell types from penetrating the top region of the fiber bundles.  
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Figure 7.4: (A) Section of polylactide wicking fiber bundle depicts a range of inter- and 
intra- fiber spaces (B) and (C) depicts cross-sectional images of two different sized 
polylactide fibers 
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Bead Wicking Distribution in Modified Wicking Bundles  
To investigate the role of size on the wicking behavior of cells through the 
system, beads of 6 and 20 μm were used to mimic cells of varying size. The distribution 
of the beads along the modified wicking bundles was investigated in bundles comprised 
of small or large cross-sectional fibers. The various bundles containing different sized 
fibers were used to explore the effect of fiber size on the bead movement. Beads were 
isolated from the top and bottom regions of the fibers and from the alginate cap. The 
results, Figure 7.5, show the forward scatter versus side scatter plot can be effectively 
used to quantify the number of each bead type. Since the beads are different sizes, the 
plots for each bead size were clearly distinguished (Image A). The scatter plots of the 
beads isolated form the bottom region depict significantly more 6 μm sized beads than 20 
μm beads for both large and small modified wicking bundles. The alginate and top region 
showed more 6 μm beads in the modified constructs containing small fibers. Minimal 20 
μm beads are detected in these regions for both fiber types.  
 The bead count was determined using the InCyte software and presented in the 
graph below, Figure 7.5. Both large and small modified wicking bundles show 
significantly more 6 μm beads in each region than the larger 20 μm beads (Image A). The 
top and bottom regions of the small wicking bundle contained significantly more 6 μm 
sized beads than the large wicking bundle. The percentage of the 6 μm beads in each 
region was similar for large and small fiber bundle constructs (Image B).  
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Figure 7.5: Bead wicking analysis with flow cytometry (A) Scatter plots showing the 
regions of the 6 μm (right) and 20 μm beads 
  
325 
 
 
Figure 7.6: Flow cytometry analysis of 6 μm and 20 μm diameter beads in alginate 
modified fibers containing small or large individual fibers. (A) Both constructs showed 
significantly more 6 μm diameter beads in each region than the 20 μm beads. The 
modified fiber bundle containing the smaller bundles contained significantly more 6 μm 
beads in the top and bottom regions of the fiber bundle than the modified construct 
containing larger cross-sectional fibers. (B) The modified large and small fiber 
constructs showed comparable percentages of both bead types in each region of the fiber 
bundle and the alginate cap 
 
Investigating Separation of MCF-10A and MCF-7 Cells in Large and Small Modified 
Wicking Bundles  
This study investigated the effect of the cross-sectional size of the wicking fiber 
on the cell separation of benign and cancer cells. Modified wicking bundles of small and 
large individual fibers were used to test the vertical cell wicking of MCF-7 and MCF-
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10A cells. The flow cytometry results, Figure 7.7, show comparable cell counts (Image 
A) and percentages (Image B) of cancerous and benign cells in the alginate cap and 
bottom region of the fiber for both modified wicking bundles containing large or small 
fibers. The top region of the bundles containing large wicking fibers showed significantly 
more MCF-10A cells than the bundles containing small wicking fibers. The scatter and 
fluorescent intensity plots from the flow cytometry analysis from each region presented 
in Figure 7.8 show for both large and small modified wicking bundles significantly less 
cells were removed from the top region of the fiber bundle and the alginate cap. The lack 
of cells in these regions is due to the cell removal processing methods. Further work 
needs to investigate alternate methods to improve the removal of cells.  
 
 
Figure 7.7 (A) Cell count in each region of the modified small and large wicking bundles. 
The alginate cap and bottom region of the wicking fiber bundle show similar cell counts 
of both cell types. The top region of the smaller fiber depicted significantly less MCF-10A 
and MCF-7 cells than the top region of the modified large fiber construct. (B) Percentage 
of each cell type in each region of the modified small and large wicking fiber constructs. 
The alginate cap and bottom fiber region show similar percentages of benign and cancer 
cells for both large and small fiber bundles. The percentage of MCF-10A cells in the top 
region of the large fiber bundle is significantly greater than the small fiber bundle.  
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Figure 7.8: Scatter and fluorescent intensity plots of benign and cancer cells in each 
region of the alginate modified construct. (A) Bottom region of modified small bundles 
(left) shows comparable amounts of benign and cancer cells as the modified large 
bundles (right). (B) Top region of modified small bundles (Left) show less cell 
penetration and less green labeled benign cells than the modified large bundle construct 
(Right). (C) Alginate cap from modified small bundle construct shows comparable 
amounts of cancer and benign cell in large bundle construct.  
 
Investigating Cytoskeletal Arrangement and Protein Expression along the Modified 
Wicking Bundles 
Materials and Methods 
Cell Culture 
 The cytoskeleton arrangement was investigated for various cancer types as well 
as mouse progenitor and pre-osteoblast cells. Benign epithelial cells, MCF-10A 
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(ATCC), and human breast cancer cells, MCF-7 (ATCC), were cultured in DMEM 
(Invitrogen) supplemented with 10% FBS (Gibco), 1% Fungizone, and MEGM single 
quots (Lonza) and DMEM (Invitrogen) supplemented with 0.01 mg/mL human 
recombinant insulin (Gibco), 10% FBS, 1% Fungizone (Gibco), 10,000 U penicillin, and 
10 mg streptomycin/mL (Sigma-Aldrich), respectively. Metastatic breast epithelial cells, 
MDA-MB-231 (ATCC) were cultured in DMEM (Invitrogen) supplemented with 10% 
FBS, 1% Fungizone (Gibco), 10,000 U penicillin, and 10 mg streptomycin/mL (Sigma-
Aldrich). Mouse mesenchymal stem cells, D1 (ATCC), and mouse pre-osteoblast cells, 
MC3T3E1 (ATCC) were cultured in growth media consisting of Dulbecco’s Modified 
Eagle’s Medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS, 
Gibco), 10,000 U penicillin, and 10 mg streptomycin/mL (Sigma-Aldrich), and Minimal 
Essential Medium α without ascorbic acid (Gibco) supplemented with 10% fetal bovine 
serum (Gibco), 10,000 U penicillin, and 10mg streptomycin/mL (Sigma), respectively. 
Immunofluorescence Staining for Actin Cytoskeleton and Vinculin 
 Staining for vinculin and actin cytoskeleton was performed on both the modified 
wicking bundles after conducting the vertical test with cell solutions, as well as cells 
seeded directly on a glass coverslip. Prior to staining along the wicking fiber bundles, 1 
mL containing 500,000 cells from each cell line being investigated was seeded in a low-
attachment 12-well plate. The modified wicking bundle was used to conduct the vertical 
test method as previously described. After two hours of incubation the modified wicking 
bundles were removed and prepared for staining. Cells were also seeded at a density of 
100,000 cells per mL on a glass cover slip in a 24-well plate. The cytoskeleton 
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organization was evaluated for MCF-10A and MCF-7 cells along the modified wicking 
bundle after performing the vertical test with both cell lines mixed in each well. 
Fluorescent images of the actin and vinculin were captured in the bottom, middle, and top 
regions of the bundle. This procedure was also performed to investigate cell mechanics of 
MCF10A and MDA-MB-231 along the fiber. D1 progenitor cells and the MC3T3E1 pre-
osteoblast cells were analyzed, however, these cell lines were not mixed and each cell 
line was analyzed separately along the construct. The table below presents the different 
cell line groups that were used to investigate cell cytoskeletal arrangement. All cell lines 
investigated along the modified wicking bundle were also analyzed on a glass slide.  
Table 7.1: Cell lines investigated 
Cell lines assessed along the modified 
wicking bundle 
Cell lines analyzed on glass slides 
MCF-10A and MCF-7  MCF-10A 
MCF-10A and MDAMB-231  MCF-7 
D1  MDA-MB-231 
MC3T3E1  D1 
 MC3T3E1 
  
 Prior to the actin and vinculin staining, the samples were washed with PBS and 
fixed in 10% formalin for 20 minutes. Formalin was removed and samples were further 
rinsed in PBS. To stain for actin and vinculin, samples were blocked for 1 hour using 
blocking solution containing 2% BSA (Sigma; St. Louis, MO, USA), 5% goat serum 
(Sigma), and 0.1% triton X (ThermoScientific; Rockford, IL). The blocking solution was 
removed and the samples were washed with PBS. To prevent auto-fluorescence from the 
polylactide fibers, the samples were blocked in 1% (w/v) sodium borohydride (Sigma; St. 
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Louis, MO) in PBS and incubated at room temperature for 30 minutes. The sodium 
borohydride was removed and the samples were washed extensively with PBS for 30 
minutes. Following the blocking step, the samples were incubated overnight at 4°C with 
the vinculin primary antibody (mouse anti-rabbit; Abcam; Cambridge, MA, USA) using a 
1:200 dilution. After the overnight incubation, the primary was removed and stored for 
later use. The samples were gently washed with PBS and incubated in 500 μL of solution 
containing Alexa Fluor 488 phalloidin (Invitrogen; Grand Island, NY) using a 1:20 
dilution, and Alexa Fluor 568 goat anti-rabbit antibody (Molecular Probes; Grand Island, 
NY, USA) using a 1:500 dilution for two hours at room temperature. Following the two 
hour incubation the phalloidin and secondary antibody solution was removed and 1 mL 
of a 2 mg/mL Hoechst 33342 solution (Thermo Scientific; Rockford, IL) was added to 
the samples and incubated for 5 minutes at room temperature. Samples were rinsed with 
PBS and stored at 4°C. To analyze cell cytoskeletal arrangement, images were obtained 
from each region of the fiber bundle using fluorescent microscopy (EVOS; Floid Cell 
Imaging Station, Life Technologies); Image J imaging software was used to overlay 
images.  
 Immunofluorescence Analysis of EpCAM and CD44 
 EpCAM expression of the MCF-10A, MDA-MB-231, and MCF-7 cells was 
investigated along the modified wicking bundles. MCF-7, MCF-10A, and MDA-MB-231 
cells were cultured and plated in low-attachment 12-well plate. Six wells were plated 
with MCF-7 and MCF-10A cells at a cell density of 500,000 cells per mL. The remaining 
six wells were seeded with MD-AMB-231 and MCF-10A cells at the same cell density. 
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The vertical test using the modified wicking bundles was performed. After 2 hours, the 
samples were removed and prepared for immunofluorescence staining. To investigate the 
amount of EpCAM and CD44 expressed by each cell type the cells were also individually 
plated at 20,000 cells per well on glass slides in a 24-well plate. 
Immunofluorescence staining for EpCAM was performed on the modified 
wicking bundles. Both EpCAM and CD44 expression was investigated on the cancer 
cells plated on the glass slides. To stain for EpCAM and CD44 samples were blocked for 
1 hour using blocking solution containing 2% BSA (Sigma; St. Louis, MO, USA), 5% 
goat serum (Sigma), and 0.1% triton X (ThermoScientific; Rockford, IL). The blocking 
solution was removed and the samples were washed with PBS. To prevent auto-
fluorescence from the polylactide fibers, the samples were blocked in 1% (w/v) sodium 
borohydride (Sigma; St. Louis, MO) in PBS and incubated at room temperature for 30 
minutes. The sodium borohydride was removed and the samples were washed extensively 
with PBS for 30 minutes. Following the blocking step, the samples were incubated 
overnight at 4°C with the primary antibody EpCAM (mouse anti-rabbit; Abcam; 
Cambridge, MA USA) using a 1:200 dilution or with the primary antibody CD44 (rabbit 
anti-human; Life Technologies; Grand Island, NY USA). After the overnight incubation, 
the primary was removed and stored for later use. The samples were gently washed with 
PBS and incubated in 500 μL of solution containing the secondary antibody Alexa Fluor 
488 goat anti-rabbit antibody (Invitrogen; Grand Island, NY) using a 1:500 dilution, or 
Alexa Fluor 568 goat anti-rabbit antibody (Molecular Probes; Grand Island, NY, USA) 
using a 1:500 dilution for two hours at room temperature. Following the two hour 
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incubation, the secondary antibody solution was removed and 1 mL of a 2 mg/mL 
Hoechst 33342 solution (Thermo Scientific; Rockford, IL) was added to the samples at a 
and incubated for 5 minutes at room temperature. Samples were rinsed with PBS and 
stored at 4°C. Fluorescent images of EpCAM expression along the fibers were obtained 
from each region of the fiber bundle using fluorescent microscopy (EVOS; Floid Cell 
Imaging Station, Life Technologies). Both EpCAM and CD44 expression was imaged for 
each cell line that was cultured on a glass cover slide. Image J imaging software was used 
to overlay images.  
Flow Cytometry Analysis of EpCAM Expression along Fibers 
Prior to EpCAM expression analysis by flow cytometry, the vertical test was 
conducted along the modified wicking bundles using a cellular mixture of MCF-10A and 
MDA-MB-231, or a mixture of MCF-10A and MCF-7 cells with all cell types seeded at 
500,000 cells. Immediately after the vertical test, the samples were removed, transferred 
to a 6-well plate, and washed with PBS. The cells were stained for EpCAM prior to the 
removal from the modified wicking bundle. To stain for EpCAM, samples were 
incubated for 30 minutes at 4°C in 1 mL of primary antibody solution containing 5% goat 
serum (Sigma) and the primary antibody EpCAM (mouse anti-rabbit; Abcam; 
Cambridge, MA USA) using a 1:200 dilution. Following incubation, the samples were 
gently washed with PBS and incubated in 1 mL of solution containing the secondary 
antibody Alexa Fluor 488 goat anti-rabbit antibody (Invitrogen; Grand Island, NY) using 
a 1:500 dilution for 30 minutes at room temperature. Samples were rinsed in PBS and 
cells were removed from each region of the construct following previous procedures and 
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resuspended in 500 μL of PBS for flow cytometry analysis. Positive and negative 
controls for each cell line were prepared by seeding 100,000 cells in microcentrifuge 
tubes. The positive controls from each cell line were rinsed with PBS and stained for 
EpCAM using the procedure described above. The negative controls were left unstained.  
The amount of EpCAM expression in each region of the modified wicking bundle 
was analyzed using a Guava easyCyteTM flow cytometer (Guava Technologies) and by 
following the manufacturer’s instructions for InCyte software (Guava Technologies). The 
green intensity plots were used to determine the amount of cells expressing EpCAM in 
each of the regions.  
Results 
Exploring Cell Mechanics of Cancer Cell Lines along Fibers 
The actin and vinculin arrangement of each cancer line was investigate both on a 
2-dimensional glass cover slide, as well as, along the modified wicking bundle. Figure 
7.9 depicts the actin and vinculin arrangement of the cell lines tested along the wicking 
fibers. The MCF-7 cell lines (Image A) portray a rounded morphology with actin fibers 
primarily unorganized and circumferentially localized. MCF-10A show more aligned 
actin stress fibers along the periphery of the cell (Image B). MDA-MB-231 cells (image 
C) depict the fibril actin abundantly distributed around the cells with a more overall 
organized fiber arrangement. Both MCF-10A and MDA-MB-231 cells show less rounded 
morphology with more a more spindle shape appearance.  
The morphology and cytoskeletal arrangement of benign, MCF-10A, and 
cancerous cells, MCF-7 was explored along the bottom, middle, and top regions of the 
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modified wicking bundles. Figure 7.10 depicts the cytoskeletal architecture of the cells 
after wicking through the bundle. The cancer cells present a rounded morphology with 
actin concentrated along the periphery in all regions of the bundle. This morphology 
suggests the cancer cells are tethered to the surface and are not spreading out on the 
fibers. The cell morphology of metastatic cancer, MDA-MB-231, and benign, MCF-10A, 
cells was also investigated along the wicking fibers after the cell mixture was wicked 
through the modified wicking bundle, Figure 7.11. The outcomes show similar rounded 
morphology in all regions of the fiber bundle. However, in comparison to the MCF-7 and 
MCF-10A separation, the MDA-MB-231 cell displacement through the fibers shows less 
cell-cell contact with more individual cell movement through the conduits.  
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Figure 7.9: Actin cytoskeletal and vinculin arrangement of the various cancer types (A) 
MCF-7 non-metastatic cancer cells show weak actin cytoskeleton lacking fiber 
arrangement (B) MCF-10A benign cells show actin fibril arrangement with alignment 
along the periphery of the cell. Benign cells depict vinculin expression concentrated in 
central region of cells. (C) MDA-MB-231 cells depict more actin fiber arrangement 
compared to the other cell lines. Images show distinct actin fibers along the periphery 
and central regions of the cell.  
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Figure 7.10: The actin and vinculin arrangement of MCF-7 and MCF-10A cells along 
the modified wicking fiber construct (A) Bottom region of the wicking fiber bundle shows 
the actin fibers are arranged along the periphery forming an outer shell. (B) Middle 
region of the wicking fiber bundle shows clumps of cells with round morphology (C) Top 
region of wicking fiber bundle depicts the same rounded morphology of the cells  
337 
 
 
Figure 7.11: Cytoskeletal architecture of MDA-MB-231 cells along the modified wicking 
fiber construct. (A) Cells in bottom region of construct depict rounded morphology with 
actin concentrated along the periphery. The middle region (B) and top region (C) of the 
modified construct shows the same rounded morphology. 
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Exploring Cell Mechanics of Mesenchymal Stem Cells and Pre-Osteoblasts along the 
Fibers 
The cell cytoskeletal architecture of mouse mesenchymal stem cells and mouse 
pre-osteoblasts was analyzed after attachment to a glass slide and wicking through the 
modified wicking bundle. Figure 7.12 depicts the fluorescent images of the actin 
cytoskeleton arrangement for D1 (Image A) and MC3T3E1 cells (Image B). The D1 
cells depict a fibroblast-like morphology with a more spindle-like shape. In 
comparison, the MC3T3E1 cells also depict a more fibroblast morphology with greater 
actin fiber alignment, suggesting the pre-osteoblasts have a stronger cytoskeleton.  
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Figure 7.12: (A) Actin arrangement of D1 mouse mesenchymal stem cells show 
fibroblast-like morphology with actin fiber formation predominantly on the periphery of 
the cell. (B) MC3T3E1 pre-osteoblast cells depicts a less spindle shaped morphology 
with more actin fiber formation within the cell  
 
 The D1 and MC3T3E1 cell movement along the fibers after the vertical wicking 
test is depicted in Figure 7.13. The MC3T3E1 cells show greater cell attachment to the 
fibers with a more spread-out actin cytoskeleton along the bottom and middle regions 
of the fiber bundles. The D1 cells show a more rounded morphology along each of the 
regions with less cell attachment.  
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Figure 7.13: (A) Pre-osteoblast cells and (B) D1 cells along the top region of the wicking 
fiber bundle show the pre-osteoblasts have a less rounded morphology and more spread-
out along the fiber. (C) Pre-osteoblast and (D) D1 cells in the middle region depict the 
pre-osteoblast have adhered more to the fiber compared to the rounded shape of the D1 
cells. The pre-osteoblasts (E) and D1 cells (F) both show more rounded morphology in 
the top regions of the fiber  
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EpCAM Expression of Cancer Cell Lines along the Fibers  
 Each cancer cell line was cultured on a glass plate and analyzed for EpCAM 
expression using immunofluorescence. Figure 7.14 illustrates the levels of EpCAM 
expression for each cell line. MCF-7 cells showed high levels of EpCAM expression 
(Image A). Both MCF-10A (Image B) and MDA-MB-231 cells (Image C) demonstrated 
low levels of EpCAM.  
 A mixture of MCF-10A and MCF-7 were used to conduct the vertical wicking 
test. After the cells wicked into the modified wicking bundle, the EpCAM expression was 
investigated along each region of the fiber bundles using both immunofluorescence and 
flow cytometry. The immunofluorescence results show some expression of EpCAM in 
the bottom region of the fiber bundle, Figure 7.15. The middle (and top regions of the 
fiber bundles depict higher percentages of EpCAM expression. This is due to the greater 
penetration of MCF-7 cells to these regions. The flow cytometry results showed similar 
results, Figure 7.18. Higher percentages of cells expressing EpCAM were found in the 
top region of the wicking fiber bundle and alginate cap (Image A). The scatter and 
intensity plots depict EpCAM expression in each region of the construct (Image B). The 
higher percentage of EpCAM expression in the top region and alginate cap correlates to 
the greater number of MCF-7 cells that wick to these regions.  
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Figure 7.14: EpCAM expression (Green fluorescence) of each cancer cell line (A) MCF-
7 cells show high expression of EpCAM (B) MCF-10A cells and (C) MDA-MB-231 show 
low expression of EpCAM 
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Figure 7.15: EpCAM expression (Tagged with red-fluorescent secondary antibody) of 
MCF-7 and MCF-10A cells in the bottom region of the wicking fiber bundle 
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Figure 7.16: EpCAM expression of MCF-7 and MCF-10A cells along central region of 
wicking fiber bundle  
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Figure 7.17: Depicts high percentage of EpCAM expression in top region of the wicking 
fiber bundle  
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Figure 7.18: Flow cytometry analysis (A) Percentage of cells expressing EpCAM (B) 
Scatter and intensity plots of EpCAM expression from each region 
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 The EpCAM expression was also investigated along modified wicking bundles 
after MCF-10A and MDA-MB-231 cells were processed through the vertical test. The 
fluorescent images of the modified wicking bundle (Figure 7.19) depict low EpCAM 
expression in all regions. As indicated previously both MCF-10A and MDA-MB-231 cell 
lines show minimal EpCAM expression. The EpCAM expression from the top and 
bottom regions of the modified wicking bundle was quantified using flow cytometry. The 
scatter and intensity plots of the control groups showed low EpCAM expression for both 
MCF-10A and MDA-MB-231 cells. Cell isolated from the top and bottom regions of the 
bundle showed low expression of EpCAM, approximately 10%. The EpCAM expression 
of MDA-MB-231 cells mixed with benign cells along the fiber bundles was significantly 
lower than MCF-7 mixed with benign. The results suggest the modified wicking bundle 
can separate cancer cells that expressing EpCAM, such as MCF-7 cells, into the top 
region of the wicking fiber bundle and alginate cap. Conversely, metastatic cancer cells 
often lack EpCAM expression and are still captured in the top region of the fiber bundle 
and the alginate cap. The outcomes imply EpCAM expression may play a role in cancer 
cell type separation along the fibers, but further investigation is needed. Preliminary 
works has also investigated expression of other proteins along the modified wicking 
bundle to determine if this separation device can be used to isolate subpopulations of 
cancer cells within cell lines. CD44 expression was assessed between each of the cell 
lines. High expression of this marker has been used to define metastatic cancer cells, as 
well as, breast cancer stem cells that are tumorigenic and can differentiate, propagating a 
heterogeneous tumor. Figure 7.21 depicts CD44 expression from benign, cancerous, and 
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metastatic cancer cell lines. The MDA-MB-231 and MCF-10A cells show high 
expression of CD44, and the MCF-7 cells show low expression. Future work involves 
investigating expression of CD44 and other tumorigenic protein markers along the fibers 
to optimize the system to distinguish cancer cells of varying phenotypic expression.  
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Figure 7.19: Depicts low EpCAM expression (tagged with green fluorescent secondary 
antibody) of MCF-10A and MDA-MB-231 cells in bottom (A), middle (B), and top 
regions (C) of the wicking fiber bundle. 
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Figure 7.20: Flow cytometry analysis of EpCAM expression along top and bottom 
regions of wicking fiber bundle (A) Percentage of cells expressing EpCAM in top and 
bottom regions of wicking fiber (B) MCF10A control group shows low expression of 
EpCAM (C) MDA-MB-231 group depicts almost no EpCAM expression 
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Figure 7.21: Levels of CD44 expression of the various cancer cell lines (A) MCF-7 show 
low CD44 expression (B) MCF10A and (C) MDA-MB-231 cells show high levels of 
CD44 expression 
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Discussion 
The first part of this chapter explored the role of cell size as a major factor in cell 
separation between different cell types. The outcomes showed that there are differences 
in cell size of the various cell types that were separated along the modified wicking fiber 
construct. Interestingly, the MCF-7 cancer cells and D1 cells were both similar in cell 
size, and significantly smaller than the benign MCF-10A and MC3T3E1 pre-osteoblast 
cells. The increased travel of the smaller cell types, D1 and MCF-7 cells suggest cell size 
may play a major role in separation along the fiber construct. Beads of 6 and 20 μm were 
used to mimic cells of different sizes in modified wicking fiber constructs containing 
small or large wicking fiber bundles. The outcomes showed approximately 90% of the 
bead populations in each region were the 6 μm sized beads for both types of modified 
wicking fiber constructs.  
 The results confirm the size of the cell will play a role in the modified wicking 
fiber construct. It also reveals using bundles with individual wicking fibers of larger 
cross-section does not increase the amount of large beads into the system. The larger 
cross-sectional fibers consist of larger individual grooves along the fiber, providing 
conduits with larger diameters. Laplace equation, shown below, describes the capillary 
pressure generated in a capillary with a defined radius. According to Laplace equation the 
larger the diameter of the capillary the less capillary pressure is generated16.  
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Equation 7.1: 𝐿𝑎𝑝𝑙𝑎𝑐𝑒 𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 
  𝑃𝐶𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦 =  
𝛾𝐿𝑉𝑐𝑜𝑠𝜃
𝑅𝑐
 
𝜃 = 𝑐𝑜𝑛𝑡𝑎𝑐𝑡 𝑎𝑛𝑔𝑙𝑒 
𝑅𝑐 = 𝑅𝑎𝑑𝑖𝑢𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦 
𝛾𝐿𝑉 = 𝑆𝑢𝑟𝑓𝑎𝑐𝑒 𝑡𝑒𝑛𝑠𝑖𝑜𝑛 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑙𝑖𝑞𝑢𝑑 𝑎𝑛𝑑 𝑎𝑖𝑟 
  
The maximum liquid height reached is also inversely proportional to the radius of the 
conduits. Jurin’s law describes the maximum height reach along a capillary when the 
pressure reaches equilibrium17.  
Equation 7.2: Jurin’s Law 
𝐻𝑀𝑎𝑥𝑖𝑚𝑢𝑚 =  
2𝛾𝐿𝑉𝑐𝑜𝑠𝜃
𝜌𝑔𝑅𝑐
 
𝜃 = 𝑐𝑜𝑛𝑡𝑎𝑐𝑡 𝑎𝑛𝑔𝑙𝑒 
𝑅𝑐 = 𝑅𝑎𝑑𝑖𝑢𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦 
𝛾 = 𝑆𝑢𝑟𝑓𝑎𝑐𝑒 𝑡𝑒𝑛𝑠𝑖𝑜𝑛  
𝜌 = 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑙𝑞𝑖𝑢𝑖𝑑 
 
The larger wicking fiber bundles consist of larger grooves or conduits with lower 
capillary pressure that will influence the vertical wicking behavior. The outcomes showed 
the modified wicking bundle containing the small groove sizes contained significantly 
more 6 μm beads than the bundles with larger groove sizes. The bundled fibers of smaller 
groove sizes create smaller capillaries that produce greater capillary pressure to transport 
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the bead solution vertically through the bundle. Although the modified wicking bundles 
contained different sized fibers, the amount of tension used to twist the fibers remained 
the same. The twist of the fibers will create pores or inter-fiber spaces between the fibers. 
The tension of the twist will result in different pore sizes. High tension can affect the 
continuity and reduce the radius of the capillaries between the fibers. Hajian and 
coworkers demonstrated twisted fibers of the same diameter with different twist rates 
exhibit different wicking behaviors. This group showed increased twisting results in 
smaller inter-fiber spaces reducing the effective radius as well as the continuity causing a 
reduction in the rate of capillary rise17. The twisting of the larger fibers in our system 
may have caused discontinuities along the fiber inhibiting the wicking action in some of 
the conduits. Although the larger conduits will decrease capillary pressure and the 
maximum height reached, increased pore size generated from the inter-fiber spaces will 
actually increase the rate of capillary action. This is described by the Lucas Washburn 
equation, which is determined by integrating the Hagen-Poiseuille equation that describes 
liquid capillary rise, shown below16–18.  
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Equation 7.3: Hagen-Poiseuille Equation 
𝒅𝒉
𝒅𝒕
=
𝒓𝟐
𝟖𝜼𝒉
𝚫𝐏 =
𝒓𝟐
𝟖𝜼𝒉
(
𝟐𝜸𝒄𝒐𝒔𝜽
𝒓
− 𝝆𝒈𝒉) 
𝜃 = 𝐶𝑜𝑛𝑡𝑎𝑐𝑡 𝑎𝑛𝑔𝑙𝑒 
𝑅𝑐 = 𝑅𝑎𝑑𝑖𝑢𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦 
𝛾 = 𝑆𝑢𝑟𝑓𝑎𝑐𝑒 𝑡𝑒𝑛𝑠𝑖𝑜𝑛  
𝜌 = 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑙𝑞𝑖𝑢𝑖𝑑 
𝜂 = 𝐷𝑦𝑛𝑎𝑚𝑖𝑐 𝑣𝑖𝑠𝑐𝑜𝑠𝑖𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑙𝑞𝑖𝑢𝑖𝑑 
ℎ = 𝐻𝑒𝑖𝑔ℎ𝑡 𝑟𝑒𝑎𝑐ℎ𝑒𝑑 𝑏𝑦 𝑙𝑖𝑞𝑢𝑖𝑑 𝑏𝑦 𝑡𝑖𝑚𝑒 𝑡 
Δ𝑃 = 𝑃𝑟𝑒𝑠𝑠𝑢𝑟𝑒 𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 
 
Equation 7.4: Lucas – Washburn Equation 
 𝒉𝟐 =
𝒓𝜸𝒄𝒐𝒔𝜽
𝟐𝜼
𝒕 = 𝒌𝒕 
𝑘 = 𝑐𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦 𝑟𝑖𝑠𝑒 𝑟𝑎𝑡𝑒 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 
 
 The Lucas-Washburn equation demonstrates the larger pore sizes between the 
fibers, the less resistance due to fiber and liquid interfaces increasing the liquid rate17,19. 
The twisting of the bundles can control the pore size. The larger the pore size the faster 
the fluid can fill and the more fluid can be absorbed by the construct16,17. The small and 
large modified wicking bundles were used to compare the wicking separation of MCF-
10A and MCF-7 cells. The bundles showed similar cell counts and percentage of cell 
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types in each region. The larger fiber, however, showed increased MCF-10A cells in the 
top region. The increased number of cells in this region can be a result of the larger pore 
sizes. The benign cells were shown to be larger than the MCF-7 cells in a suspended 
solution. The larger pore sizes along the modified large fiber bundle has less liquid-fiber 
action allowing larger cells to fit through and travel with the liquid through the pores. 
Future work will investigate the various bundling configurations and tension rates to 
increase the wicking rate, as well as, the amount of capillary pressure generated to 
increase the amount of cells in the top regions of the fiber and with alginate cap. The 
system can be optimized to determine an effective cross-sectional size and twist rate to 
enhance the rate of separation and improve the separation and isolation of non-metastatic 
and metastatic cancer cell types.  
 This chapter also investigated the role of cell morphology and cytoskeletal 
arrangement of various cell types on their wicking behavior along the modified wicking 
bundles. The immunofluorescence staining of the cytoskeletal components on a 2-
dimensional surface showed the cancer cell types had different morphology and actin 
arrangement. The non-metastatic cancer cells showed the least disorganized actin 
arrangement with a round morphology. Both the benign cells and metastatic cancer cells 
showed a more spindle shaped phenotype with more actin fiber arrangement. The 
difference in cell morphology is a factor of cell origin. MCF-10A and MDA-MB-231 
cells are both basal epithelial cells and MCF-7 cells are luminal. Generally, basal type 
cells show a more spindle mesenchyme-like morphology and luminal cells show a more 
cobblestone appearance20. Although the MCF-10A and MDA-MB-231 cells illustrated a 
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more spindle-like morphology the cytoskeletal arrange will greatly impact the cell 
mechanics of the cell. The fibrous actin organization, as well as, microtubule structure 
will affect the cell stiffness or deformability of the cells. The metastatic cancer cells are 
shown to be more deformable than both cancerous and benign cells. Guck and coworkers 
measured optical deformability of MCF-7, MCF-10A, and MDA-MB-231 cells. The 
metastatic cancer cells deformed more than both non-metastatic cancer cells MCF-7 and 
benign MCF-10A cells21. The increased deformation and reduction of cytoskeletal 
strength of the metastatic cancer cells correlates to their ability to squeeze through tissue 
to reach the blood stream and penetrate other tissue21,22. The cancerous cells, however, 
showed significantly more deformation than the MCF-10A cells. The degree of 
deformability of the cell has been correlated with metastatic potential. Other groups have 
developed microfluidic systems to isolate circulating tumor cells using the ability of 
cancer cells to deform. These systems include arrays, posts, or channels in combination 
with a hydrodynamic force to deform the cells through the size-limited barriers to isolate 
the more flexible cancer cells, which are also considered to have more metastatic 
potential12. Biomechanical measurements from atomic force microscopy (AFM) and 
optical tweezer measurements confirm the cell stiffness of cancer cells are significantly 
softer than normal cells, relating to the cancer cell’s increased deformability and 
metastatic potential 11,12. The ability of MCF-7 and MDA-MB-231 cells to deform may 
play a significant role in their ability to wick along the wicking fiber bundles. The 
cytoskeletal arrangement of the cancer cells along the wicking fiber bundles showed 
mostly round morphology. The images showed cancer cells tethered along the fibers with 
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very minimal cell spreading. This suggests cell morphology may play less of a role in cell 
separation in our system. The staining along the fibers containing MCF-7 and MCF-10A 
cells showed clusters of cells within the bundles of the fiber. The staining of MDA-MB-
231 and MCF10A cells showed more individual cell movement with significantly less 
clusters. The clumping and moving of cells as clumps is characteristic migratory behavior 
of both MCF-10A and MCF-7 cells. Metastatic cancer cells, MDA-MB-231, migrate 
individually, which is characteristic for a mesenchyme-like cell. Regardless of the 
clusters shown, each of the cancer cell lines investigated showed a round phenotype 
along the fiber. In addition to cell morphology, cell adhesion can play a role. Chen and 
coworkers investigated cancer cell separation based on the cell adhesion to a substrate 
and found cancer cell types will adhere preferentially23,24. Further work can investigate 
the cell adhesion strength along the wicking fibers of the various cell types and the 
effects of modifying surface topography on cell wicking behavior. The outcomes of this 
work show cell size and cell deformability may play greater roles in the mechanism for 
cell wicking than cell morphology.  
The mouse mesenchymal stem cells and pre-osteoblast cells depicted 
morphological differences. The D1 stem cells showed weaker actin alignment and fiber 
formation compared to the more differentiated MC3T3E1 cells. Titushki and coworkers 
investigated cellular mechanic changes during cell differentiation. This group found 
changes in the cell mechanics of progenitor cells as they differentiate into bone cells25. 
Furthermore, stem cells have been shown to be highly deformable12.  The thick bundle 
actin shown in the fluorescent image of the MC3T3E1 cells suggests the cells are less 
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deformable with higher cells stiffness. Further work will need to investigate the 
deformability of D1 cells and MC3T3E1 cells, but the outcomes suggest the D1 cells are 
more deformable and this characteristic may explain the high cell densities of D1 cells in 
the top region and alginate cap of the modified bundle. The D1 cells showed a similar 
round morphology as the cancer cells along the wicking fiber bundles. Interestingly, the 
MC3T3E1 cells depicted a more fibroblast morphology along the bottom and middle 
regions of the fibers. The pre-osteoblasts showed cell attachment and spreading along the 
grooves. The high actin fiber arrangement of the MC3T3E1 cells may limit deformability 
of the cell causing minimal penetration into the bundle. The pre-osteoblasts also show 
higher adhesion preference to the wicking fibers. The topography of the wicking fibers 
was shown to have a rough surface. The pre-osteoblasts may have a greater affinity to 
adhere to the rough surface than the D1 progenitor cells. This is reflected by the low 
amount of cells in the top regions of the fibers and the increased adherence and cell 
spreading of the pre-osteoblasts along the bottom regions of the fibers. 
 The standard for isolating CTCs involves isolating cells based on the expression 
of EpCAM and/or cytokeratin and the negative expression of CD45. The only FDA 
approved technology to isolate CTCs from blood biopsy samples is the CellSearch 
system (Verdex, USA). This system isolates cells expressing EpCAM using an 
immunomagnetic approach26. The major limitation of these EpCAM based systems is the 
specificity for one type of cancer cell. Cancer cells of high metastatic potential have been 
defined with negative EpCAM expression and high expression of mesenchymal markers. 
Circulating tumor cells are transient and may transition into mesenchymal phenotypes by 
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a process called epithelial-mesenchymal transition (EMT)27. In this conversion, cells lose 
epithelial markers, such as EpCAM, and express mesenchymal markers, resulting in a 
more aggressive, motile cell type. Aggressive CTC populations with mesenchymal 
phenotype in the bloodstream are missed by these conventional technologies 4–8. Tumor-
initiating cells with high metastatic potential are a small subpopulation of cancer cells 
that have been defined by CD44+ and CD24-. In this work we investigated EpCAM 
expression along the modified wicking bundle. EpCAM expression was analyzed in each 
region after separation of MCF-10A and MCF-7 cells. The results for this study showed 
higher percentages of EpCAM expression in the top region and alginate cap, because of 
high percentages of MCF-7 cells wicking to these regions. This suggests the construct 
can separate cancer cells expressing EpCAM. However, low expression of EpCAM was 
observed along the construct for cell separation of MCF-10A and MDA-MB-231. Since 
both cancer cell lines MCF-7 and MDA-MB-231 were observed in the top region of the 
fiber bundle and the alginate cap, EpCAM expression may not play a role in the 
mechanism for separation. However, the outcomes show cells expressing EpCAM are 
captured in the top region and alginate cap of modified fiber construct. Preliminary work 
investigated CD44 expression of each cancer cell line used. The results showed the 
different cancer types contain varying expression of CD44. Further work will investigate 
the expression of CD44 and CD24, markers of highly metastatic cancer cells along the 
fibers. The goal of the system is to isolate and distinguish between cancerous and 
metastatic cancer cells. We have shown the modified wicking bundle will separate both 
non-metastatic and cancerous cell types from benign cells. However, further work is 
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needed to enhance separation of cancer cells of varying metastatic potential. Due to the 
heterogeneity of tumors and CTC, there is a need for a CTC isolation technology that can 
capture and distinguish the heterogeneous phenotype.  
 This heterogeneity has also been translated to cell lines. Fillmore and coworkers 
has shown phenotypic and functional differences within cell lines and found that 
established breast cell lines contain a small subpopulation of tumorigenic self-renewing 
cells that can differentiate into various phenotypic cells28. The results of this chapter 
show the mechanism of separation along the modified wicking fiber construct is due to 
functional and physical properties of the cancer cells, including cell size, deformability, 
and cell adhesion potential. Further work will optimize the system to separate 
subpopulations of highly metastatic cancer cells between cell lines.  
 
Conclusions 
 This chapter investigated various factors that may contribute to the separation of 
various cell types along the modified wicking fiber bundles. The outcomes showed cell 
size, deformability, and ability to adhere to substrates play a major role in the cell 
wicking behavior. By understanding the mechanism of separation we can optimize the 
wicking fiber construct to not only separate cancer from benign cells but also cells of 
varying metastatic potential. Further work will optimize the tension and cross-sectional 
sizes of the wicking fiber bundles to increase efficiency of separation. Alterations to the 
topography of the grooves and the alginate cap will be explored to improve the separation 
of metastatic and non-metastatic cancer cells.   
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CHAPTER EIGHT 
DEVELOPMENT OF A BONE TISSUE ENGINEERING LEARNING MODULE FOR 
MIDDLE SCHOOL STUDENTS  
Introduction 
The National Academy of Sciences has reported that the United States 
educational system is lagging in the production of students in STEM (Science 
Technology Engineering Mathematics) fields compared to other countries1. Due to the 
lack of interest in STEM careers there is a shortage of professionals to fill STEM 
positions1,2. To encourage STEM participation there is a major push for STEM education, 
especially for elementary school students, who during this time develop perceptions and 
interests in STEM related fields. STEM education also strives to increase the lack of 
diversity, as well as, the low interest of women involvement. The American Society for 
Engineering Education has reported the percentage of women earning a bachelor’s degree 
in engineering was 18.4% in 20113. Lower female participation in STEM fields reflects a 
need to increase awareness and involvement of female students at an earlier age. Howard 
and coworkers describe middle school as critical years where students begin to consider 
careers and develop personal career goals, which is reflected in their class choices and 
activities in high school4. Educational researchers have shown introducing and 
emphasizing STEM activities to middle school students, especially women, can impact 
student interest in STEM fields4.  
The purpose of STEM education is to not only increase numbers and awareness of 
the field, but to provide students a foundation for life problem-solving skills and critical 
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thinking2. This chapter focuses on the development and testing of a biomedical 
engineering learning module to effectively teach concepts focused on bone tissue 
engineering to young female students in middle school. The activities introduced the 
engineering design process involving systematic critical thinking. The student’s 
knowledge of engineering and tissue engineering concepts were assessed before and after 
the learning module. Additionally, interest in student educational and career path towards 
engineering was evaluated.  
The educational program was conducted in coordination with ProjectWise 
summer camp for young girls in middle school. This camp provides experiences and 
hands-on learning activities in the field of science and engineering. During the camp the 
girls participated in six different mini courses of different engineering and science 
disciplines. The developed bioengineering mini course was held on two different days for 
an hour and fifteen minutes long each day. Each day consisted of an interactive lecture 
introducing bone tissue engineering concepts followed by a hands-on activity to reinforce 
the concepts of the lecture and further introduce the engineering design process. The bone 
tissue engineering concepts presented to the students focused primarily on transport 
phenomena in tissues of the human body and how this applies to tissue engineering 
applications. The module on the first day specifically focused on diffusion concepts and 
the second day presented another transport phenomena in the body, capillary action. Pre- 
and post- quizzes were implemented before and after the teaching module to investigate 
the effectiveness of the module. Pre- and post- surveys were also implemented to assess 
if the students interest in engineering was affected by the teaching module. Fifty middle 
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school girls participated in the bioengineering teaching modules. An Institutional Review 
Board (IRB) was approved prior to implementation of the module to collect and publish 
the survey and quiz data from the students. The Clemson University Office of Research 
Compliance (ORC) reviewed and approved the IRB exempt protocol submitted, 
IRB2013-202: IBIOE-Project WISE Perception by Female Students. Parental permission 
and child agreement forms were implemented as part of the IRB for consent from both 
parents and students to participate in study.   
 
Teaching Modules  
Day 1 – Diffusion Concepts Related to the Human Body 
Interactive Teaching Module 
The first day provided an interactive presentation that introduced the students to 
bioengineering and how the field impacts them and the field of medicine. The 
presentation showed the young girls how bioengineering can be both a rewarding and an 
exciting career. The presentation further introduced the tissue engineering segment of 
bioengineering and demonstrated the impact and significance of this field in their lives. 
This segment of the presentation described design criteria for tissue engineered scaffolds 
and how different tissues require different design specs. The second part of the 
presentation specifically focused on transport concepts in the body including diffusion 
and osmosis and how these concepts relate to designing tissue engineered constructs. 
Demos, shown Figure 8.1, were conducted during the presentation to show diffusion in 
various applications and what parameters affect the rate of diffusion.  
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Figure 8.1: Demos presented to students to illustrate diffusion and osmosis (A) Diffusion 
of smell (B) Osmosis in an egg in a hypertonic or hypotonic solution after the shell is 
removed with vinegar (C) Osmosis in gummy bears in hypertonic or hypotonic solutions 
 
The remaining half of the teaching module, the students participated in a hands-on 
group activity, adapted by Hove and coworkers, investigating diffusion in materials 
representing tissues of different stiffness5. The students were first given three different 
materials that simulated three different tissues of varying stiffness, depicted in image A 
of Figure 8.2. The students worked in groups to determine which material best 
represented the mechanical properties of fat, bone, or muscle5.  
To further demonstrate diffusivity of tissues the students worked in groups to 
hypothesize how stiffness might affect diffusion. The group activity involved exploring 
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diffusion of a dye solution on hydrogels of varying stiffness. The hydrogels were pre-
made using varying concentrations of agarose (0.5%, 1%, and 2% agarose) to represent 
the three different tissues consisting of different stiffness. Students first predicted how the 
stiffness would affect the movement of a colored solution. Prior to conducting the 
experiment, students were given worksheets to record their predictions, as well as track 
their measurements and results. To begin the study, students used transfer pipettes to 
pipette one drop of dye solution on each of the agarose gels, Image B of Figure 8.2. The 
students measured the diameter of spread on each agarose gel every 3 minutes for a 15 
minutes.  
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Figure 8.2: (A) Different materials with varying stiffness to represent muscle, fat, and 
bone tissues (B) The group activity where students determine the rate of movement of the 
dye solution in various agarose stiff gels 
 
Following the recording of measurements the students made a plot of diameter of 
the colored solution over time. The worksheets used for this group activity are shown in 
Appendix B. The students explored any differences in diffusion rates between samples 
and determined if stiffness of tissue would influence the rate of diffusion. As a group, the 
outcomes of the study were discussed and the students learned that diffusivity changes 
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with different tissue types causing the colored solution to move faster in less stiff tissues 
such as fat.  
Day 2 – Transport Phenomena in Tissue Engineered Scaffolds 
Interactive Teaching Module 
The second day provided another interactive presentation focusing on the lack of 
vascularity in tissue-engineered scaffolds and the need for vascularity. The presentation 
introduced capillary action and provided a demonstration using celery stalks with food 
coloring.  
 
Figure 8.3: Demonstration of water moving through capillaries or xylem in the celery 
stalks by capillary action 
 
A group activity was develop to show the students the various factors that 
influence capillary action. The students were shown how to conduct a vertical test with 
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fabric and assess the movement of the colored solution over time. Students were provided 
yarns of various sizes and materials. The students were allowed to bundle the yarns and 
use various blends to increase capillary action. The students worked together in groups to 
follow the engineering design process to optimize the capillary action in a yarn system. 
The students followed the engineering design process by first brainstorming, developing 
ideas, choosing a solution, testing the solution, communicating the problems with that 
particular solution, and as a group going back and redesigning. Worksheets were 
developed to help students work through the engineering design process and record 
measurements of the testing (Appendix B).  
The final demo evaluate vertical test of dye-solution with various types of paper 
towel brands. The students predicted which paper towel brand would perform the best 
based on the porosity, strength, weaves, and patterns. These activities illustrated how the 
architecture of a tissue-engineered scaffold can affect the diffusion and transport, which 
can affect cell survival.  
373 
 
 
Figure 8.4: (A) Designing and testing capillary action in various yarn materials (B) 
Architecture of the paper towel will affect capillary action 
 
Assessment of Modules 
Pre- and post- surveys (Appendix B) were conducted using a likert ranked system, 
open-ended questions, and a drawing question to assess any change in interest in the field 
of science and engineering after the modules. The first part of the survey investigated 
interest and attitude of the students towards STEM (Science, Technology, Engineering, 
and Mathematics) fields. This part of the survey included 21 questions with Likert scale 
responses. The questions were adapted from existing established STEM interest surveys 
developed by Lyons and colleagues, and previous work conducted by IBIOE lab 
members6,7.   To further investigate the student’s attitude and perception of engineering 
two open-ended questions and a “Draw an Engineer test” (DAET) were also included in 
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the assessment. The open-ended questions asked the students to describe engineering and 
what engineers do. To analyze the responses for the open-ended questions, categories 
were established to code the responses and the frequency of each category was analyzed. 
The DAET was adapted from Knight and colleagues8. This test was developed to 
investigate student’s perceptions of engineering. To assess the drawings various 
categories were created and the pictures were coded for each category. The frequency of 
activities drawn, common objects, and images were assessed.   
Pre- and post- quizzes (Appendix B) were used to evaluate the effectiveness of 
the modules to evaluate if the students have an improved understanding of bioengineering 
and related transport phenomena. The quizzes consisted of four open-ended questions 
each worth 3 points. A grading scale was developed for each question based on the 
student responses. The table below describes the grading scale used to determine the 
percentage grade of the pre- and post- quizzes.  
Statistical Analysis  
Statistical analysis was conducted in JMP 10 using Wilcoxin Signed-Rank Test to 
determine significant change of the student responses to the likert scale survey questions. 
The data distribution was assumed non-parametric and tested with a significance level of 
0.05. The Wilcoxin Signed-Rank Test was also used to investigate changes in grade 
percentages for each question as well as the total score because data distribution was 
assumed without a normal distribution. The purpose of the quizzes was to investigate if 
the module positively affected the students understanding of bioengineering, tissue 
engineering scaffolds, as well as transport phenomena that occurs in scaffolds, 
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specifically diffusion and capillary action. The table below describes the questions and 
the grading scale used to determine the percentage scores for each student. The total 
number of students who participated in the WISE module was n=50. Due to lost surveys 
and lack of interest to participate in the study, the number of students who participated in 
the sample size for the surveys and quizzes was n=44.  
Table 8.1: Grading Scale 
 Score 0 Score 1 Score 2 Score 3 
What does a 
bioengineer do? 
No Response 
“I don’t know”     
“I forgot” 
Connects biology 
and life with 
engineering 
Understands 
bioengineering can 
improve medicine 
and the well-being 
of people 
Understands 
bioengineering is 
a broad field with 
the goal to 
improve the field 
of medicine 
What is 
diffusion? 
No Response 
“I don’t know”     
“I forgot” 
Describes some 
relation to 
spreading or 
moving 
Describes change 
in concentrations 
and balancing of 
substances 
Describes the 
movement of 
particles from 
high 
concentrations to 
lower 
concentration 
What is the 
length of your 
thumb in cm? 
No Response 
“I don’t know”     
“I forgot” 
>15 cm or use of 
different units 
10-14 cm 
1-2 cm 
3-9 cm 
What is 
capillary 
action? 
No Response 
“I don’t know”     
“I forgot” 
Describes 
movement 
Understands the 
vertical movement 
of water in a tube 
is caused by 
capillary action 
Understands 
capillary action 
occurs in pores or 
tubes based on 
adhesion and 
cohesion of water 
molecules 
 
Results 
Both pre- and post- survey questions assessing student interest in STEM using 
Likert scale questions showed high percentages of students interested in STEM fields. 
Table 8.2 shows the frequency of student responses as percentages for each question.  
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Table 8.2: Pre Survey responses. Table depicts the percentage of students who agree or 
disagree for each survey question 
Survey Questions 
Strongly 
Disagree 
(%) 
Somewhat 
Disagree 
(%) 
Not sure 
(%) 
Somewhat 
Agree 
(%) 
Strongly 
Agree 
(%) 
I like engineering 2.3 4.5 13.6 54.5 27.3 
I like math 4.5 6.8 6.8 40.9 40.9 
I like science 2.3 4.5 6.8 29.5 36.4 
Boys are better at being 
engineers than girls 84.1 11.4 4.5 0.0 0.0 
Engineering has nothing to 
do with our lives 81.8 11.4 6.8 0.0 0.0 
Engineering and science 
help make people's lives 
better 0.0 0.0 4.5 20.5 75.0 
I find it boring to hear new 
ideas 65.9 15.9 11.4 6.8 0.0 
I would like to join a 
science club 6.8 13.6 34.1 20.5 25.0 
I dislike science lessons 38.6 29.5 18.2 6.8 6.8 
I get bored watching science 
programs on TV 29.5 25.0 18.2 25.0 2.3 
I am good at solving 
problems 0.0 0.0 18.2 63.6 18.2 
I am nervous to take an 
engineering class 25.0 31.8 36.4 6.8 0.0 
I would like to join an 
engineering club 2.3 4.5 52.3 20.5 20.5 
Boys know more about 
engineering and technology 
than girls 79.5 9.1 9.1 2.3 0.0 
I like doing experiments 0.0 4.5 4.5 15.9 75.0 
I like reading and thinking 
about science 2.3 13.6 20.5 43.2 22.7 
I find engineering boring  34.1 31.8 18.2 11.4 4.5 
I am smart enough to be an 
engineer 6.8 2.3 15.9 25.0 50.0 
Being an engineer is more 
fun than other jobs 4.5 22.7 40.9 22.7 9.1 
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Table 8.3: Post survey questions depicts similar responses to pre survey questions 
Survey Questions 
Strongly 
Disagree 
Somewhat 
Disagree 
Not sure 
Somewhat 
Agree 
Strongly 
Agree 
I like engineering 2.3 6.8 4.5 50.0 36.4 
I like math 0.0 9.1 6.8 34.1 50.0 
I like science 2.3 2.3 6.8 20.5 68.2 
Boys are better at being 
engineers than girls 
84.1 11.4 4.5 0.0 0.0 
Engineering has nothing 
to do with our lives 
81.8 4.5 9.1 2.3 2.3 
Engineering and science 
help make people's lives 
better 
4.5 2.3 2.3 9.1 81.8 
I find it boring to hear 
new ideas 
68.2 20.5 6.8 4.5 0.0 
I would like to join a 
science club 
6.8 13.6 29.5 25.0 25.0 
I dislike science lessons 47.7 31.8 18.2 2.3 0.0 
I get bored watching 
science programs on TV 
27.3 27.3 15.9 22.7 6.8 
I am good at solving 
problems 
0.0 0.0 15.9 50.0 34.1 
I am nervous to take an 
engineering class 
43.2 25.0 11.4 15.9 4.5 
I would like to join an 
engineering club 
11.4 9.1 22.7 22.7 34.1 
Boys know more about 
engineering and 
technology than girls 
88.6 4.5 6.8 0.0 0.0 
I like doing experiments 0.0 0.0 9.1 15.9 75.0 
I like reading and thinking 
about science 
4.5 13.6 20.5 31.8 29.5 
I find engineering boring 59.1 15.9 9.1 9.1 6.8 
I am smart enough to be 
an engineer 
2.3 0.0 15.9 22.7 59.1 
Being an engineer is more 
fun than other jobs 
9.1 6.8 38.6 31.8 13.6 
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Table 8.4: Significant positive change between pre and post survey responses, no 
negative changes were seen 
Survey Questions 
Significant Positive 
Change  
I like engineering  
I like math p=0.0366 
I like science  
Boys are better at being engineers than girls  
Engineering has nothing to do with our lives  
Engineering and science help make people's lives better  
I find it boring to hear new ideas  
I would like to join a science club  
I dislike science lessons p=0.0217 
I get bored watching science programs on TV  
I am good at solving problems  
I am nervous to take an engineering class  
I would like to join an engineering club  
Boys know more about engineering and technology than 
girls  
I like doing experiments  
I like reading and thinking about science  
I find engineering boring  p=0.0388 
I am smart enough to be an engineer  
Being an engineer is more fun than other jobs  
 
Most of the questions showed no significant difference between the pre- and post- 
surveys responses, shown in tables below. The results showed significantly more students 
liked math and science lessons; as well as did not find engineering boring.  
The first open-ended question on the pre- and post- surveys asked the students to 
describe engineering. The students’ responses to this question were similar for the pre 
and post surveys, as illustrated in the frequency chart below. No significant difference 
was observed in the responses to this question. The most common engineering themes 
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described to this question were helping people, as well as, solving, improving, and 
building.  
 
 
Figure 8.5: Student responses to the open-ended question "What is engineering?" 
  
The second open-ended question asked the students to describe what engineers 
do. The post survey responses to this question were similar to the pre survey responses, 
as shown in the figure below. The most common engineering activities described were 
similar to those mention in question one. The common responses include helping people, 
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building, creating, and solving problems. The most common engineering theme described 
was medical related for both pre and post surveys.  
 
Figure 8.6: Student responses to second open-ended question: "What does an engineer 
do?" 
  
The final assessment analyzed the student’s perception of an engineer before and 
after the module. The students drew a picture of an engineer at work. The drawings were 
characterized based on common themes found in the drawings. The chart below 
summarizes the frequency of each of the categories. The frequency plot shows under the 
people category more male engineers were drawn than females on both pre and post 
surveys. Most of the drawings from the pre surveys showed actions of building and 
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fixing. Interestingly, the post survey drawings showed an increase in pictures related to 
lab and research and less related to fixing. The related themes described by the pre and 
post surveys were also different. Drawings of robots and computers were higher for the 
pre survey than the post survey. The post survey showed a significant increase in the 
amount of tissue engineering related pictures compared to the pre survey. These 
outcomes show drawing pictures as an assessment may provide educators and researchers 
a tool to determine perception and attitude of students.  
 
 
Figure 8.7: Categorizes the drawings of pre and post surveys. The categories include 
people, actions, and themes 
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The pre and post quizzes were implemented to determine the effectiveness of the 
teaching module. The outcomes of the post quiz showed improvement in the students 
understanding of bioengineering, measurements, and transport phenomena including 
diffusion and capillary action. The figure below shows there was a significant increase in 
grade percentage for the post quiz for all post quiz questions, p<0.05. Question 1 
responses showed improved understanding of bioengineering (p=0.0001). Question 2, 3, 
and 4 responses reflected a better understanding of diffusion, measurements, and 
capillary action (p=0.0001, p=0.0254, p=0.0001 respectively). The overall average test 
score for the post quizzes was significantly higher than the average pre quiz scores 
(p=0.0001). The post quiz scores showed a 30 % increase in grade percentage. The 
outcomes suggest the module was effective in teaching students tissue engineering 
related concepts.  
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Figure 8.8: The post quiz grade percentages were significantly greater than the pre quiz 
grade percentages, (*) signifies p<0.05.  
 
Discussion 
The outcomes revealed this module did not influence the student’s interest in 
STEM fields. The post survey responses of the Likert style questions showed no 
significant difference compared to the pre survey responses. The results from the 
questionnaire showed high interest in STEM prior to the module. This may be a factor of 
the ProjectWise summer camp. Most of the students participating in this camp express 
interests in STEM fields prior to attending. The post survey of the open-ended question 
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responses also showed no difference. Interestingly, the DAET of the post survey depicted 
different trends in responses than the pre survey. The pre survey showed a majority of the 
students drew pictures related to building and robots or computes. The post survey 
showed a number of students drew pictures related to tissue engineering and research. 
This variety of pictures can also be influenced by the other engineering related activities 
the students are participating in. Prior to attending this module students participated in 
electrical computer science engineering activities related to robots and computers. The 
additional activities of the camp may influence the student’s perceptions and attitudes of 
engineering. However, the DAET analysis suggests students may have a greater 
understanding of what an engineers can do. The outcomes also indicate the DAET can 
capture more information about student’s perceptions and attitudes through the drawings 
than open-ended questions or the Likert-scale questions  
The interactive modules improved their understanding of tissue engineering and 
how the field impacts them as well as the medical field. The responses on the post-quiz 
reflected greater understanding of what bioengineering is and the concepts involve in 
developing a tissue-engineered scaffold. The post-quiz showed the module was effective 
in providing the students a better understanding of transport phenomena that occurs in the 
body and tissue engineered scaffolds. This module was developed for students in grades 
6-8th. Future work will tailor the activities and presentation for students in high school or 
in lower grades.   
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Conclusion 
The assessment showed the module had no effect on the interest of the students in 
STEM fields. However, the outcomes from the pre and post quizzes demonstrate the 
module was effective in teaching the students tissue engineering concepts. The post quiz 
results showed a significant increase in grade percentages than the results of the quiz prior 
to student participation in the module. This module can be an effective tool for teachers in 
the classroom to introduce students to bioengineering.   
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CHAPTER NINE 
CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE WORK 
Conclusions 
This work developed and tested the ability of a wicking bundle system to (1) 
improve mass transport and cellular distribution in large bone tissue engineered scaffolds 
and (2) separate cell types based on their wicking behavior. A major limitation of large 
bone defects is the vascularity to support all regions of the defect site to provide 
homogeneous bone regeneration. Conventional approaches to improving transport of 
tissue engineered grafts involving incorporated angiogenic factors or vascular-promoting 
cells have shown very limited success. The survival and success of large tissue 
engineered constructs are dependent on the vascularity of surrounding tissue and 
sufficient mass transport. We developed and tested a new approach to provide a synthetic 
vascular like system within a large bone graft to improve mass transport and cell 
infiltration.  
The second application of the wicking fiber system involved cell separation and 
isolation based on signature cell wicking characteristics for both cancer and progenitor cell 
identification applications. A major challenge of cancer diagnostics is the heterogeneity 
and transient properties of the tumor, and subsequently cancer cells that have detached 
from the tumor (CTCs). Tumors and CTCs have been reported to have different 
subpopulations of cancer cells with varying phenotypes and degrees of tumor-initiating 
capabilities. The inherent dynamic heterogeneity of cancer cells limits the ability molecular 
biomarker detection, typically gene and protein expression. Molecular biomarker detection 
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can be unreliable, lack specificity, and provide limited information regarding cancer cell 
stage. We developed a cell identification based on the signature wicking profiles of various 
cell types. This work showed a proof-of-concept identification system using cancer cell 
types with varying metastatic potential and progenitor cells of varying differentiation 
potential. This work further explored the mechanisms of cell separation along the wicking 
fiber system. The following conclusions were drawn from each of the aims investigated: 
Characterization of Fluid, Biomolecule, and Cellular Transport by Wicking Fibers 
1. The fluid transport tests showed the wicking fibers significantly enhanced the 
wicking rate and maximum height reach of fluid compared to round fibers. The 
twisted configuration of the wicking fibers showed superior wicking behavior 
compare to the braided configuration. 
2. The wicking fibers enhanced the transport rate of FITC conjugated albumin into a 
collagen-agarose hydrogel compared to round fibers, suggesting the fibers provide 
conduits that can enhance and facilitate biomolecule movement. 
3. The wicking fibers can recruit and distribute cells by wicking and providing conduits 
for cell travel. Progenitor cell vertical displacement along wicking fibers was 
significantly greater than round fibers. The wicking fibers showed enhanced 
distribution of progenitor cells in collagen gel compared to round fibers.   
Assessment of Wicking Fibers in ChronOS Strip Bone Scaffolds 
1. The wicking fiber bundles enhanced the fluid retention and distribution in the 
chronOS strip scaffolds.  
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2. The wicking fiber bundles improved cell viability, proliferation, and distribution by 
increasing the porosity of the scaffold and providing conduits to facilitate diffusion 
and enhanced capillary action.  
3. The osteogenic differentiation of pre-osteoblast cells in modified chronOS strip 
scaffolds showed earlier and increased bone forming related protein expression 
compared to the unmodified scaffolds. Higher gene expression and ALP was 
observed earlier in the differentiation study compared to unmodified scaffolds 
suggesting the wicking fiber may augment osteogenic differentiation. 
4. The major limitation of the differentiation study was the scaffold size used. Due to 
the small geometry of the scaffolds used and the in vitro set-up, mass transport may 
not have been limited in the scaffolds.  
Characterizing Modified Wicking Bundles and Their Effect on Cell Seeding  
 
1. The wicking fiber bundles were successfully modified with an absorbent cap. The 
wicking rate and fluid absorbed were significantly increased by the modification of 
the wicking bundle. The enhanced wicking rate was a result of the greater change in 
pressure generated by the transpiration of fluid from the alginate cap. The 
transpiration pressure primes the system leading to an increased wicking rate and 
fluid height.  
2. The modified wicking bundles increased the recruitment of progenitor cells and the 
rate of FITC conjugated albumin into a hydrogel compared to the unmodified 
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bundles. In a submerged system the alginate enhanced the transport of cells and 
biomolecules until the hydrogel reached swollen capacity.  
3. The modified wicking bundles significantly improved the cell viability, proliferation, 
and distribution of the chronOS strip scaffolds following cell seeding with a perfusion 
pack system. The modified wicking bundles provide an intrinsic cell seeding 
approach for scaffolds to initially improve the recruitment and distribution of cells 
that could be easily implemented for clinical use.  
Investigation of Modified Wicking Bundles as an Antibiotic Release System 
1. Three loading mechanisms of gentamicin antibiotic into polylactide fibers were 
developed and tested. The third mechanism, mixing the gentamicin with the 
polylactide pellets prior to extrusion, showed elution levels above the minimal 
inhibitory concentration for the duration of the study. The first mechanism, wicking 
the antibiotic solution into the bundles, and second mechanism, incorporating the 
antibiotic in the water bath, were not loaded initially with enough antibiotic solution 
to sustain release.  
2. The cross-section of the polylactide fiber affects the amount of antibiotic loaded and 
the release profile. The wicking fibers loaded by mechanism 2, incorporated a higher 
concentration of antibiotic, and showed increased elution compared to the round 
fibers. The single large fiber loaded by mechanism 3 showed significantly faster 
release of the antibiotic compared to the small fiber bundle. The bundle incorporated 
more antibiotic and showed a slower constant release profile.  
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3. The release from the alginate cap showed sustained release of gentamicin above the 
MIC for 7 days. The results suggest higher initial loading concentration may improve 
the duration of release. 
4. The DSC results suggest the incorporation of gentamicin may affect the crystallinity 
of the polylactide and alter the degradation of the polymer. 
Cell Separation and Isolation using Modified Wicking Bundles 
1. Cell separation of cancer and normal cells was observed along unmodified wicking 
bundles. A mixture of mesenchymal stem cells and monocytes was also separated 
using the unmodified wicking fibers.  
2. The modified wicking bundles increased the amount of cells separated along the 
system and provided a mechanism for isolating cancer cells by the absorbent cap. 
3. The modified wicking bundles showed separation of non-metastatic cancerous and 
benign breast epithelial cells. The cancer cells were observed and isolated from the 
top region of the fiber bundles and alginate cap.  
4. Metastatic cancer cells were also separated and isolated from benign cells using the 
modified wicking bundle. 
5. The modified wicking bundle showed greater densities of metastatic cancer cells than 
non-metastatic cancer cells, however, more work is needed to more efficiently 
separate metastatic for non-metastatic cancer cells.  
6. Mesenchymal stem cells were separated and isolated from a more differentiated pre-
osteoblast cells using the modified bundles.  
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7. Stem cells and cancer cells showed similar wicking behaviors along the modified 
fiber bundles 
Investigation of Cell Separation Factors of the Wicking Fibers 
1. The cell types (D1, mouse mesenchymal stem cells, and MCF-7, human epithelial 
cancer cells) that displace to the top regions of the bundle and alginate cap showed 
smaller size cell diameters than the cells that remain in the bottom region of the 
bundle (MC3T3E1, mouse pre-osteoblast cells, and MCF-10A, human benign 
epithelial cells). Cell size may play a role in cell separation along fibers.  
2. The beads used to mimic cell size in the modified wicking fibers showed very limited 
penetration of the larger beads into the system. The smaller beads were isolated from 
the top region of the fiber and alginate cap. 
3. The modified wicking bundles containing smaller fibers increased the number of 
beads isolated in the alginate cap and the fiber bundles. The smaller conduits of the 
fiber bundle generated greater capillary pressure increasing the fluid height and 
subsequently the amount of beads in the system.  
4.  The inter-fiber spaces created by the tension of fiber bundle influence the wicking 
rate of the fluid and affect the cell wicking behavior.  
5. The cancer cell types differed in cell morphology and cytoskeletal arrangement, 
which influenced the deformability of the cell. Cell deformation also plays a role in 
the ability of different cell types to move through the system. Cancer cells of high 
metastatic potential are more deformable than non-metastatic cancer and benign cells. 
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Additionally, the mesenchymal stem cells have less actin stress fibers than the pre-
osteoblast, which may contribute to the increased deformability of stem cells.  
6. The cytoskeletal arrangement of cancer cell types along the fibers showed a rounded 
morphology with limited cell spreading. Uniquely, the pre-osteoblasts adhered to the 
fibers and illustrated spread morphology along the grooves. This suggests the surface 
topography and cell adherence properties may also contribute to varying levels of cell 
separation.  
7. The modified bundle fibers separated and isolated both non-metastatic cancer cells 
expressing EpCAM and metastatic cancer cells that show very limited expression of 
EpCAM. This suggests the system can isolate cancer cells of varying phenotypic 
expression but further work investigate optimizing the separation of the various 
phenotypes.  
Bone Tissue Engineering Teaching Module for Middle School Students 
1. The outcomes of the pre and post surveys showed the module had no effect on the 
students interest in engineering. This is a factor of the type of students surveyed. Most 
of the students who participated were already interested in engineering and chose to 
participate in the Women in Science and Engineering (WISE) summer camp. 
2. The drawings reflecting the student’s perception of engineering showed a difference 
between the pre and post quizzes. The outcomes of this assessment were influenced 
by the other engineering related activities the students participated in during the 
camp.  
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3. The post quizzes showed a significant increase in grading percentages compared to 
the pre quiz results. This indicates the module was effective in improving the students 
understanding of tissue engineering and related transport phenomena. 
 
Future Work 
1. Further work can investigate the effects of bundle tension and architecture on the 
wicking behavior of the bundle. A twisting apparatus should be developed that can 
incrementally adjust the tension and provide a bundle with homogenous tension 
across it. Other bundling configurations can also be explored, such as various braided 
and weaved configurations.  
2. Further work can investigate the transpiration pressure generated from the alginate 
cap. Hydrogels of varying stiffness and swelling potential can also be investigated to 
experimentally determine the effect of different hydrogels on the wicking behavior of 
the fluid.  
3. To further our understanding of the fluid transport phenomena in the system 
permeability measurements can be performed. A micro CT scanner could also be 
used to better quantify the biomolecule and cellular movement.  
4. A COMSOL model can also be developed to investigate transport of fluid, 
biomolecules, and cells within the modified wicking fiber system to optimize the 
system for the different applications. The model can investigate the effects of 
changing the hydrophobicity of the polymer, as well as the effects of bundles of 
various tensions and fiber sizes.  
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5. The oxygen levels of the unmodified and modified chronOS strip samples in the 
central and peripheral regions of the scaffold can be quantified using fiber-optic 
oxygen microsensors. A model can be developed using this data to determine the 
oxygen gradients in modified and unmodified chronOS strip scaffolds. This data can 
provide information to help determine ideal fiber arrangement and placement in the 
scaffolds.  
6. Test the mechanical properties of the chronOS strips with and without modified 
wicking bundles.  
7. The differentiation of pre-osteoblast cells on the alginate modified polylactide fiber 
bundles should also be investigated to assess if the alginate caps should be removed 
prior to implantation.  
8. Further work can test the modified chronOS strip scaffolds in an in vitro test system 
to better simulate the vascular limitations of the specific implant site for the bone 
graft.  
9. A rabbit posterolateral fusion animal model can be used to compare the modified and 
unmodified chronOS strip samples in vivo.  
10. Future work can also consider functional modifications to the fiber and coatings to 
the alginate to direct and sustain transport 
11. Future work will investigate long-term release of antibiotic from the wicking bundles. 
The initial loading concentration and fiber size and bundle should be optimized to 
provide antibiotic release ideally for six weeks to a year based on application.  
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12. Bacterial studies should also be performed to verify the gentamicin was not altered 
from the processing of the fibers and the concentration is high enough to prevent 
bacterial growth. Other studies need to determine the toxicity of the gentamicin and 
any effect on bone differentiation.  
13. The DSC results indicated the gentamicin may alter the crystallinity of the 
polylactide. Further work should investigate changes in degradation and mechanical 
properties of the polylactide.  
14. Future work should improve the efficiency of the modified wicking bundles to 
separate and isolate cancer cells. Modifications to the fibers, such as tapering the top 
region of the bundles and altering the fiber tension may improve the separation of 
non-metastatic and metastatic cancer cells.  
15. More physiologically relevant cell densities should be tested to determine the 
efficiency of the system. Circulating tumor cells (CTCs) are found in the blood 
typically at a density of 10-100 cells per mL. Future work would determine if the 
modified wicking bundle can recover cancer cells seeded at this density.  
16. To further prove the efficacy of the modified bundle system metastatic and non-
metastatic cancer cells, spiked volunteer blood at the physiologically relevant 
concentration of 10 cells per mL should be evaluated. Determine if erythrocytes 
and/or leukocytes will effect cell movement along fibers. 
17. Future work should also investigate the mesenchymal and epithelial phenotypes of 
the cells recovered by the system.   
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18. A statistical model could be developed to further investigate interactions of different 
fiber configurations as well as variations of cell lines. 
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Appendix A 
Educational Surveys and Activities 
 
Figure A-1: Survey questions evaluating perception of engineering. 
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Figure A-2: Survey questions evaluating interests in engineering. 
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Figure A-3: Activity worksheet for exploring diffusion. 
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Figure A-4: Activity worksheet for exploring capillary action. 
 
 
